id,seed_number,title,level,score,state,reason
0a2998ac-8233-4868-a688-0bb461cc98b7,1,SEED: s43856-025-01156-3.pdf,1,10,Processed,"This paper is principally about pharmacogenomics: it directly examines CYP2C19 loss-of-function variants (rs4244285 *2 and rs4986893 *3), uses genetic data (genotyping/WES) to predict CYP2C19 metabolizer status, and tests whether family history of early amitriptyline discontinuation enriches for pharmacogenomic risk. The study’s objective, analyses, results (significant enrichment of genetically predicted poor CYP2C19 metabolizers), and clinical implications (flagging patients for targeted PGx testing) all center on pharmacogenetic approaches."
e58f2ec3-09e6-4b60-aa91-dc13414fc65a,2,SEED: fphar-14-1080117.pdf,1,10,Processed,"The paper directly investigates pharmacogenetics — specifically CYP2D6 and CYP2C19 genotypes/phenotypes — and their clinical utility in antidepressant response (ADRs and ineffectiveness). It uses genotyping, CPIC guideline-based phenotype translation, and analyzes gene–drug–response actionability, so pharmacogenetics is the primary focus."
ff10e3a0-dd19-49a0-8eed-cf60bea95f07,1,"Pirmohamed, M. Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet24, 350–362 (2023).",2,10,Processed,"This editorial is explicitly focused on pharmacogenetics/pharmacogenomics in psychiatry. It discusses PGx concepts (pharmacokinetics vs pharmacodynamics), polymorphic enzymes (e.g., CYP2D6), clinical implementation (PGx benefit score, CPIC-guided prescribing), a systematic review/meta-analysis of PGx-guided antidepressant prescribing, and molecular mechanisms relevant to drug response — i.e., the paper is primarily about pharmacogenetic approaches."
ccc1ae24-0841-4332-998c-39f4a06b154e,1,"McDermott, J. H. et al. Clinical pharmacogenetics implementation consortium guideline for the use of aminoglycosides based onMT-RNR1 genotype.Clin. Pharm. Ther.https://doi.org/10.1002/cpt.2309(2021).",2,10,Processed,"This paper is squarely focused on pharmacogenomics/pharmacogenetics: it develops and benchmarks targeted long-read sequencing approaches (ONT adaptive sampling versus Twist long‑read PGx panel) specifically for genotyping pharmacogenes (e.g., CYP2D6, CYP2C19, NAT2, HLA loci), evaluates star-allele and diplotype calling against GeT‑RM and CPIC-relevant genes, and discusses clinical PGx implementation implications (phasing, structural variant resolution, and phenotype translation). The methods, results, and conclusions all center on improving pharmacogenetic testing accuracy, so the work is primarily about pharmacogenetics."
3eab1903-afa3-4dc0-b0db-eaa7d766c5d6,1,"Haga, S. B. & Orlando, L. A. Expanding family health history to include family medication history.J. Pers. Med.13, 410 (2023).",2,10,Processed,"This case report is primarily about pharmacogenetics: it describes preemptive and reactive PGx panel testing (100 variants/30 genes) across three generations, focuses on CYP2D6 and CYP2B6 genotype→phenotype interpretation, uses PGx results to validate self‑reported family drug-related problems and to guide perioperative analgesic/anesthetic decisions, and discusses CPIC/DPWG/PharmGKB evidence and clinical implementation considerations."
23a532c4-c480-46fa-b5e8-3d2476cabdc8,1,"Hicks, J. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) forCYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.Clin. Pharm. Ther.102,3 7–44 (2017).",2,10,Processed,"This is a Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline specifically addressing CYP2D6 and CYP2C19 genotypes and gene-directed dosing of tricyclic antidepressants. The paper centers on translating genotype to phenotype, provides detailed gene-based dosing recommendations, discusses testing interpretation, implementation in EHRs, and clinical implications — i.e., it is primarily about pharmacogenetic approaches."
ae215de0-b85e-46fa-a09e-aaa921c23afe,1,"Magavern, E. et al. CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel.JACC Adv.https://doi.org/10.1016/j.jacadv.2023.100573 (2023).",2,10,Processed,"The slides/paper are centrally focused on pharmacogenetics/pharmacogenomics (PGx): defining gene–drug interactions, CYP450 metaboliser variation (CYP2C19, CYP2D6), examples with clopidogrel and other drugs, population prevalence data, ADR mitigation potential, real-world cohort analyses (Genes & Health, British-South Asians), and implementation/ethical/equity issues. The primary aims, data and discussion all revolve around PGx implementation and its effects on prescribing and health equity."
8dec14c0-efdc-491b-a050-09627771f992,2,url:https://doi.org/10.1016/j.neubiorev.2022.104965,2,10,Processed,"This paper is primarily about pharmacogenetics/pharmacogenomics: it is a systematic review and meta-analysis of randomized controlled trials evaluating pharmacogenomic-guided (PGx) antidepressant treatment versus treatment as usual in major depressive disorder. It explicitly discusses PGx tests, decision-support tools, pharmacogenes (e.g., CYP2D6, CYP2C19), and clinical outcomes (remission, response), and draws conclusions about the effectiveness and certainty of PGx-guided care."
4cdbeece-9105-45a1-877c-d11f85492681,2,url:https://doi.org/10.2217/pgs-2018-0142,2,10,Processed,"The paper is explicitly focused on pharmacogenomics/pharmacogenetics: it is a systematic review and meta-analysis of randomized controlled trials assessing pharmacogenomic (PGx)-guided treatment versus treatment-as-usual for major depressive disorder. It discusses PGx tests (single-gene and combinatorial), specific pharmacogenes (CYP2D6, CYP2C19), clinical outcomes (remission, response), and trial-level evidence — i.e., the article primarily evaluates pharmacogenetic approaches."
0a23a5a8-f98a-42b2-859a-f9e992909db0,2,url:https://doi.org/10.1186/s12888-017-1230-5,2,10,Processed,"The paper is explicitly and primarily focused on pharmacogenomics/pharmacogenetics: it is a systematic review and meta-analysis evaluating pharmacogenomic-guided (PGx) antidepressant treatment in major depressive disorder, discusses specific pharmacogenes (CYP2D6, CYP2C19), PGx decision-support tools, CPIC guidelines, and synthesizes RCT evidence on PGx testing outcomes."
4cca0f6c-937a-478c-ab41-1eb9119ac440,2,url:https://doi.org/10.2217/pgs-2019-0157,2,10,Processed,"The paper is centrally focused on pharmacogenomics/pharmacogenetics: it is a systematic review and meta-analysis of randomized controlled trials comparing pharmacogenomic-guided (PGx) antidepressant treatment versus treatment-as-usual for major depressive disorder. It discusses specific pharmacogenes (CYP2D6, CYP2C19), PGx decision‑support tools, CPIC guidelines, and clinical outcomes (remission, response, adverse events), so pharmacogenetic approaches are the primary subject."
d7e6f1ce-40b9-438d-8c53-dddad2d3ad68,2,url:https://doi.org/10.3389/fgene.2020.491895,2,10,Processed,"The editorial is primarily focused on pharmacogenomics in psychiatry: it discusses CYP2C19 and CYP2D6 genetic polymorphisms, their impact on antidepressant/antipsychotic pharmacokinetics and side effects, clinical implementation guidelines (CPIC, DPWG), cost-effectiveness data, and ongoing multicenter pharmacogenetic trials (PSY‑PGx). The entire piece centers on applying pharmacogenetic approaches to personalize psychiatric pharmacotherapy."
ac756e65-18a3-4b5f-b3e4-ac6277d4ef16,2,url:https://doi.org/10.1111/cts.12692,2,10,Processed,"The paper centrally investigates CYP2D6 genotype-to-phenotype translation and activity scores in people with codeine use disorder, compares genotype/phenotype frequencies to a population sample, examines genotype–drug (codeine → morphine) effects on treatment dosing, uses CPIC guidelines and explicit genotyping methods, and discusses pharmacogenomic clinical implications—thus it is primarily a pharmacogenetics study."
61838d88-e9f0-4b3c-8018-773b6aa2a997,2,url:https://cpicpgx.org/genes-drugs/,2,10,Processed,"This CPIC guideline is primarily focused on pharmacogenetics: it systematically reviews genetic variants (CYP2C9, VKORC1, CYP4F2, rs12777823), presents evidence from GWAS and randomized trials (EU-PACT, COAG, GIFT), discusses genotyping, algorithms for genotype-guided warfarin dosing, ancestry-specific recommendations, and clinical implementation — all central pharmacogenetic content."
0c287f39-0fe1-41ba-9232-dd2b91380830,2,url:https://cpicpgx.org/prioritization/#flowchart,2,10,Processed,"This supplement is centrally focused on pharmacogenetics — specifically CYP2C19 genotype effects on clopidogrel pharmacokinetics, pharmacodynamics, clinical outcomes, testing, diplotype-to-phenotype translation, guideline recommendations for genotype-guided therapy, and implementation resources (EHR/CDS). It reviews trials and meta-analyses of genotype-guided antiplatelet strategies, so pharmacogenetic assessment is the primary subject."
2a6e79f9-1f99-4e3f-aa17-8c19087ce81c,2,url:https://doi.org/10.1002/cpt.2149,2,10,Processed,"This document is a Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline focused on CYP2D6, OPRM1, and COMT genotypes and their impact on opioid therapy. It includes systematic literature review of genotype–phenotype associations, genotype interpretation (alleles, activity scores, phenotype translation), and clinical prescribing recommendations (codeine, tramadol, hydrocodone, oxycodone, methadone) based on genetic test results — i.e., it is primarily about pharmacogenetics."
642388b7-a909-49f6-b9ca-613fe0ddaf05,2,url:https://doi.org/10.1016/j.biopha.2022.113202,2,10,Processed,"The paper is primarily about pharmacogenetics: it genotypes CYP2C19 (*2, *3, *17), predicts metabolizer phenotypes, compares genotype-predicted versus measured CYP2C19 activity (phenoconversion), and quantifies drug–drug–gene interaction effects of CYP2C19 inhibitors on phenotype. The study directly assesses how genetic variation and non-genetic factors affect pharmacogenetic phenotype interpretation and DDI-informed prescribing."
bb89f818-873a-492c-8928-d8bf3980fa37,2,url:https://doi.org/10.1038/tp.2012.99,2,10,Processed,"The paper is explicitly focused on pharmacogenetics: it is a guideline for the clinical use of pharmacogenetic testing in psychiatry, reviews evidence (GRADE) for genotype-guided prescribing, discusses CYP enzymes (primarily CYP2C19 and CYP2D6), presents dosing recommendations and implementation considerations, and summarizes clinical trials of pharmacogenetic-guided treatment—making pharmacogenetics the primary topic."
37125e0f-8891-4b10-ba99-b551fbfb0abc,2,url:https://doi.org/10.1002/cpt.597,2,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and gene-guided dosing of tricyclic antidepressants, including genotype-phenotype interpretation, dosing recommendations, therapeutic drug monitoring, and implementation — i.e., it is primarily and directly about pharmacogenetics."
47ed0a42-5efd-493f-bfc4-3c98a8231d59,2,url:https://doi.org/10.3389/fgene.2022.1016416,2,10,Processed,"The manuscript is explicitly focused on pharmacogenomics/pharmacogenetics: it reviews long-read sequencing applications, analytical strategies, challenges, and future perspectives specifically for pharmacogenomic testing, discusses pharmacogenes (e.g., CYP2D6, CYP2C19, NUDT15, HLA), haplotyping/diplotype calling, clinical implementation, and PGx tools—making pharmacogenetics the primary topic."
5ace35b5-cfc5-4445-adb9-356208fe3b59,2,url:https://doi.org/10.1016/j.psychres.2022.114535,2,10,Processed,"The thesis is explicitly focused on pharmacogenetics — the title and abstract state ‘Clinical Application of Pharmacogenetics’, and the work centers on genotype–phenotype analyses and clinical utility for pharmacogenes (CYP2D6, CYP2C19, CYP2C9, SLCO1B1, ABCG2), with chapters dedicated to pharmacogenetic investigation of antidepressant response, statin-induced myotoxicity, and PPI (omeprazole) treatment failure, use of CPIC/PharmGKB evidence, genotyping and sequencing methods, and clinical actionability assessments."
7fce5184-2f64-446e-afc1-eff572407d77,2,url:https://doi.org/10.1176/appi.ajp.2017.17050550,2,10,Processed,"The article is explicitly focused on pharmacogenetics in psychiatry: it reviews genotyping methods (SNP/NGS), structural variants (star alleles/CNVs/hybrids), genotype-to-phenotype translation (activity scores), clinical evidence (RCTs, meta-analyses, cohort studies), guideline/actionability (CPIC, DPWG, FDA, PharmGKB), cost-effectiveness, and implementation challenges. Pharmacogenetic testing for CYP2D6 and CYP2C19 and its clinical usability is the central topic throughout."
4e0440d6-2bfd-494c-94a3-895f0ae8cb10,2,url:https://doi.org/10.1038/sj.mp.4001494,2,10,Processed,"The paper is centrally focused on pharmacogenetics: it investigates CYP2D6 genotypes and predicted metabolizer phenotypes, measures their effects on risperidone and 9‑hydroxyrisperidone pharmacokinetics, performs a meta‑analysis, and derives genotype‑based dose recommendations for different ethnic populations. Genotyping methods, allele frequencies, phenotype assignment, and clinical dosing implications are all core elements of pharmacogenetic research."
180bf923-40af-4453-8434-9ff14373b927,2,url:https://doi.org/10.3390/jcm9092890,2,10,Processed,"The article is a focused review of pharmacogenomics/pharmacogenetics: it evaluates knowledge, attitudes, barriers and implementation of PGx testing among physicians, pharmacists and students in the UAE, Arab and Middle Eastern region, discusses PGx applications, genes, guidelines (CPIC/PharmGKB), and educational/implementation issues — making pharmacogenetics the primary subject."
e8990700-39d1-42ff-9e10-7ac6eaeb1b52,2,url:https://doi.org/10.1002/cpt.2015,2,10,Processed,"This article is primarily a pharmacogenetics guideline: it systematically reviews CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genetic variation and provides genotype-based dosing and therapeutic recommendations for multiple antidepressants (CPIC guideline), making pharmacogenetics the central focus."
72a52505-84fb-4d3a-afad-0e443b8b14a1,2,url:https://doi.org/10.4088/JCP.08m04773blu,2,10,Processed,"The issue contains a full-length, focused article titled ""Pharmacogenomic Testing in Child and Adolescent Psychiatry"" that reviews pharmacokinetic and pharmacodynamic genetic variants, CPIC guidance, FDA labeling, clinical applications, limitations, and pediatric-specific considerations — i.e., it directly assesses pharmacogenetic approaches in detail."
f9bebbe8-ecb8-4151-af90-a6e9394eb4a8,2,url:https://doi.org/10.1080/17425255.2022.2160317,2,10,Processed,"The document is explicitly a medical policy on pharmacogenomics/gene testing for behavioral health. It discusses pharmacogenetic concepts (CYP enzymes, HLA), cites CPIC/FDA/APA guidance, lists specific gene–drug tests (CYP2D6, CYP2C19, CYP2B6, HLA-A/B), and defines coverage, clinical validity/utility requirements and testing criteria — i.e., it directly assesses pharmacogenetic approaches."
51f612e0-3e6c-4110-8099-a699687fff87,2,url:https://doi.org/10.1111/j.1365-2125.1996.tb00173.x,2,10,Processed,"The thesis is centered on pharmacogenetics — it investigates how genetic variation (CYP2D6, CYP2C19, CYP2C9, SLCO1B1, ABCG2, etc.) influences drug response (antidepressants, statins, omeprazole), uses genotyping, sequencing (Sanger, WES/WGS), CPIC evidence, eQTLs and reference cohorts, and assesses clinical actionability. Multiple chapters are devoted to pharmacogenetic analyses, interpretation and clinical application, making it primarily about pharmacogenetic approaches."
b7a5b9cf-e31a-4515-b4ab-0ad0c5920f8a,2,url:https://doi.org/10.1016/j.jmoldx.2018.01.011,2,10,Processed,"The manuscript is entirely focused on pharmacogenetics: it presents AMP Pharmacogenomics Working Group recommendations for clinical CYP2C19 genotyping allele selection (Tier 1/Tier 2), discusses allele function, population frequencies, clinical implications for drug response, available reference materials, testing platforms, and relation to CPIC/DPWG guidelines — all central pharmacogenetic topics."
5427ccd7-d432-412c-ad1b-2593f03eaf54,2,url:https://doi.org/10.1016/j.jad.2018.08.056,2,10,Processed,"The paper is primarily focused on pharmacogenomics: it is a systematic review and meta-analysis of randomized controlled trials evaluating pharmacogenomic (PGx) testing (including combinatorial and single-gene tests such as CYP2C19/CYP2D6) to guide antidepressant selection for major depressive disorder, assessing clinical outcomes (remission, response, adverse events). Thus pharmacogenetic approaches are the central topic."
7cc8413f-455b-42df-9cc0-4f2dc24b624f,2,url:https://doi.org/10.1055/s-2006-946705,2,10,Processed,"This doctoral thesis is explicitly focused on pharmacogenetics — its clinical application to explain drug response (ineffectiveness and adverse reactions) across multiple drug classes (antidepressants, statins, PPIs). It includes genotyping, haplotyping, whole-exome/whole-genome data, comparisons to reference cohorts, and assessment of clinical actionability using CPIC/evidence frameworks, so pharmacogenetics is the primary subject."
a992f6d0-0d22-4035-a315-5bdc961b43a6,2,url:https://doi.org/10.1016/S0140-6736(22)01841-4,2,10,Processed,"The paper is primarily about pharmacogenetics: it defines and analyzes ‘PGx drugs’ using PharmGKB/CPIC/DPWG recommendations, quantifies pediatric exposure to drugs with pharmacogenetic dosing/testing guidance, identifies key pharmacogenes (e.g., CYP2C9, CYP2D6, DPYD, CYP2C19, MT‑RNR1), evaluates potential drug–gene interactions, and discusses implications for PGx testing implementation in children."
edaacde2-66ad-42b0-8ba5-7ddf7da712a5,2,url:https://doi.org/10.1016/j.biopsych.2012.10.030,2,10,Processed,"The article is directly focused on pharmacogenomics/pharmacogenetic approaches—it's a systematic review and meta-analysis evaluating pharmacogenomic (PGx) testing to guide antidepressant treatment in major depressive disorder, discusses PGx decision-support tools, genes (CYP2D6, CYP2C19), guidelines (CPIC), and RCT evidence."
ca27515f-627c-4a40-adc0-8267eadfc464,2,url:https://doi.org/10.3389/fpsyt.2020.00094,2,10,Processed,"The editorial is primarily focused on pharmacogenetics/pharmacogenomics in psychiatry: it discusses CYP2C19 and CYP2D6 polymorphisms, genotype–phenotype relationships, clinical guidelines (CPIC, DPWG), implementation challenges, cost-effectiveness data, and ongoing pharmacogenomics trials and initiatives (e.g., PSY-PGx). The central theme is applying pharmacogenetic approaches to individualize psychiatric pharmacotherapy."
2d739497-eb13-4a3e-aea1-8ca79258c10c,2,url:https://doi.org/10.1038/s41397-021-00219-7,2,10,Processed,"The article is primarily a pharmacogenetics review: it systematically examines how CYP2C19 genetic variants (*2, *3, *17, etc.) affect metabolism, efficacy, safety, and dosing of SSRIs (citalopram, escitalopram, sertraline) in MDD patients, discusses allele frequencies, cites pharmacogenetic-guided treatment outcomes, and recommends pre-treatment pharmacogenetic testing. These elements make pharmacogenetic approaches the central focus."
52f43736-4af5-483f-8a99-1be3b3a12f93,2,"Arnone, D., Omar, O., Arora, T., Ostlundh, L., Ramaraj, R., Javaid, S., et al. (2023). Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analy",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes and inferred phenotypes in patients with antidepressant adverse reactions or ineffectiveness, applies CPIC guidelines to assess actionability, and discusses clinical utility of pharmacogenetic testing. The methods, results, and conclusions center on pharmacogenetic approaches."
fe06c1a4-7cf0-4d2e-9d2d-9f102112651c,2,"Bahramali, E., Firouzabadi, N., Yavarian, I., Shayesteh, M. R., Erfani, N., Shoushtari, A. A., et al. (2016). Inﬂuence of ACE gene on differential response to sertraline versus ﬂuoxetine in patients with major depression: A randomized controlled trial.Eur",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19, infers metabolizer phenotypes per CPIC guidelines, evaluates genotype–drug response (ADRs and ineffectiveness) for antidepressants, quantifies ‘actionable’ gene–drug pairs, and discusses clinical utility and implementation—all core pharmacogenetic topics."
46e76056-56be-48dd-9d20-eea9986dc517,2,"Bousman, C. A., Arandjelovic, K., Mancuso, S. G., Eyre, H. A., and Dunlop, B. W. (2019). Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials.Pharmacogenomics 20 (1), 37– 47. doi:10.2217/pgs-2018-0142",2,10,Processed,"This mini-review is centrally focused on pharmacogenetics in psychiatry: it evaluates CYP2D6/CYP2C19 genotyping and structural variant detection, genotype-to-phenotype translation, randomized trials and cohort evidence, guideline/actionability (CPIC/DPWG/FDA/PharmGKB), cost-effectiveness, and implementation challenges — i.e., the paper primarily assesses pharmacogenetic approaches."
67cc9775-5b64-44f8-9fed-7da42f605774,2,"Bousman, C. A., Forbes, M., Jayaram, M., Eyre, H., Reynolds, C. F., Berk, M., et al. (2017). Antidepressant prescribing in the precision medicine era: A prescriber ’s primer on pharmacogenetic tools. BMC Psychiatry 17 (1), 60. doi:10.1186/s12888-017-1230-",2,10,Processed,"The paper is focused on pharmacogenomics: it evaluates the feasibility, acceptability, and preliminary effectiveness of pharmacogenomic (PGx) testing (CYP2D6, CYP2C19, etc.) to guide antidepressant therapy in primary care, uses CPIC-guided recommendations, and reports a randomized wait-list trial design—i.e., it primarily assesses pharmacogenetic approaches."
c42bce2c-8335-4a2b-aa9d-cc06137385b5,2,"Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J., Kennedy, J. L., Muller, D. J., et al. (2014). Inﬂuence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 14 (2), 176– 181. doi:10.1038/t",2,10,Processed,"The paper’s primary focus is pharmacogenetics: it systematically assesses CYP2D6 and CYP2C19 genotypes/phenotypes in a case series of antidepressant responses, applies CPIC genotype-to-phenotype guidelines, examines gene–drug actionability (ADRs and ineffectiveness), and reports proportions of actionable pharmacogenetic pairs. The study’s methods, analyses, and conclusions are centered on pharmacogenetic evaluation and clinical utility."
64a6c8e9-b679-4dcf-8549-29252a174f67,2,"Brown, J. T., Schneiderhan, M., Eum, S., and Bishop, J. R. (2017). Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.Pharmacogenomics 18 (7), 601– 605. doi:10.2217/pgs-2017-0015",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19, translates genotypes to CPIC phenotype recommendations, analyzes gene–drug–response pairs in an antidepressant-treated cohort, assesses clinical actionability, and discusses implementation and limitations — all central pharmacogenetic topics."
d6b733cf-26d0-414e-a352-325e9a58d8f1,2,"Brown, L. C., Stanton, J. D., Bharthi, K., Maruf, A., Muller, D. J., and Bousman, C. A. (2022). Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective, controlled clinical trials.Clin. Pharmacol. The",2,10,Processed,"The article is explicitly and primarily focused on pharmacogenomics/pharmacogenetics in psychiatry: it reviews the emergence, evidence base, clinical implementation, and guidelines (CPIC, DPWG) for gene–drug pairs (e.g. CYP2C19, CYP2D6, HLA genes), presents a table of actionable drug–gene pairs, discusses clinical trials and implementation barriers, and outlines future pharmacogenomic and multi-omic directions. This makes pharmacogenetic approaches the central topic."
6c8d592c-9912-4ba7-851c-49437de8424e,2,"Brown, L., Vranjkovic, O., Li, J., Yu, K., Al Habbab, T., Johnson, H., et al. (2020). The clinical utility of combinatorial pharmacogenomic testing for patients with depression: A meta-analysis. Pharmacogenomics 21 (8), 559– 569. doi:10.2217/pgs-2019-0157",2,10,Processed,"The paper directly investigates pharmacogenetics — genotyping CYP2D6 and CYP2C19 in a clinical case series of antidepressant responses, infers phenotypes per CPIC, assesses gene–drug actionability, and reports proportions of actionable gene–drug–response pairs. Its primary focus is the clinical utility of pharmacogenetic testing."
e032346b-0378-48da-906c-8653571e6264,2,"Campos, A. I., Byrne, E. M., Mitchell, B. L., Wray, N. R., Lind, P. A., Licinio, J., et al. (2022). Impact of CYP2C19 metaboliser status on SSRI response: A retrospective study of 9500 participants of the Australian genetics of depression study.Pharmacoge",2,10,Processed,"The paper is primarily about pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes/phenotypes in a clinical case series of antidepressant adverse reactions and ineffectiveness, uses CPIC guidelines to assign gene–drug evidence levels, assesses actionability of genotypes for prescribing, and discusses clinical utility and limitations of pharmacogenetic testing."
86b79470-b92c-4214-a2b3-232ba7cbf743,2,"Campos, A. I., Mulcahy, A., Thorp, J. G., Wray, N. R., Byrne, E. M., Lind, P. A., et al. (2021). Understanding genetic risk factors for common side effects of antidepressant medications. Commun. Med. 1 (1), 45. doi:10.1038/s43856-021-00046-8",2,10,Processed,"The paper is centrally focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in patients with antidepressant adverse reactions or ineffectiveness, infers metabolizer phenotypes per CPIC guidelines, analyzes gene–drug–response pairs, and assesses clinical actionability of pharmacogenetic information. The study’s aims, methods and conclusions all directly evaluate pharmacogenetic approaches to antidepressant prescribing."
34326cce-d15f-4171-ab22-2d54ea599857,2,"Carvalho Henriques, B., Yang, E. H., Lapetina, D., Carr, M. S., Yavorskyy, V., Hague, J., et al. (2020). How can drug metabolism and transporter genetics inform psychotropic prescribing? Front. Genet. 11, 491895. doi:10.3389/fgene.2020.491895",2,10,Processed,"The editorial explicitly focuses on pharmacogenomics in psychiatry: it reviews pharmacogenetic polymorphisms (notably CYP2C19 and CYP2D6), discusses genotyping, guideline recommendations (CPIC, DPWG, FDA/EMA comparisons), clinical implementation, cost-effectiveness, and related research initiatives (e.g., PSY‑PGx). The paper is centrally about pharmacogenetic approaches."
4f835363-0520-4e27-8f66-8238c1a84ccc,2,"Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., et al. (2020). Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and Du",2,10,Processed,"The paper is centrally focused on pharmacogenetics: it reports consensus recommendations for translating CYP2D6 genotypes to metabolizer phenotypes (activity score systems, allele function assignments including CYP2D6*10, phenotype categories) and discusses implications for clinical pharmacogenetic guidelines, laboratory reporting, and drug-specific recommendations."
508c2d5d-0c6f-4184-93eb-da41ac738f19,2,"Cicali, E. J., Elchynski, A. L., Cook, K. J., Houder, J. T., Thomas, C. D., Smith, D. M., et al. (2021). How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: A tutorial. Clin. Pharmacol. Ther. 110 (3), 677– 687. doi:10.1002/cpt.2354",2,10,Processed,"The paper directly evaluates pharmacogenetic approaches — genotyping CYP2D6 and CYP2C19 in 52 cases, inferring phenotypes per CPIC guidelines, assessing gene–drug actionability for antidepressant adverse reactions and ineffectiveness, and discussing clinical utility and implementation. This makes pharmacogenetics the primary focus."
4fe55ea1-5862-43a3-abf7-0a8cedade782,2,"Cicali, E. J., and Wiisanen, K. (2022). The importance of phenoconversion when using the CYP2D6 genotype in clinical practice.Pharmacogenomics 23 (14), 749– 752. doi:10.1080/17425255.2022.2160317",2,10,Processed,"The paper is primarily about pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes/phenotypes in a clinical case series of antidepressant responses, assesses CPIC evidence levels, determines genotype 'actionability' for adverse reactions and ineffectiveness, and discusses clinical utility and implementation—all core pharmacogenetic topics."
b8a16e3a-6467-41db-b4e5-2533f0803c58,2,"Cipriani, A., Salanti, G., Furukawa, T. A., Egger, M., Leucht, S., Ruhe, H. G., et al. (2018b). Antidepressants might work for people with major depression: Where do we go from here?Lancet Psychiatry 5 (6), 461– 463. doi:10.1016/S2215-0366(18)30133-0",2,10,Processed,"The paper directly investigates pharmacogenetic approaches: genotyping CYP2D6 and CYP2C19 in a clinical case series, inferring metabolizer phenotypes per CPIC guidelines, assessing genotype–drug response 'actionability', and discussing clinical utility and implementation. The focus is explicitly on pharmacogenetics in antidepressant prescribing."
698d271b-b32b-4f5b-831f-611ef0861181,2,Clinical Pharmacogenetics Implementation Consortium (2021a). Genes-drugs. Retrieved from: https://cpicpgx.org/genes-drugs/.,2,10,Processed,"This is a CPIC guideline focused on pharmacogenetics—specifically CYP2D6, CYP2C19, CYP2B6, SLC6A4 and HTR2A genotypes and antidepressant dosing. It includes genotype-to-phenotype translation, evidence tables, dosing recommendations, testing considerations, and EHR/clinical decision support implementation, so the paper is primarily about pharmacogenetic approaches."
1cdd27a9-ccc7-41eb-bf45-53defcfc884e,2,Clinical Pharmacogenetics Implementation Consortium (2021b). Prioritization. Retrieved from: https://cpicpgx.org/prioritization/#ﬂowchart.,2,10,Processed,"This paper is primarily about pharmacogenetics: it assesses CYP2D6 and CYP2C19 genotypes/phenotypes in a clinical case series of antidepressant responses, applies CPIC evidence levels to gene–drug pairs, evaluates 'actionability' of genotypes for adverse reactions and ineffectiveness, and discusses clinical utility and implementation — all central pharmacogenetic themes."
a035fd48-2586-41bf-aef4-a749b1069499,2,"Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., et al. (2021). Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther. 110 ",2,10,Processed,"The article is centrally focused on pharmacogenetics: it analyzes real-world pharmacogenetic (PGx) test requests from general practitioners, the genes and drug–gene interactions tested, reasons for testing, panel vs single-gene use, and GP surveys about barriers to implementing PGx in primary care. The study's aim, methods, results and discussion all directly address pharmacogenetic approaches and their implementation."
b1947fdf-a93a-4ba3-9c7c-89b5dfab29e3,2,"Eugene, A. R. (2019). Optimizing drug selection in psychopharmacology based on 40 signiﬁcant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors.PeerJ 7, e7860. doi:10.7717/peerj.7860",2,10,Processed,"The paper’s primary focus is pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in patients with antidepressant adverse reactions or ineffectiveness, infers metabolizer phenotypes per CPIC guidelines, analyzes ‘actionability’ of gene–drug pairs, and discusses clinical utility and implementation of pharmacogenetic testing."
5621bb24-f162-4e9e-8b7b-9c781b9e0d8f,2,"Firouzabadi, N., Raeesi, R., Zomorrodian, K., Bahramali, E., and Yavarian, I. (2017). Beta adrenoceptor polymorphism and clinical response to sertraline in major depressive patients. J. Pharm. Pharm. Sci.20, 1– 7. doi:10.18433/J3W31F",2,10,Processed,"The study directly investigates pharmacogenetics: it tests associations between ACE gene polymorphisms (ACE I/D, rs4343, rs4291), their haplotypes and response to the antipsychotic risperidone in autistic children, using genotyping (PCR‑RFLP) and statistical association analyses of treatment outcomes. This is a primary pharmacogenetic research paper."
2c7b9bd0-352e-49f3-a0f6-ed7dc903cdaf,2,"Gaedigk, A., Casey, S. T., Whirl-Carrillo, M., Miller, N. A., and Klein, T. E. (2021). Pharmacogene variation consortium: A global resource and repository for pharmacogene variation.Clin. Pharmacol. Ther.110 (3), 542– 545. doi:10.1002/cpt.2321",2,10,Processed,"The paper is explicitly about pharmacogenetics: it presents ursaPGx, an R package for annotating pharmacogenetic ""star"" alleles from phased whole‑genome sequencing data, describes algorithms and implementation, benchmarks calls for pharmacogenes (CYP2C8/CYP2C9/CYP2C19/CYP2D6) against GeT‑RM and Cyrius, and relies on PharmVar definitions—making pharmacogenetics the primary focus."
b586db4a-2481-4756-bf2f-b0956bc94131,2,"Gaedigk, A., Ingelman-Sundberg, M., Miller, N. A., Leeder, J. S., Whirl-Carrillo, M., Klein, T. E., et al. (2018). The pharmacogene variation (PharmVar) consortium: Incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin. Pharm",2,10,Processed,"The paper is primarily about pharmacogenetics: it is a case report demonstrating pharmacogenetic testing (CYP2D6, CYP2C19, CYP3A5, MDR1, etc.), identification of a novel CYP2D6 allele (∗119), genotype-to-phenotype translation, discussion of drug–gene and drug–drug interactions, and how pharmacogenetic results informed precision psychiatry treatment decisions. It cites PharmVar, CPIC, and focuses on how genetic variation explained adverse events and guided therapy."
03447493-2677-4218-9991-3de2dd67b81f,2,"Gillman, P. K. (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol.151 (6), 737– 748. doi:10.1038/sj.bjp.0707253",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes/phenotypes in relation to antidepressant adverse reactions and ineffectiveness, applies CPIC guideline evidence levels, assesses clinical actionability of genotypes, and discusses implementation and clinical utility of pharmacogenetic testing."
9e61394e-d6eb-436b-ab2e-fdf5124effdd,2,"Gloor, Y., Lloret-Linares, C., Bosilkovska, M., Perroud, N., Richard-Lepouriel, H., Aubry, J. M., et al. (2022). Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants. Biomed. Pharmacother",2,10,Processed,"The paper is centrally focused on pharmacogenetics: it develops and compares phenotypic models combining genetic polymorphisms (activity scores, PM/EM/UM phenotypes) with drug–drug (inhibition) effects, discusses CPIC guidelines, dose-adjustment recommendations, and evaluates pharmacogenetic modeling approaches and assumptions — making pharmacogenetics the primary subject."
a1468772-6c42-4964-937b-f9682fd23009,2,"Hahn, M., and Roll, S. C. (2022). A collaborative approach in pharmacogenetic testing: Actionable genotypes of antidepressants and their avoidance in a retrospective study. J. Explor. Res. Pharmacol.doi:10.14218/JERP.2022.00054",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it evaluates CYP2D6 and CYP2C19 genotypes and genotype-inferred phenotypes (per CPIC) in a case series of antidepressant adverse reactions and ineffectiveness, analyzes gene–drug response pairs and their clinical actionability, and discusses implementation and clinical utility of pharmacogenetic testing."
a953e185-1c3d-49e1-aab1-714a5c4f7246,2,"Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., et al. (2012). Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry 2, e172. doi:10.1038/tp.2012.99",2,10,Processed,"The article directly investigates pharmacogenetics: it genotypes CYP2D6 and CYP2C19, infers metabolizer phenotypes per CPIC guidelines, assesses gene–drug response (ADRs/ineffectiveness) pairs, and evaluates clinical utility/actionability of pharmacogenetic information for antidepressant prescribing."
211a887f-51be-4fc7-9479-b4de60d28b89,2,"Hansen, M. R., Kuhlmann, I. B., Pottegard, A., and Damkier, P. (2017). Therapeutic drug monitoring of venlafaxine in an everyday clinical setting: Analysis of age, sex and dose concentration relationships. Basic Clin. Pharmacol. Toxicol. 121 (4), 298– 302",2,10,Processed,"The paper centrally examines pharmacogenetics—specifically CYP2D6 and CYP2C19 genotyping—and their association with antidepressant adverse reactions and ineffectiveness. It uses genotype-to-phenotype translation (CPIC guidelines), reports phenotype frequencies, evaluates actionability of gene–drug pairs, and discusses clinical utility, implementation and limitations—making pharmacogenetics the primary focus."
c4a4142f-bb0d-4860-b3fa-b8b7e67774cc,2,"He, Q., Yuan, Z., Liu, Y., Zhang, J., Yan, H., Shen, L., et al. (2017). Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenetics Genomics 27 (8), 279– 284. doi:10.1097/FPC.000",2,10,Processed,"The paper is centrally focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in patients with antidepressant adverse reactions or ineffectiveness, infers metabolizer phenotypes per CPIC guidelines, analyzes gene–drug–response pairs and ‘actionability’ of genotypes for prescribing, and discusses clinical utility and guideline implications. Pharmacogenetics is the primary topic throughout."
771a2c0f-319e-495e-a886-ee75622c3ef2,2,"Hicks, J. K., Bishop, J. R., Sangkuhl, K., Muller, D. J., Ji, Y., Leckband, S. G., et al. (2015). Clinical pharmacogenetics implementation,CClinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19, infers metabolizer phenotypes per CPIC guidelines, analyzes gene–drug–response pairs for antidepressants, assesses clinical actionability of pharmacogenetic results, and discusses implications for genotype-guided prescribing and ADR/ineffectiveness outcomes."
7095709c-ce88-4e46-bda7-dddaf4ccf9b9,2,"Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Muller, D. J., Shimoda, K., et al. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updat",2,10,Processed,"The paper directly addresses pharmacogenetics: it compares genotype-to-phenotype translations for CYP2D6 and CYP2C19 between a commercial pharmacogenetics lab (GeneSight) and CPIC guideline assignments, reports discrepancy rates (28.8% for CYP2D6, 32.2% for CYP2C19) from a retrospective chart review of 205 patients, and discusses implications for psychotropic prescribing and guideline implementation. This focus on genetic testing interpretation and clinical prescribing recommendations makes it centrally a pharmacogenetics study."
dd0d8874-e1d7-4e87-87cb-79e3c4635400,2,"Hitchman, L. M., Faatoese, A., Merriman, T. R., Miller, A. L., Liau, Y., Graham, O. E. E., et al. (2022). Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Paciﬁc peoples. Front. Genet. 13, 1016416. doi:10.3389/fgene.2022.1016416",2,10,Processed,"The study directly investigates a key pharmacogene (CYP2D6), characterises allele and haplotype diversity in Māori and Pacific populations using long-read sequencing, reports novel alleles, and discusses implications for metaboliser phenotype prediction and pharmacogenetic testing—i.e. it is squarely a pharmacogenetics study."
119d18fb-988c-4a3d-b3ae-77884a185cb3,2,"Hodgson, K., Tansey, K. E., Uher, R., Dernovsek, M. Z., Mors, O., Hauser, J., et al. (2015). Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacol. Berl. 232 (14), 2609– 2617. doi:10.1007/s00213-015-3898-x",2,10,Processed,"The study directly evaluates pharmacogenetic factors: Sanger sequencing of CYP2D6, CYP2C19, and CYP2C9, assignment of metabolizer phenotypes using CPIC guidelines, and testing associations between these pharmacogenes and antidepressant side-effect tolerability. The paper’s primary focus is on pharmacogenetics and its clinical implications for antidepressant prescribing."
1c123d67-e828-41a9-9ab2-422ab38c113d,2,"Jokovic ,D .,M i l o s a v l j e v i c ,F . ,S t o j a n o v i c ,Z . ,S u p i c ,G . ,V o j v o d i c ,D . ,U z e l a c ,B . ,e ta l . ( 2 0 2 2 ). CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efﬁcacy and tolerability.Psychi",2,10,Processed,"The paper is explicitly focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19, infers metabolizer phenotypes per CPIC guidelines, analyzes gene–drug–response pairs and the clinical actionability of pharmacogenetic results in antidepressant adverse reactions and ineffectiveness. Pharmacogenetics is the central subject of the study."
30ad25d7-381a-446b-94a7-20929a0d4333,2,"Jukic, M. M., Haslemo, T., Molden, E., and Ingelman-Sundberg, M. (2018). Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients.Am. J. Psychiatry175 (5), 463– 470. doi:10.1176/appi.ajp.20",2,10,Processed,"The presentation is primarily about pharmacogenetics in psychiatry: it discusses pharmacogenetic concepts, CYP gene panels (CYP2D6, CYP2C19, etc.), clinical guidelines (CPIC), drug-specific dosing implications (e.g., escitalopram, codeine), clinical trials and outcome data, cost analyses, and practical testing recommendations and cases — all focused on implementing PGx testing."
9ddc7575-8173-4017-9fcd-8d72bac670a1,2,"Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M. L., Licinio, J., Roots, I., et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry 9 (5), 442– 473.",2,10,Processed,"This study directly investigates pharmacogenetics: it genotypes CYP2D6 alleles, translates genotypes to metabolizer phenotypes (PM/IM/NM/UM), analyzes effects on risperidone pharmacokinetics, performs a meta-analysis across studies, and derives genotype‑based dose recommendations for different populations (Asian vs white). The primary focus is applying genetic variation in CYP2D6 to guide drug dosing."
43e15155-6bb5-4857-b589-c1c6f1c483d3,2,"Klomp, S. D., Manson, M. L., Guchelaar, H. J., and Swen, J. J. (2020). Phenoconversion of cytochrome P450 metabolism: A systematic review.J. Clin. Med.9 (9), 2890. doi:10.3390/jcm9092890",2,10,Processed,"The paper is a systematic review focused on phenotype–genotype mismatches (phenoconversion) of CYP450 enzymes, explicitly analyzing CYP2D6, CYP2C19, CYP3A5, etc., genotype-based predicted metabolizer phenotypes, and how nongenetic factors alter genotype-predicted drug metabolism. It discusses implications for pharmacogenetics-guided dosing and cites CPIC/DPWG guidelines — i.e., it is centrally about pharmacogenetic approaches and their clinical limitations."
bc4c8e69-7fdf-420f-9ff5-ccd72edb96fd,2,"Lobello, K. W., Preskorn, S. H., Guico-Pabia, C. J., Jiang, Q., Paul, J., Nichols, A. I., et al. (2010). Cytochrome P450 2D6 phenotype predicts antidepressant efﬁcacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder.J. Clin. ",2,10,Processed,"The paper directly investigates pharmacogenetics: it genotypes CYP2D6 and CYP2C19, assigns genotype-inferred phenotypes per CPIC guidelines, and analyzes their clinical utility/actionability in antidepressant adverse reactions and ineffectiveness. The entire study is centered on pharmacogenetic assessment and its implications for prescribing."
0b25c348-2bc8-4a77-ad96-18caebd0b4e4,2,"Lunenburg, C., Thirstrup, J. P., Bybjerg-Grauholm, J., Baekvad-Hansen, M., Hougaard, D. M., Nordentoft, M., et al. (2021). Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Transl. Psychiatry 11 (1),",2,10,Processed,"The paper directly investigates CYP2D6 and CYP2C19 genotypes and genotype‑inferred phenotypes in relation to antidepressant adverse reactions and ineffectiveness, uses CPIC guidelines for phenotype translation and actionability, and evaluates the clinical utility of pharmacogenetic testing — i.e., it is primarily about pharmacogenetics."
393dd539-3eb0-4017-b1ae-9d77ff59975d,2,"Maggo, S. D., Chua, E. W., Chin, P., Cree, S., Pearson, J., Doogue, M., et al. (2017). A New Zealand platform to enable genetic investigation of adverse drug reactions.N. Z. Med. J. 130 (1466), 62– 69.",2,10,Processed,"The study’s primary aim is pharmacogenetic: it genotypes CYP2C19 variants (CYP2C19*17 and the CYP2C:TG haplotype), infers metabolizer phenotypes, and tests their association with clinical response to omeprazole in GERD. It directly links genetic variation to drug metabolism, pharmacokinetics/phenotype inference, and clinical treatment failure, and discusses dosing implications — all core pharmacogenetics elements."
ee8dea05-8bc7-4b32-b062-d423199009bd,2,"Maggo, S., Kennedy, M. A., Barczyk, Z. A., Miller, A. L., Rucklidge, J. J., Mulder, R. T., et al. (2019a). Common CYP2D6, CYP2C9, and CYP2C19 gene variants, health anxiety, and neuroticism are not associated with self-reported antidepressant side effects.",2,10,Processed,"This paper directly investigates pharmacogenetic approaches: it genotypes CYP2D6 and CYP2C19 in a clinical case series, translates genotypes to CPIC phenotype recommendations, assesses actionability of gene–antidepressant pairs, and discusses clinical utility and implementation — making pharmacogenetics the central focus."
e169d23b-9f76-4081-8029-b125a9d8e040,2,"Maggo, S., Sycamore, K., Miller, A., and Kennedy, M. (2019b). The three ps: Psychiatry, pharmacy, and pharmacogenomics, a brief report from New Zealand. Front. psychiatry 10, 690. doi:10.3389/fpsyt.2019.00690",2,10,Processed,"The paper’s primary focus is pharmacogenetics: it genotypes CYP2D6 and CYP2C19, infers metabolizer phenotypes using CPIC guidelines, analyzes gene–drug–response pairs (ADRs and ineffectiveness) in an antidepressant-treated cohort, and evaluates the clinical utility/actionability of pharmacogenetic information."
45f919fa-7f18-4648-8f1d-bfd05a405c4e,2,"Morris, S. A., Alsaidi, A. T., Verbyla, A., Cruz, A., Macfarlane, C., Bauer, J., et al. (2022). Cost effectiveness of pharmacogenetic testing for drugs with clinical pharmacogenetics implementation consortium (CPIC) guidelines: A systematic review. Clin. ",2,10,Processed,"The article is primarily about pharmacogenomics/pharmacogenetic approaches: it explains pharmacogenomic testing methods (targeted vs panel), indications (pre-emptive, concurrent, reactive, incidental), specific gene–drug pairs (e.g. HLA-B*57:01, HLA-B*58:01, CYP2C19, TPMT, NUDT15, DPYD, CYP2C9/VKORC1), guideline sources (RCPA, CPIC), implementation issues, testing logistics, costs and reimbursement, and clinical challenges—all central aspects of assessing pharmacogenetic approaches."
aa4b4e97-b1f6-4cd5-9ed1-e5d8f29cc0f0,2,"Mostafa, S., Polasek, T. M., Bousman, C. A., Mueller, D. J., Shefﬁeld, L. J., Rembach, J., et al. (2022). Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing. Pharmacogenomics 2",2,10,Processed,"The editorial is primarily focused on pharmacogenetics/pharmacogenomics in psychiatry: it frames the Research Topic as “Pharmacogenetics of psychiatric disorders,” discusses PGx concepts (pharmacokinetics, CYP2D6, pharmacodynamics), describes a PGx benefit score (PGxBS), summarizes a systematic review/meta‑analysis of PGx‑guided antidepressant prescribing, and addresses clinical implementation challenges and evidence — all central to pharmacogenetic approaches."
ab19c607-0735-4e39-80c5-f312a117dee7,2,"Mrazek, D. A., Biernacka, J. M., O’Kane, D. J., Black, J. L., Cunningham, J. M., Drews, M. S., et al. (2011). CYP2C19 variation and citalopram response. Pharmacogenet Genomics 21 (1), 1– 9. doi:10.1097/fpc.0b013e328340bc5a",2,10,Processed,"The paper is explicitly focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in patients with antidepressant adverse reactions or ineffectiveness, applies CPIC genotype-to-phenotype guidelines, analyzes gene–drug-response pairs and 'actionability', and draws clinical conclusions about the utility of pharmacogenetic testing. Thus pharmacogenetics is the primary topic."
ece89878-35a9-4db8-9bf6-8fea51774ee2,2,"Nahid, N. A., and Johnson, J. A. (2022). CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin. Drug Metab. Toxicol. 18 (11), 769– 785. doi:10.1080/17425255.2022.2160317",2,10,Processed,"The entire administrative policy is dedicated to pharmacogenomics for behavioral health: background on gene–drug interactions (CYPs, MTHFR, HLA), discussion of clinical validity/utility, CPIC and other guideline recommendations, coverage decisions, specific CPT codes/panels, and extensive references to pharmacogenetic studies and guidance. It directly assesses pharmacogenetic approaches and their evidence base."
df74d238-f688-4b86-9c97-af9f450ffa89,2,"Nielsen, K. K., Brosen, K., Hansen, M. G., and Gram, L. F. (1994). Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther.55 (5), 518– 527. doi:10.1038/clpt.1994.65",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in a clinical case series (UDRUGS), translates genotypes to phenotypes per CPIC guidelines, analyzes gene–drug–response (ADR/ineffectiveness) pairs and actionability, and discusses clinical utility and implementation — all central pharmacogenetics topics."
8ee5824f-23f0-4515-b6d2-ae3524457bfb,2,"Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T., Rudolph, R. L., and Sellers, E. M. (1996). Venlafaxine oxidationin vitrois catalysed by CYP2D6.Br. J. Clin. Pharmacol.41 (2), 149– 156. doi:10.1111/j.1365-2125.1996.tb00173.x",2,10,Processed,"The paper directly investigates pharmacogenetics: genotyping CYP2D6 and CYP2C19 in a case series of antidepressant adverse reactions and ineffectiveness, uses CPIC phenotype translation, evaluates gene–drug actionability, and assesses clinical utility of pharmacogenetic information—making pharmacogenetics the primary focus."
9b614cee-3f5d-4faf-b488-ad90a8f40e31,2,"Pain, O., Hodgson, K., Trubetskoy, V., Ripke, S., Marshe, V. S., Adams, M. J., et al. (2021). Identifying the common genetic basis of antidepressant response. Biol. Psychiatry 2, 115– 126. doi:10.1016/j.bpsgos.2021.07.008",2,10,Processed,"The study is centrally focused on genetic predictors of antidepressant response (GWAS of remission and percent improvement), estimates SNP heritability, examines pharmacogenetic candidate genes (e.g., CYP2D6/CYP2C19) and discusses implications for pharmacogenetic testing and personalized treatment — i.e., it is primarily a pharmacogenetics investigation."
35eaded9-ae37-4247-9a66-97e5f7299687,2,"Penas-Lledo, E., Trejo, H., Dorado, P., Ortega, A., Jung, H., Alonso, E., et al. (2013). CYP2D6 ultrarapid metabolism and early dropout fromﬂuoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol. Psychiatry 18 (1), 8– 9. doi:10",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes/phenotypes in a clinical case series, applies CPIC guideline evidence levels, assesses actionability of genotype-informed prescribing for antidepressants, and discusses clinical utility and implementation—all central pharmacogenetic topics."
3c69066f-e561-4ca0-bb1a-d24c569f2fb9,2,"Pratt, V. M., Del Tredici, A. L., Hachad, H., Ji, Y., Kalman, L. V., Scott, S. A., et al. (2018). Recommendations for clinical CYP2C19 genotyping allele selection: A report of the association for molecular Pathology.J. Mol. Diagn20 (3), 269– 276. doi:10.1",2,10,Processed,"The study directly investigates pharmacogenetics: genotyping common functional CYP2C8, CYP2C9 and CYP2C19 variants, inferring metabolic phenotypes, and testing associations with NSAID cross-hypersensitivity in a large cohort. It discusses clinical pharmacogenetic implications (pre-emptive genotyping), cites CPIC/PGx guidelines, and centers on how genetic variation in drug-metabolizing enzymes affects adverse drug reactions."
8d23a277-58cf-4890-8287-f173a74a62f6,2,"Rosenblat, J. D., Lee, Y., and McIntyre, R. S. (2018). The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.J. Affect Disord.241, 484– 491. doi:10.1016/j.jad.2018.08.056",2,10,Processed,"The document is centrally focused on pharmacogenetics: it describes the GeneSight Psychotropic combinatorial pharmacogenomic test (genes, alleles, medications covered), reviews clinical evidence and guidelines (GUIDED trial, meta-analyses, FDA and professional society statements), discusses clinical utility/validity, and concludes on investigational status — i.e., it primarily assesses pharmacogenetic approaches to psychotropic medication selection."
cf262975-628c-493c-ad20-e0bc4bf68712,2,"Shams, M., Arneth, B., Hiemke, C., Dragicevic, A., Müller, M., Kaiser, R., et al. (2006). CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.J. Clin. Pharm. Ther. 31 (5), 493– 502. doi:10.1111/j.1365-2710.2006.00763.x",2,10,Processed,"The study directly investigates pharmacogenetics: it genotypes CYP2D6, CYP2C19, and CYP2C9 by Sanger sequencing, assigns metabolizer phenotypes using CPIC guidelines, and tests associations between these pharmacogenes and antidepressant side-effect tolerability. The design, methods, and conclusions center on pharmacogenetic influences on drug response."
4431b3f7-85c5-488b-bf3c-80136f794703,2,"Solomon, H. V., Cates, K. W., and Li, K. J. (2019). Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 271, 604– 613. doi:10.1016/j.psychres.2018.12.053",2,10,Processed,"The paper directly investigates pharmacogenetics: genotyping CYP2D6 and CYP2C19, inferring metabolizer phenotypes per CPIC guidelines, and assessing their clinical utility/actionability in antidepressant adverse reactions and ineffectiveness. The study focuses primarily on pharmacogenetic approaches and interpretation."
7c0b7e78-9142-487a-8a6b-a21dcd804246,2,"Stephan, P. L., Jaquenoud Sirot, E., Mueller, B., Eap, C. B., and Baumann, P. (2006). Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 de ﬁciency and low CYP 3A4/5 activity. Pharmacopsychiatry 39 (4), 150– 152. doi:10.1055/s",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it analyzes CYP2D6 and CYP2C19 genotypes/phenotypes in a clinical case series of antidepressant responses, applies CPIC guideline evidence levels, assesses genotype-derived actionability for ADRs and ineffectiveness, and discusses clinical utility and implementation—all central pharmacogenetics topics."
df357e04-1406-4570-9af4-da6f6fd9fedf,2,"Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implem",2,10,Processed,"The paper is centrally focused on pharmacogenetics: it describes ten years of DPYD pharmacogenetic testing implementation, variant panels, genotype-guided dosing guidelines (CPIC/DPWG/SIF-AIOM), genotyping technologies, phenotyping considerations, clinical decision support, and regulatory/reimbursement impacts—all core pharmacogenetic topics."
4faf8767-87dd-4e43-af00-0aed6d5f418c,2,"Tansey, K. E., Guipponi, M., Hu, X., Domenici, E., Lewis, G., Malafosse, A., et al. (2013). Contribution of common genetic variants to antidepressant response.Biol. Psychiatry 73 (7), 679– 682. doi:10.1016/j.biopsych.2012.10.030",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it evaluates CYP2D6 and CYP2C19 genotypes/phenotypes in patients with antidepressant adverse reactions or ineffectiveness, applies CPIC guideline evidence levels, assesses gene–drug actionability, and discusses clinical utility and implementation of pharmacogenetic testing."
64e49f13-1c8a-4aea-81c0-f8f7a1747393,2,"Taranu, A., Colle, R., Gressier, F., El Asmar, K., Becquemont, L., Corruble, E., et al. (2017). Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efﬁcacy in depressed patients treated in psychiat",2,10,Processed,"The paper is primarily focused on pharmacogenetics: it evaluates CYP2D6 and CYP2C19 genotypes/phenotypes in relation to antidepressant adverse reactions and ineffectiveness, uses CPIC guideline-based phenotype translation, assesses actionability of gene–drug pairs, and discusses clinical utility and implementation — all central pharmacogenetics topics."
d1edb535-8625-4755-804c-66ec9a9f4d64,2,"Thiele, L. S., Ishtiak-Ahmed, K., Thirstrup, J. P., Agerbo, E., Lunenburg, C., Muller, D. J., et al. (2022). Clinical impact of functional CYP2C19 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: A Danish cohort ",2,10,Processed,"The paper directly investigates pharmacogenetics: it genotypes CYP2D6 and CYP2C19 in a clinical case series of antidepressant responses, maps genotypes to CPIC phenotype recommendations, assesses actionability of gene–drug pairs, and discusses clinical utility and implementation — i.e., it is primarily about pharmacogenetic approaches."
311501a3-e487-4830-8ef1-7b9634ef2d7d,2,"Zastrozhin, M. S., Skryabin, V. Y., Petukhov, A. E., Torrado, M. V., Pankratenko, E. P., Zastrozhina, A. K., et al. (2021). Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.",2,10,Processed,"The article directly investigates pharmacogenetics: genotyping CYP2D6 and CYP2C19 in patients with antidepressant adverse reactions or ineffectiveness, maps genotype-inferred phenotypes to CPIC guideline evidence levels, assesses actionability of gene–drug pairs, and discusses clinical utility and implementation—making pharmacogenetics the primary focus."
d4e2bb30-5eb5-408c-a7a3-15e59fc7d1a2,1,"Allegra S, De Francia S, Comità S, Morgese MG and Polasek TM (2025) Editorial: Pharmacogenetics of psychiatric disorders. Front. Genet. 15:1523071. doi: 10.3389/fgene.2024.1523071",3,10,Processed,"The editorial is explicitly focused on pharmacogenetics/pharmacogenomics in psychiatry (title and content). It reviews PGx implementation (PGx benefit score), summarizes a systematic review/meta-analysis of PGx-guided antidepressant prescribing, discusses clinical challenges and study design issues, and includes mechanistic genomics work—making pharmacogenetics the primary topic."
25f4e905-1a49-4905-9623-1e777fe80a1c,1,"Biso, L., Aringhieri, S., Carli, M., Scarselli, M., and Longoni, B. (2024). Therapeutic drug monitoring in psychiatry: enhancing treatment precision and patient outcomes. Pharm. (Basel). May16, 17. doi:10.3390/ph17050642",3,10,Processed,"The editorial is primarily focused on pharmacogenomics in psychiatry: it defines PGx, discusses pharmacokinetic (e.g., CYP2D6) and pharmacodynamic genetic influences, presents a PGx benefit score (PGxBS), summarizes a meta-analysis of PGx-guided antidepressant prescribing, reviews implementation challenges, and examines molecular genetic mechanisms related to treatment — all directly assessing pharmacogenetic approaches."
9d21f81f-40ce-4110-99f2-435e49732b9b,1,"Brown, L. C., Stanton, J. D., Bharthi, K., Maruf, A. A., Müller, D. J., and Bousman, C. A. (2022). Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials.Clin. Pharmacol. ",3,10,Processed,"The article is a dedicated narrative review of pharmacogenomics/pharmacogenetics in psychiatry: it summarizes historical emergence, gene–drug pairs and CPIC/DPWG guidelines, evidence from clinical trials, implementation barriers and exemplars, and future multi-omic integrations. The paper’s primary focus is on assessing and implementing pharmacogenetic approaches."
7edb0e95-ed3a-410e-9b34-8e0756c379ab,1,"Mostafa, S., Polasek, T. M., Bousman, C. A., Müeller, D. J., Shefﬁeld, L. J., Rembach, J., et al. (2022). Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing. Pharmacogenomics 2",3,10,Processed,"The editorial is explicitly focused on pharmacogenetics/pharmacogenomics in psychiatry: it reviews PGx-guided antidepressant prescribing, describes a PGx benefit score for clinical implementation, summarizes a systematic review/meta‑analysis of PGx-guided treatment, discusses pharmacokinetic (e.g., CYP2D6) and pharmacodynamic genetic factors, and highlights challenges for clinical PGx implementation. Pharmacogenetics is the primary topic."
15f2408a-bb0d-40cf-9570-a32ed0e8fd01,1,"Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet.24, 350– 362. doi:10.1038/s41576-022-00572-8",3,10,Processed,"This is a comprehensive review focused squarely on pharmacogenomics/pharmacogenetics: it reviews genetic variation in pharmacogenes, mechanisms of gene–drug associations (pharmacokinetic and pharmacodynamic), clinical examples (CYP2D6, CYP2C19, HLA, DPYD, TPMT/NUDT15, warfarin), implementation strategies (pre-emptive genotyping, CPIC and other guidelines, RCTs and real‑world evidence), cost‑effectiveness and policy issues, and future methods (biobanks, rare variants, polygenic scores). The article directly assesses pharmacogenetic approaches across discovery, validation and clinical implementation."
59f67b55-5114-4ef1-a9e6-bd39d1757e00,1,"Smoller, J. W. (2014). Psychiatric genetics and the future of personalized treatment. Depress Anxiety. 31, 893– 898. doi:10.1002/da.22322",3,10,Processed,"This editorial is explicitly focused on pharmacogenomics/pharmacogenetics in psychiatry: it reviews PGx-guided antidepressant prescribing, introduces a PGx benefit score (PGxBS), discusses CPIC guideline-based testing, CYP2D6 and other pharmacokinetic/pharmacodynamic genes, summarizes a meta-analysis of PGx-guided treatment, and considers clinical implementation challenges — i.e., the paper is primarily about pharmacogenetic approaches."
cade8b8d-9657-4ffc-8e26-751f1b2656e6,1,"Barthélémy, D., Belmonte, E., Pilla, L. D., Bardel, C., Duport, E., Gautier, V., et al. (2023). Direct comparative analysis of a pharmacogenomics panel with PacBio hiﬁ®long-read and illumina short-read sequencing. J. Personalized Med. 13 (12), 1655. doi:1",3,10,Processed,"The article is primarily focused on pharmacogenetics/pharmacogenomics: it directly compares long‑read (PacBio HiFi) and short‑read (Illumina) sequencing approaches for a pharmacogenomics panel, evaluates key pharmacogenes (CYP2D6, UGT1A1, NAT2), analyzes haplotyping, CNVs, repeats and phasing, and discusses clinical phenotype/metabolizer implications and implementation in routine testing."
c071093a-5b90-45d0-9457-52a986cad16f,1,"Bettinotti, M. P., Ferriola, D., Duke, J. L., Mosbruger, T. L., Tairis, N., Jennings, L., et al. (2018). Characterization of 108 genomic DNA reference materials for 11 human leukocyte antigen loci: a GeT-RM collaborative project.J. Mol. Diagnostics 20 (5)",3,10,Processed,"The manuscript’s primary focus is pharmacogenetics: it describes GeT‑RM efforts to create and update characterized, publicly available DNA reference materials for PGx (and HLA), presents the consolidated PGx/HLA table and a searchable PGx tool, and details characterization of major pharmacogenes (CYP2C9, CYP2C19, CYP2D6, TPMT, NUDT15, DPYD, etc.), allele/star‑allele annotation, and implications for clinical PGx testing."
4445d977-969d-4582-b26a-8c3fc1da5869,1,"Bourgeois, J., Costa, E., Devos, C., Hulstaert, F., Luyten, J., Ombelet, S., et al. (2024). Gebruik van farmacogenetische tests in belgië. Health Services Research (HSR). Brussels, Belgium: Federaal Kenniscentrum voor de Gezondheidszorg. Report No.: 382AS",3,10,Processed,"The manuscript directly evaluates pharmacogenomic testing methods—comparing ONT adaptive sampling and the Twist long-read PGx panel—for accurate pharmacogenetic profiling (star-allele calling, CYP2D6 diplotyping, CPIC Level A genes, HLA typing, phasing). The primary focus and results pertain to pharmacogenetics, variant calling, and clinical PGx implementation."
e92ea4e7-32db-49b5-879f-d60d4b1e4523,1,"Bourgeois, J., Costa, E., Devos, C., Luyten, J., Ombelet, S., Thiry, N., et al. (2025). Unravelling the implementation of pharmacogenetic testing in Belgium.Eur. J. Clin. Pharmacol. 81 (5), 711–718. doi:10.1007/s00228-025-03816-8",3,10,Processed,"The paper is explicitly focused on pharmacogenomics/pharmacogenetics: it develops and benchmarks targeted long-read sequencing approaches (ONT adaptive sampling vs Twist long-read PGx panel) for pharmacogenomic profiling, examines star‑allele calling and diplotyping (notably CYP2D6), references CPIC Level A genes and GeT‑RM truth sets, and discusses clinical PGx implementation — making pharmacogenetics its primary subject."
9b2aa6f3-ff04-4983-8b8a-a97727c002ea,1,"Deserranno, K., Tilleman, L., Rubben, K., Deforce, D., and Van Nieuwerburgh, F. (2023). Targeted haplotyping in pharmacogenomics using Oxford nanopore Technologies’ adaptive sampling.Front. Pharmacol.14, 1286764. doi:10.3389/fphar.2023.1286764",3,10,Processed,"The manuscript directly evaluates pharmacogenomic (PGx) testing approaches: reanalyzing an Oxford Nanopore adaptive-sampling (ONT-AS) long‑read PGx panel, comparing it to the Twist long‑read PGx hybrid-capture panel (PacBio and ONT), assessing star-allele calling (notably CYP2D6), phasing, and clinical-panel coverage. The focus is squarely on methods for pharmacogenetic profiling and their clinical utility."
c009d1a4-034e-4c3d-810e-a793ec3c2028,1,"Desta, Z., El-Boraie, A., Gong, L., Somogyi, A. A., Lauschke, V. M., Dandara, C., et al. (2021). PharmVar GeneFocus: CYP2B6.Clin. Pharmacol. Ther.110 (1), 82–97. doi:10.1002/cpt.2166",3,10,Processed,"The manuscript is directly focused on pharmacogenomics/pharmacogenetics: it evaluates targeted PGx testing approaches (ONT adaptive sampling vs Twist long-read PGx panel), benchmarks star‑allele calling and diplotyping for key pharmacogenes (notably CYP2D6), and discusses CPIC Level A genes and clinical PGx implications."
1f4409e9-e1c8-4a1b-8830-351bbd65c185,1,"EMA (2018).Guideline on good pharmacogenomic practice. London, UK: European Medicines Agency. First version.",3,10,Processed,"This document is an EMA guideline specifically focused on pharmacogenomics/pharmacogenetics. It covers definitions, genetic variation (common/rare, HLA), analytical methods (genotyping, NGS, CNV, allele specificity), sample handling, quality assurance, phenotyping, clinical study design (exploratory and confirmatory), and implications for product information — all central to assessing pharmacogenetic approaches."
615c4732-1603-4ada-9d12-6abefd58c15d,1,"Gaedigk, A., Turner, A., Everts, R. E., Scott, S. A., Aggarwal, P., Broeckel, U., et al. (2019). Characterization of reference materials for genetic testing of CYP2D6 alleles: a GeT-RM collaborative Project. J. Mol. Diagnostics 21 (6), 1034–1052. doi:10.1",3,10,Processed,"The paper focuses directly on pharmacogenetics: comprehensive characterization of CYP2D6 alleles (including CNVs and hybrids), development of reference materials, assay validation, and implications for clinical pharmacogenetic testing and phenotype prediction."
67324ec8-c4dc-43b7-adee-18698c2bf8b4,1,"Gan, H. P. P., Han Lin, Y., Irfan Bin Hajis, M., Maulana, Y., Ng Qi Hui, A., Nathanael Ramanto, K., et al. (2025). Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping.medRxiv Preprint. doi:10.1101/2025.05.05.253",3,10,Processed,"The paper directly evaluates pharmacogenomic (PGx) approaches — comparing Oxford Nanopore adaptive sampling and the Twist long-read PGx panel — including benchmarking of star‑allele calling, variant calling, phasing, and performance on clinically relevant pharmacogenes (e.g., CYP2D6). It is primarily focused on methods and accuracy for pharmacogenetic profiling."
6a026116-b267-42be-b7f5-9dbaba517a5e,1,"Githup (2024). Nanoporetech. pod5-ﬁle-format. San Francisco, CA: Githup.",3,10,Processed,"The manuscript directly evaluates pharmacogenomic (PGx) testing methods—comparing Oxford Nanopore adaptive sampling and the Twist long‑read PGx panel—focusing on star‑allele calling, CYP2D6 typing, phasing, and performance across CPIC Level A pharmacogenes. It is primarily about pharmacogenetics."
8c0c51bc-db72-4a6d-a6dc-77bf23ad43c8,1,"Knezevic, C. E., Stevenson, J. M., Merran, J., Snyder, I., Restorick, G., Waters, C., et al. (2025). Implementation of integrated clinical pharmacogenomics testing at an academic Medical center.J. Appl. Laboratory Med.10 (2), 259–273. doi:10.1093/jalm/jfa",3,10,Processed,"The paper is explicitly focused on pharmacogenomics/pharmacogenetics: it develops and benchmarks targeted long-read PGx assays (ONT adaptive sampling vs Twist long‑read PGx panel), evaluates star‑allele calling, CYP2D6 diplotyping, variant phasing, and comparison to GeT‑RM and clinical PGx gene sets — i.e., it primarily assesses pharmacogenetic approaches."
7427754b-381c-4edb-adb1-701f47a8eab4,1,"Lai, S.-K., Luo, A. C., Chiu, I.-H., Chuang, H.-W., Chou, T.-H., Hung, T.-K., et al. (2024). A novel framework for human leukocyte antigen (HLA) genotyping using probe capture-based targeted next-generation sequencing and computational analysis. Comput. S",3,10,Processed,"The paper is explicitly focused on pharmacogenomics/pharmacogenetics: it compares targeted PGx approaches (ONT adaptive sampling vs. Twist long-read PGx panel), evaluates star-allele calling and diplotyping (notably CYP2D6), benchmarks CPIC Level A genes, and discusses clinical PGx testing implications—making pharmacogenetics the primary topic."
04550b14-a669-46d5-b5fb-7379f89f2404,1,"Lauschke, V. M., Zhou, Y., and Ingelman-Sundberg, M. (2024). Pharmacogenomics beyond single common genetic variants: the way forward. Annu. Rev. Pharmacol. Toxicol. 64 (1), 33–51. doi:10.1146/annurev-pharmtox-051921-091209",3,10,Processed,"The paper is explicitly focused on pharmacogenomics/pharmacogenetics: it evaluates targeted long‑read sequencing approaches (ONT adaptive sampling vs Twist long‑read PGx panel) for PGx profiling, star‑allele calling, CYP2D6 genotyping, CPIC Level A genes, and generation of PGx passports. The entire study and results center on pharmacogenetic testing methods and accuracy."
332a0c8f-cee2-4ca9-b393-2f17e8317b6a,1,"McDermott, J. H., Wolf, J., Hoshitsuki, K., Huddart, R., Caudle, K. E., Whirl-Carrillo, M., et al. (2022). Clinical pharmacogenetics implementation consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype.Clin. Pharmacol. Ther.111 (2)",3,10,Processed,"The article specifically surveys pharmacogenes and their evidence of drug–gene associations using CPIC, DPWG, and PharmGKB, ranks genes by clinical impact, and proposes a prioritized gene panel for pharmacogenetic testing—making pharmacogenetics the primary focus."
d458729c-28bb-454f-a9f5-5e25ec17ae76,1,"Oxord Nanopore Technologies (2025). Pharmacogenomic Oxford nanopore sequencing of the twist alliance long-read PGx panel. Oxord, UK: Oxord Nanopore Technologies.",3,10,Processed,"The paper is focused on pharmacogenomics: it develops and benchmarks targeted long‑read sequencing approaches (ONT adaptive sampling vs. Twist long‑read PGx panel) for PGx profiling, evaluates star‑allele calling and phasing (including CYP2D6 and other CPIC Level A genes), and discusses clinical PGx implications—making pharmacogenetics the primary topic."
8d26e9d3-5b71-4482-a6cc-c4a92b27b7eb,1,"PacBio (2023). Scalable HiFi sequencing with twist biosciences long read alliance panels. Menlo Park, California: PacBio.",3,10,Processed,"The paper describes development and evaluation of a pharmacogenomics (PGx) research panel: it targets 49 PGx genes (including CPIC and FDA PGx genes), assesses CPIC-relevant variants and star(*) allele diplotypes using PharmCAT and Pangu, compares calls to GeT‑RM reference samples, and discusses impacts on phenotype prediction and clinical utility. The focus is squarely on pharmacogenetic approaches and their assessment using long‑read sequencing."
4e89caf7-7615-4e3c-be4c-15cbb10627af,1,"Pereira, N. L., Cresci, S., Angiolillo, D. J., Batchelor, W., Capers, Q., Cavallari, L. H., et al. (2024). CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientiﬁc statement from the American heart association.Circulation 150 (6), e129–e150. ",3,10,Processed,"The study explicitly incorporates CYP2C19 genotyping (loss-of-function alleles) via the ABCD-GENE score and stratifies outcomes and P2Y12 selection (clopidogrel vs ticagrelor) by that score. It performs genotype-informed analyses and evaluates genotype-guided antiplatelet strategy effectiveness and safety, making pharmacogenetics a primary focus."
8e5d33ad-7c48-4739-997c-66e69ee88ed0,1,"Pratt, V. M., Cavallari, L. H., Fulmer, M. L., Gaedigk, A., Hachad, H., Ji, Y., et al. (2024). DPYD genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, American college of medical genetics and genomics,",3,10,Processed,"This article is centrally focused on pharmacogenetics: it provides joint consensus recommendations for DPYD genotyping for clinical pharmacogenomic testing, discusses variant functional effects, allele frequency, testing tiers, reference materials, testing platforms, phenotype implications for fluoropyrimidine toxicity, and references CPIC/DPWG guidelines — all core pharmacogenetic topics."
b23855d9-eaa1-4fdb-b9b8-82338cf0347f,1,"Rubben, K., Tilleman, L., Deserranno, K., Tytgat, O., Deforce, D., and Van Nieuwerburgh, F. (2022). Cas9 targeted nanopore sequencing with enhanced variant calling improves CYP2D6-CYP2D7 hybrid allele genotyping. PLoS Genet. 18 (9), e1010176. doi:10.1371/",3,10,Processed,"The paper focuses on genotyping the pharmacogene CYP2D6 (and CYP2D6–CYP2D7 hybrids), developing an enrichment/sequencing assay and analysis pipeline (nCATS–CoLoRGen) to improve detection and phasing of variants relevant to drug metabolism. It explicitly frames work in the pharmacogenetics context, discusses star‑alleles, enzyme function prediction, and clinical genotyping limitations, so it is directly and primarily about pharmacogenetic approaches."
415aa61c-0855-48dd-9cfb-c732de88a814,1,"Swen, J. J., van der Wouden, C. H., Manson, L. E. N., Abdullah-Koolmees, H., Blagec, K., Blagus, T., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover imp",3,10,Processed,"This paper is primarily about pharmacogenetics: it reports a large, multicentre, cluster‑randomised crossover implementation study of a pre‑emptive 12‑gene pharmacogenetic panel (the PGx‑passport) used to guide prescribing. The study evaluates clinical utility (reduction in clinically relevant adverse drug reactions), implementation across seven countries, DPWG‑based recommendations, and uptake — all core pharmacogenetics topics."
b47518a0-0d3e-4d5c-99a5-61710bc9d387,1,"Tafazoli, A., Guchelaar, H.-J., Miltyk, W., Kretowski, A. J., and Swen, J. J. (2021). Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice. Front. Pharmacol. 12, 693453. doi:10.3389/fphar.2021.693453",3,10,Processed,"The paper is focused on pharmacogenomics/pharmacogenetics: it reviews use of next-generation sequencing for PGx testing in clinical practice, discusses actionable pharmacogenes (CYP2D6, UGT1A1, HLA, etc.), variant types (SNV, InDel, CNV), interpretation tools, guidelines (CPIC, DPWG), and clinical implementation challenges — i.e., it is primarily about pharmacogenetic approaches."
c9ee6f1a-61c9-4d3f-8058-b3abd8563a93,1,"Tayeh, M. K., Gaedigk, A., Goetz, M. P., Klein, T. E., Lyon, E., McMillin, G. A., et al. (2022). Clinical pharmacogenomic testing and reporting: a technical standard of the American college of medical genetics and genomics (ACMG). Genet. Med. 24 (4), 759–",3,10,Processed,"The document is a dedicated medical coverage policy on pharmacogenetic testing. It defines pharmacogenetics, lays out coverage criteria, lists CPT/HCPCS codes, discusses clinical utility, FDA guidance, evidence/literature, and cites numerous pharmacogenetics studies and guidelines — i.e., the paper is primarily and directly about pharmacogenetic approaches."
f02511d4-7c77-466e-b73f-777e8ece3947,1,"Tremmel, R., Pirmann, S., Zhou, Y., and Lauschke, V. M. (2025). Translating pharmacogenomic sequencing data into drug response predictions — How to interpret variants of unknown signiﬁcance. Br. J. Clin. Pharmacol. 91 (2), 252–263. doi:10.1111/bcp.15915",3,10,Processed,"The manuscript is primarily focused on pharmacogenomics (PGx): it evaluates targeted long-read sequencing approaches for PGx profiling, benchmarks Oxford Nanopore adaptive sampling against the Twist long‑read PGx panel, and assesses star‑allele calling, phasing, and diplotyping for clinically important pharmacogenes (notably CYP2D6 and other CPIC Level A genes). The study’s aims, methods, and results directly address pharmacogenetic testing performance and clinical applicability."
ac191088-d359-47dc-b44a-a5ae7b397c53,1,"Turner, A. J., Nofziger, C., Ramey, B. E., Ly, R. C., Bousman, C. A., Agúndez, J. A., et al. (2023). PharmVar tutorial on CYP2D6 structural variation testing and recommendations on reporting. Clin. Pharmacol. Ther. 114 (6), 1220–1237. doi:10.1002/cpt.3044",3,10,Processed,"The paper is centrally focused on pharmacogenetics/pharmacogenomics: it analyzes actionable PGx variants in 1,777 pediatric clinical exomes, compares PGx calling pipelines (DRAGEN vs PyPGx), reports phenotype/actionability frequencies (including CPIC/FDA-relevant genes and HLA alleles), and discusses clinical implementation and ancestry-specific PGx variation. Thus pharmacogenetic approaches are the primary subject."
e17cefe3-246f-458c-826e-0ebf2f59b366,1,"van der Lee, M., Allard, W. G., Bollen, S., Santen, G. W., Ruivenkamp, C. A., Hoffer, M. J., et al. (2020). Repurposing of diagnostic whole exome sequencing data of 1,583 individuals for clinical pharmacogenetics. Clin. Pharmacol. Ther. 107 (3), 617–627. ",3,10,Processed,"The manuscript is explicitly and primarily about pharmacogenomics/pharmacogenetic approaches: it compares targeted long-read sequencing strategies (ONT adaptive sampling and Twist long‑read PGx panel) for pharmacogenomic profiling, evaluates star‑allele calling, CYP2D6 diplotyping, variant phasing, and benchmarking against GeT‑RM and Twist data. The title, keywords, methods, and results all center on PGx testing and implementation."
9e302771-32ce-4421-8f5e-e9321679901a,1,"van der Lee, M., Allard, W. G., Vossen, R. H., Baak-Pablo, R. F., Menafra, R., Deiman, B. A., et al. (2021). Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Sci. Transl. Med. 13 (603), eabf3637. doi:10.1126/scitr",3,10,Processed,"The paper is primarily focused on pharmacogenomics/pharmacogenetics: it compares targeted long‑read sequencing approaches (ONT adaptive sampling vs Twist long‑read PGx panel) for PGx profiling, evaluates star‑allele calling (notably CYP2D6), benchmarks against GeT‑RM and CPIC Level A genes, and discusses clinical PGx testing implications."
d48a15a5-d5fd-47b3-88a1-f39bdaadae4a,1,"Zhou, Y., Tremmel, R., Schaeffeler, E., Schwab, M., and Lauschke, V. M. (2022). Challenges and opportunities associated with rare-variant pharmacogenomics.Trends Pharmacol. Sci. 43 (10), 852–865. doi:10.1016/j.tips.2022.07.002",3,10,Processed,"The paper is centrally focused on pharmacogenomics/pharmacogenetics: it reviews long‑read sequencing applications, analytical strategies, challenges, and future perspectives specifically for pharmacogenomic testing, discusses core pharmacogenes (e.g., CYP2D6, CYP2C19, NUDT15, HLA), diplotype/phasing, star‑allele calling, and clinical implementation—making pharmacogenetics the primary subject."
098961ab-d866-4ede-9d0e-45c0a2a1e9c4,1,"ZonMw (2025). Gehonoreerde projecten personalised medicine . Den Haag, Netherlands: ZonMw. Available online at: https://www.zonmw.nl/nl/artikel/gehonoreerde-projecten-personalised-medicine.",3,10,Processed,"The manuscript is squarely focused on pharmacogenomics/pharmacogenetics: it evaluates targeted PGx testing strategies (ONT adaptive sampling vs Twist long-read PGx panel), benchmarked star‑allele/diplotype calling (including CYP2D6), variant phasing, and implications for clinical PGx profiling. The central aim and results directly address pharmacogenetic approaches."
fd116026-18b7-4399-818b-ce8e94f6a5d5,1,"5. Smith TR, Kearney E, Hulick PJ, Kisor DF. History repeats itself: the family medi-cation history and pharmacogenomics. Pharmacogenomics. 2016;17(7):669–78. https:/ /doi.or g/10.22 17/p gs-2015-0015.",3,10,Processed,"The article is a pharmacogenetics-focused case report: it uses a PGx panel to evaluate CYP2B6 and CYP2D6 variants across three generations, interprets genotype-predicted phenotypes, discusses implications for propofol and opioid (codeine/tramadol) management, cites CPIC/DPWG guidance and PharmGKB evidence levels, and advocates integrating PGx into family medication history — thus the paper’s primary subject is pharmacogenetic approaches."
47acbbed-fc5a-4c3c-b852-07eeea34974d,1,7. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999;56(4):247–58.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 3 4 / j . 1 3 9 9 - 0 0 0 4 . 1 9 9 9 . 5 6 0 4 0 1 . x     .,3,10,Processed,"This case report is centered on pharmacogenetics: it describes preemptive PGx panel testing (100 variants in 30 genes), reports genotype→phenotype assignments for CYP2D6 and CYP2B6 (and other genes), uses those results to validate a family medication history and to guide perioperative analgesic/anesthetic decisions, and discusses CPIC/DPWG guidance and evidence levels for drug–gene interactions. The primary focus and methods are pharmacogenetic assessment and clinical application."
5a57043b-6c0a-4ba5-8ef6-bff7f46fe5e2,1,"8. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–9.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 9 7 / 0 0 0 0 8 5 7 1 - ",3,10,Processed,"The study explicitly investigates pharmacogenetics: genotyping candidate PGx (pharmacogenetic) variants (24 SNVs) in genes affecting metformin pharmacokinetics and pharmacodynamics (e.g., SLC22A2, PCK1) and testing their association with metformin efficacy and adverse drug reactions in T2D patients. The primary aim, methods, and conclusions center on PGx determinants of drug response, making it fully relevant to pharmacogenetic approaches."
6b34d033-05c5-43a4-acc3-c392b58fbd58,1,9. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529–37. https:/ /doi.or g/10.10 56/N EJMra020021.,3,10,Processed,"The article is primarily a pharmacogenetics case report: it centers on preemptive PGx panel testing across three generations, analyzes CYP2B6 and CYP2D6 genotypes/phenotypes, interprets drug–gene interactions (propofol, codeine, tramadol), references CPIC/DPWG guidance and PharmGKB evidence levels, and discusses using PGx to validate family medication history and guide perioperative therapy."
d75a9350-e41e-430e-84f4-50ee2f6ef6dd,1,"10. Holtzman NA, Marteau TM, Engl. J Med. 2000;343(2):141–4.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 5 6 / N E J M 2 0 0 0 0 7 1 3 3 4 3 0 2 1 3     .",3,10,Processed,"The article is primarily about pharmacogenetics: it reports a family case series using a 30-gene PGx panel (including CYP2D6, CYP2B6, ABCB1, OPRM1, COMT), interprets genotype-predicted phenotypes, references CPIC/DPWG guidance, and shows how PGx results validated (or refuted) suspected drug-gene interactions and informed perioperative analgesic/anesthetic decisions."
dd7fb5a0-c57d-438d-bfb3-8f464b1eb9a5,1,"12. Chairman, Verma DR, Wee PMYK, et al. Pre-operative Assessment and Patient Preparation - the role of the anaesthetist. Association Anaesthetists Great Br Irel. 2010. https:/ /doi.or g/10.21 466/ g.PAAPP-T.2010.",3,10,Processed,"The paper is a case report focused on pharmacogenetics: it describes preemptive PGx panel testing (CYP2B6, CYP2D6 and other genes) across a family, interprets genotype-predicted phenotypes, evaluates drug–gene interactions (propofol, codeine, tramadol), references CPIC/DPWG guidance and PharmGKB evidence levels, and uses PGx results to guide perioperative medication decisions — i.e. the core topic is pharmacogenetic assessment."
e2cf369c-61c7-48dc-bd0f-ff3a94fc4443,1,"13. Gray CE, Baruah-Young J, Payne C. Preoperative assessment in patients pre-senting for elective surgery. Anaesth Intensive Care Med. 2021;22(10):597–602. https:/ /doi.or g/10.10 16/j .mpaic.2021.07.005.",3,10,Processed,"This article is primarily about pharmacogenetics: it reports a family case series using a commercial PGx panel (100 variants/30 genes), interprets CYP2B6 and CYP2D6 genotypes into phenotypes, applies CPIC/DPWG guidance and PharmGKB evidence to perioperative analgesic/anesthetic decisions, and discusses using PGx to validate family medication history and inform clinical care (including limitations of the panel). The focus and analyses are squarely on PGx approaches and their clinical implementation."
e3bcc584-4de9-4697-b233-4938608c56ec,1,"14. Litman RS, Joshi GP . Malignant hyperthermia in the ambulatory surgery center: how should we prepare? Anesthesiology. 2014;120(6):1306–8.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 9 7 / A L N . 0 0 0 0 0 0 0 0 0 0 0 0 0 2 5 6     .",3,10,Processed,"The paper is primarily about pharmacogenetics: it reports PGx panel testing across three generations of a family, interprets CYP2B6 and CYP2D6 genotypes/phenotypes, relates results to drug-gene interactions (propofol, codeine, tramadol), cites CPIC/DPWG guidance, and discusses how PGx informed perioperative medication decisions and validation of self‑reported family medication history."
92694126-492d-45a7-87d4-b3c34bd86332,1,"15. Janssens ACJW, Henneman L, Detmar SB, et al. Accuracy of self-reported family history is strongly influenced by the accuracy of self-reported personal health status of relatives. J Clin Epidemiol. 2012;65(1):82–9.  h t t  p s : /  / d o  i .  o r g / ",3,10,Processed,"The manuscript is a case report centered on pharmacogenetics: it describes preemptive and family-wide PGx panel testing (CYP2B6, CYP2D6 and other PGx genes), interpretation of genotypes to predicted phenotypes, discussion of CPIC/DPWG guidance and PharmGKB evidence levels, and application of PGx results to perioperative medication decisions and validation of family drug-related problems. The primary focus is PGx approaches and their clinical use."
7ca115fb-62e1-4c98-bb02-019b61e05454,1,16. Hastrup JL. Inaccuracy of family health information: implications for preven-tion. Health Psychol. 1985;4(4):389–97.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 3 7 / / 0 2 7 8 - 6 1 3 3 . 4 . 4 . 3 8 9     .,3,10,Processed,"This case report is primarily focused on pharmacogenetics: it describes preemptive and reactive PGx panel testing (100 variants in 30 genes), interpretation of CYP2B6 and CYP2D6 genotypes/phenotypes, use of CPIC/DPWG guidance, and how PGx results validated (or refuted) suspected drug-gene interactions and informed perioperative medication decisions. The core topic and methods are explicitly pharmacogenetic."
c919ccf6-76be-4820-bce6-2d885d73d469,1,"18. Fiederling J, Shams AZ, Haug U. Validity of self-reported family history of cancer: a systematic literature review on selected cancers. Int J Cancer. 2016;139(7):1449–60. https:/ /doi.or g/10.10 02/i jc.30203.",3,10,Processed,"The article is a case report centered on pharmacogenetics: it describes preemptive and reactive PGx panel testing (CYP2D6, CYP2B6 and others) across a family, interprets genotypes/phenotypes, uses results to guide perioperative analgesia/anesthesia decisions, discusses drug–gene interactions, PGx guidelines (CPIC/DPWG/PharmGKB), and the role of PGx in validating family medication history—making pharmacogenetics the primary focus."
615412bd-9d20-4161-9aa7-2b3ce1fe410e,1,"19. Hull LE, Natarajan P . Self-rated family health history knowledge among all of us program participants. Genet Med. 2022;24(4):955–61.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 1 6 / j . g i m . 2 0 2 1 . 1 2 . 0 0 6     .",3,10,Processed,"The paper is fundamentally about pharmacogenetics: it reports a family case series using a 30-gene PGx panel (including CYP2D6 and CYP2B6), interprets genotypes to predicted metabolizer phenotypes, discusses drug–gene interactions for propofol, codeine and tramadol, refers to CPIC/DPWG guidance, and uses PGx results to inform perioperative medication decisions and to validate self‑reported family medication history."
0e26dad1-0ad2-4a88-a5c2-c4a186e10452,1,20. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Phar-macol. 2001;52(4):345–7. https:/ /doi.or g/10.10 46/j .0306-5251.2001.01498.x.,3,10,Processed,"This case report centers on pharmacogenetics: it describes PGx panel testing across a family, interprets CYP2B6 and CYP2D6 genotypes/phenotypes, discusses PGx-guided perioperative medication decisions and relevant CPIC/DPWG guidelines, and uses PGx to validate family medication history—making pharmacogenetics the primary focus."
eda8a2a8-66cc-4d03-b503-7ffd8b147c02,1,"21. González-Covarrubias V, Lozano K, Texis T et al. Pharmacogenomics: current actionable variants. Rev Invest Clin. 2020;73(3).",3,10,Processed,"This case report is centered on pharmacogenetics: it describes preemptive and reactive PGx panel testing across three generations, interprets CYP2D6 and CYP2B6 genotypes/phenotypes, uses PGx results to guide perioperative analgesic/anesthetic choices, discusses PGx evidence/guidelines (CPIC, DPWG, PharmGKB), and explicitly proposes integrating PGx with family medication history—therefore the paper is primarily about pharmacogenetic approaches."
008a81c1-b213-4727-95aa-9a419d86273b,1,"22. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81(3):429–44. https:/ /doi.or g/10.10 38/s j.clpt.6100095.",3,10,Processed,"The case report is centrally focused on pharmacogenetics: it describes preemptive and reactive PGx panel testing across a family, interprets CYP2B6 and CYP2D6 genotypes/phenotypes, discusses gene–drug interactions (propofol, codeine, tramadol), cites CPIC/DPWG guidelines and PharmGKB, and uses PGx results to guide perioperative medication decisions and validate family medication history."
bb7e396e-f973-4317-8ca8-6adb59bcdf55,1,"23. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clini-cal Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–23. https:/ /doi.or g/10.10 ",3,10,Processed,"The paper is directly and primarily about pharmacogenetics: it describes CPIC’s consensus process (Delphi method) to standardize terminology for pharmacogenetic allele function and inferred phenotypes, addresses implementation in clinical reporting, EHRs, LOINC/HL7 coding, and clinical decision support, and is intended to improve clinical pharmacogenetics interoperability and guideline use."
f4c6e151-88a4-4730-997e-88f5b8290354,1,"24. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diver-sity. Pharmacogenomics J. 2005;5(1):6–13.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 3 8 / s j . t p j . 6",3,10,Processed,"This review is explicitly focused on pharmacogenomics/pharmacogenetics: it discusses germline and somatic pharmacogenomic biomarkers, CYP enzymes, HLA associations, DPYD/TPMT/SLCO1B1 and other pharmacogenes, rare variants and population specificity, NGS and long‑read technologies for genotyping, clinical implementation and trials. The paper centrally assesses pharmacogenetic approaches and their clinical implications."
62a0390c-bd72-4d5a-9efd-d1ffd121b08e,1,"25. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–96.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 1 4 6 / a n n u r e v . p h a r m t o x . 3 7 . 1 . 2 6 9     .",3,10,Processed,"The paper is primarily focused on pharmacogenetics: it reports a family case series using a 30-gene PGx panel to evaluate CYP2B6 and CYP2D6 (and other PGx-relevant genes), discusses genotype–phenotype interpretation, CPIC/DPWG guidance, and how PGx results informed perioperative medication decisions and validation of self-reported family drug-related problems."
a9a2ab9c-79ae-472a-b7b4-0e80210bdee2,1,"26. Wolf CR, Smith G, Smith RL, Pharmacogenetics. BMJ. 2000;320(7240):987–90. https:/ /doi.or g/10.11 36/b mj.320.7240.987.",3,10,Processed,"This case report is primarily focused on pharmacogenetics: it uses a 30-gene PGx panel to genotype a family, interprets CYP2B6 and CYP2D6 variants, discusses phenotype prediction (IM/PM), relates findings to perioperative drug selection (propofol, codeine, tramadol), and considers CPIC/DPWG guidance and evidence levels. The manuscript evaluates how PGx testing can validate family medication history and inform clinical decision-making, so pharmacogenetic approaches are central to the paper."
e60b778d-db69-4057-a98c-d55031daeda9,1,"27. Matic M, Nijenhuis M, Soree B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2022;30(10):1105–13. https:/ /doi.or g/10.10 38/s ",3,10,Processed,"The article is entirely focused on pharmacogenetics: it analyzes real-world PGx test requests by general practitioners (genes tested, panels vs single-gene tests), the drugs/drug groups prompting testing, reasons for testing (side effects, non-response, pre-therapy), and surveys GPs about experiences and barriers to PGx implementation in primary care. This makes pharmacogenetics the primary subject."
f8b43d24-3f75-45ce-99fb-717d00dc56e6,1,"28. Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implemen-tation Consortium Guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–96.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1",3,10,Processed,"The manuscript explicitly reviews pharmacogenomics/pharmacogenetics throughout: it discusses gene–drug pairs, genotype-guided dosing and CPIC guidelines, and provides numerous examples (TPMT, CYP2C19, DPYD, HLA‑B*57:01, SLCO1B1, UGT1A1, CYP2D6, etc.), implementation studies, and clinical implications for personalized emergency medicine — making pharmacogenetics the primary focus."
e8e53087-0fdd-4520-afe7-38db86641d51,1,"29. Landau R, Bollag LA, Kraft JC. Pharmacogenetics and anaesthesia: the value of genetic profiling. Anaesthesia. 2012;67(2):165–79.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 1 1 1 / j . 1 3 6 5 - 2 0 4 4 . 2 0 1 1 . 0 6 9 1 8 . x     .",3,10,Processed,"The case report centers on pharmacogenetics: preemptive PGx panel testing across three generations, interpretation of CYP2B6 and CYP2D6 genotypes/phenotypes, discussion of gene–drug interactions (propofol, codeine, tramadol), use of PGx to validate family medication history and guide perioperative medication decisions, and reference to CPIC/DPWG guidelines. The primary focus is the application and implications of pharmacogenetic testing."
c618f2b7-9ea8-459b-b3f2-21d62d502ec7,1,"31. Karwacki Z, Niewiadomski S, Rzaska M, Witkowska M. The effect of bispectral index monitoring on anaesthetic requirements in target-controlled infusion for lumbar microdiscectomy. Anaesthesiol Intensive Ther. 2014;46(4):284–8. https:/ /doi.or g/10.56 0",3,10,Processed,"The paper is primarily about pharmacogenetics: it reports a family case series using a commercial PGx panel to detect CYP2B6 and CYP2D6 variants, interprets genotype-to-phenotype results (IM/PM), compares findings across relatives, discusses implications for propofol and CYP2D6‑activated opioids, references CPIC/DPWG guidelines and PharmGKB evidence levels, and advocates integrating PGx testing into clinical decision‑making. Thus pharmacogenetic approaches are the central topic."
177d7cd3-78d5-43da-b080-28e2913ede05,1,"32. Restrepo JG, Garcia-Martín E, Martínez C, Agúndez JAG. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009;10(3):236–46.  h t t  p s : /  / d o  i .  o r g / 1 0 . 2 1 7 4 / 1 3 8 9 2 0 0 0 9 7 8 7 8 4 6 3 0 5     .",3,10,Processed,"This case report is centered on pharmacogenetics: it describes preemptive and reactive PGx panel testing across three generations, interprets CYP2B6 and CYP2D6 genotypes/phenotypes, links results to drug–gene interactions (propofol, codeine, tramadol), discusses guideline-based opioid recommendations, and uses PGx to validate family medication history and guide perioperative medication decisions. The primary focus and conclusions are about applying pharmacogenetic approaches in clinical care."
9ad6a6b7-1457-4b39-ba66-aaafecf1a425,1,"33. Michelet R, Van Bocxlaer J, Allegaert K, Vermeulen A. The use of PBPK modeling across the pediatric age range using propofol as a case. J Pharmacokinet Pharmacodyn. 2018;45(6):765–85.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 0 7 / s 1 0 9 2 8 - ",3,10,Processed,"The case report centers on pharmacogenetics: it describes preemptive and family-wide PGx panel testing, interpretation of CYP2B6 and CYP2D6 genotypes/phenotypes, use of PGx results to validate self-reported drug-related problems and to guide perioperative analgesic/anesthetic decisions, and discusses PGx evidence and guidelines. Thus the paper is primarily about pharmacogenetic approaches."
1662b3a6-e626-4e67-b5fa-700d77b3e2f5,1,"34. Mikstacki A, Skrzypczak-Zielinska M, Tamowicz B, Zakerska-Banaszak O, Szalata M, Slomski R. The impact of genetic factors on response to anaesthetics. Adv Med Sci. 2013;58(1):9–14. https:/ /doi.or g/10.24 78/v 10039-012-0065-z.",3,10,Processed,"The article is a focused narrative review of genetic determinants (SNPs/alleles) influencing propofol pharmacokinetics and pharmacodynamics. It discusses pharmacogenetic variants in UGT1A9, CYP2B6, CYP2C9, ABCB1 and GABA-related genes, their effects on dosing, metabolism, and clinical outcomes, and the clinical utility of pharmacogenomic testing — i.e., it is primarily about pharmacogenetics."
f79a2054-881e-454b-ad04-2f4c74854630,1,"35. Mourão AL, de Abreu FG, Fiegenbaum M. Impact of the cytochrome P450 2B6 (CYP2B6) gene polymorphism c.516G > T (rs3745274) on Propofol Dose Variability. Eur J Drug Metab Pharmacokinet. 2016;41(5):511–5.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 0 ",3,10,Processed,"The article is primarily about pharmacogenetics: it presents a case series using a PGx panel to investigate CYP2B6 and CYP2D6 variants, validate self-reported family drug-related problems, and guide perioperative analgesic/anesthetic decisions. It discusses PGx testing methods, specific gene–drug interactions (propofol, codeine, tramadol), references CPIC/DPWG guidance, and considers implementation implications, making pharmacogenetics the central focus."
53fba242-13a4-4f08-91f1-4c4566efa66d,1,"36. Mastrogianni O, Gbandi E, Orphanidis A, et al. Association of the CYP2B6 c.516G > T polymorphism with high blood propofol concentrations in women from northern Greece. Drug Metab Pharmacokinet. 2014;29(2):215–8. https:/ /doi.or g/10.21 33/d mpk.dmpk-1",3,10,Processed,"This is a focused review of pharmacogenetics: it systematically examines genetic polymorphisms (CYP2B6, UGT1A9, CYP2C9, ABCB1, GABA receptor genes, etc.) that affect propofol pharmacokinetics and pharmacodynamics and discusses clinical/pharmacogenomic testing implications, so the paper is primarily about pharmacogenetic approaches."
c436ee4b-ee60-46fd-92d6-1b63ea600888,1,"37. Kansaku F, Kumai T, Sasaki K, et al. Individual differences in pharmacokinet-ics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab Pharmacokinet. 2011;26(5):532–7. https:/ /doi.or g",3,10,Processed,"This is a focused review of pharmacogenetics: it systematically examines how genetic polymorphisms (CYP2B6, CYP2C9, UGT1A9, ABCB1, GABA receptor genes, etc.) affect propofol pharmacokinetics and pharmacodynamics, discusses clinical pharmacogenomic testing, and evaluates genotype-guided dosing—making pharmacogenetics the primary subject."
7057d753-caff-4c6f-b372-8055f8bc3d27,1,"38. Mikstacki A, Zakerska-Banaszak O, Skrzypczak-Zielinska M, et al. The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia. J Appl Genet. 2017",3,10,Processed,"This is a focused review of pharmacogenetics in anesthesiology—specifically genetic polymorphisms (UGT1A9, CYP2B6, CYP2C9, ABCB1, GABAA genes, etc.) affecting propofol pharmacokinetics and pharmacodynamics, discussion of genotype–phenotype studies, and clinical utility of pharmacogenomic testing. The article’s primary topic is pharmacogenetic approaches to propofol response."
1d6c63ad-de2d-44f3-a8f6-355a38869cf2,1,"39. Schwarz UI, Gulilat M, Kim RB. The role of Next-Generation sequencing in Pharmacogenetics and Pharmacogenomics. Cold Spring Harb Perspect Med. 2019;9(2):a033027. https:/ /doi.or g/10.11 01/c shperspect.a033027.",3,10,Processed,"The article is primarily a pharmacogenetics case report: it centers on preemptive and family-based PGx panel testing, interpretation of CYP2B6 and CYP2D6 genotypes/phenotypes, implications for anesthetic and opioid use, and discussion of PGx guidelines and evidence — all core pharmacogenetics topics."
b5abe11f-5b6a-40dd-a3cc-95f08e3a02a4,1,"41. Zhang Y, Li Y, Wang H, Cai F, Shen S, Luo X. Correlation of MDR1 gene poly-morphism with propofol combined with remifentanil anesthesia in pediatric tonsillectomy. Oncotarget. 2018;9(29):20294–303.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 8 6 3 2 ",3,10,Processed,"This narrative review is primarily about pharmacogenetics: it systematically examines how genetic polymorphisms (SNPs) in genes such as CYP2B6, UGT1A9, CYP2C9, ABCB1 and GABA receptor genes affect propofol pharmacokinetics and pharmacodynamics, summarizes clinical study findings, and discusses the clinical utility and implementation challenges of pharmacogenomic testing in anesthesiology."
aeebc198-4676-4a03-9dab-b013e4febd61,1,"42. Ren ZY, Xu XQ, Bao YP , et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18(2):131–52.",3,10,Processed,"The manuscript is a systematic review and meta-analysis of genetic single-nucleotide polymorphisms (OPRM1 A118G, CYP3A4/3A5, CYP2D6, ABCB1, COMT, etc.) and their effects on opioid analgesic efficacy, consumption, and side effects in postoperative pain — i.e., a direct pharmacogenetics study with discussion of clinical implications for individualized opioid therapy."
6bc2ef86-2f0d-457e-a5f6-d30982469505,1,"43. Desta Z, El-Boraie A, Gong L, et al. PharmVar GeneFocus: CYP2B6. Clin Phar-macol Ther. 2021;110(1):82–97. https:/ /doi.or g/10.10 02/c pt.2166.",3,10,Processed,"The article is centered on pharmacogenetics: it reports a family case series using a preemptive PGx panel, analyzes CYP2B6 and CYP2D6 (and other PGx-relevant genes), interprets genotype-predicted phenotypes, applies CPIC/DPWG guidance to perioperative medication decisions, and discusses the use of PGx testing to validate family medication history—thus the primary focus is pharmacogenetic approaches."
5fe38e34-1bd8-4ca0-9c3d-1ecf15681109,1,"44. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Phar-macogenet Genomics. 2001;11(5):399.",3,10,Processed,"The review is explicitly focused on pharmacogenetics: it analyzes CYP2B6 genetic polymorphisms, their functional mechanisms (splicing, expression, catalytic effects), substrate-dependent impacts, in vitro/in vivo and clinical pharmacokinetic evidence (e.g., efavirenz, bupropion, cyclophosphamide), genotype-guided dosing, and population allele frequencies — i.e., it is primarily about pharmacogenetic approaches and their clinical relevance."
941fe536-f6ea-4ab9-b8d4-e910ede566f1,1,"45. Lee GY, Yamada J, Kyololo O, Shorkey A, Stevens B. Pediatric Clinical Practice guidelines for Acute Procedural Pain: a systematic review. Pediatrics. 2014;133(3):500–15. https:/ /doi.or g/10.15 42/p eds.2013-2744.",3,10,Processed,"The article is primarily focused on pharmacogenetics: it reports preemptive and reactive PGx panel testing across a family, details genotypes/phenotype predictions (CYP2D6, CYP2B6 and others), discusses drug–gene interactions (propofol, codeine, tramadol), references CPIC/DPWG guidance, and shows how PGx results informed perioperative medication decisions and validation of family medication history."
8ecec0cf-8e15-4447-bb5a-94007f907131,1,"46. Chidambaran V, Costandi A, D’Mello A, PROPOFOL: A REVIEW OF, ITS ROLE IN PEDIATRIC ANESTHESIA AND SEDATION. CNS Drugs. 2015;29(7):543–63. https:/ /doi.or g/10.10 07/s 40263-015-0259-6.",3,10,Processed,"The article is a pharmacogenetics-focused case report: it performs and interprets a PGx panel (CYP2B6, CYP2D6 and others), reconstructs inheritance, compares genotypes to family drug-related problems, discusses PGx evidence, guidelines, and clinical implications for perioperative medication — i.e. the paper primarily assesses pharmacogenetic approaches."
79604128-40cf-46c2-9d0f-32944c90c599,1,"48. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7(3):154–79. https:/ /doi.or g/10.10 38/s",3,10,Processed,"This case report is primarily about pharmacogenetics: it describes preemptive and reactive PGx panel testing across a family, focuses on CYP2B6 and CYP2D6 genotype–phenotype interpretation, applies PGx results to perioperative medication decisions, discusses evidence levels (PharmGKB, CPIC/DPWG), testing methodology and limitations — all central pharmacogenetic topics."
5c9324c8-f692-444a-88ac-181a3ba6d2b1,1,50. PharmGKB. Clinical Annotations for propofol. 2024.  h t t  p s : /  / w w  w .  p h a  r m g k  b . o  r g  / c h e m i c a l / P A 4 5 1 1 4 1 / c l i n i c a l A n n o t a t i o n     . Accessed 08 Oct 2024.,3,10,Processed,"The article is fundamentally about pharmacogenetics: it describes preemptive and family-wide pharmacogenetic panel testing, interpretation of CYP2D6 and CYP2B6 (and other genes) results, use of PGx findings to validate self‑reported drug‑related problems and to guide perioperative analgesia/anesthesia decisions, and discussion of guidelines (CPIC/DPWG) and evidence levels. Pharmacogenetics is the primary focus throughout."
4bf12c12-952a-4218-a6a6-75d002ee6207,1,"51. Kim S, Hahn S, Jang M, jin, et al. Evaluation of the safety of using propofol for paediatric procedural sedation: a systematic review and meta-analysis. Sci Rep. 2019;9:12245. https:/ /doi.or g/10.10 38/s 41598-019-48724-x.",3,10,Processed,"This case report centers on pharmacogenetics: it describes preemptive and reactive PGx panel testing (CYP2D6, CYP2B6 and other genes), interpretation of genotypes/phenotypes, use of PGx results to validate family medication history and to inform perioperative drug selection and dosing, and discussion of PGx guidelines and evidence — making pharmacogenetics the primary focus."
a3442294-4b4a-4b51-b2a2-838ba248e248,1,"52. Newstead B, Bradburn S, Appelboam A, et al. Propofol for adult procedural sedation in a UK emergency department: safety profile in 1008 cases. BJA: Br J Anaesth. 2013;111(4):651–5. https:/ /doi.or g/10.10 93/b ja/aet168.",3,10,Processed,"The paper is centrally focused on pharmacogenetics: it reports preemptive PGx panel testing across a family, analyzes CYP2B6 and CYP2D6 (and other PGx loci), interprets genotype→phenotype, discusses PGx-guided perioperative medication recommendations and the role of PGx in validating family medication history and informing clinical decisions."
76ec27aa-bf11-4b62-9417-e766efacab2a,1,"53. Shi NJ, Zhang WX, Zhang N, Zhong LN, Wang LP . Correlation of MDR1 gene polymorphisms with anesthetic effect of sevoflurane–remifentanil following pediatric tonsillectomy. Med (Baltim). 2017;96(24):e7002.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0",3,10,Processed,"This case report centers on pharmacogenetics: it documents preemptive PGx panel testing (CYP2D6, CYP2B6 and others), genotype-to-phenotype interpretation, use of results to validate family medication history and guide perioperative analgesic/anesthetic decisions, and discusses PGx evidence, guidelines and limitations."
6c8fa09c-5fb7-486b-af29-070ab638c4da,1,"54. Thorn CF, Whirl-Carrillo M, Hachad H, et al. Essential characteristics of phar-macogenomics study publications. Clin Pharmacol Ther. 2019;105(1):86–91. https:/ /doi.or g/10.10 02/c pt.1279.",3,10,Processed,"The paper is centered on pharmacogenetics: it reports a family case series using a 30‑gene PGx panel to assess CYP2B6 and CYP2D6 variants, discusses drug–gene interactions (propofol, codeine, tramadol), interpretation of genotype‑predicted phenotypes, application of CPIC/DPWG guidance, and the use of PGx results to validate family medication history and guide perioperative medication decisions. Pharmacogenetics is the primary focus."
4dee6875-60b2-4abe-80d0-5c03fa3baeec,1,"55. Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374–80.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 9 7 / F P C . 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 7     .",3,10,Processed,"This case report is primarily focused on pharmacogenetics: it describes preemptive and family pharmacogenetic panel testing (CYP2B6, CYP2D6 and others), genotype-to-phenotype interpretation, implications for drug response (propofol, codeine, tramadol), and use of PGx results to validate family medication history and guide perioperative prescribing, citing CPIC/DPWG guidance and PharmGKB. Therefore pharmacogenetic approaches are the central subject."
ca07ab3f-2c95-4a0f-8c2e-e2a291a624b2,1,"56. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73. https:/ /doi.or g/10.10 38/c lpt.2011.34.",3,10,Processed,"This case report is centered on pharmacogenetics: it describes preemptive and reactive PGx panel testing across a family, reports CYP2D6 and CYP2B6 genotypes/phenotypes, discusses gene–drug interactions (propofol, codeine, tramadol), references CPIC/DPWG guidance, and uses PGx results to validate family medication history and inform perioperative prescribing."
eb4a15a5-b5ee-44c1-9f02-95a525dc90aa,1,"57. McCallum L, Lip S, Padmanabhan S. Chapter 18 - pharmacodynamic pharma-cogenomics. In: Padmanabhan S, editor. Handbook of Pharmacogenomics and Stratified Medicine. Academic; 2014. pp. 365–83.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 1 6 / B 9 7 8",3,10,Processed,"The article is primarily focused on pharmacogenetics: it describes preemptive and reactive pharmacogenetic panel testing across three generations, interprets CYP2B6 and CYP2D6 genotypes and predicted phenotypes, links results to anesthetic and opioid management (propofol, codeine, tramadol), discusses PGx evidence, guidelines (CPIC/DPWG), limitations of panels, and the clinical utility of PGx for validating family medication history and informing perioperative decisions."
ef2a23ec-8e0a-47a4-bf72-a0f4bccd1104,1,"61. Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37(2):148–52. https:/ /doi.or g/10.11 11/j .1365-2710.2011.01258.x.",3,10,Processed,"The article is a case report centered on pharmacogenetics: it documents preemptive and family pharmacogenetic panel testing (CYP2D6, CYP2B6, ABCB1, etc.), interpretation of genotypes/phenotypes, implications for drug-gene interactions, and use of PGx results to guide perioperative analgesic/anesthetic decisions and validate self‑reported family drug reactions. Pharmacogenetics is the primary topic."
3b260555-b24c-4fee-95df-a9d593eb0a22,1,"63. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken). 2010;62(6):791–9.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 0 2 ",3,10,Processed,"This case report is centered on pharmacogenetics: it describes preemptive and reactive PGx panel testing across three generations, analyzes CYP2B6 and CYP2D6 genotypes/phenotypes, discusses drug–gene interactions (propofol, codeine, tramadol), applies CPIC/DPWG guidance, and explicitly evaluates how PGx testing validates family medication history and informs perioperative medication decisions. Pharmacogenetics is the primary focus."
e6729734-666b-4621-ad32-f6b1bb6ebbcb,1,"64. Franic DM, Pathak DS. Communicating the frequency of adverse drug reac-tions to female patients. Ther Innov Regul Sci. 2000;34(1):251–72.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 1 7 7 / 0 0 9 2 8 6 1 5 0 0 0 3 4 0 0 1 3 4     .",3,10,Processed,"The paper is primarily about pharmacogenetics: it centers on a case series using a pharmacogenetic panel to evaluate CYP2B6 and CYP2D6 genotypes across a family, interprets genotype-predicted phenotypes, discusses drug–gene interactions (propofol, codeine, tramadol), cites CPIC/DPWG guidance, and uses PGx results to inform perioperative medication decisions and validate self-reported family drug-related problems."
de55e613-c99d-4946-a7f1-f86e95f87e90,1,67. Tharpe N. Adverse drug reactions in women’s Health Care. J Midwifery Women’s Health. 2011;56(3):205–13.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 1 1 1 / j . 1 5 4 2 - 2 0 1 1 . 2 0 1 0 . 0 0 0 5 0 . x     .,3,10,Processed,"The article is primarily focused on pharmacogenetics: it reports a family case series using a commercial pharmacogenetic panel (CYP2B6, CYP2D6 and others) to validate self-reported drug-related problems, interprets genotype-to-phenotype results, discusses clinical recommendations (perioperative anesthetic and analgesic choices) and the implications of PGx testing for family medication history and clinical decision-making."
a03c3a2c-f42c-4d64-a2da-30b5e1c23cee,1,"70. Theken KN, Lee CR, Gong L, et al. Clinical pharmacogenetics implementation Consortium (CPIC) Guideline for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 0 2 / c p ",3,10,Processed,"The article directly studies pharmacogenetics: it identifies 82 pediatric drugs with PGx guideline annotations linked to 24 genes, analyzes nationwide claims data to quantify pediatric exposure to PGx drugs, ranks implicated genes (e.g., CYP2C9, CYP2D6, DPYD, CYP2C19), and discusses implications for preemptive PGx testing in children. The study’s primary focus is assessing pharmacogenetic approaches and their potential implementation in paediatrics."
64817a16-ff88-4e99-aa02-5278ed6d35d2,1,[Accessed September 16 2016] PGx Gene-specific Information Tables for CYP2D6. <https://www.pharmgkb.org/page/cyp2d6RefMaterials>,3,10,Processed,"This CPIC guideline is explicitly focused on pharmacogenetics: it systematically reviews CYP2D6 genetic variation, interprets genotypes into activity scores/phenotypes, links genotype to ondansetron and tropisetron efficacy, and provides genotype-based therapeutic recommendations and implementation resources."
f36ca496-3451-4a8f-b666-0b78edbe2a3e,1,"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical pharmacology and therapeutics. 2008; 83:234–42. [PubMed: 17971818]",3,10,Processed,"The paper is primarily pharmacogenetic: it develops and validates CYP2D6 activity-score methods that integrate detailed genotyping (alleles, duplications) and co-medication (CYP2D6 inhibitors) to predict tamoxifen metabolism (endoxifen/NDM ratio). It directly addresses genotype–phenotype prediction and pharmacogenetic clinical application."
ee0b540e-8b38-459c-b6da-9750d0e14e0a,1,"Hicks JK, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical pharmacology and therapeutics. 2015; 98:127–34. [PubMed: 25974703]",3,10,Processed,"This is a CPIC guideline explicitly focused on pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes to assign metabolizer phenotypes and provides genotype-directed dosing recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and other TCAs), discusses allele function, activity scoring, therapeutic drug monitoring, drug–gene and drug–drug interaction considerations, and EHR implementation — i.e., the paper is primarily about pharmacogenetic approaches."
3124497e-0a4e-44f9-8ccf-f4d14e116ad7,1,[Accessed September 16 2016] PGx Gene-specific Information Tables for CYP2C19. <https://www.pharmgkb.org/page/cyp2c19RefMaterials>,3,10,Processed,"This article is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and their use to guide dosing and selection of tricyclic antidepressants. It systematically reviews genotype–phenotype relationships, describes genotype interpretation (star alleles, activity scores), provides gene-based dosing recommendations, addresses combined genotype effects, and discusses implementation and clinical decision support — i.e., it is primarily about pharmacogenetics."
35aa6c69-b027-4ef3-b0c0-ce8c0dbe90d8,1,"Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical pharmacology and therapeutics. 2011; 90:328–32. [PubMed: 21716271]",3,10,Processed,"This is a CPIC guideline focused explicitly on pharmacogenetics — it interprets CYP2D6 and CYP2C19 genotypes to provide gene-based dosing recommendations for tricyclic antidepressants, includes phenotype assignment, dosing tables, combinatorial guidance, and implementation considerations for genotype-guided prescribing."
48250fba-40f4-4f50-9b21-2dc7abb5a56d,1,"Sim SC, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical pharmacology and therapeutics. 2006; 79:103–13. [PubMed: 16413245]",3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and their impact on dosing and selection of tricyclic antidepressants. The paper reviews pharmacogenetic evidence, provides phenotype definitions, genotype-to-phenotype translation, and gene-based dosing recommendations and tables — i.e., it is primarily about pharmacogenetics."
eba9bd10-e3d4-4924-9cf9-4bfa62020600,1,"Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical pharmacology and therapeutics. 2012; 91:321–6. [PubMed: 22205192]",3,10,Processed,"This is a CPIC guideline focused specifically on pharmacogenetics — reviewing CYP2D6 and CYP2C19 genetic variation, linking genotypes to TCA pharmacokinetics and clinical outcomes, and providing gene-based dosing and implementation recommendations (including testing interpretation, phenotype assignment, and therapeutic drug monitoring). The paper’s primary purpose is pharmacogenetic-guided drug therapy."
5c062eba-2e30-45b8-b5cd-c61bd6b064e1,1,"de V os A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. The pharmacogenomics journal. 2011; 11:359–67. [PubMed: 20531370]",3,10,Processed,"The document is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and their impact on dosing of tricyclic antidepressants. It reviews genetic variants, phenotype assignment, genotype-based dosing recommendations, therapeutic drug monitoring, and implementation—i.e., it is primarily about pharmacogenetics."
b27582f0-411c-434d-8003-3df08c4ae1c8,1,Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British journal of pharmacology. 2007; 151:737–48. [PubMed: 17471183],3,10,Processed,"This CPIC guideline directly evaluates and provides genotype-based dosing recommendations for tricyclic antidepressants based on CYP2D6 and CYP2C19 variants. The paper is primarily focused on pharmacogenetics, including genotype-phenotype interpretation, dosing guidance, evidence review, combined genotype considerations, and implementation resources."
523c3681-55d3-42f1-b7ce-34ada6b71b9a,1,"Shimoda K, Jerling M, Bottiger Y , Yasuda S, Morita S, Bertilsson L. Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol. 1999; 19:393–400. [PubMed: 10505580]",3,10,Processed,"This document is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and their impact on dosing and selection of tricyclic antidepressants. It extensively discusses pharmacogenetic testing, allele/function interpretation, phenotype assignment, and genotype-guided dosing recommendations — i.e., it is primarily about pharmacogenetics."
0c3c04c9-13bc-4c5d-943b-6e8f9fdb2321,1,"Jiang ZP, et al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J Clin Pharmacol. 2002; 58:109–13. [PubMed: 12012142]",3,10,Processed,"This CPIC guideline is focused on pharmacogenetics: it reviews CYP2D6 and CYP2C19 genetic variation, links genotypes to TCA pharmacokinetics and clinical outcomes, and provides genotype-directed dosing recommendations and implementation guidance. The paper’s primary aim is applying pharmacogenetic approaches to tricyclic antidepressant therapy."
ecf0630b-fd92-4686-8704-c752ff4e7f2e,1,Watson CP. The treatment of neuropathic pain: antidepressants and opioids. The Clinical journal of pain. 2000; 16:S49–55. [PubMed: 10870740],3,10,Processed,"This CPIC guideline directly addresses pharmacogenetics: it systematically reviews CYP2D6 and CYP2C19 genetic variation, provides genotype-to-phenotype interpretation, and gives gene-based dosing and implementation recommendations for tricyclic antidepressants (including tables, evidence grading, and clinical decision support), so the paper is primarily about pharmacogenetic approaches."
05c00539-9f03-455c-80e6-81ca7e824a8a,1,"Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. European journal of cancer. 2008; 44:1078–82. [PubMed: 18439818]",3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and genotype-guided dosing of tricyclic antidepressants. It systematically reviews pharmacogenetic evidence, defines genotype-to-phenotype interpretation, and provides dosing recommendations and clinical decision support — i.e., it is primarily about pharmacogenetics."
5a34616c-e09c-47db-9f59-398247630156,1,"Rudorfer MV , Potter WZ. Metabolism of tricyclic antidepressants. Cellular and molecular neurobiology. 1999; 19:373–409. [PubMed: 10319193]",3,10,Processed,"This is a CPIC clinical guideline focused explicitly on pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes to guide dosing and selection of tricyclic antidepressants, includes genotype–phenotype assignments, dosing recommendations, and implementation considerations — i.e., the paper is primarily about pharmacogenetic approaches."
d8260fcd-bc83-4eb7-b842-c8fcb5a1c1dd,1,"Potter WZ, Zavadil AP 3rd, Kopin IJ, Goodwin FK. Single-dose kinetics predict steady-state concentrations on imipramine and desipramine. Archives of general psychiatry. 1980; 37:314–20. [PubMed: 7362419]",3,10,Processed,"This CPIC guideline is centrally focused on pharmacogenetics: it systematically reviews CYP2D6 and CYP2C19 genetic variation, explains genotype-to-phenotype interpretation, and provides gene-based dosing recommendations for tricyclic antidepressants (including tables for CYP2D6, CYP2C19, and combined genotypes). It directly addresses implementation of genotype-guided therapy and clinical decision support, so pharmacogenetics is the primary topic."
1f98a419-ff28-4990-aa2c-d3fecc7becb0,1,"Stingl JC, Brockmoller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Molecular psychiatry. 2012",3,10,Processed,"This CPIC guideline is squarely focused on pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes/diplotypes, assigns metabolic phenotypes, and provides genotype-directed dosing and clinical recommendations for tricyclic antidepressants (including single-gene and combined-gene guidance, implementation/EHR resources, and therapeutic drug‑monitoring advice)."
ffa86e63-a343-46fb-9f0d-e0b1463b0584,1,"Cooke RG, Warsh JJ, Stancer HC, Reed KL, Persad E. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clinical pharmacology and therapeutics. 1984; 36:343–9. [PubMed: 6467794]",3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and gene-guided dosing of tricyclic antidepressants. The document reviews pharmacogenetic evidence, defines genotype-to-phenotype interpretation, provides genotype-based dosing recommendations and implementation guidance, and explicitly addresses pharmacogenetic testing — making it primarily about pharmacogenetics."
e4f8638d-2537-414d-8223-fa47cb4e5e3c,1,"Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clinical pharmacology and therapeutics. 1998; 63:444–52. [PubMed: 9585799]",3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and genotype-directed dosing of tricyclic antidepressants. It directly addresses pharmacogenetic testing, phenotype assignment, and gene-based dosing recommendations, so the paper is primarily about pharmacogenetics."
67f55b2a-8243-4b0e-9d2c-158a26d3138f,1,"Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et biophysica acta. 2007; 1770:489–94. [PubMed: 17113714]",3,10,Processed,"This is a CPIC guideline focused specifically on pharmacogenetics: it reviews CYP2D6 and CYP2C19 genetic variation and provides genotype-directed dosing recommendations for tricyclic antidepressants, including phenotype assignment, dosing tables, combined genotype guidance, and implementation considerations."
cdb33caf-e24c-4087-8cfe-b1c987c2c6e5,1,"Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Therapeutic drug monitoring. 1985; 7:478–80. [PubMe",3,10,Processed,"This is a CPIC guideline specifically focused on pharmacogenetics: it reviews CYP2D6 and CYP2C19 genetic variation, explains genotype-to-phenotype translation, and provides genotype-directed dosing recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and related TCAs), including therapeutic monitoring and implementation considerations."
a8b5d550-8403-4a6f-b39f-a5723cc35b09,1,"Bertilsson L, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993; 341:63.",3,10,Processed,"The document is primarily pharmacogenetic: it compiles multiple studies linking CYP2D6 genotypes/phenotypes (PM/IM/UM) to nortriptyline pharmacokinetics (AUC, Clor, Css, t1/2), clinical outcomes and dose-adjustment recommendations, including genotype-based prescribing actions."
f0e9e38a-a8ae-41b0-9871-7b20c0187aa0,1,"Penas-Lledo EM, et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Molecular psychiatry. 2013; 18:8–9. [PubMed: 22733128]",3,10,Processed,"This is a CPIC guideline specifically focused on pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes/phenotypes, provides allele and activity scoring, and gives genotype-directed dosing recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and others), including implementation and therapeutic drug monitoring guidance—i.e., the paper is primarily about pharmacogenetic approaches."
f91e403d-d990-4def-89a0-6d26371949c8,1,"Hodgson K, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014; 28:133–41. [PubMed: 24257813]",3,10,Processed,"This CPIC guideline is centrally focused on pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes to provide gene-based dosing and therapeutic recommendations for tricyclic antidepressants, discusses phenotype assignment, genotype testing, and implementation — making pharmacogenetics the primary topic."
2463cb84-ba6e-4298-bdd6-02251742f39e,1,"Swen JJ, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clinical pharmacology and therapeutics. 2011; 89:662–73. [PubMed: 21412232]",3,10,Processed,"This is a CPIC guideline specifically focused on CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants. The paper reviews pharmacogenetic evidence, defines genotype-to-phenotype translation, and provides gene-based dosing recommendations, therapeutic monitoring guidance, and implementation resources — i.e., it is primarily about pharmacogenetics."
fc24ac43-48dc-4f90-8e6d-eb7e43e6fae9,1,"Bertilsson L, Mellstrom B, Sjokvist F, Martenson B, Asberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981; 1:560–1.",3,10,Processed,"This CPIC guideline is explicitly about pharmacogenetics: it interprets CYP2D6 and CYP2C19 genotypes to guide dosing and selection of tricyclic antidepressants, provides genotype-to-phenotype translation, gene-based dosing recommendations, combined genotype guidance, implementation considerations (EHR/clinical decision support), and evidence review — i.e., the paper’s primary focus is pharmacogenetic approaches."
f8208012-66ce-4c7d-8411-4c81b8b8067d,1,"Shimoda K, et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002; 22:371–8. [PubMed: 12172336]",3,10,Processed,"This CPIC guideline centrally evaluates CYP2D6 and CYP2C19 genotypes to guide dosing and selection of tricyclic antidepressants, including systematic literature review, phenotype assignment, genotype-based dosing recommendations, combined-gene considerations, and implementation—i.e., it is primarily about pharmacogenetics."
c0104f9f-7f8f-43d2-825f-19851ec6d5ef,1,"Steimer W, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clinical chemistry. 2005; 51:376–85. [PubMed: 15590749]",3,10,Processed,"This CPIC guideline is centrally focused on pharmacogenetics: it reviews CYP2D6 and CYP2C19 genetic variation and provides genotype-directed dosing recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and others), discusses phenotype assignment, therapeutic drug monitoring, combinatorial genotype effects, pediatric considerations, and EHR implementation—all core pharmacogenetic content."
f68888e1-6b00-4348-8da9-7457de9e7c9d,1,"Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. British journal of clinical pharmacology. 2008; 65:134–8. [PubMed: 17764479]",3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and genotype-directed dosing of tricyclic antidepressants. The paper centers on pharmacogenetic interpretation, phenotype assignment, and clinical dosing recommendations based on genetic variation, so it is primarily about pharmacogenetics."
ead3fdab-2082-42e8-a2db-84581ee16938,1,"Dworkin RH, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132:237–51. [PubMed: 17920770]",3,10,Processed,"This is a CPIC guideline focused explicitly on pharmacogenetics: it reviews CYP2D6 and CYP2C19 genetic variation, links genotypes to metabolizer phenotypes, and provides genotype-guided dosing and therapeutic recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and others). The paper's primary aim is implementing pharmacogenetic approaches to guide TCA therapy."
ec7fd941-f282-4964-b609-ed19b7792c4c,1,"Preskorn SH, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013; 74:614–21. [PubMed: 23541126]",3,10,Processed,"This is a CPIC guideline specifically focused on CYP2D6 and CYP2C19 genotypes and genotype-guided dosing of tricyclic antidepressants, including phenotype assignment, activity scoring, clinical recommendations, and implementation—i.e., it is primarily about pharmacogenetics."
c823f124-e3be-4b85-8298-4367740769b7,1,"el-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. Journal of clinical pharmacology. 1995; 35:17–21",3,10,Processed,"This CPIC guideline explicitly evaluates pharmacogenetic approaches — it focuses on CYP2D6 and CYP2C19 genotypes, translates genotypes to predicted phenotypes (activity scores), and provides genotype-directed dosing recommendations for tricyclic antidepressants (amitriptyline, nortriptyline and related drugs), including therapeutic monitoring and considerations of combined genotypes and drug–drug interactions."
b4b03b7b-039c-4ee4-aa9a-e7a75f927c6a,1,"Ketter TA, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995; 15:387–98. [PubMed: 8748427]",3,10,Processed,"The paper is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and gene-guided dosing of tricyclic antidepressants, providing pharmacogenetic evidence, phenotype interpretation, and concrete genotype-based therapeutic recommendations — i.e., it is primarily about pharmacogenetics."
40868264-001f-42f1-b9d0-ac838e6d9a53,1,Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. International journal of psychiatry in medicine. 1995; 25:277–90. [PubMed: 8567194],3,10,Processed,"This is a CPIC guideline focused on CYP2D6 and CYP2C19 genotypes and genotype-directed dosing of tricyclic antidepressants. The paper reviews genetic variation, phenotype assignment, pharmacokinetic/clinical evidence, and provides pharmacogenetic dosing recommendations—making it primarily and directly about pharmacogenetics."
c05e077c-a4ee-494f-97ef-27ef48be00be,1,"Royal College of Physicians and British Pharmacological Society. Personalised prescribing: using pharmacogenomics to improve patient outcomes. Report of a working party. London: RCP and BPS, 2022.",3,10,Processed,"The document is primarily focused on pharmacogenetics/pharmacogenomics: it discusses gene–drug interactions (CYP2C19, CYP2D6), pharmacokinetics/pharmacodynamics, PGx-mitigatable ADRs, population prevalence of pharmacogenes, clinical examples (clopidogrel), implementation challenges, equity and representation (Genes & Health cohort), and stakeholder perspectives—all central pharmacogenetics topics."
8a974cf3-1bdc-44c8-973b-659dfcf186de,1,"Emma F Magavern, Maia Megase, Jack Thompson, Gabriel Marengo, Julius Jacobsen, Damian Smedley, Mark J Caulfield. Pharmacogenetics and adverse drug reports: insights from a national database from the United Kingdom . Manuscript Under review",3,10,Processed,"The document is centrally focused on pharmacogenetics/pharmacogenomics: it covers gene–drug interactions (CYP450 metaboliser phenotypes), population prevalence of pharmacogenes, PGx-mitigatable ADRs, CYP2C19-clopidogrel clinical associations (including real-world outcomes in a British South Asian cohort), and practical implementation, equity, and trust issues. Both analytic data and implementation research are discussed, so pharmacogenetics is the primary subject."
02373682-6d9c-46d5-85eb-35a63b3023d5,1,Data: Yellow Card ADR reports to the Medicines and Healthcare Products Regulatory Agency (MHRA) from 1963-2024,3,10,Processed,"The slides focus directly on pharmacogenetics/pharmacogenomics: mechanisms (CYP450, pharmacokinetics/pharmacodynamics), population prevalence of pharmacogene variants (CYP2C19, CYP2D6), clinical examples (clopidogrel, antiplatelet therapy), real-world outcome data linking genotype to recurrent MI in a British South Asian cohort, implementation barriers, guidelines (AHA, NICE, RCP/BPS), and equity/engagement considerations. This is primarily and centrally about PGx approaches and their assessment."
e23e065d-5679-4b3c-8a84-e72e55870f09,1,"Kimpton JE, Carey IM, Threapleton CJD, Robinson A, Harris T, Cook DG, DeWilde S, Baker EH. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Phar",3,10,Processed,"The document is centrally about pharmacogenetics/pharmacogenomics: it defines gene–drug interactions, discusses CYP450 metaboliser genotypes (CYP2C19, CYP2D6), ADR mitigation by PGx, clinical examples (clopidogrel, antiplatelet therapy), population prevalence and biogeographic variation, implementation and guideline considerations, and original research (Genes & Health CYP2C19 study and community focus groups). Pharmacogenetics is the primary focus throughout."
a7a7b74e-537c-4cdd-8d96-29059e7998ba,1,"Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ.  The Role ",3,10,Processed,"The document is primarily focused on pharmacogenetics/pharmacogenomics: it defines gene–drug interactions, discusses CYP450 metaboliser genotypes (CYP2C19, CYP2D6), quantifies PGx‑mitigatable ADRs, presents population prevalence data, a British‑South Asian CYP2C19 validation study linking genotype to clopidogrel outcomes, and addresses clinical implementation, guidelines, and equity/engagement — all central to assessing pharmacogenetic approaches."
6d98f957-3ffe-4754-a7c8-6c3891014f70,1,"Magavern E, Jacobs B, Warren H, et al. CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel. JACC Adv. 2023 Sep, 2 (7) . https://doi.org/10.1016/j.jacadv.2023.100573",3,10,Processed,"The document is centrally focused on pharmacogenetics/pharmacogenomics: it defines gene–drug interactions (pharmacokinetics/pharmacodynamics), discusses CYP450 metaboliser genotypes (CYP2C19, CYP2D6), quantifies PGx‑mitigatable ADRs, presents population prevalence and cohort data (Genes & Health), links CYP2C19 genotype to clopidogrel outcomes, and addresses clinical implementation, guidance, and equity/engagement—all core aspects of assessing pharmacogenetic approaches."
d0b63aac-df7d-432b-aec1-37dbc1d2c89f,1,Hosted by the NHS England Pharmacogenomics Network of Excellence https://www.nw-gmsa.nhs.uk/patients/patient-information-and-resources,3,10,Processed,"The document is squarely focused on pharmacogenetics/pharmacogenomics: it defines PGx concepts (PK/PD), discusses CYP450 metaboliser genotypes/phenotypes, quantifies PGx‑mitigatable ADRs, reports population pharmacogene prevalence, analyzes CYP2C19 effects on clopidogrel efficacy with outcome data in a British South Asian cohort, and addresses clinical implementation, equity, and patient perspectives. These elements show the paper primarily assesses pharmacogenetic approaches and their real‑world application."
6dd53055-6952-4871-a216-d0f197d2227b,1,NICE guidance for PGx guided antiplatelet therapy,3,10,Processed,"The manuscript is primarily focused on pharmacogenetics: it develops and implements a pharmacogenomic-driven clinical decision support (PGx-CDS) algorithm to guide antiplatelet therapy, includes genotyping of CYP2C19*2 and PON1 rs662, integrates platelet function testing, and evaluates clinical outcomes (MACCEs/bleeding) based on genotype-guided versus standard care. The study design, endpoints, and analyses center on genotype-informed drug selection and response, making it highly relevant to pharmacogenetics."
1bf540cb-6376-4c30-a1fd-938c9771bacd,1,Yellow Card ADR reports to the Medicines and Healthcare Products Regulatory Agency (MHRA) from 1963-2024,3,10,Processed,"The document is primarily focused on pharmacogenetics/pharmacogenomics: it discusses gene–drug interactions, CYP450 metaboliser genotypes (notably CYP2C19 and CYP2D6), population prevalence, PGx-mitigatable ADRs, clinical examples (clopidogrel), real-world outcome data in a British South Asian cohort, implementation challenges, and equity/engagement considerations — all central to pharmacogenetic approaches."
2dd905f9-c1ff-4a09-a794-92e0e200a725,1,https://www.nw-gmsa.nhs.uk/patients/patient-information-and-resources,3,10,Processed,"The submission is centrally focused on pharmacogenetics/pharmacogenomics: it discusses gene–drug interactions (CYP2C19/CYP2D6), population prevalence of pharmacogenes, PGx-mitigatable ADRs, clinical examples (clopidogrel), genotype–outcome association data (British South Asian cohort showing CYP2C19 LOF linked to recurrent MI), and implementation/ethical/equity considerations. Both quantitative and qualitative assessments of PGx approaches are presented, so the paper is primarily about pharmacogenetics."
124e890d-99d4-4305-bc46-7c6246bf2f45,1,"Muller, D. J. (2020). Pharmacogenetics in psychiatry. Pharmacopsychiatry 53, 153– 154. doi:10.1055/a-1212-1101",3,9,Processed,"The paper directly examines pharmacogenetic (PGx) testing alongside diagnostic genetic testing: it reports rates of PGx ordering (32.2%), reasons for ordering, clinicians’ perceived current and future utility of PGx, clinicians’ understanding/misinterpretation of PGx results, and predictors of PGx use. While it also covers other genetic tests, PGx is a major, explicitly analyzed component of the study, making the paper highly relevant to pharmacogenetic approaches."
3ad282b7-08b4-4646-955e-ef1fc0ab4711,2,url:https://doi.org/10.1016/j.bpsgos.2021.07.008,2,8,Processed,"The paper is a genome-wide investigation of genetic predictors of antidepressant response, estimating SNP heritability, performing GWAS/TWAS/MAGMA analyses, and testing polygenic scores — all central to pharmacogenomics. It discusses pharmacokinetic candidate genes (CYP2D6/CYP2C19), pharmacogenetic implications, and the potential for pharmacogenetic testing, but it is broader (polygenic and genetic-architecture focused) rather than a focused clinical pharmacogenetic trial of specific actionable variants, so it is highly relevant but not exclusively a pharmacogenetics study."
01dcd3d9-f19d-4564-8140-d515fca37f44,2,"Lima, J. J., Thomas, C. D., Barbarino, J., Desta, Z., Van Driest, S. L., El Rouby, N., et al. (2021). Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin. Pharmacol. Ther. 109 (6), 1417– ",2,8,Processed,"The paper directly investigates CYP2C19 genetic polymorphisms (rs4244285/*2 and rs12248560/*17), assigns diplotype-inferred metabolic phenotypes using CPIC guidelines, and links enzyme activity to estrogen metabolism and endometriosis risk. Those are core pharmacogenetic methods. It is not primarily about drug dosing or therapeutic pharmacogenetic implementation, focusing instead on disease susceptibility, so it is highly relevant but not exclusively a clinical pharmacogenetics implementation study."
f558ac95-a8e3-4e3e-8e6f-07b0743126e1,2,url:https://doi.org/10.1038/s41397-022-00267-7,2,7,Processed,"The paper includes a clear pharmacogenetic component — it infers CYP2C19 star alleles and metabolizer phenotypes (using PGxPOP/PharmCAT) and tests associations with SSRI non‑response — and also considers genetic predictors (polygenic scores) of antidepressant response. However, pharmacogenetics is one part of a broader analysis that emphasizes sociodemographic and clinical predictors; the CYP2C19 findings are reported as nominal and do not dominate the study. Thus the work is relevant to pharmacogenetics but is not primarily a pharmacogenetics-focused paper."
300f84a7-d636-41da-8ba8-233ac17f9e97,1,"9. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006; 27(8): 949–53. DOI: https://doi.org/10.1093/eurheartj/ehi825",3,7,Processed,"The Rotterdam Study is not primarily a pharmacogenetics paper, but it devotes a substantial and explicit component to pharmaco-epidemiology and pharmacogenetic analyses. The article describes a dedicated pharmaco-epidemiology program, extensive genotyping/GWAS resources (~11,000 samples), and multiple reported drug–gene findings (e.g. OCT1/MATE1 and metformin response, OCT1 and Parkinson drug response, VKORC1/CYP2C9 with phenprocoumon/warfarin-type dosing, CYP2D6 effects on antidepressants and beta‑blockers, NOS1AP associations). Thus pharmacogenetic approaches are well assessed as an important subtheme, though not the study’s sole or principal focus."
8330f0bd-c657-4ed0-8c61-d817d10976f1,2,url:https://doi.org/10.1097/fpc.0b013e328340bc5a,2,6,Processed,"The review discusses genetic polymorphisms and clinical pharmacogenetic consequences for multiple enzymes and transporters (e.g. CYP2D6, CYP2C9, CYP2C19, CYP3A5, UGT1A1, SLCO1B1, ABCG2) and cites CPIC guidance for specific drugs (tacrolimus, warfarin, clopidogrel, statins), so pharmacogenetics is a meaningful component. However, the paper’s primary aim is mapping drug metabolism and transport of the top 100 drugs (using in vitro data) rather than systematically assessing pharmacogenetic approaches, testing strategies, or implementation—hence a moderate (not maximal) relevance score."
b120bec7-7257-4729-a39d-b16370c195e7,1,"20.   Holford NHG. Pharmacokinetics and pharmacodynam-
ics: rational dosing and the time course of drug action.  
In: Katzung B, ed. Basic and Clinical Pharmacology. 9th 
ed. New York, NY: Lange Medical Books/McGraw-Hill, 
Medical Publishing Division; 200",3,6,Processed,"This is a broad pharmacology textbook that includes a dedicated chapter on pharmacogenomics (Chapter 5) and multiple index references to pharmacogenetic topics (CYP2C9, TPMT, UGT1A1, VKORC1, transporter genetic variation, etc.). Thus it assesses pharmacogenetic approaches meaningfully, but pharmacogenetics is one section within a much wider coverage rather than the primary focus."
0ffcc06f-fe45-4058-80c5-53f2e9b2acda,1,"Hiemke C, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011; 44:195–235.",3,6,Processed,"The guideline includes a dedicated pharmacogenetics section (CYP polymorphisms, genotyping vs phenotyping, ABCB1/P-gp, when to combine TDM with pharmacogenetic tests) and cites many relevant studies, but the primary focus of the paper is therapeutic drug monitoring/pharmacokinetics and reference ranges rather than being primarily a pharmacogenetics paper."
956650c1-7a2d-4747-a12b-dc80225faa2a,1,"163. Guo J, Guan T, Fan S, Chao B, Wang L, Liu Y.  Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China. Am J Cardiol. 2018; 122(12): 2055–61. DOI: https:// doi.org/10.1016/j.amjcard.2018.08.057",3,6,Processed,"The paper is a general review of warfarin anticoagulation practice in China that includes a substantial and specific section on pharmacogenetic dosing (VKORC1, CYP2C9, trials, CPIC/IWPC algorithms, Chinese validation studies and guideline advice). However, pharmacogenetics is one component of a broader clinical-practice review rather than the primary focus, so relevance is moderate rather than high."
89731344-c1e0-4d11-b30e-70bec558475e,1,"172. Gu Y, Doughty RN, Freedman B, Kennelly J, Warren J, Harwood M, et al. Burden of atrial fibrilla - tion in Māori and Pacific people in New Zealand: A cohort study. Intern Med J. 2018; 48(3): 301–9. DOI: https://doi.org/10.1111/imj.13648",3,5,Processed,"The thesis develops a high‑throughput calcium‑imaging assay to characterise RyR2 genetic variants and tests effects of anti‑arrhythmic compounds (e.g., allopurinol, phenytoin) and designer binders. This places it at the interface of genetics and pharmacology. However, it does not primarily investigate pharmacogenetic questions (i.e., how specific RyR2 genotypes alter drug responses across multiple variants or patient cohorts). Rather, it focuses on assay development and proof‑of‑principle drug/nanobody screening, so it is relevant to but not centered on pharmacogenetics."
97f1b319-d346-4ef9-9307-2817b5d79bfa,2,url:https://doi.org/10.18433/J3W31F,2,4,Scored,"The review mentions genetic polymorphisms and pharmacogenetic findings (e.g., CRH/CRHR, FKBP5, GNB3 C825T, FTO, ACE I/D rs4291, G1165C associated with sertraline response) and discusses genotype-related differential antidepressant effects — but this is a small part of a broader paper on hypertension, obesity and anxiety-depressive disorders. The article does not systematically evaluate pharmacogenetic approaches or provide in-depth pharmacogenetic analysis, methods or recommendations, so pharmacogenetics is a minor/ancillary topic rather than the primary focus."
a704e201-5619-4eb6-bcf8-bacf74dc9072,2,url:https://doi.org/10.1111/j.1365-2710.2006.00763.x,2,4,Scored,"The review discusses pharmacogenetic factors as contributors to serotonin syndrome, citing CYP2D6 and CYP2C19 metabolizer status, 5-HT2A receptor polymorphisms (T102C), CPIC guidance, meta-analyses and case reports, and calls for future genetic studies. However, pharmacogenetics is a secondary topic within a broader pharmacology-focused review rather than the primary subject—coverage is descriptive and limited to a single subsection rather than an in-depth pharmacogenetic analysis."
09c53e5c-c723-4cb4-85c3-c8cd50996a5d,2,url:https://doi.org/10.3390/ph15070870,2,4,Scored,"The thesis includes a pharmacogenetic component — genotyping and analysis of the SOD2 rs4880 (Val16Ala) polymorphism and discussion of pharmacogenetics (e.g. CYP2D6/CYP2C19 recommendations) — but this is one of three study axes. The primary focus is on metabolomics and mitochondrial biomarkers (ALC, L‑carnitine, acylcarnitines) and their relation to depression and antidepressant response, so pharmacogenetics is a secondary, limited part of the work rather than the main topic."
58220e68-82a8-4e03-b918-e367c95627bd,1,"66. Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reac-tions in women and men: aggregated evidence from globally collected individual case reports during half a century. eClinicalMedicine. 2019;17. https:/ /doi.or g/10.10 16/j .eclin",3,4,Processed,"The paper addresses sex-specific differences in expression of FDA‑approved drug target genes across tissues and discusses implications for precision medicine, dosing, pharmacokinetics/pharmacodynamics, and adverse events — topics adjacent to pharmacogenetics. However, it does not analyze genetic variants (SNPs, pharmacogenetic biomarkers) or genotype–drug response associations, so it is only indirectly relevant rather than a pharmacogenetics study per se."
47744113-1188-4d78-9ecf-1da1fcc88ba6,1,"Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68–80 (2021).",3,4,Processed,"The review is not primarily a pharmacogenetics paper, but it contains several pharmacogenetically-relevant observations and implications. It discusses how APOE genotype (ε2/ε3/ε4 and rare variants) modifies disease risk, neuropathology and responses to therapies (e.g., higher ARIA risk with ε4 during anti‑Aβ immunotherapy; differential bexarotene PET/CSF findings by APOE status; rationale for APOE‑targeted gene therapies and isoform‑specific antisense/antibody strategies). However, it does not systematically evaluate drug–gene interactions, dosing/response stratification, predictive biomarkers or clinical pharmacogenetic guidance—so it is relevant but not focused on pharmacogenetics."
63ebf1aa-bc96-4bbb-b6d1-d2bd72bfdaf6,1,"Roden, D. M. & George, A. L. Jr The genetic basis of variability in drug responses. Nat. Rev. Drug Discov.1,3 7–44 (2002).",2,3,Processed,"The document (a pharmacotherapeutics course/reference list) is primarily about pharmacokinetics, pharmacodynamics, and factors affecting drug action (exercise, gender, delivery routes). Only a single cited article (#6: Roden & George, “The genetic basis of variability in drug responses”) explicitly addresses genetics of drug response; some textbook chapters may touch on genetic variability, but pharmacogenetics is not a primary focus. Therefore the paper has limited but present relevance to pharmacogenetic approaches."
55da524b-41ad-44f4-b490-46bbe04a5d85,1,"Smith, T. R., Kearney, E., Hulick, P. J. & Kisor, D. F. History repeats itself: the family medication history and pharmacogenomics. Pharmacogenomics 17, 669–678 (2016).",2,3,Processed,"The paper is primarily about evaluating family health history (FHH) apps and an abbreviated quality-review process (derived from ISO/TS 82304-2) for primary care. It only briefly references pharmacogenomics: e.g., noting that FHH apps could link to genomic records including pharmacogenomic data, listing “clinical use of genomics and pharmacogenomics” as one potential app purpose, and suggesting inclusion of family medication history and pharmacogenomic results as future work. There is no substantive assessment of pharmacogenetic methods, tests, algorithms, or clinical pharmacogenetic implementation—so pharmacogenetics is a minor, peripheral topic rather than the paper’s focus."
94effacd-40d7-4f93-aeab-b23b54fa9191,2,url:https://doi.org/10.1007/s00228-016-2079-0,2,3,Scored,"This CV is primarily focused on cancer immunology, immune cell therapy, and genetic association studies. It includes a few studies that touch drug-response genetics (notably a randomized trial on ACE gene influence on sertraline vs fluoxetine), but most publications are disease-association, immunological, or vaccine/proteomics work rather than dedicated pharmacogenetics. Thus it has limited relevance to pharmacogenetic approaches overall."
0c3b4f21-de3d-413c-85a7-274c442fcd01,1,"19.   Duhlmeier R, Hacker A, Widdel A, von Engelhardt W , 
Sallmann HP . Mechanisms of insulin-dependent glucose 
transport into porcine and bovine skeletal muscle. Am J 
Physiol Regul Integr Comp Physiol. 2005;289(1):R187–
R197.",3,3,Processed,"The document is a general pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, exercise and drug interactions, and clinical drug principles. It contains only minimal coverage of genetic variability (one explicit citation: Roden & George, 2002, on genetic basis of variability in drug responses) and related topics (stereoselectivity, gender differences), but it is not primarily about pharmacogenetic approaches nor does it appear to assess pharmacogenetic methods or applications in depth."
fffc86c7-bb91-4817-b789-09eedcc5032d,1,"47. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care, 2000, 12:423-434.",3,3,Processed,"The paper focuses on predicting drug efficacy and safety across populations using a clinical knowledge graph integrating drugs, diseases, and population/eligibility features. While the background KG includes biological resources (e.g., disease–gene associations, protein targets) and the authors note the framework could be extended to individual omics/patient data, the work does not specifically assess pharmacogenetic approaches (no explicit analyses of genetic variants, genotype–drug response associations, or pharmacogenomic biomarkers). Thus it has mild relevance (could incorporate pharmacogenetics) but is not primarily about pharmacogenetics."
82f92450-61b6-46db-bef9-73bb98f060b9,1,"6. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338(25):1793–7.  h t t  p s : /  / d o  i .  o r g ",3,3,Processed,"The study examines genetic thrombophilia (factor V Leiden, prothrombin G20210A) and hyperhomocysteinemia as modifiers of ischemic stroke risk in women using oral contraceptives, i.e., genetic effects on a drug-associated adverse outcome. However, it is an epidemiologic risk-factor interaction study rather than a pharmacogenetic investigation of drug response mechanisms, biomarkers for tailoring therapy, or pharmacokinetic/pharmacodynamic genes. Thus it is only marginally relevant to pharmacogenetics, not primarily a pharmacogenetic paper."
48509c40-7c26-4d32-be37-70e98a30cc54,1,"Houwink, E.J.; Van Teeffelen, S.R.; Muijtjens, A.M.M.; Henneman, L.; Jacobi, F.; Van Luijk, S.J.; Dinant, G.J.; Van Der Vleuten, C.; Cornel, M.C. Sustained effects of online genetics education: A randomized controlled trial on oncogenetics. Eur. J. Hum. G",3,3,Processed,"Pharmacogenetics is discussed as one of several 'emerging' genomic areas and the survey reports specific metrics (e.g. 28% have it as part of practice, ~4–5% confident), but the paper’s primary focus is on integration of genomic medicine into primary care broadly (family history, referrals, attitudes, resources). Pharmacogenetics is a minor component rather than the main topic."
31ae464a-3f37-402d-998f-2c745384ceec,1,"32. Lau C-P, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, et al. Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. J Cardiovasc Electrophysiol. 2013; 24(4): 381–7. DOI: https://doi.org/10.1111/jce.12066",3,3,Processed,"The review briefly mentions pharmacogenetics in one paragraph—noting ethnic differences in warfarin metabolism and CYP2C9/VKORC1 allele frequencies as a possible factor in TTR and dose variability—but it does not assess pharmacogenetic approaches (e.g., genotyping-guided dosing, clinical implementation, or outcomes) in any depth. The primary focus is epidemiology, TTR and clinical outcomes by ethnicity rather than pharmacogenetic strategies."
4cb1d516-065c-4235-997c-6b9f757e694c,1,"143. Bonny A, Ngantcha M, Yuyun M, Karaye KM, Scholtz W, Suliman A,  et al. Cardiac arrhythmia services in Africa from 2011 to 2018: The second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. Europace. 20",3,3,Processed,"The document is a broad bibliography of ACE centre research across genomics, infectious diseases, agriculture, engineering, etc. While several cited studies address genetic determinants of pathogen drug resistance (e.g., Plasmodium kelch13, Pfcrt/Pfmdr1, HIV‑1 drug resistance, antimalarial resistance monitoring), and there is extensive genomics/surveillance work, there is little explicit focus on human pharmacogenetics (host genetic variation and drug response). Thus it has some indirect relevance (pathogen resistance genomics) but is not primarily assessing pharmacogenetic approaches."
ed4eb037-f7ed-4ca6-bb15-841c8f4c9df1,1,"144. Bonny A, Ngantcha M, Yuyun MF, Karaye KM, Scholtz W, Suliman A, et al. Cardiac arrhythmia services in Africa from 2011 to 2018: The second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. EP Europace.",3,3,Processed,"This bibliography is primarily a compilation of infectious-disease and genomics research (pathogen genomics, molecular epidemiology, drug-resistance loci in Plasmodium and HIV, genomic surveillance, diagnostics, and phytomedicine). While several entries examine genetic determinants of pathogen drug resistance and therapeutic efficacy, very few (if any) focus on human host pharmacogenetics—i.e., human genetic variation affecting drug metabolism or individualized drug response. Thus it is only tangentially relevant to pharmacogenetic approaches."
150d2f89-ea38-468a-ab30-791fc94da375,1,"180. Rodriguez-Bernal CL, Peiro S, Hurtado I, Garcia-Sempere A, Sanfelix-Gimeno G.  Primary Non - adherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Popu - lation-Based Cohort. J Manag Care Spec Pharm . 2018; 24(",3,3,Processed,"This is a general pharmacoepidemiology conference program with only a few explicit references to pharmacogenetics/genomics (e.g., a SIG on Genomics & Precision Medicine and pre‑conference courses such as “Introduction to Pharmacogenomics & Precision Medicine” and “Cancer Pharmacoepidemiology and Genomics”). The bulk of the content covers vaccines, drug safety, methods, pregnancy, RWE, etc., so pharmacogenetic approaches are present but not a primary focus."
05b1bb35-cb11-4662-99b9-bac7207d9e14,1,"246. Fox CS, Parise H, D’Agostino RB, Sr., Lloyd-Jones DM, Vasan RS, Wang TJ,  et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004; 291(23): 2851–5. DOI: https://doi.org/10.1001/jama.291.23.2851",3,3,Processed,"The review discusses genetic contributions to atrial fibrillation (multiple loci, familial mutations) and briefly notes that recognition of genes could facilitate a future pharmacogenomic treatment approach. However, it does not assess pharmacogenetic strategies, evidence, or clinical implementation in any depth—pharmacogenetics is only mentioned as a prospective concept rather than analyzed or reviewed. Therefore relevance to pharmacogenetic assessment is low."
f22f1463-f76b-46e1-aea3-669eeebd790b,1,"National Institute for Health and Care Excellence.Depression in Adults: Treatment and Management(NICE Guideline NG222, 2022).",2,2,Processed,"The guideline extensively covers pharmacological management of depression (antidepressant choice, starting/stopping, augmentation with lithium or antipsychotics, monitoring, ECT, etc.), but it contains no assessment, recommendations or discussion of pharmacogenetic or genotyping approaches (no mention of CYP enzymes, pharmacogenomic testing, genetic biomarkers, or genotype-guided prescribing). Therefore it is only marginally relevant to pharmacogenetics — relevant insofar as it addresses drug use generally, but it does not evaluate pharmacogenetic methods."
631b6755-5bef-4215-b3ac-9233986180d7,2,url:https://doi.org/10.1016/S2215-0366(18)30133-0,2,2,Scored,"The paper only briefly mentions pharmacogenetic research in the introduction as part of the rationale for personalized medicine, but it does not analyze or assess pharmacogenetic data or methods. The study is a meta-analysis/simulation of variance in antidepressant response using clinical trial symptom scores, with no genetic biomarkers, pharmacogenetic subgroup analyses, or evaluation of pharmacogenetic approaches."
e29afe56-09b7-4c70-8714-f6c67536f4d6,2,url:https://doi.org/10.1038/s41398-021-01417-4,2,2,Scored,"The paper focuses on genotype–phenotype mapping using eQTLs, SNPs, gene networks and graph-embedded neural networks for disease classification. It does not address drug response, drug metabolism, dosing, or clinical pharmacogenetic markers, and contains no analyses or examples specific to pharmacogenetics. The methods could be applied to pharmacogenetic problems (hence not a zero score), but pharmacogenetics is not a stated aim or primary focus."
1a42f629-aaf2-42fd-8673-8f03ec74e606,2,url:https://doi.org/10.1002/cpt.2754,2,2,Scored,"The report is focused on real-world data/evidence for regulatory decision making and does not assess pharmacogenetic approaches. It contains only minor, incidental references to genotype-matching in a single natural-history case study (MoCD Type A) but lacks substantive discussion of pharmacogenomics, genetic biomarkers, or tailored pharmacogenetic strategies. Therefore relevance to pharmacogenetics is very low."
94fbeedd-b6f2-4e9c-bdcd-59f79232c083,2,"Marken, P. A., and Munro, J. S. (2000). Selecting a selective serotonin reuptake inhibitor: Clinically important distinguishing features.Prim. Care Companion J. Clin. Psychiatry 2 (6), 205– 210. doi:10.4088/pcc.v02n0602",2,2,Scored,"The document primarily reviews antidepressant classes, formulations, side effects, and general metabolism (lists CYP enzymes and dosing adjustments). It does not evaluate or recommend pharmacogenetic testing, genotype-guided dosing, or implementation of PGx approaches—aside from one citation about CYP2D6/CYP2C19 and a metabolism column, there is no substantive assessment of pharmacogenetics. Thus it is minimally relevant to pharmacogenetic approaches."
73d616f5-dfb6-438e-9300-55b3aaeccdfc,2,"Miller, S. A., Dykes, D. D., and Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic acids Res.16 (3), 1215. doi:10.1093/nar/16.3.1215",2,2,Scored,"The syllabus focuses on molecular methods for clinical microbiology (PCR, sequencing, MALDI-TOF, hybridization, population genetics, epigenetics) rather than on drug–gene interactions, drug metabolism, personalized medicine or pharmacogenomic testing. While several techniques taught (sequencing, genotyping, methylation analysis) are tools that can be used in pharmacogenetics, the course content and learning outcomes center on microbiological diagnostics and methods, not on pharmacogenetic approaches or their clinical application."
c2fe654d-ea3f-4795-8cc1-bbc0d5b5039a,1,"Wilson BJ, Qureshi N, Santaguida P , et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med  2009; 151: 878-885.",3,2,Processed,"The article discusses family history and genetic testing broadly in the context of hospital admissions and genetic counselling, but it does not address pharmacogenetics, drug–gene interactions, or pharmacogenetic testing or implementation. Thus it has minimal relevance to pharmacogenetic approaches."
a23b866c-1a7f-4421-9c28-27ae8f936add,1,"Murabito JM, Nam BH, D’Agostino RB Sr, et al. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med 2004; 140: 434-440.",3,2,Processed,"The editorial discusses family history and genetic testing broadly in clinical care but does not address pharmacogenetics (drug–gene interactions, drug response markers, or medication-guiding genetic tests). It is only tangentially related to genetics, so relevance to pharmacogenetic approaches is very low."
146c708c-5183-4a96-94eb-eb0071f52644,1,"1.     Holford NH, Sheiner LB. Understanding the dose-ef-
fect relationship: clinical application of pharmacoki-
netic-pharmacodynamic models. Clin Pharmacokinet. 
1981;6(6):429-453.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, drug interactions and exercise effects. It contains a single, brief citation addressing genetic variability in drug responses (Roden & George, 2002) but does not otherwise evaluate or center pharmacogenetic approaches; thus pharmacogenetics is only minimally represented."
26a73106-83f6-45ad-8151-381208f6ffe6,1,"2.     Ross EM, Kenakin TP . Pharmacodynamics. In: Hardman 
JG, Limbird LE, Gilman AG, eds. Goodman and Gilman’s 
The Pharmacological Basis of Therapeutics. 10th ed. New 
York, NY: McGraw-Hill, Medical Publishing Division; 
2001:31-45.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics, exercise and drug interactions. It contains one reference (Roden & George) on genetic variability in drug responses, but the overall content and majority of references do not focus on pharmacogenetic methods, genetic polymorphisms, or personalized-genotype-guided therapy. Therefore it shows only minimal relevance to pharmacogenetic approaches."
cd6339f5-4897-477f-9c44-d5b5e9cebc5a,1,"3.     Duggan AW , North RA. Electrophysiology of opioids. 
Pharmacol Rev. 1983;35(4):219-281.",3,2,Processed,"The document is a general pharmacology/therapeutics course bibliography focused on pharmacokinetics, pharmacodynamics, drug interactions and exercise effects. It contains only a single explicit reference to genetic variability in drug responses (Roden & George, 2002) and no substantive discussion or emphasis on pharmacogenetic methods or approaches. Therefore it is only minimally relevant to pharmacogenetics."
2dc0d927-142c-443a-b2a7-b37885b265c4,1,"4.     Goodman RR, Pasternak GW . Visualization of mu1 
opiate receptors in rat brain by using a computerized 
autoradiographic subtraction technique. Proc Natl Acad 
Sci U S A. 1985;82(19):6667–6671.",3,2,Processed,"This is a general pharmacology/pharmacotherapeutics course focused on pharmacokinetics, pharmacodynamics, drug delivery and effects of exercise, sex, and other factors on drug action. Only a single reference (#6) explicitly addresses the genetic basis of variability in drug responses; there is no substantive focus on pharmacogenetic approaches, methods, or clinical implementation. Therefore relevance to pharmacogenetics is minimal."
fa6c5265-242f-4334-a6c4-309df1e0966c,1,"5.     Brown NJ, Vaughan DE. Angiotensin-converting enzyme 
inhibitors. Circulation. 1998;97(14):1411-1420.",3,2,Processed,"The document is a general pharmacology/ pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics, drug–exercise interactions, and clinical pharmacology. Only one cited reference (Roden & George) addresses genetic variability in drug responses; there is no substantive evidence in the provided material that the paper assesses pharmacogenetic approaches (no discussion of genotyping, pharmacogenomic methods, or personalized drug selection). Therefore it has minimal relevance to pharmacogenetics."
e06c0a89-9bc2-4060-8c43-dfe3a0340850,1,"6.     Roden DM, George AL Jr. The genetic basis of variability 
in drug responses. Nat Rev Drug Discov. 2002;1(1):37-44.",3,2,Processed,"The document is a general pharmacology/therapeutics course reading list and references focusing on pharmacokinetics, pharmacodynamics, exercise and drug interactions, and clinical pharmacology. It contains only a single clear genetics-related citation (Roden & George on genetic basis of variability) and a few items touching on stereoselectivity or gender differences, but it does not assess pharmacogenetic approaches or present pharmacogenetic analyses or recommendations. Therefore relevance to pharmacogenetics is minimal."
a7413e61-8835-41cd-90d2-2c239e81544e,1,"7.     Bourne H, von Zastrow M. Drug receptors and pharma-
codynamics. In: Katzung B, ed. Basic and Clinical Phar-
macology. 9th ed. New York, NY: Lange Medical Books/
McGraw-Hill, Medical Publishing Division; 2004:11-33.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics and exercise–drug interactions. It includes one reference on genetic variability in drug responses, but the content and citations largely do not focus on pharmacogenetic approaches or detailed assessment of genotypic-guided therapy. Therefore relevance to pharmacogenetics is minimal."
24062f04-ceee-454b-a930-5ecb138908be,1,"8.     Katzung B, ed. Basic and Clinical Pharmacology, 9th ed. 
New York, NY: Lange Medical Books/McGraw-Hill, 
Medical Publishing Division; 2004.",3,2,Processed,"The reference list is largely general pharmacology/pharmacokinetics and pharmacodynamics (exercise effects, stereoselectivity, drug delivery, ACE inhibitors, opioids, etc.). Only one cited work (Roden & George, 2002) explicitly addresses the genetic basis of variability in drug responses, but pharmacogenetic approaches are not a central theme of the course material shown. Therefore the paper is minimally but not meaningfully focused on pharmacogenetics."
ec43ca13-20a5-4067-8025-469117b34af7,1,"9.     Hardman JG, Limbird LE, Gilman AG, eds. Goodman 
and Gilman’s The Pharmacological Basis of Therapeutics. 
10th ed. New York, NY: McGraw-Hill, Medical Publish-
ing Division; 2001.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics, dosing, and exercise–drug interactions. Only a single listed reference (Roden & George, 2002) explicitly addresses genetic variability in drug responses; there is no substantive focus on pharmacogenetic approaches, methods, or clinical applications. Therefore relevance to pharmacogenetics is minimal."
2b5db3e5-84eb-4d51-aac6-7e6e12adfd6b,1,"10.   Walle T , Webb JG, Bagwell EE, Walle UK, Daniell HB, 
Gaffney TE. Stereoselective delivery and actions of beta 
receptor antagonists. Biochem Pharmacol. 1988;37(1):115-
124.",3,2,Processed,"The document is a general pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, drug–exercise interactions and clinical pharmacology. It contains a single citation directly addressing genetic variability in drug responses (Roden & George, 2002), but the overall content and many references do not assess pharmacogenetic approaches or personalized/genotype-guided therapy. Therefore relevance to pharmacogenetics is very low."
410128b7-13c9-4891-8f95-996b7c8e119d,1,"12.   Oates JA. The science of drug therapy. In: Brunton LL, 
Lazo JS, Parker KL, eds.  Goodman and Gilman’s The Phar-
macological Basis of Therapeutics. 11th ed. New York, NY: 
McGraw-Hill, Medical Publishing Division; 2006:117-
136.",3,2,Processed,"The document is a general principles-of-pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics, drug–exercise interactions, and delivery routes. Only one cited reference (#6) explicitly addresses genetic variability in drug responses; there is no evidence the paper primarily assesses pharmacogenetic approaches, methods, or data. Therefore relevance to pharmacogenetics is minimal."
8a8b25cc-9ad0-4b93-9085-dbc9657edd98,1,"13.   Reuter I, Harder S, Engelhardt M, Baas H. The effect of 
exercise on pharmacokinetics and pharmacodynamics of 
levodopa. Mov Disord. 2000;15(5):862-868.",3,2,Processed,"The document is a general pharmacology/ pharmacotherapeutics course reference list focused on pharmacokinetics, pharmacodynamics, drug interactions and exercise effects. It contains one citation explicitly about genetic variability in drug responses (Roden & George), but the overall material does not assess pharmacogenetic approaches or discuss genetic testing, genotype-guided therapy, or pharmacogenomic methods in depth. Therefore relevance to pharmacogenetics is minimal."
af853e41-6170-4e6c-868f-6d7b43755765,1,"14.   Luzier AB, Killian A, Wilton JH, Wilson MF , Forrest A, 
Kazierad DJ. Gender-related effects on metoprolol phar-
macokinetics and pharmacodynamics in healthy volun-
teers. Clin Pharmacol Ther. 1999;66(6):594-601.",3,2,Processed,"The document is a general pharmacotherapeutics course with references focused on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and clinical pharmacology. Only one cited reference (Roden & George, 2002) explicitly addresses the genetic basis of variability in drug responses; there is no other evidence of coverage of pharmacogenetic methods, genotype-guided therapy, polymorphisms, or pharmacogenomic testing. Thus it minimally touches pharmacogenetics but does not assess pharmacogenetic approaches in any substantive way."
41b52999-84ff-4a8f-a9ea-bcb54f889c91,1,"15.   Hinderling PH, T endolkar A, Dee CM, Barr WH, Seiber-
ling M, Duerr H. Single-dose interaction study of diprafe-
none HCl and propranolol HCl in healthy volunteers. J 
Clin Pharmacol. 1995;35(7):721-729.",3,2,Processed,"The document is a general pharmacology/therapeutics reference list focused on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and clinical pharmacology. Only one clear citation (Ref. 6: Roden & George, “The genetic basis of variability in drug responses”) directly addresses genetic variability/pharmacogenetics. Overall the content is not centered on pharmacogenetic approaches."
57b9d9f4-d8fb-45de-83ff-561f65090f4c,1,"16.   Buxton ILO. Pharmacokinetics and pharmacodynamics: 
the dynamics of drug absorption, distribution, action and 
elimination. In: Brunton LL, Lazo JS, Parker KL, eds. 
Goodman and Gilman’s The Pharmacological Basis of Ther-
apeutics. 11th ed. New York",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, drug interactions and exercise effects. It is not centered on pharmacogenetics — only one cited item (#6: genetic basis of variability in drug responses) touches on genetics. Thus pharmacogenetic approaches are only minimally represented, not assessed in depth."
154628e9-b705-442c-bbc5-f49c159f8dc3,1,"17.   Flynn EJ. Pharmacodynamic and pharmacokinetic prin-
ciples of pharmacology and drug therapy. J Neurol Phys 
Ther. 2003;27:93-100.",3,2,Processed,"The document is a references list for a general pharmacotherapeutics course focused on pharmacokinetics, pharmacodynamics, receptor pharmacology, drug–exercise interactions, and clinical drug therapy. Only one cited paper (Roden & George, 2002) explicitly addresses the genetic basis of variability in drug responses; there is no substantive focus on pharmacogenetic methods, genotyping, or personalized drug-response strategies. Thus it has minimal relevance to pharmacogenetic approaches."
5fd36cd0-e08f-4e79-ae73-4494047664dd,1,"18.   Cross JH. Reevaluation of the employment of Fick’s 
law for diffusion dosimeters. Environ Sci T echnol. 
2003;37(8):1633-1638.",3,2,Processed,"The course and reference list focus primarily on general pharmacology, pharmacokinetics/pharmacodynamics, dosing, and exercise–drug interactions. Only a single cited reference (#6: Roden & George) explicitly addresses genetic variability in drug responses, and there is no indication the paper systematically assesses pharmacogenetic approaches. Therefore relevance to pharmacogenetics is minimal but not entirely absent."
b67dea82-8563-4dcf-b650-24ab533deedc,1,"21.   Potts RO, Lobo RA. T ransdermal drug delivery: clinical 
considerations for the obstetrician-gynecologist. Obstet 
Gynecol. 2005;105(5 pt 1):953-961.",3,2,Processed,"The document is a general pharmacology/continuing education course with references focused on pharmacokinetics, pharmacodynamics, drug interactions, and exercise effects. It includes one cited paper explicitly on the genetic basis of variability in drug responses (Roden & George), but there is no indication the course primarily addresses pharmacogenetic approaches, testing, allele-specific effects, or personalized medicine. Therefore relevance to pharmacogenetics is minimal."
9678e4f6-14a2-4ae5-8b14-edccc7cbdb07,1,"22.   Correia M. Drug biotransformation. In: Katzung B, ed. 
Basic and Clinical Pharmacology. 9th ed. New York, NY: 
Lange Medical Books/McGraw-Hill, Medical Publishing 
Division; 2004:51-63.",3,2,Processed,"The course and reference list focus broadly on pharmacokinetics, pharmacodynamics, exercise/drug interactions, and clinical pharmacology. Only a single cited paper (Roden & George, 2002) directly addresses genetic variability in drug responses; there is no evidence the course primarily assesses pharmacogenetic approaches or methods. Therefore relevance to pharmacogenetics is minimal."
a20bb1c9-b7ad-4f13-9741-74f7c1d3ac80,1,"23.   Dossing M. Effect of acute and chronic exercise on hepat-
ic drug metabolism. Clin Pharmacokinet. 1985;10(5):426-
431.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics course with emphasis on pharmacokinetics, pharmacodynamics, drug interactions, exercise effects, and clinical considerations. It contains only a single reference explicitly about genetic variability in drug responses (Roden & George), and there is no evidence here that the paper primarily assesses or develops pharmacogenetic approaches. Therefore it is only minimally relevant to pharmacogenetics."
184fe3b1-8614-4aba-a091-2258d97fa1c2,1,"24.   Lenz TL, Lenz NJ, Faulkner MA. Potential interac-
tions between exercise and drug therapy. Sports Med. 
2004;34(5):293-306.",3,2,Processed,"The document is a general pharmacology/clinical therapeutics course with emphasis on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and clinical drug topics. Only one cited reference (#6, Roden & George) explicitly addresses genetic variability in drug responses; there is no substantive treatment of pharmacogenetic methods, testing, or tailored therapeutic approaches. Thus it has minimal relevance to pharmacogenetic approaches."
843fa36f-eba4-485c-b564-08a426009c33,1,"25.   McArdle WD, Katch FL, Katch VL. Exercise Physiology, 
Energy, Nutrition and Human Performance. 3rd ed. Phila-
delphia, PA: Lea & Febiger; 1991.",3,2,Processed,"The document is a general pharmacology/ pharmacotherapeutics course and reference list focused on pharmacokinetics, pharmacodynamics, exercise effects, and drug delivery. It contains only a single clear genetics-focused citation (Roden & George, 2002 on genetic basis of drug response) and no evident discussion, methods, or primary assessment of pharmacogenetic approaches. Thus it is minimally but not substantively relevant to pharmacogenetics."
774687bb-99d1-4465-8ca3-76205b251fe9,1,"26.   Brouns F , Saris WH, Rehrer NJ. Abdominal complaints 
and gastrointestinal function during long-lasting exercise. 
Int J Sports Med. 1987;8(3):175-189.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, drug interactions, and exercise effects on drug therapy. Only a single cited reference (Roden & George, 2002) directly addresses the genetic basis of variability in drug responses; there is no substantive emphasis or multiple citations on pharmacogenetic methods or approaches. Therefore it is minimally but not primarily relevant to pharmacogenetics."
da3e1d59-3fda-4025-b0fb-bda3f14bed38,1,"27.   Cordain L, Latin RW , Behnke JJ. The effects of an aerobic 
running program on bowel transit time. J Sports Med Phys 
Fitness. 1986;26(1):101-104.",3,2,Processed,"The document is a general pharmacology/PK‑PD reference list and course material focused on pharmacotherapeutics, pharmacokinetics, exercise effects, stereoselectivity, and drug interactions. It contains only a single citation explicitly about genetic variability in drug responses (Roden & George), and no substantive emphasis on pharmacogenetic methods, genotype‑guided therapy, or detailed assessment of pharmacogenetic approaches. Therefore it is minimally but not directly relevant to pharmacogenetics."
3b668fc8-717e-4dfd-bea4-161b50abc91f,1,"28.   Klemsdal TO, Gjesdal K, Bredesen JE. Heating and 
cooling of the nitroglycerin patch application area modify 
the plasma level of nitroglycerin. Eur J Clin Pharmacol. 
1992;43(6):625-628.",3,2,Processed,"The document is a reference list for a general pharmacotherapeutics course focused mainly on pharmacokinetics, pharmacodynamics, drug delivery, and exercise–drug interactions. Only one cited item (reference 6: “The genetic basis of variability in drug responses”) directly addresses genetics; there is no substantive focus on pharmacogenetic approaches, methods, or data. Therefore relevance to pharmacogenetics is minimal."
e6a15e80-b6bc-4556-85c6-5e211a75d270,1,"29.   van Baak MA. Influence of exercise on the pharmacoki-
netics of drugs. Clin Pharmacokinet. 1990;19(1):32-43.",3,2,Processed,"The document is a general pharmacology/therapeutics course bibliography focused on pharmacokinetics, pharmacodynamics, drug–exercise interactions, and clinical drug principles. It contains a single reference that touches on genetic variability in drug responses (Roden & George) but does not otherwise address pharmacogenetic methods, testing, or approaches. Therefore it is only minimally relevant to pharmacogenetics."
d97e8297-58ab-4d7a-aaa0-0b905d596898,1,"30.   Villa JG, Bayon JE, Gonzalez-Gallego J. Changes in 
metabolism and urinary excretion of antipyrine induced 
by aerobic conditioning. J Sports Med Phys Fitness. 
1999;39(3):197-201.",3,2,Processed,"The document is a general pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and clinical pharmacology. Only one cited item (Roden & George, 2002) explicitly addresses genetic variability in drug responses, and there is no substantive focus on pharmacogenetic methods, testing, or implementation. Therefore it has minimal relevance to pharmacogenetic approaches."
f8a53647-7e99-4c85-a532-89cd26453aef,1,"31.   Stoschitzky K, Lindner W , Klein W . Stereoselective release 
of (S)-atenolol from adrenergic nerve endings at exercise. 
Lancet. 1992;340(8821):696-697.",3,2,Processed,"The document is a broad pharmacology/pharmacotherapeutics reference list focused on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and clinical drug topics. It contains a single directly relevant citation (Roden & George, 2002) on the genetic basis of variability in drug responses, but the overall content and many references do not assess pharmacogenetic approaches. Thus pharmacogenetics is only minimally represented."
5d11b91f-6f38-4af9-ae4b-7f5e45442014,1,"32.   Ylitalo P , Hinkka H. Effect of exercise on plasma 
levels and urinary excretion of sulphadimidine and 
procainamide. Int J Clin Pharmacol Ther T oxicol. 
1985;23(10):548-553.",3,2,Processed,"The document is a general pharmacology/PK-PD course with many references on pharmacokinetics, pharmacodynamics, exercise–drug interactions, and drug delivery. Only one cited reference (#6: Roden & George) specifically addresses the genetic basis of drug response; there is no evidence the paper primarily evaluates pharmacogenetic approaches or contains substantial pharmacogenetics analysis. Therefore it is minimally but not meaningfully relevant to pharmacogenetics."
f51088bb-a742-4194-8889-4e64ce59822a,1,"33.   Ciccone CD. Basic pharmacokinetics and the potential 
effect of physical therapy interventions on pharmacokinet-
ic variables. Phys Ther. 1995;75(5):343-351.",3,2,Processed,"This document is a broad pharmacology course/reference list focused on pharmacokinetics, pharmacodynamics, exercise and drug interactions. It contains only a single explicit citation addressing genetic variability in drug responses (Roden & George, 2002) and no sustained coverage or emphasis on pharmacogenetic approaches, so pharmacogenetics is only minimally represented."
144a1a7b-c272-4065-b6be-a23cb1599a13,1,"Lohoff, F. W., and Ferraro, T. N. (2010). Pharmacogenetic considerations in the treatment of psychiatric disorders.Expert Opin. Pharmacother. 11, 423– 439. doi:10.1517/14656560903508762",3,2,Processed,"The review focuses on plant polyphenols, mechanisms of antidepressant action and nanoformulations. It contains only a brief section mentioning candidate genes (5-HTTLPR, BDNF Val66Met) in the context of depression etiology, but it does not evaluate pharmacogenetic approaches, drug–gene interactions, or genotype-guided treatment strategies. Hence minimal relevance to pharmacogenetics."
d05c14e7-1633-4ca5-a604-8c631084e158,1,"Salazar de Pablo, G., Studerus, E., Vaquerizo-Serrano, J., Irving, J., Catalan, A., Oliver, D., et al. (2021). Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophr. Bull. 47, 284– 297.",3,2,Processed,"The review focuses on individualized prediction models across psychiatry (diagnostic, prognostic, predictive) with emphasis on clinical, sociodemographic, neuroimaging and other biomarkers. Pharmacogenetic approaches are only marginally represented (genetic predictors in ~2.3% of studies and proteomic in 0.1%), and pharmacogenetics is not a primary focus—only a few predictive models (e.g., antidepressant response, one GWAS-based ML study) touch on genetic data. Thus relevance to pharmacogenetics is minimal."
42259ab9-532f-45f6-b81c-ea2e30496ed7,1,"13. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, World Health Organization, 2002.",3,2,Processed,"This WHO Assembly document is a broad collection of resolutions on public‑health topics. It includes a general resolution on genomics and world health (WHA57.13) that calls for capacity‑building, ethical/regulatory frameworks and research coordination, but it does not assess or focus on pharmacogenetic approaches specifically. Thus it has only minimal indirect relevance to pharmacogenetics (through the genomics theme), not a substantive evaluation of pharmacogenetic methods or applications."
8a292ed7-def8-4296-ab3d-4bab53ef5a7c,1,"16. Burt VL et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 1995, 25:305-313.",3,2,Processed,"This is an epidemiologic review of hypertension in Black populations focusing on prevalence, risk factors, and genetic epidemiology. It discusses candidate genes and molecular genetics but contains no substantive analysis of genetic influences on drug response or personalized therapy. It briefly mentions pharmacologic control rates but does not address pharmacogenetic approaches, so relevance is very low."
882969b1-9fff-4890-aacd-eb1da2c36158,1,"20. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda, MD, National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, National Institutes o",3,2,Processed,"This is a clinical guideline on hypertension (JNC7) focused on prevention, diagnosis, and treatment. Although the table of contents includes a brief section titled “Genetics of Hypertension,” the report is not an assessment of pharmacogenetic approaches and contains no substantive evaluation of genotype-guided drug selection or pharmacogenetic strategies. Therefore relevance to pharmacogenetics is minimal."
0bc9dd63-3fd7-46df-b840-ca4cffea5ab0,1,"41. Marion RJ, Creer TL, Reynolds RV . Direct and indirect costs associated with the management of childhood asthma. Annals of Allergy, 1985, 54:31-34.",3,2,Processed,"The report is a broad WHO/NHLBI guideline on asthma epidemiology, pathophysiology, prevention and management. It mentions genetic predisposition (atopy, inheritance of IgE responses) and notes possible steroid resistance mechanisms, but it does not evaluate pharmacogenetic strategies, genotype-guided drug selection, drug–gene interactions, or personalized pharmacotherapy. Therefore it is only minimally related to pharmacogenetics."
bc260c99-9b48-4ea3-8ecc-c89006796f46,1,"42. Mahapatra P . Social, economic and cultural aspects of asthma: an exploratory study in Andhra Pradesh, India. Hyderabad, India, Institute of Health Systems, 1993.",3,2,Processed,"The document is a broad global strategy and clinical/public-health guideline for asthma (definition, epidemiology, mechanisms, diagnosis, management, prevention, education). It discusses genetic predisposition/atopy as risk factors but contains no substantive assessment of pharmacogenetic approaches (drug–gene interactions, genotype-guided therapy, or personalized pharmacotherapy). Thus it is minimally relevant to pharmacogenetics."
933997e4-3fd5-4590-af68-f64ae885bd33,1,"26. Gifford AL et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 2000, 23:386-395.",3,2,Processed,"This is a narrative review of antiretroviral therapy effects on quality of life, adherence, and adverse effects. It contains only brief, passing references to genetics (eg, a single-nucleotide polymorphism in the resistin gene linked to metabolic changes and a genetic analysis implicating resistin in lipodystrophy) but does not evaluate pharmacogenetic testing, genotype-guided prescribing, gene–drug interactions, or tailored therapeutic strategies. Therefore it is minimally relevant to pharmacogenetic approaches."
cb07ef69-b7bc-4c91-960d-59b282cf284a,1,"59. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. 1979.Journal of the Ame",3,2,Processed,"This is a clinical guideline (JNC7) focused on epidemiology, classification, measurement, prevention, and treatment of hypertension with lifestyle and pharmacologic recommendations. While the table of contents lists a brief “Genetics of Hypertension” section, the document is not about pharmacogenetic approaches and contains no substantive discussion of genotype-guided therapy, drug–gene interactions, or use of genetic testing to select or dose antihypertensive drugs. Hence it is minimally relevant to pharmacogenetics."
c2f30435-9730-4ba1-8309-700323109e60,1,"16. Hasford JM. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. Journal of Human Hypertension,2002, 16:569-575.",3,2,Processed,"This is a general pharmacology/clinical review of irbesartan focusing on pharmacokinetics, efficacy, safety, and clinical trials. It contains only a brief mention of a single pharmacogenetic finding (CYP2C9*3 affecting irbesartan levels in a Chinese population) and does not assess pharmacogenetic approaches, testing, or personalized therapy in depth. Therefore pharmacogenetics is minimally represented."
ded42ed5-89a8-4327-b765-310bc9eaf808,1,"25. Taggart VS et al.You can control asthma: evaluation of an asthma education program for hospitalized inner-city children. Patient Education & Counseling,1991, 17:35-47.",3,2,Processed,"This WHO/NHLBI asthma strategy report focuses on epidemiology, pathophysiology, diagnosis, prevention, clinical management and education. It discusses genetic predisposition/atopy in risk-factor context but does not evaluate pharmacogenetic approaches (drug response by genotype) or personalized pharmacogenomic strategies. Therefore it is minimally relevant to pharmacogenetics."
521887e4-0be9-4914-945c-5c38ecc7551d,1,"36. Ward S et al. Patient education in pain control. Supportive Care in Cancer, 2001, 9:148-155.",3,2,Processed,"This is a broad clinical review of cancer pain management (WHO ladder, opioids, adjuvants, interventional therapies, barriers, etc.) and is not focused on pharmacogenetics. It contains only a brief mention of genetic variability affecting codeine metabolism (poor metabolizers) but does not assess pharmacogenetic approaches, testing, or strategies. Therefore relevance to pharmacogenetics is minimal."
c7af6dca-d30b-4568-990d-437f8d36c71f,1,"Chin, C.-S., Wagner, J., Zeng, Q., Garrison, E., Garg, S., Fungtammasan, A., et al. (2020). A diploid assembly-based benchmark for variants in the major histocompatibility complex. Nat. Commun. 11 (1), 4794. doi:10.1038/s41467-020-18564-9",3,2,Processed,"The paper focuses on applications of long‑read sequencing to cancer genomics (germline/somatic SVs, transcriptomics, methylation, benchmarking, clinical translation). It does not evaluate pharmacogenetic approaches or discuss drug–gene interactions in depth; pharmacogenes are only mentioned briefly as an example of genes that can be impacted by structural variation. Therefore relevance to pharmacogenetics is minimal."
d2cbefc9-401a-41a5-8dd9-d3b4b71c6822,1,"Hari, A., Zhou, Q., Gonzaludo, N., Harting, J., Scott, S. A., Qin, X., et al. (2023). An efﬁcient genotyper and star-allele caller for pharmacogenomics.Genome Res. 33 (1), 61–70. doi:10.1101/gr.277075.122",3,2,Processed,"The paper focuses on KIR (immunogenetics) allele and copy‑number genotyping and benchmarking of KIR-specific tools. It only references pharmacogenomic tools and methods (e.g., Aldy, Stargazer) as methodological inspiration/comparison; it does not assess pharmacogenetic loci, drug-response variants, or pharmacogenetic workflows. Thus it has minimal relevance to pharmacogenetics."
f73c42b2-c723-41b0-9cb9-f6b4f13401cb,1,"Thuesen, N. H., Klausen, M. S., Gopalakrishnan, S., Trolle, T., and Renaud, G. (2022). Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions.Front. Immunol.,1 3–2022. doi:10.3389/ﬁmmu.2022.987655",3,2,Processed,"The paper focuses on developing and evaluating T1K for KIR and HLA genotyping (immunogenetics) from sequencing data. It is not about pharmacogenetic approaches; pharmacogenetics is only briefly mentioned as a potential application (e.g., CYP2D6/PharmVar) in the Discussion. Thus it is only minimally relevant to pharmacogenetics."
84e47dbc-8a0e-4ecd-a238-934386a51bf4,1,58. Marchant B. Pharmacokinetic factors influencing variability in Human Drug Response. Scand J Rheumatol. 1981;10(sup39):5–14.  h t t  p s : /  / d o  i .  o r g / 1 0 . 3 1 0 9 / 0 3 0 0 9 7 4 8 1 0 9 0 9 5 3 2 8     .,3,2,Processed,"The thesis focuses on diagnostic criteria, biomarkers, mast cell biology, and clinical/ laboratory evaluation of MCAS. It discusses genetic findings (e.g., KIT mutations, TPSAB1 copy number/HαT) and mentions targeted therapies for mastocytosis, but it does not assess how genetic variation informs drug selection, dosing, or individualized pharmacologic response. Thus it has minimal relevance to pharmacogenetic approaches."
95cd1096-56ef-49c2-975a-9eace93247ce,1,"Wildin, R.S.; Messersmith, D.J.; Houwink, E.J.F. Modernizing family health history: Achievable strategies to reduce implementation gaps. J. Community Genet.2021, 12, 493–496. [CrossRef]",3,2,Processed,"The paper is primarily about assessing family health history (FHH) apps and ISO-based quality review; pharmacogenetics is only mentioned briefly as an example/use case (family medication history and pharmacogenomic data could be included in FHH pedigrees and future work). It does not evaluate or analyze pharmacogenetic approaches or methods in any depth, so relevance is minimal but not entirely absent."
c8c2dc66-da7f-4da7-8e97-6b7c087ae6ba,1,"Ginsburg, G.S.; Wu, R.R.; Orlando, L.A. Family health history: Underused for actionable risk assessment. Lancet 2019, 394, 596–603. [CrossRef]",3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and ISO-based quality review processes. Pharmacogenomics/pharmacogenetic content is only mentioned briefly—as an example of data types that could be linked (family medication history, pharmacogenomic results) and as a suggested future enhancement—without any substantive assessment, methodology, results, or discussion of pharmacogenetic approaches. Hence minimal relevance."
03097c1d-b810-4c62-943f-01b72b6c8527,1,"Hujoel, M.L.; Loh, P .R.; Neale, B.M.; Price, A.L. Incorporating family history of disease improves polygenic risk scores in diverse populations. Cell Genom.2022, 2, 100152. [CrossRef]",3,2,Processed,"The paper is primarily about evaluating family health history (FHH) apps and an ISO-based quality review process. Pharmacogenetics is only mentioned briefly (examples suggesting inclusion of family medication history and pharmacogenomic results, and a general note about pharmacogenomic innovations) and is not assessed or explored in depth. Therefore it has very low relevance to pharmacogenetic approaches."
8bd11226-9c0b-45ca-bfb2-ac6c0a717ce0,1,"Allen, C.G.; Duquette, D.; Guan, Y.; McBride, C.M. Applying theory to characterize impediments to dissemination of community-facing family health history tools: A review of the literature. J. Community Genet.2020, 11, 147–159. [CrossRef]",3,2,Processed,"The paper is focused on evaluating family health history (FHH) apps and an ISO-based quick review process; pharmacogenetics is only briefly mentioned (e.g., suggesting inclusion of family medication history and pharmacogenomic results in pedigrees) and is not assessed or developed in the paper. Thus it has minimal, incidental relevance to pharmacogenetic approaches."
8ecf0b16-f7ac-486e-a3f7-4ea9bfa54fce,1,"Wu, R.R.; Orlando, L.A. Implementation of health risk assessments with family health history: Barriers and beneﬁts. Postgrad. Med. J.2015, 91, 508–513. [CrossRef] [PubMed]",3,2,Processed,"The paper is focused on evaluating family health history (FHH) apps and an abbreviated quality review process (ISO/TS 82304-2). Pharmacogenetics/pharmacogenomics are only briefly mentioned as examples or future opportunities (e.g., family medication history and including pharmacogenomic results in pedigrees) and are not assessed or analyzed in the study. Thus it is minimally relevant to pharmacogenetic approaches."
a1a8b83f-3533-4487-91bb-98e35b5a7363,1,"Lin, J.; Marcum, C.S.; Myers, M.F.; Koehly, L.M. Put the Family Back in Family Health History: A Multiple-Informant Approach. Am. J. Prev. Med.2017, 52, 640–644. [CrossRef]",3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and ISO-based quality review processes. Pharmacogenetics is mentioned only peripherally (e.g., recommending inclusion of family medication history and linking to pharmacogenomic records) but the manuscript does not assess pharmacogenetic approaches, methods, data, or clinical implementation in any substantive way. Thus relevance to pharmacogenetics is minimal."
b1365ab3-57c0-451b-84d3-fe5d7aa1a9f0,1,"Welch, B.M.; Dere, W.; Schiffman, J.D. Family Health History: The case for better tools. JAMA 2015, 313, 1711–1712. [CrossRef]",3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and ISO-based quality review processes. Pharmacogenetics is only mentioned briefly (e.g., as a potential application, family medication history and pharmacogenomic results should be included), but the manuscript contains no substantive assessment, methods, data, or discussion of pharmacogenetic approaches. Thus it is minimally relevant."
9c7f20ab-74b5-4cc7-ab10-9b2d015aeba8,1,"Manolio, T.A.; Chisholm, R.L.; Ozenberger, B.; Roden, D.M.; Williams, M.S.; Wilson, R.; Bick, D.; Bottinger, E.P .; Brilliant, M.H.; Eng, C.; et al. Implementing genomic medicine in the clinic: The future is here. Genet. Med.2013, 15, 258–267. [CrossRef]",3,2,Processed,"The article is a broad review of integrating genomics into healthcare, national initiatives, data sharing, and evidence-generation. It only briefly mentions pharmacogenomics (e.g., the Southeast Asian Pharmacogenomics Research Network and drug-response examples) as illustrative examples, but does not assess pharmacogenetic approaches in detail. Therefore relevance to pharmacogenetics is minimal."
ff8ed4ee-85e8-4864-90b1-b948a7b75437,1,"David, S.P .; Johnson, S.G.; Berger, A.C.; Feero, W.G.; Terry, S.F.; Green, L.A.; Phillips, R.L.; Ginsburg, G.S. Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable. Ann. Fam. Med. 2015, 13, 373–",3,2,Processed,"The paper is a qualitative study of primary care providers’ experiences and attitudes toward integrating genetics into practice (family history, referrals, education, access and rural vs urban barriers). It does not evaluate or assess pharmacogenetic approaches; pharmacogenetics is only mentioned in passing (one sentence about genetic profiles to direct drug therapy) and there are no methods, results, or recommendations specific to pharmacogenetics."
2dc08b5a-1e4b-47ed-93d1-34f5da6e821d,1,"Hantula, D.A. Editorial: Reductionism and Holism in Behavior Science and Art. Perspect. Behav. Sci.2018, 41, 325–333. [CrossRef]",3,2,Processed,"The paper is primarily about evaluating family health history (FHH) apps using an ISO-based quick review; pharmacogenetics is only briefly mentioned as a potential use case (e.g., family medication history, pharmacogenomic results, and integrating pharmacogenomics into treatment workflows) and cited in passing. It does not assess pharmacogenetic approaches, methods, or evidence in any depth."
726b4ebb-c465-4958-85bc-00e666ca406c,1,"Smith, T.R.; Kearney, E.; Hulick, P .J.; Kisor, D.F. History repeats itself: The family medication history and pharmacogenomics. Pharmacogenomics 2016, 17, 669–678. [CrossRef]",3,2,Processed,"The paper is primarily about assessing family health history (FHH) apps and an abbreviated quality review process based on ISO/TS 82304-2. Pharmacogenetics/pharmacogenomics are mentioned only briefly as illustrative examples (e.g., family medication history should be included, and genomic/pharmacogenomic data could be linked), and as a suggested future enhancement. The manuscript does not evaluate pharmacogenetic approaches, perform analyses, or focus on PGx methods, so relevance to pharmacogenetics is minimal."
95d93984-842c-43cb-89e3-929623048743,1,"Facio, F.M.; Feero, W.G.; Linn, A.; Oden, N.; Manickam, K.; Biesecker, L.G. Validation of My Family Health Portrait for six common heritable conditions. Genet. Med.2010, 12, 370–375. [CrossRef]",3,2,Processed,"The paper primarily focuses on assessing family health history (FHH) apps and an abbreviated ISO-based quality review for primary care; pharmacogenetics is only mentioned briefly (family medication history and including pharmacogenomic results as a potential future enhancement) and is not analyzed or assessed. Thus it is minimally relevant, not a focal topic."
1b7f7127-fbea-41fe-beb1-5aa17c77c86c,1,International Standards Organization (ISO). Available online: https://www.iso.org/home.html (accessed on 1 June 2022).,3,2,Processed,"Pharmacogenetics is only briefly mentioned in passing (e.g., advocacy for including family medication history and pharmacogenomic results in FHH pedigrees, and noting pharmacogenomic data as part of a genomic record). The paper’s primary focus is on assessing family health history apps and applying ISO/TS 82304‑2 — it does not evaluate or analyze pharmacogenetic approaches, methods, evidence, or outcomes."
612015f6-1565-4d05-939e-ccc24fac4cfc,1,ISO. ISO/TS 82304-2:2021 Health Software—Part 2: Health and Wellness Apps—Quality and Reliability. Available online: https://www.iso.org/standard/78182.html (accessed on 1 June 2022).,3,2,Processed,"The paper briefly mentions pharmacogenomics and family medication history as potential uses of family health history apps and suggests including pharmacogenomic results in pedigrees, but it does not evaluate, analyze, or assess pharmacogenetic approaches or tools. Pharmacogenetics is only a peripheral topic rather than the focus of the study."
52c73b83-c0f6-495f-aca9-4d3b86f19eb7,1,The European Union. mHealth Label Published. Available online: https://digital-strategy.ec.europa.eu/en/news/mhealth-label-published (accessed on 1 June 2022).,3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and an abbreviated quality review process (ISO/TS 82304-2). Pharmacogenetics is only mentioned briefly (e.g., family medication history and pharmacogenomics as a potential use case or data type to integrate) but is not assessed or analyzed in depth. Thus pharmacogenetics is a minor, peripheral topic rather than the paper’s subject."
fc4d236d-6f76-449a-a1dd-fd29108b344f,1,Stichting Koninklijk Nederlands Normalisatie Instituut. New International Guidelines to Help to Sort the Best from the Rest. Available online: https://www.nen.nl/en/health-and-welness-apps (accessed on 1 June 2022).,3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and an abbreviated ISO-based quality review process. Pharmacogenetics is mentioned only briefly as an example (family medication history and pharmacogenomic results could be included in FHH pedigrees) and cited as a potential future integration. The manuscript does not assess pharmacogenetic approaches, methods, evidence, or clinical implementations in any depth, so relevance to pharmacogenetics is minimal."
5e10e4cc-d582-4cb6-b089-10e3adaa028f,1,Table 1 Only from the Paper Cited in Reference #1 Above. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8 241955/table/Tab1/?report=objectonly (accessed on 1 June 2022).,3,2,Processed,"The paper focuses on evaluating family health history (FHH) apps and an abbreviated ISO-based quality review for primary care; pharmacogenetics is only mentioned briefly as an example/possible extension (family medication history and pharmacogenomic results) and not assessed or analyzed. Thus pharmacogenetic approaches are only tangentially noted, not a subject of evaluation."
c2bc6f6f-027d-4d1f-a133-8e607def2696,1,Global Genomic Medicine Collaborative. Family Health History. Available online: https://g2mc.org/family-health-history/ (accessed on 1 June 2022).,3,2,Processed,"The paper is primarily about evaluating family health history (FHH) apps using an ISO-based quick review and interoperability/implementation issues. Pharmacogenomics/pharmacogenetic approaches are only briefly mentioned as examples (e.g., inclusion of pharmacogenomic results or family medication history) and as part of broader genomic data integration; the manuscript does not assess pharmacogenetic methods, evidence, or clinical approaches in any depth."
2ec9a4a8-87bc-4f25-9cb3-c78183fa1d6d,1,"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).",3,2,Processed,"This is a large GWAS/meta-analysis identifying Alzheimer’s disease risk loci, pathways and prioritized genes and discussing potential therapeutic targets and genetic risk scores. However, it does not evaluate drug response, gene–drug interactions, dose adjustment, or clinical pharmacogenetic biomarkers or strategies. Thus it is minimally relevant to pharmacogenetics (translational/target implications only), not an assessment of pharmacogenetic approaches."
d3891fd9-ef5c-4532-8092-84088633d4cf,1,"Andrews, S. J. et al. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine 90, 104511 (2023).",3,2,Processed,"The editorial summarizes genetics, biomarkers, imaging, and various therapies for AD/PD/dementia but contains no substantive discussion of pharmacogenetics (i.e., genetic predictors of drug response, drug–gene interactions, or personalized drug dosing). Only general genetics findings and therapeutic strategies are mentioned, so relevance to pharmacogenetic approaches is minimal."
846d6f5d-78ad-4a21-8577-92d0148c5357,1,"Bothongo, P. L. K. et al.  Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Reg. Health Eur. 15, 100321 (2022).",3,2,Processed,"The paper analyzes common genetic variation and population-attributable risk for Alzheimer’s and Parkinson’s across ancestries and discusses prioritizing therapeutic targets, but it does not evaluate pharmacogenetic approaches (i.e., genotype-guided drug response, dosing, metabolism, or treatment stratification based on pharmacokinetic/pharmacodynamic variants). Thus it’s only tangentially related to therapeutics, not pharmacogenetics per se."
fa351726-1c3f-43ea-ae8c-59e242c84dc0,1,"Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404, 572–628 (2024).",3,2,Processed,"The report is a broad, multidisciplinary review of dementia prevention, intervention, and care and only briefly touches on genetics (eg, APOE ε4, biomarker use, and mention of genetic testing and differential risks with anti‑amyloid therapies). It does not evaluate or develop pharmacogenetic approaches (drug selection or dosing tailored by genotype) in any depth, so relevance to pharmacogenetics is minimal."
a55432a5-a7a1-4c75-806d-6737b617b1f0,1,"Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019).",3,2,Processed,"The paper focuses on targeting tau pathology with antisense oligonucleotides and reviews therapeutic and biomarker developments in Alzheimer’s disease. It is not about pharmacogenetics (i.e., how genetic variation affects drug response). It only briefly mentions protective genetic variants in familial AD as disease biology, not as a basis for pharmacogenetic strategies, dosing, or response prediction, so relevance to pharmacogenetics is minimal."
7a718724-528f-4c78-bd20-36d0ec10dabe,1,NICE guideline on dementia,3,2,Processed,"The guideline is about clinical assessment and management of dementia and standard pharmacological treatments. It only briefly mentions genetics (young-onset genetic causes) and advises against APOE genotyping for diagnosis, but it contains no evaluation of pharmacogenetic testing to guide drug choice, dosing or outcomes. Thus it is minimally relevant to pharmacogenetics."
4bd19b9f-37cd-47ab-a24f-c01e19e47df4,1,"Pereira NL at al ; American Heart Association Professional/Public Education and Publications Committee of the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nur",3,2,Processed,"This ESC guideline is primarily a comprehensive clinical practice document on blood pressure measurement, risk stratification, and management (lifestyle, pharmacotherapy, devices, special populations). It briefly includes sections/recommendations on genetic testing and genetic contributors to secondary forms of hypertension (e.g. primary aldosteronism, familial conditions) and mentions genetic testing in the work-up, but it does not focus on or systematically assess pharmacogenetic approaches to guide antihypertensive drug choice or dosing. Thus pharmacogenetics is only marginally addressed rather than being a substantive topic of the paper."
2b8b5124-9605-476f-93bc-611cf3d1bbbc,1,"Chew SM, Lee JH, Lim SF, Liew MJ, Xu Y, Towle RM. Prevalence and predictors of medication non-adherence among older community-dwelling people with chronic disease in Singapore. J Adv Nurs. 2021;77:4069–80.",3,2,Processed,"The paper is primarily an observational study of colchicine adherence in pediatric FMF. It reports MEFV genotypes (e.g., M694V homozygosity) and an association with non‑adherence, but it does not evaluate pharmacogenetic methods, genotype‑guided dosing, drug metabolism, or personalized therapy strategies. Therefore it has only a minor, indirect genetic mention and is not focused on pharmacogenetics."
da306052-5767-46b0-a1ef-b4ed0bc7c64c,1,"Lam WY, Fresco P . Medication adherence measures: an overview. Biomed Res Int. 2015;2015:1–12.",3,2,Processed,"The review focuses on medication nonadherence and its clinical/economic consequences across diseases. It only briefly mentions interindividual biological response, pharmacokinetics/pharmacodynamics, and the need for personalized approaches, but it does not assess or evaluate pharmacogenetic methods, data, or interventions. Hence very low relevance to pharmacogenetics."
76b5ee9a-7182-4869-822f-0ceb46305b40,1,"4. Wann LS, Alpert LS, Calkins H, Cigarroa JE, Cleveland JC, Jr., et al. AHA/ACC/HRS guide - line for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Gui",3,2,Processed,"This guideline is focused on clinical management of atrial fibrillation (diagnosis, stroke prevention, rate/rhythm control, ablation, etc.). It briefly mentions genetic susceptibility/familial AF in places but does not assess or review pharmacogenetic approaches (e.g., genotype-guided drug dosing or drug–gene interactions such as VKORC1/CYP2C9-guided warfarin therapy). Thus pharmacogenetics is at most peripherally noted and not a subject of evaluation."
0079c0e4-60c6-4b9b-99c4-51c6ccaa8410,1,"12. Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018; 11(7): e006350. DOI: https://d",3,2,Processed,"The editorial only makes a brief, passing mention of “genetic variations” as one of many challenges with warfarin; it does not evaluate or discuss pharmacogenetic testing, genotypes, gene–drug interactions, genotyping methods, or results. The cited study and the editorial focus on health literacy and anticoagulation quality (INR/TTR), not pharmacogenetic approaches, so relevance to pharmacogenetics is minimal."
40cf0c98-98c9-4f6c-9c7f-2ba593d9304b,1,"41.  Nguyen TN, Hilmer SN, Cumming RG.  Review of epidemiology and management of atrial fibrilla - tion in developing countries. Int J Cardiol . 2013; 167(6): 2412–20. DOI: https://doi.org/10.1016/j. ijcard.2013.01.184",3,2,Processed,"The review is not focused on pharmacogenetics. It only briefly mentions genomics integration and AI-enabled prediction (e.g., combining genetic risk scores with ECG data and an AI study predicting in‑silico drug responses), but it does not assess genotype‑guided therapy, pharmacogenomic markers, drug metabolism polymorphisms, or provide substantive analysis of pharmacogenetic approaches. Therefore relevance to pharmacogenetics is minimal."
229cfb42-0d4d-459d-8225-6365e7d857b0,1,"56. Misialek JR, Rose KM, Everson‐Rose SA, Soliman EZ, Clark CJ, Lopez FL, et al. Socioeconomic status and the incidence of atrial fibrillation in whites and blacks: The Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc. 2014; 3(4): e0011",3,2,Processed,"The CV describes extensive epidemiologic and pharmacoepidemiology work on arrhythmias, anticoagulants, and drug outcomes, and includes some genetic and proteomic studies. However, it does not present studies of genotype-guided therapy or investigations of genetic variants affecting drug response (pharmacogenetics) as a primary focus. Thus relevance to pharmacogenetic approaches is minimal."
888fff88-ae72-423b-b62c-8a6043368b58,1,"123. Marshall DA, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G,  et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med. 2004; 141(9): 653–61. DOI: https://doi.org/10.7326/0003-4819-141-9-200411020-00005",3,2,Processed,"The consensus focuses on clinical management of atrial fibrillation in the elderly (anticoagulation, risk scores, geriatric assessment, drug choices and interactions). It contains only a brief, incidental mention of a genetic factor (CYP2C9) in the Hemorr2hages score but does not assess pharmacogenetic testing, genotype-guided dosing, or broader pharmacogenetic approaches. Therefore pharmacogenetics is minimally and tangentially covered."
8e67502d-9316-430b-ad3b-14d81be8ac56,1,"129. Markey GC, Salter N, Ryan J.  Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. J Emerg Med . 2018; 54(3): 320–7. DOI: https://doi.org/10.1016/j. jemermed.2017.11.016",3,2,Processed,"This is a comprehensive clinical guideline on atrial fibrillation management focused on diagnostics, anticoagulation, rate/rhythm control, comorbidity management, and service delivery. It contains occasional references to genetics, GWAS, and polygenic risk for AF, but there is no substantive assessment of pharmacogenetic approaches (no discussion of genotype-guided drug selection, dosing, or drug–gene interactions). Therefore pharmacogenetics is only marginally mentioned and not a focus."
3cdbc415-02ba-456b-97d0-4e446ff633d0,1,"155. Hicks T, Stewart F, Eisinga A.  NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open heart. 2016; 3(1): e000279. DOI: https://doi.org/10.1136/ openhrt-2015-000279",3,2,Processed,"The document is an HTA report listing many studies on oral anticoagulants (clinical trials, observational studies, safety/effectiveness, cost-effectiveness). Only a single entry (Pink et al.: ""Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. Alternative anticoagulation"") explicitly addresses pharmacogenetics; the vast majority of items do not. Thus pharmacogenetic assessment is only minimally represented, not a primary focus."
ac19c3f1-8d02-4a53-879d-2a75d7bb84e7,1,"165. Karthikeyan G, Connolly SJ, Ntsekhe M, Benz A, Rangarajan S, Lewis G, et al. The INVICTUS rheu - matic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonis",3,2,Processed,"The review focuses on rheumatic fever/rheumatic heart disease: epidemiology, pathogenesis, genetics (HLA, GWAS), vaccines, diagnostics, and prevention/management. It discusses host genetic susceptibility and bacterial resistance, but it does not evaluate drug–gene interactions, genotype-guided drug selection/dosing, or pharmacogenetic strategies. Thus it is minimally relevant to pharmacogenetics."
9c66ddb4-c820-4010-9ecb-b643275a7155,1,"166. Guimarães HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F,  et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020; 383(22): 2117–26. DOI: https://doi.org/10.1056/NEJMoa20296",3,2,Processed,"This is an ESC clinical guideline on atrial fibrillation focused on diagnosis, AF‑CARE (comorbidity/risk‑factor management), anticoagulation, rate/rhythm control, ablation, screening, and related clinical pathways. It does not evaluate pharmacogenetic strategies or recommend genotyping for drug selection/dosing. There are a few peripheral references to genetics/GWAS or polygenic risk scores in the bibliography, but pharmacogenetics is not an assessed topic, so relevance is minimal."
0b59678f-2044-4043-a7f7-2da952987aee,1,"189. Martinez C, Wallenhorst C, Rietbrock S, Freedman B.  Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study. J Am Heart Assoc. 2020; 9(2): e014376. DOI: https",3,2,Processed,"The guide is a clinical practical document on NOAC use in AF, focusing on pharmacology, dosing, renal/hepatic issues, interactions, peri‑procedural management and adherence. It does not assess pharmacogenetic approaches beyond brief, peripheral mentions (in references/discussion of warfarin dosing algorithms and genotype-guided VKA dosing) and contains no substantive evaluation of pharmacogenetics for NOACs. Therefore relevance to pharmacogenetics is minimal."
7512b82f-df0f-41fb-a8ad-a1121d5724bb,1,"203. Eckman MH, Costea A, Attari M, Munjal J, Wise RE, Knochelmann C,  et al. Shared decision- making tool for thromboprophylaxis in atrial fibrillation – A feasibility study. Am Heart J. 2018; 199: 13–21. DOI: https://doi.org/10.1016/j.ahj.2018.01.003",3,2,Processed,"This is a comprehensive 2020 ESC clinical guideline on atrial fibrillation focused on diagnosis, stroke prevention, anticoagulation, rate/rhythm control, ablation, and integrated care. It does not center on pharmacogenetics and contains at most isolated references to genetic factors; there are no substantive genotype-guided recommendations or dedicated sections on pharmacogenetic approaches, so relevance to pharmacogenetics is minimal."
8f18673a-83d6-455d-a30e-87176d4d21d4,1,"207. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,  et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagu - lants in patients with atrial fibrillation: executive summ",3,2,Processed,"This Practical Guide focuses on clinical use of NOACs in atrial fibrillation (drug selection, dosing, interactions, renal/hepatic considerations, peri‑procedural management, bleeding, etc.). It is not centered on pharmacogenetics. There are only brief/limited references to genotype‑guided warfarin dosing and related algorithms in the VKA section and reference list, but no substantive assessment of pharmacogenetic approaches for NOACs or detailed analysis of genetic testing. Thus pharmacogenetics is only a minor, tangential topic."
ac28ef23-3242-47fb-9057-01b2a81f55c8,1,"262. Aune D, Sen A, Schlesinger S, Norat T, Janszky I, Romundstad P, et al. Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: A systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol . 201",3,2,Processed,"The statement focuses on obesity and cardiovascular disease, covering epidemiology, pathophysiology, risk factors, imaging, lifestyle measures, pharmacotherapies and bariatric procedures. It briefly mentions genetic causes of obesity (monogenic, polygenic) and a targeted treatment (setmelanotide) for rare monogenic disorders, but it contains no substantive discussion of pharmacogenetic approaches, drug–gene interactions, genetic testing to guide therapy, or personalized pharmacogenomic strategies. Thus pharmacogenetics is only minimally touched on and is not a focus."
47895eee-2fc0-4d40-8c1b-9fac077f4d14,1,"263. Desai R, Patel U, Singh S, Bhuva R, Fong HK, Nunna P, et al. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: Insights from the National Inpatient Sample. Int J Cardiol. 2019; 281: 49–55. DOI: https://doi.org/10.1016/j.ij",3,2,Processed,"This is the 2020 ESC clinical guideline on atrial fibrillation focusing on diagnosis, integrated management, anticoagulation, rate/rhythm control, ablation, and comorbidity/risk-factor management. It does not assess pharmacogenetic approaches as a topic area or provide genotype-guided recommendations. There are only incidental mentions/references to genetic research in the extensive bibliography, but pharmacogenetics is not a focus of the document."
edb71714-57b8-40e0-88ed-5b3ab245e922,1,"264. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,  et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018",3,2,Processed,"This is a clinical Practical Guide focused on use, dosing, interactions, and management of NOACs in atrial fibrillation. Pharmacogenetics is not a focus — only brief, peripheral mentions (e.g. references to genotype-guided warfarin dosing in the bibliography/late sections) rather than any substantive assessment or analysis of pharmacogenetic approaches."
4166cc97-6d8c-47b4-9ccb-cad086991354,1,"Guttmacher, A. E., Collins, F. S. & Carmona, R. H. The family history—more important than ever.N. Engl. J. Med.351, 2333–2336 (2004).",2,1,Processed,"The editorial discusses family history, genetic testing, genetic literacy and screening for heritable diseases (eg, HNPCC), and the practicalities of recording family history in acute care. It does not address pharmacogenetics or drug–gene interactions, nor does it evaluate pharmacogenetic testing or approaches to drug selection/dosing based on genomic markers."
faf4e47e-30f0-4e2b-8430-ca99c864b9f8,1,"Six, A. J., Backus, B. E. & Kelder, J. C. Chest pain in the emergency room: value of the HEART score.Neth. Heart J.16, 191–196 (2008).",2,1,Processed,"This paper describes the HEART clinical risk score for chest‑pain patients (History, ECG, Age, Risk factors, Troponin) and its performance for predicting myocardial infarction, revascularisation and death. It focuses on clinical assessment, diagnostics and triage in the emergency setting and contains no discussion of genetic testing, drug‑gene interactions, genotype‑guided therapy, or any pharmacogenetic methods or results."
049cd624-1879-4aac-919c-46822816b32e,1,"World Health Organization. Adherence to Long-Term Therapies: Evidence for Action.https://iris.who.int/handle/10665/42682 (World Health Organization, 2003).",2,1,Processed,"The WHO report is a comprehensive review of adherence to long‑term therapies, focusing on behavioural, health‑system, socioeconomic and therapy‑related determinants and interventions. While it discusses treatment tolerability, side‑effects, regimen complexity and monitoring, it contains no analysis of genetic or genomic predictors of drug response, pharmacogenetic testing, or genotype‑guided prescribing. Therefore it does not assess pharmacogenetic approaches."
c2d65347-2d00-437c-aaa0-2a22c173bff6,1,"Finer, S. et al. Cohort proﬁle: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people.Int. J. Epidemiol.49,2 0–21i (2020).",2,1,Processed,"This is a genetic epidemiology/association study of APOE alleles and dementia risk (and related biomarkers) in British South Asians. It does not evaluate drug response, medication–genotype interactions, dosing, pharmacogenetic testing, or treatment stratification. While it mentions implications for prediction, prevention and drug discovery generally, it contains no pharmacogenetic analyses or assessments."
7a658d2e-45cf-4e3a-8e9b-95552a089b3e,1,"Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses.Am. J. Hum. Genet.81, 559–575 (2007).",2,1,Processed,"This supplementary material describes genetic data quality control, population stratification, telomere-length analyses, and comparison of ALS cases (including C9orf72 expansion) versus controls. It is an ALS genomics/association study and contains no discussion of drug response, medication-genotype interactions, or pharmacogenetic testing—so it is not relevant to pharmacogenetic approaches."
6f066746-5fbd-4103-9689-e0465b1dc6e9,1,"National Institute for Health and Care Excellence. BNF: Amitriptyline hydrochloride. https://bnf.nice.org.uk/drugs/amitriptyline-hydrochloride/#indications-and-dose (British National Formulary, 2025).",2,1,Processed,"This patient information leaflet describes amitriptyline use, benefits, side effects, dosing, and precautions but contains no discussion of genetic factors, genotyping, metabolizer phenotypes, or gene–drug interactions. It does not assess or mention pharmacogenetic approaches."
1d8ca441-6e62-4c35-9298-aed31b960771,1,"Ge, L., Heng, B. H. & Yap, C. W. Understanding reasons and determinants of medication non-adherence in community-dwelling adults: a cross-sectional study comparing young and older age groups. BMC Health Serv. Res.23, 905 (2023).",2,1,Processed,"The paper is a population-based cross-sectional study of medication non-adherence (prevalence, reasons, and socio-demographic/clinical factors) in young and older adults. It does not discuss pharmacogenetics, genetic testing, gene–drug interactions, biomarkers, or personalized genotype-guided therapy—so it is not relevant to pharmacogenetic approaches."
f8bf7a15-cc3a-495e-8d28-51012a1fc356,1,"Reading, S. R. et al. Risk factors for medication non-adherence among atrial ﬁbrillation patients.BMC Cardiovasc. Disord.19, 38 (2019).",2,1,Processed,"The roadmap focuses on epidemiology, screening, digital technologies, clinical management (rate/rhythm control), and anticoagulation policy/implementation (NOACs vs VKAs), but it does not evaluate or discuss pharmacogenetic or genomic-guided prescribing strategies. Genetic content is limited to population-level differences and familial risk of AF, not pharmacogenetics (e.g., genotype-guided anticoagulant dosing or CYP/VKORC1 testing). Therefore it is not relevant to assessing pharmacogenetic approaches."
b407e546-1b5c-4071-a174-5b39264a4e0e,2,url:mailto:paul.chin@otago.ac.nz,2,1,Scored,"The paper is an HCI/VR study on conducting in-VR interviews and their effects on presence, rapport, and participant feedback. It discusses virtual environments, avatar representation, and qualitative/quantitative interview methods. There is no discussion of pharmacology, genetics, genotyping, drug response, biomarkers, or any pharmacogenetic approaches."
b363ecfd-d543-4178-b265-806d7001d104,2,url:https://creativecommons.org/licenses/by/4.0/,2,1,Scored,"The papers focus on animal-assisted intervention programs, infection control, hospital implementation frameworks, and a mathematical model of CLABSI/CAUTI prevention (CHG bathing, standardized central-line kits). There is no discussion of genetics, genotypes, drug response, pharmacogenomics, or pharmacogenetic testing—so they are not relevant to pharmacogenetic approaches."
d35ef7a0-e613-401a-92c7-3c325d82da5c,2,url:https://www.frontiersin.org/journals/pharmacology,2,1,Scored,"The paper focuses on biophysical (scalp cooling) and biochemical (antioxidant) strategies to prevent chemotherapy-induced hair follicle damage, with in vitro and ex vivo experiments on ROS, keratinocyte viability, and hair follicle function. It contains no discussion of genetic variation, genotype-guided therapy, pharmacogenetic biomarkers, or patient-specific genetic analyses, so it is not relevant to pharmacogenetic approaches."
d363cbb6-7609-4043-9461-d7121ef4636e,2,url:https://www.frontiersin.org,2,1,Scored,"The paper focuses on biomechanical biomarkers and perturbation-based exercise interventions to prevent gait-related falls in older adults (trunk kinematics, stepping responses, perturbation training). It discusses clinical/biomechanical assessment, epidemiology, and exercise-based prevention — with no discussion of pharmacology, genetics, drug–gene interactions, or pharmacogenetic approaches."
d24a1dd9-7fd7-46b4-a637-00c9bffb7983,2,url:https://www.frontiersin.org/journals/pharmacology#editorial-board,2,1,Scored,"The paper investigates biomechanical/biochemical interventions (scalp cooling and antioxidants) to prevent chemotherapy-induced hair follicle damage using cell and ex vivo follicle models, focusing on ROS and cytoprotection. It contains no assessment of genetic variation, genotyping, biomarker or polymorphism analysis, nor discussion of tailoring therapy based on patient genotypes—i.e., no pharmacogenetic approaches."
9e9ad41e-0fec-4a8f-b99f-df2dbf3abe83,2,url:https://doi.org/10.1093/ijnp/pyy071,2,1,Scored,"The study is a pharmacology/neurobiology paper (rat CCH model, behavioral testing, immunohistochemistry, homology modelling, docking and MD). It examines receptor subunit expression (ε) and zolpidem binding, but contains no genetic analyses, genotyping, polymorphism data, population genetics, or investigation of genetic determinants of drug response — i.e. it does not assess pharmacogenetic approaches."
f87eccdd-226f-4c70-9b1f-778ccff87cff,2,url:https://doi.org/10.1038/tpj.2013.12,2,1,Scored,"The paper investigates psilocybin’s effects on brain effective connectivity (TPJ, insula, AG) and subjective out-of-body experiences using fMRI and DCM. It contains no genetic data, genotyping, discussion of genetic moderators of drug response, metabolic enzymes, or personalized/ pharmacogenetic approaches. A fixed dose was used and grouping was based on subjective scores, not genetic factors, so pharmacogenetics is not addressed."
1a57ce31-87cf-4bba-8dd5-8084ac45498f,2,url:https://doi.org/10.1038/s41398-021-01533-1,2,1,Scored,"The article examines time course and impact of antidepressant side effects, treatment type, and anxiety on outcomes using clinical scales (FIBSER, HRSD17, QIDS-SR16). It contains no discussion of genetic testing, genotypes, pharmacogenetic markers, CYP enzymes, or related methodologies, so it is not relevant to pharmacogenetic approaches."
eb0f2d00-d85d-48cf-9821-4f6b1d7f034c,2,url:https://doi.org/10.2217/pgs-2017-0015,2,1,Scored,"The article focuses on epidemiology, clinical presentation, antimicrobial stewardship, and non‑antimicrobial prevention/treatment options for urinary tract infections in the elderly (e.g., cranberry, OM‑89, estrogen, xyloglucan device). It contains no discussion of pharmacogenetics, genetic markers, genotype‑guided therapy, or related testing — therefore it is not relevant to pharmacogenetic approaches."
d95f1022-8c9c-428b-a6ba-b8e3d51f1036,2,url:https://doi.org/10.1002/cpt.2748,2,1,Scored,"The report focuses on real‑world data (RWD) and real‑world evidence (RWE) for regulatory decision‑making, data sources, study design, ethics and case studies. It does not assess pharmacogenetic approaches; only a single case mentions genotype‑matching in a natural history comparison for a very rare disease, but there is no substantive discussion of pharmacogenetics (gene–drug interactions, genetic biomarkers, or pharmacogenomic study methods). Therefore pharmacogenetics is not a topic of the paper."
438b4c6c-def4-4628-a0d1-15fc3f577a23,2,url:https://doi.org/10.1002/cpt.2354,2,1,Scored,"The report is a broad consensus document on real-world data and real-world evidence for regulatory decision-making. It addresses study design, data sources, ethics, and use cases across the product lifecycle, but does not assess pharmacogenetic approaches. Genomics is only briefly listed among many “big data” examples; there is no focused discussion of pharmacogenetic methods, markers, testing, or implementation. Therefore relevance to pharmacogenetics is negligible."
a7e50a50-0c90-4166-86d2-7c9a2136baa3,2,url:https://doi.org/10.2217/pgs-2022-0087,2,1,Scored,"The review focuses on neuromodulation (SCS, TENS, NMES), AI-driven platforms (EcoAI), cognitive dysfunction, and remote monitoring in chronic pain. It discusses pharmacologic treatments only in passing (risks of opioids, NSAIDs, adjuvants) but contains no discussion of pharmacogenetics, genetic biomarkers, drug–gene interactions, or personalized medication selection based on genotype. Therefore it is not relevant to pharmacogenetic approaches."
0361542d-86c4-436d-89f2-ee278653053f,2,url:https://doi.org/10.1016/S0140-6736(17)32802-7,2,1,Scored,"The document discusses SSRIs, mechanisms of action, guideline recommendations, and comparative effectiveness reviews for MDD, but contains no discussion of genetic testing, pharmacogenomic markers, genotype-guided prescribing, CYP enzymes, or other pharmacogenetic approaches."
6af92b26-654c-4346-8988-7a3eea979026,2,url:https://www.openepi.com/Menu/OE_Menu.htm,2,1,Scored,"The document discusses faculty development programs, leadership academy participants, sample size tools, and AI in medical education. It contains no content on pharmacogenetics, pharmacogenomic testing, drug–gene interactions, or related methodologies, so it is not relevant to pharmacogenetic approaches."
5c7dadba-cb38-42ef-bd47-b7b35ad55a6e,2,url:https://doi.org/10.7717/peerj.7860,2,1,Scored,"The paper investigates in vitro colonization of Lactiplantibacillus plantarum in human colonic microbiota and identifies valerate as a carrying-capacity modulator. It focuses on microbial ecology, community composition, and metabolite effects (SCFAs) in continuous fermentation models — not on drug response, human genetic variation, genotype–phenotype interactions, or pharmacogenetic methods. Therefore it is not relevant to pharmacogenetic approaches."
3f2e4972-55de-45f1-af2a-2c8b9c6f6957,2,url:https://doi.org/10.1016/j.euroneuro.2018.05.009,2,1,Scored,"This CV documents research on literacy, reading/writing development, dyslexia, and some genetics (GWAS, dyslexia loci) but contains no discussion of pharmacogenetics, drug response, medications, pharmacokinetics, or related clinical pharmacology. Therefore it is not relevant to pharmacogenetic approaches."
bd1cf986-3fb1-4c0b-8f68-887250675689,2,url:https://doi.org/10.1002/cpt.2321,2,1,Scored,"The report focuses on real‑world data/evidence, regulatory decision‑making, data sources, methods, and ethics — not on pharmacogenetics. There are only incidental mentions (e.g., a genotype‑matched natural history control in one rare‑disease case study and a brief listing of genomics among ‘big data’ types), but no substantive assessment or discussion of pharmacogenetic approaches, biomarkers, gene–drug interactions, or tailored drug response strategies."
6a92cc3b-257a-40e7-b3b4-fcef290c0bc8,2,url:https://doi.org/10.1002/cpt.910,2,1,Scored,"The report focuses on real-world data/evidence, regulatory use, study design, data sources, and ethics. It does not assess pharmacogenetic approaches; only a single passing mention of genotype-matching in a rare-disease natural history case study appears, but there is no discussion of pharmacogenetics, genetic biomarkers, testing strategies, or related methods."
747c5359-f34c-43ee-90d5-eaa6545bc387,2,url:https://doi.org/10.1038/sj.bjp.0707253,2,1,Scored,"This paper focuses on the biochemical and pharmacological effects of mianserin on R-spondin2-mediated Wnt/β-catenin signaling and osteoarthritis models (cell lines, human synovial fluid, and a rat DMM model). It reports drug screening, molecular mechanism (blocking Rspo2–Lgr5 binding), and therapeutic effects, but contains no pharmacogenetic analyses (no evaluation of genetic variants affecting drug response, no patient genotype–drug response correlations, and no discussion of personalized/genotype-guided therapy). The brief mention of RSPO2 single-nucleotide variations is descriptive and not developed into a pharmacogenetic approach."
ad2eb6aa-3979-4b1c-ac73-9f5e8af3c86c,2,url:https://doi.org/10.1111/bcpt.12796,2,1,Scored,"The thesis focuses on human biomonitoring of environmental chemicals (BPA, metals, pesticides, mixtures) and effect biomarkers (e.g., BDNF) related to neurodevelopment. It only briefly mentions susceptibility biomarkers and examples of genetic polymorphisms (GST, NAT) as indicators of inter-individual toxicity, but contains no pharmacogenetic aims, methods, or discussion of drug–gene interactions or treatment response. Therefore it is not relevant to pharmacogenetic approaches."
7b44abc9-59bc-4e16-baf6-336b03ab243b,2,url:https://doi.org/10.1007/s00213-015-3898-x,2,1,Scored,"The paper is a literature review of Hericium erinaceus (lion’s mane) focusing on neurobiological mechanisms (NGF/BDNF, neurotransmitters), anti‑inflammatory effects, and gut‑microbiota modulation in relation to depression and neuroprotection. It does not discuss pharmacogenetic concepts (e.g., genetic polymorphisms, genotype‑guided dosing, pharmacogenomic biomarkers, or genotyping methods). While it briefly notes potential interactions with psychotropic medications and the need to study them, there is no assessment of pharmacogenetic approaches or data, so relevance to pharmacogenetics is negligible."
79fb5e76-77aa-43d9-8f1a-9ed1c08f00d3,2,url:https://doi.org/10.3389/fgene.2019.01199,2,1,Scored,"This is a microbiology study of Pseudomonas aeruginosa metabolic adaptation in cystic fibrosis sputum (catabolism of DNA, transcriptomics/proteomics, purK mutations). It does not address pharmacogenetics, drug–gene interactions, human genetic variation, or personalized drug response; therefore it is not relevant to pharmacogenetic approaches."
55a5694c-5ad2-4d2b-bc3d-80bd78f706d7,2,url:https://doi.org/10.4274/tjps.galenos.2020.49799,2,1,Scored,"The manuscript focuses on clinical practice guidelines to improve antidepressant adherence (therapeutic alliance, psychoeducation, collaborative care, smartphone follow-up, choice based on tolerability, and mentions therapeutic drug monitoring). It contains no discussion of pharmacogenetic testing, genotype-guided prescribing, CYP450 or pharmacogenomic algorithms. Therapeutic drug monitoring is not a pharmacogenetic approach. Therefore it is not relevant to pharmacogenetics."
2da84b3f-004a-4da8-bc97-a87d4532cd8e,2,url:https://doi.org/10.4088/pcc.v02n0602,2,1,Scored,"The manuscript investigates SSRI effects on neural differentiation, metabolomics, and cord‑blood lipid associations with neurodevelopmental outcomes; it does not evaluate pharmacogenetic questions. There is no analysis of genetic variants affecting drug response (e.g., CYP/P-gp genotypes), no pharmacogenomic association testing, and no discussion of personalized prescribing based on genetics. Although multiple iPSC lines with different genetic backgrounds were used, the study did not perform pharmacogenetic analyses or report genotype–drug interaction findings."
10a28a80-ac35-4b9f-ad53-5650da5a3d25,2,url:https://doi.org/10.1093/nar/16.3.1215,2,1,Scored,"This document is a laboratory protocol for extracting high-molecular-weight DNA from whole blood (salting-out method). It describes reagents, buffers, and stepwise procedures for sample processing and DNA isolation. It does not discuss drug response, genetic variants affecting pharmacokinetics/pharmacodynamics, clinical pharmacogenetic testing, or related analyses, so it is not relevant to pharmacogenetics."
15c81a44-146e-4cc2-ad4e-569ee14adba4,2,url:https://doi.org/10.2217/pgs-2022-0104,2,1,Scored,"This departmental newsletter contains faculty/resident updates, events, fellowships, clinical work, and a long list of publications, but there is no discussion of pharmacogenetics, pharmacogenomic testing, genetic markers, or individualized drug–gene approaches. Any medication- or toxicology-related items do not assess pharmacogenetic strategies."
229eddce-7c6c-445b-a79d-81ba27fd8125,2,url:https://doi.org/10.1038/clpt.1994.65,2,1,Scored,"This study investigates the effects of passive smoking on children’s gingival health and measures salivary cotinine and clinical oral indices. It contains no discussion of genetics, genetic variants, drug response, pharmacokinetic/pharmacodynamic variability, or any pharmacogenetic methods — therefore it is not relevant to pharmacogenetics."
24921a3c-6c3b-4c3a-ba23-e389ef61e99a,2,url:https://doi.org/10.1038/mp.2012.91,2,1,Scored,"This paper is an epidemiological Mendelian randomization and observational study of depression and cardiovascular disease risk and mediators (e.g., hyperlipidemia, hypertension, diabetes, prescription opioid use). It does not examine pharmacogenetic concepts such as drug–gene interactions, genotype-guided prescribing, pharmacokinetics/pharmacodynamics, or individualized drug response. The brief mention of prescription opioid use is epidemiologic rather than a pharmacogenetic analysis."
d77b0482-c3b3-4377-9a57-f2dccc8c592e,2,url:https://doi.org/10.1016/j.psychres.2018.12.053,2,1,Scored,"The article is a narrative review of environmental neurotoxic and neuro‑disruptive chemicals in food and packaging and their potential effects on youth neurodevelopment and mental health. It focuses on pesticides, heavy metals, ultra‑processed food additives, microplastics, bisphenols, phthalates, exposure trends, biomonitoring, and regulatory research needs. It does not discuss genetics, drug response variability, gene–drug interactions, or any pharmacogenetic methods or approaches, so it is not relevant to pharmacogenetics."
fc1422fe-3cc2-496b-b585-0d191b0628dc,2,url:https://doi.org/10.2217/pgs-2017-0003,2,1,Scored,"The thesis focuses on decision-making, cognitive fatigue, and working memory in traumatic brain injury using behavioral tasks (IGT, n‑back) and self-report measures. It discusses fatigue conceptualizations and mentions some pharmacological treatments (e.g., modafinil, methylphenidate, melatonin) in passing, but contains no discussion, data, or analysis of genetic factors, gene–drug interactions, genotype-guided therapy, or any pharmacogenetic methodology. Therefore it is not relevant to pharmacogenetic approaches."
adde4d04-9370-4b97-9d07-774721ef4ca4,2,"Berg, K. A., and Clarke, W. P. (2018). Making sense of pharmacology: Inverse agonism and functional selectivity.Int. J. Neuropsychopharmacol.21 (10), 962– 977. doi:10.1093/ijnp/pyy071",2,1,Scored,"This is a review of GPCR pharmacology (constitutive receptor activity, inverse agonism, and functional selectivity/biased agonism). It focuses on receptor signaling, ligand efficacy, and drug discovery concepts, not on pharmacogenetic approaches. While it notes receptor mutations in disease and cites some pharmacogenomic work, it does not assess genetic variation, genotyping methods, or pharmacogenetic strategies for individualized therapy."
a2735424-cbd6-426d-9374-c639c9727fa6,2,"Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., et al. (2018a). Comparative efﬁcacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review an",2,1,Scored,"The document reviews SSRIs, their mechanisms, clinical guideline recommendations, and comparative effectiveness systematic reviews for MDD, but contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or related biomarkers. Therefore it is not relevant to pharmacogenetic approaches."
a3171194-5dcc-4cd7-be38-878a4f83ce20,2,"Dean, A. G., Sullivan, K. M., and Soe, M. M. (2013). OpenEpi: Open source epidemiologic statistics for public health. Retrieved from:https://www.openepi.com/Menu/OE_Menu.htm.",2,1,Scored,"The study is a cross-sectional survey of depression, anxiety and stress among medical/paramedical students using DASS-21 and PSS questionnaires. It contains no investigation of genetics, drug response, gene–drug interactions, biomarkers, genotyping, or any pharmacogenetic methods or discussion, so it is not relevant to pharmacogenetic approaches."
c4f3eabd-ef39-4363-b8b9-3028b94ceda1,2,"Marasine, N. R., and Sankhi, S. (2021). Factors associated with antidepressant medication non-adherence. Turk J. Pharm. Sci. 18 (2), 242– 249. doi:10.4274/tjps.galenos.2020.49799",2,1,Scored,"The manuscript focuses on behavioral, organizational, and technology-based interventions to improve antidepressant adherence (collaborative care, psychoeducation, therapeutic alliance, smartphone follow-up, adherence monitoring). It contains no discussion of pharmacogenetic testing, gene–drug interactions, pharmacogenomic-guided prescribing, or genetic markers influencing antidepressant response or tolerability."
b1c1b45c-7e31-4067-b125-868103d4b9f0,1,"Vasen HF, Watson P , Mecklin JP , Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastro-enterology 1999; 116: 1453-1456.",3,1,Processed,"The article focuses on hereditary colorectal cancer syndromes, genetic diagnosis, counseling, surveillance, and surgical/clinical management. It does not discuss pharmacogenetic approaches to drug selection, dosing, or drug-response genetic markers (only brief mentions of chemoprevention with aspirin/celecoxib and an unrelated citation), so it is not relevant to pharmacogenetics."
6de1a6ef-feb8-43d5-a946-9052209c927b,1,"Guttmacher AE, Collins FS, Carmona RH. The family history — more important than ever. N Engl J Med 2004; 351: 2333-2336.",3,1,Processed,"The editorial discusses family history and genetic testing in the context of acute hospital admissions and genetic counselling generally, but it contains no discussion of pharmacogenetics, drug–gene interactions, pharmacogenomic testing, or medication management based on genetic variants. Therefore it is not relevant to pharmacogenetic approaches."
0c978a7e-f7de-4e8d-947e-d64db29fa2bd,1,"Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: family history and improving health. Ann Intern Med 2009; 151: 872-877.",3,1,Processed,"The paper discusses targeted genetic testing for adoptees to identify highly penetrant, actionable disease-risk variants (e.g., BRCA, cancer predisposition, carrier conditions) and the limits of family history. It does not address pharmacogenetics, drug-response genes, or medication-related testing strategies, so it is not relevant to pharmacogenetic approaches."
e7167575-f193-433f-af5d-1d69c0828203,1,"Cannon CP, Braunwald E. Unstable angina and non-ST elevation myocardial infarction. In Zipes, Libby, Bonow and Braunwald (eds.): Braunwald’s Heart Disease. A textbook of cardiovascular medicine. Elsevier Saunders 2005. pp 1243-79.",3,1,Processed,"The paper evaluates the HEART clinical risk score for chest pain triage and outcomes (history, ECG, age, risk factors, troponin). It contains no discussion, data, or analysis of genetics, genetic testing, drug response variability, or pharmacogenetic approaches."
969a0753-a347-48a1-a4c2-90fd206b9546,1,"Hirsch A, Windhausen F, Thijssen JGP, Verheugt FWA, Cornel JH, De Winter RJ. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (",3,1,Processed,"This randomized clinical trial compares early invasive versus selectively invasive management strategies for non–ST-elevation acute coronary syndromes and reports clinical outcomes (death, MI, rehospitalization). It does not include any genetic testing, genotype stratification, analyses of genetic polymorphisms (e.g., CYP2C19), or exploration of differential drug response by genotype. Therefore it is not relevant to pharmacogenetics."
6ec6797b-6faf-4632-906f-7c433fc36fde,1,"Miller CD, Lindsell CJ, Khandelwal S, et al. Is the initial diagnostic impression of “Noncardiac Chest Pain” adequate to exclude cardiac disease? Ann Emerg Med2004;44:565-74.",3,1,Processed,"The article is an editorial about adapting the HEART pathway for chest pain risk stratification in Korean ED patients, focusing on clinical criteria (history, ECG, age, risk factors, troponin) and BMI threshold modification. It discusses triage, MACE outcomes, and validation studies — there is no mention of pharmacogenetics, genotyping, drug–gene interactions, or personalized drug therapy."
bf45a3bc-2e64-4dcb-a9ca-e4eedb0859b0,1,"Blackburn H, Keys A, Simonson E, et. The electrocardiogram in population studies: a classification system. Circulation 1960;21: 1160-75.",3,1,Processed,"This is an ECG methods and coding manual (Minnesota Code) focused on electrocardiographic measurement, lead placement, waveform classification, and quality control. It does not discuss genetic variation, genotyping, drug–gene interactions, or pharmacogenetic study approaches. (Only a brief mention of ECG use in drug trials/QT measurement appears, but not pharmacogenetics.)"
3f8036dc-7914-4253-aa1d-52b2a9a579f6,1,"Hollander JE. Acute coronary syndrome in the emergency department: Diagnosis, risk stratification, and management. In: P Théroux (Ed.): Acute coronary syndromes. A companion to Braunwald’s heart disease. Saunders/Elsevier, 2003.",3,1,Processed,"The paper focuses on clinical risk stratification for chest pain using the HEART score (History, ECG, Age, Risk factors, Troponin). It is an observational study of emergency-room triage and outcomes (AMI, revascularisation, death) and does not discuss genetics, genotyping, drug–gene interactions, or any pharmacogenetic approaches."
e174f8c2-29e4-4307-a9bb-b708c01b13fe,1,ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. J Am Coll Cardiol2007;50:e1-157.,3,1,Processed,"The document is a quality/performance-measure report for acute myocardial infarction care (process measures, composite defect-free care rates, reliability/validity testing) and contains no discussion of genes, genetic testing, pharmacogenetics, genotype-guided therapy, or related terminology. Therefore it is not relevant to pharmacogenetic approaches."
1e23d23e-f108-41af-83c7-7e457afb1766,1,"Bassand JP, Hamm CW, Ardessino D, et al. Guidelines for the diagnosis and treatment of non ST-segment elevation Acute Coronary Syndromes. Eur Heart J2007;28:1598-660.",3,1,Processed,"The paper describes the HEART clinical risk score for chest pain triage and evaluates clinical predictors (History, ECG, Age, Risk factors, Troponin) and outcomes (AMI, revascularisation, death). It contains no discussion of genetics, genetic markers, drug response variability, or pharmacogenetic testing, so it is not relevant to pharmacogenetic approaches."
6143e07d-1b96-4256-9a4c-8896a17b4a48,1,"Apgar V. A Proposal for a New Method of Evaluation of the Newborn Infant. Current Researches in Anesthesia and Analgesia, July-August, 1953, page 260.",3,1,Processed,"The document is an epidemiologic report (1981 NCHS) on Apgar scores and newborn outcomes by demographics, birth weight, maternal factors, and prenatal care. It contains no discussion of genetics, drug response, pharmacologic interventions, or individualized therapy; therefore it is not relevant to pharmacogenetic approaches."
87a125d6-f681-428f-ab14-46d3bcae821b,1,"Antman EM, Cohen Mk Bernink PJLM, et al. The TIMI risk score for unstable angina/ non-ST elevation MI. JAMA 2000; 284:835-42.",3,1,Processed,"The paper focuses on clinical risk stratification for chest pain in the ED using the HEART score (History, ECG, Age, Risk factors, Troponin), outcomes (AMI, revascularisation, death) and triage recommendations. It contains no discussion of genetics, gene–drug interactions, biomarkers for pharmacogenomics, genotype-guided therapy, or personalized drug response — therefore it is not relevant to pharmacogenetic approaches."
8735512c-f331-4f2a-ae9d-730d45132f50,1,"Boersma E, Pieper KS, Steyerberg EW, et al. for the PURSUIT investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 2000; 101",3,1,Processed,"The article reviews clinical risk prediction models for acute coronary syndromes (TIMI, GRACE, PURSUIT, CRUSADE, etc.), model development/validation, and applicability to Singapore. It does not discuss pharmacogenetics, genetic markers, gene–drug interactions, or personalized drug response. Although it mentions ethnic differences in MI incidence, no pharmacogenetic approaches are assessed."
e13c59d0-9f3f-4979-b679-bf105c58651e,1,"Granger CB, Goldberg RJ, Dabbous OH, et al. for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med2003;163:2345-53.",3,1,Processed,"This paper describes development and validation of a clinical risk prediction tool (GRACE) for acute coronary syndrome outcomes using clinical, ECG, and laboratory variables. It contains no discussion of genetic markers, genetic testing, drug–gene interactions, or pharmacogenetic approaches; therefore it is not relevant to pharmacogenetics."
98bdaded-8d97-48ae-960b-ec305f226fff,1,"Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.",3,1,Processed,"This study develops and validates a clinical risk prediction model for death and myocardial infarction after acute coronary syndrome using demographic, clinical, ECG and laboratory variables. It contains no assessment of genetic markers, gene–drug interactions, or pharmacogenetic approaches; pharmacogenetics is not discussed."
2281b6d3-fc72-4dc0-abf7-8d94a61b90c3,1,"De Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005;26:865-72.",3,1,Processed,"The manuscript focuses on clinical risk‑stratification scores (e.g., GRACE, TIMI, HEART, Chinese score) and predictors of major adverse cardiovascular events in non‑ST‑elevation myocardial infarction patients. It contains no discussion or data on genetics, genotypes, drug response variability, pharmacogenetic testing, or genotype‑guided therapy (no mentions of CYP enzymes, genomic markers, polymorphisms, or personalized pharmacotherapy). Therefore it is not relevant to pharmacogenetic approaches."
8a25135d-e0e3-493d-86c6-aa6f3f0694e4,1,Barlati et al.,3,1,Processed,"The editorial and the studies it summarizes focus on mental health outcomes, psychosocial risk/protective factors, surveys, and population-level impacts of COVID-19. There is no discussion of pharmacogenetics, genotype-guided therapy, genetic markers, drug–gene interactions, or related methodologies anywhere in the text or references."
b9d3ecc3-a0a6-4f18-88c9-8a8dd031a61c,1,Tesfamicael et al.,3,1,Processed,"The paper concerns mathematics education in Ethiopia during COVID-19, focusing on opportunity-to-learn, teaching practices, structures, and advocacy. It contains no discussion of pharmacology, genetics, drug–gene interactions, biomarkers, or any pharmacogenetic methods — therefore it is not relevant to pharmacogenetic approaches."
519525a7-d1bc-4bef-a7be-7da7d5d36d3e,1,Wang et al.,3,1,Processed,"The paper is an IEEE image-processing article about image quality assessment and the Structural Similarity (SSIM) index, covering topics like human visual system modeling, JPEG/JPEG2000 compression, and perceptual metrics. It contains no discussion of pharmacology, genetics, genotypes, biomarkers, drug response, or personalized medicine, and therefore is not relevant to pharmacogenetic approaches."
1ff9f190-4b23-45fe-bfb3-785548c8cf63,1,Polasek,3,1,Processed,"The text is an internship posting for the Albin Polasek Museum and Sculpture Gardens describing curatorial, collections, exhibition, and archival duties. It contains no discussion of genetics, pharmacology, drug response, personalized medicine, genotyping, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
05d4cd38-3c59-4f42-afa5-d3d1aa772314,1,"1. Sabate E. WHO Adherence Meeting Report. Geneva, World Health Organization, 2001.",3,1,Processed,"The WHO report focuses on patient adherence to long-term therapies, health-system factors, behavioural interventions, disease-specific adherence issues and economics. It contains no assessment of pharmacogenetics, genetic testing, genotype-guided prescribing, or related personalized-medicine approaches. Mentions of drug resistance (e.g. HIV, TB) are discussed in the context of adherence, not genetic variation or pharmacogenetic strategies."
cfa0a23d-4e93-4f01-8567-3a6ce8140bdb,1,"2. Haynes RB. Determinants of compliance: The disease and the mechanics of treatment. Baltimore MD, Johns Hopkins University Press, 1979.",3,1,Processed,"The paper addresses behavioral interventions to improve adherence in acute otitis media (visualizing the tympanic membrane) and discusses health belief models, appointment keeping, and clinical outcomes. It contains no discussion of genetics, genetic testing, drug-gene interactions, or personalized/pharmacogenetic approaches."
88f5e0ad-2ce8-4c86-bd13-6c2c2d3aaf5d,1,"3. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. American Journal of Cardiology, 1993, 72:68D-74D.",3,1,Processed,"The review focuses on psychosocial, behavioral, cultural and patient-related factors affecting adherence to lifestyle changes and medication in cardiometabolic disease. It contains no discussion of genomics, genetic testing, gene–drug interactions, biomarkers, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
45bd18ad-fab1-482d-926d-273cef86ee85,1,"4. Dictionary of health services management, 2nd ed. Owing Mills, MD, National Health Publishing, 1982.",3,1,Processed,"The text is the NIOSH Manual of Analytical Methods focused on occupational exposure assessment, sampling and analytical laboratory procedures (air, surface, wipes, elements like beryllium, methamphetamine wipe analysis), method development/evaluation, and measurement uncertainty. It contains no discussion of genetics, drug–gene interactions, genotyping, or individualized drug response; therefore it is not relevant to pharmacogenetics."
029a0854-7f0f-4208-9580-a6c056edbdcc,1,"5. Timmreck TC, Randolph JF . Smoking cessation: clinical steps to improve compliance. Geriatrics, 1993, 48:63-66.",3,1,Processed,"This WHO report focuses on adherence to long‑term therapies (behavioral, health‑system, economic and disease‑specific interventions) and measurement of adherence; it contains no discussion of pharmacogenetics, genetic testing, genotype‑guided therapy, or personalized pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetic assessment."
8814fd07-5631-447c-8e2a-0302c1c9012b,1,"6. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics,1999, 21:1074-1090.",3,1,Processed,"This study examines behavioral, demographic, socioeconomic, medical, and ocular predictors of adherence to topical glaucoma therapy using electronic dosing monitors. It does not discuss genetic factors, genetic testing, gene–drug interactions, or pharmacogenetic methodologies. Although race is analyzed as a predictor, no pharmacogenetic assessment is performed or proposed."
30b2f571-078d-49ca-beda-9cbbda78b900,1,"7. DiMatteo MR, DiNicola DD. Achieving patient compliance. New York, Pergamon, 1982.",3,1,Processed,"The article focuses on patient and health professional perceptions of adherence to diabetes management (diet, medication-taking behavior, self‑monitoring, barriers, communication). It contains no discussion of genetics, genotype‑guided therapy, drug–gene interactions, biomarkers, or pharmacogenetic testing, so it is not relevant to pharmacogenetic approaches."
23a3067c-6c46-48a8-9300-41416ebaea70,1,"8. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Social Science & Medicine - Part E, Medical Psychology,1981, 15:57-61.",3,1,Processed,"The paper focuses on patient compliance/adherence, self-prediction, behavioral and social-psychological determinants of following medical regimens, and physician awareness. It discusses side effects and outcomes but contains no discussion of genetics, genotype-driven drug response, pharmacogenetic testing, gene–drug interactions, or personalized/precision medicine approaches. Therefore it is not relevant to pharmacogenetic approaches."
391f3e1e-c815-46be-aa93-0da853f4bbb9,1,"9. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, eds.Patient compliance in medical practice and clinical trials. New Y ork, Raven Press, 1991:123-137.",3,1,Processed,"The document is a WHO 2003 report on adherence to long-term therapies focused on behavioural, health-system, measurement, economic and disease-specific issues (e.g., diabetes, hypertension, asthma, HIV/TB). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or related biomarkers — therefore it is not relevant to pharmacogenetic approaches."
0088d3f1-f551-4240-9956-2f3d10aa16ef,1,"10. Spector SL et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. Journal of Allergy & Clinical Immunology,1986, 77:65-70.",3,1,Processed,"The document is a broad WHO/NHLBI report on asthma epidemiology, pathology, prevention and management (1995). It discusses genetic predisposition/atopy and general mechanisms but contains no assessment of pharmacogenetic approaches (drug–gene interactions, genotype-guided therapy, or personalized pharmacotherapy). Therefore it is not relevant to pharmacogenetics."
625be06a-6411-46a7-a86b-3d0d407c58c1,1,"11. Morisky DE, Green LW , Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care,1986, 24:67-74.",3,1,Processed,"The trial evaluates a peer-led self-management program for chronic medical conditions in people with serious mental illness. It focuses on group education, action planning, health behaviors, patient activation, and recovery; there is no assessment, mention, or use of pharmacogenetic testing, genetic markers, genotype-guided prescribing, or related outcomes. Therefore it is not relevant to pharmacogenetic approaches."
aa9a0903-ed6b-4461-97d2-77b115485ab1,1,"12. Freudenheim JL. A review of study designs and methods of dietary assessment in nutritional epidemiology of chronic disease. Journal of Nutrition, 1993, 123:401-405.",3,1,Processed,"The review focuses on resveratrol and other stilbenoids’ bioavailability, pharmacokinetics, delivery systems, and bioenhancers. Although it mentions metabolic enzymes (UGTs, SULTs, CYPs), transporters (BCRP, MRPs, P-gp) and microbiota-related metabolism, it does not assess genetic variability, genotype–phenotype relationships, pharmacogenetic testing, or personalized dosing strategies. Thus it does not evaluate pharmacogenetic approaches."
e20e1390-9cd8-43c1-b82a-17d0a05e062b,1,"13. Sumartojo E.When tuberculosis treatment fails. A social behavioral account of patient adherence. American Review of Respiratory Disease, 1993, 147:1311-1320.",3,1,Processed,"The article focuses on behavioral and social science research at CDC (surveillance, behavioral determinants, intervention studies) across topics such as violence against women, tuberculosis adherence, HIV prevention, and occupational health. It contains no discussion of genetics, pharmacogenetics, genotyping, personalized drug response, or related pharmacologic/genomic approaches, so it is not relevant to pharmacogenetic assessment."
939637fc-7c06-4daf-9935-e2a41e1cac45,1,"14. Matsui D et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. Journal of Clinical Pharmacology,1994, 34:944-949.",3,1,Processed,"The study investigates the effect of electronic medication containers on adherence in patients with type 2 diabetes (measurement reactivity), using self-report (MARS), electronic monitoring, and HbA1c outcomes. It contains no discussion or assessment of genetics, genotyping, gene–drug interactions, biomarkers, or personalized/pharmacogenetic approaches."
dbe50831-ae79-4126-b812-1216436e415f,1,"15. Vitolins MZ et al. Measuring adherence to behavioral and medical interventions. Controlled Clinical Trials,2000, 21:188S-194S.",3,1,Processed,"The study evaluates physicians’ ability to predict patient adherence to antihypertensive medication using VAS and MEMS monitoring. It focuses on adherence measurement, physician/patient estimates, and related statistics in primary care. There is no discussion of genetics, genotyping, gene–drug interactions, polymorphisms, or any pharmacogenetic methods or outcomes, so it is not relevant to pharmacogenetics."
573f0d9f-571a-4264-ae50-a118e359dfd1,1,"16. Nunnally JC, Bernstein IH. Psychometric theory, 3rd ed. New Y ork, McGraw-Hill, 1994.",3,1,Processed,"The paper focuses on psychometric assessment (Cronbach’s alpha, scale reliability, factor analysis, Rasch models) in educational/psychological measurement. It contains no discussion of drugs, genetics, SNPs, pharmacogenomics, or pharmacogenetic methods. Therefore it is not relevant to pharmacogenetic approaches."
cefb4898-557d-4674-b28e-bef6bd476bed,1,"1. Haynes RB. Interventions for helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews, 2001 Issue1.",3,1,Processed,"This Cochrane review evaluates behavioral, educational, organizational and pharmaceutical-care interventions to improve medication adherence (counseling, reminders, packaging, dosing schedules, nurse/pharmacist follow-up, etc.). It contains no discussion or assessment of pharmacogenetic strategies (genotype-guided therapy, genetic testing, metabolizer status, or gene–drug interactions). Therefore it is not relevant to pharmacogenetics."
2ebf5882-e8a4-4af5-a60c-63d6914cd8ff,1,"2. Sackett D et al. Patient compliance with antihypertensive regimens. Patient Counselling & Health Education, 1978, 11:18-21.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, health systems, behavioural determinants, measurement and interventions across chronic diseases (asthma, diabetes, HIV, TB, etc.). It contains no discussion of pharmacogenetics, genetic testing, genotype‑guided prescribing, variability in drug response due to genetics, or related molecular approaches. Therefore it is not relevant to pharmacogenetic assessment."
210d12ac-92d2-4495-94f5-906bca4b0350,1,"3. Bovet P et al. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bulletin of the World Health Organization, 2002, 80:33-39.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, health-system and economic factors across chronic diseases. It discusses compliance, self-management, interventions, measurement and policy but contains no discussion of genetic factors, pharmacogenetics, genotyping, or individualized genetic-guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
ff0a714b-b33b-4c14-808e-a4721106a19e,1,"4. Graves JW. Management of difficult-to-control hypertension Mayo Clinic Proceedings,2000, 75:278-284 [erratum published in Mayo Clinical Proceedings,2000, 75:542].",3,1,Processed,"The WHO report is focused on patient adherence, behavioural, health‑system and economic factors for long‑term therapies across several diseases. It covers measurement, interventions, and policy issues but contains no discussion of pharmacogenetics, genetic testing, or genotype‑guided prescribing. Therefore it is not relevant to pharmacogenetic approaches."
2a372265-3563-4bf2-87bc-e2f66d4b08d0,1,"5. van der Sande MA et al. Blood pressure patterns and cardiovascular risk factors in rural and urban Gambian communities. Journal of Human Hypertension, 2000, 14:489-496.",3,1,Processed,"The article is a socio-cultural overview of cardiovascular disease risk factors in sub‑Saharan Africa (hypertension, diabetes, dyslipidemia, lifestyle, health systems, traditional healers, the PEN-3 cultural model). It contains no discussion of genetics, pharmacogenetics, gene–drug interactions, personalized drug response, genomic testing, or related methods. Only generic references to medication access and adherence appear, not pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
9e487c4a-10fc-4917-a117-63bfbe3b2bd2,1,"6. Guo H, He H, Jiang J. [Study on the compliance of antihypertensive drugs in patients with hypertension.] [Chinese] Chung-Hua Liu Hsing Ping Hsueh Tsa Chih [Chinese Journal of Epidemiology], 2001, 22:418-420.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, system and economic factors, measurement methods and disease-specific adherence issues. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or personalized drug-response genetics, so it is not relevant to pharmacogenetic approaches."
f690c126-b48d-493e-a1c2-54196091d72d,1,"7. Anonymous. Critical overview of antihypertensive therapies: what is preventing us from getting there? Based on a presentation by Mark A. Munger, PharmD.American Journal of Managed Care, 2000, 6 (4 Suppl):S211-S221.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies—behavioural, health‑system, economic and disease‑specific factors and interventions. Its table of contents and excerpts show no discussion of genetic or pharmacogenetic testing, drug–gene interactions, or personalized genomics. Therefore it is not relevant to pharmacogenetic approaches."
5f76ac6c-4c97-459c-80d9-13cc6bd4f905,1,"8. Demyttenaere K. Noncompliance with antidepressants: who’s to blame? International Clinical Psychopharmacology,1998, 13 (Suppl 2):S19-S25.",3,1,Processed,"The report focuses on adherence to long-term therapies, behavioural, health-system and economic determinants and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, or genotype-guided therapy; pharmacogenetic approaches are not assessed."
a1edf575-9240-4858-9ef0-80f20dd79a63,1,"9. Reid D et al. Management and treatment perceptions among young adults with asthma in Melbourne: the Australian experience from the European Community Respiratory Health Survey. Respirology,2000, 5:281-287.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, covering behavioral, systems, measurement and disease-specific intervention issues. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or related concepts of personalized/precision pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
75638dfb-dcfc-42d2-8a8c-afb6d5ddbbc3,1,"10. Markowitz AJ, Winawer SJ. Screening and surveillance for colorectal cancer. Seminars in Oncology, 1999, 26:485-498.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, system and economic factors across chronic diseases; it contains no discussion of genetic testing, gene–drug interactions, personalized medicine or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
f75fac5b-f8be-4466-a049-a0652069c20f,1,"11. Stein MD et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. American Journal of Drug & Alcohol Abuse, 2000, 26:195-205.",3,1,Processed,"The document is a public health guidance on integrated prevention services for infectious diseases among persons who use drugs illicitly. It focuses on screening, vaccination, behavioral interventions, substance use treatment (e.g., methadone, buprenorphine), outreach, and service integration. It contains no discussion of genetic testing, genotype-guided therapy, pharmacogenetics, or pharmacogenomic approaches to personalize medication, so it is not relevant to pharmacogenetics."
c557521b-3060-49f7-ae40-9299601e39f4,1,"12. Laine C et al. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstetrics & Gynecology,2000, 95:167-173.",3,1,Processed,"This study examines adherence to postpartum antiretroviral regimens and the association with breastmilk HIV-1 transmission using pill counts, bottle weights, and self-report. It contains no analyses of genetic variation, genotyping, gene–drug interactions, or individualized drug response based on genetics. The only pharmacology mention is general pharmacokinetic boosting of protease inhibitors, not pharmacogenetic investigation."
7fb30dc2-87f7-4d84-8f56-2bb6bb621917,1,"14. Murray CJL, Lopez A. The global burden of disease. Geneva, World Health Organization, 1996.",3,1,Processed,"The document is a WHO technical paper on Global Health Estimates, DALYs, YLL/YLD methods, disability weights and cause-of-death coding. It focuses on epidemiological methods and burden estimation and contains no discussion of pharmacogenetics, pharmacogenomics, personalized drug response, or related topics."
aa70a1c6-9cca-4265-bfb6-c48cb8853351,1,"15. Timmreck TC, Randolph JF . Smoking cessation: clinical steps to improve compliance. Geriatrics, 1993, 48:63–66.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, system-level, disease-specific and economic factors. There is no discussion of pharmacogenetics, pharmacogenomic testing, genotype-guided therapy, or related personalized-medicine approaches in the table of contents or the excerpts provided. Therefore it is not relevant to pharmacogenetic assessment."
544cf2ad-f091-4ece-9626-a2d466d54291,1,"16. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics,1999, 21:1074–1090.",3,1,Processed,"The article is a literature review on adherence to topical dermatological treatments, focusing on patient behaviour, doctor–patient interaction, measurement of adherence, and interventions to improve compliance. It contains no discussion of genetics, genetic testing, genotype-guided therapy, biomarkers, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
bfa1fa8b-1712-472c-84fa-0412b862ca66,1,"17. Robinson KM. Family caregiving: who provides the care, and at what cost? Nurse Economics, 1997, 15:243-247.",3,1,Processed,"The paper focuses on psychosocial, social and care-related dimensions of Alzheimer’s disease (stigma, caregiver burden, support services, policy) and does not discuss genetics, drug–gene interactions, personalized drug response, or pharmacogenetic testing. Aside from a brief general remark that pharmacological treatments are limited, there is no assessment of pharmacogenetic approaches."
b4606948-5315-432a-92dc-cf7e9fbd15b1,1,"1. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. Journal of the American Pharmaceutical Association, 2002, 42:63-71.",3,1,Processed,"The WHO 2003 report focuses on adherence to long-term therapies, behavioural, health-system, and economic determinants and interventions across chronic diseases. It contains no discussion of genetic testing, drug–gene interactions, personalized dosing based on genotype, or pharmacogenetic strategies. Therefore it is not relevant to pharmacogenetic approaches."
68201c70-3cd6-4067-92aa-41e64cebf753,1,"2. Dunbar-Jacob J et al. Adherence in chronic disease. Annual Review of Nursing Research, 2000, 18:48-90.",3,1,Processed,"The article focuses on patient adherence to adjuvant endocrine therapy for breast cancer and nursing interventions to improve adherence. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, biomarkers, or individualized genetic approaches. Therefore it is not relevant to pharmacogenetic assessment."
5e1009f2-89da-4983-b488-3c3dfc62d003,1,"3. Liebl A et al. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study.] [German] Deutsche Medizinische Wochenschrift, 2001, 126:585-589.",3,1,Processed,"The document is a WHO 2003 report on adherence to long-term therapies focusing on patient behaviour, health systems, measurement of adherence, and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or related concepts. Therefore it is not relevant to pharmacogenetic approaches."
01924819-13ea-4d90-9b47-fce078168d50,1,"4. Liebl A et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Experimental & Clinical Endocrinology & Diabetes, 2002, 110:10-16.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, behavioural, health-system and economic factors across chronic diseases. It does not discuss pharmacogenetics, genetic testing, gene–drug interactions, or personalized genomic approaches; pharmacogenetics is not assessed in the text."
e2c38545-e01a-4536-b1f6-0d4ba6e58023,1,"6. Lustman PJ, Griffith LS, Clouse RE. Depression in adults with diabetes. Seminars in Clinical Neuropsychiatry, 1997, 2:15-23.",3,1,Processed,"The article discusses depression in diabetes, its causes, identification, and general treatments (medication and psychotherapy). It only briefly mentions genetic factors as one possible cause of depression and contains no evaluation of pharmacogenetic approaches, genetic testing to guide therapy, or gene–drug interactions. Therefore it is not relevant to pharmacogenetics."
415d77df-c711-4e9a-9266-21332e5cf455,1,"7. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs.Archives of Internal Medicine, 2000, 27:3278-3285.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, system and economic determinants, and disease‑specific adherence issues. It contains no discussion of pharmacogenetics, genetic testing, genotype‑guided therapy, or related personalized medicine approaches, so it is not relevant to pharmacogenetic assessment."
1aef522e-951c-4542-8b67-14bdf8db8fef,1,"8. Kangas T et al. Direct costs of health care of drug-treated diabetic patients in Finland in 1989. In: Kangas T.The Finndiab Report. Stakes, Research Reports 58, 1995.",3,1,Processed,"This WHO report focuses on adherence to long‑term therapies, behavioural, system and economic factors, measurement methods and disease-specific adherence issues. It does not discuss pharmacogenetics, genetic testing, genotype‑guided prescribing, or personalized genomic approaches to drug therapy, so it is not relevant to pharmacogenetic assessment."
02b116d6-5390-4a8d-ad23-1f4e1d9d7bb4,1,"9. Henriksson F et al. Direct medical costs for patients with type 2 diabetes in Sweden. Journal of Internal Medicine, 2000, 248:387-396.",3,1,Processed,"The paper evaluates cost-effectiveness of lifestyle interventions (diet, physical activity, weight loss) to prevent type 2 diabetes using a Markov model. It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, or genotype-guided therapy, so it is not relevant to pharmacogenetic approaches."
f4752a02-63d8-4418-9584-d8fd759852f3,1,"10. Herman WH, Eastman RC.The effects of treatment on the direct costs of diabetes. Diabetes Care,1998, 21 (Suppl 3):C19-C24.",3,1,Processed,"The article is a clinical review of oral antihyperglycemic agents (mechanisms, efficacy, adverse effects, and trial outcomes) and does not discuss pharmacogenetics, genetic predictors of response, or personalized/genotype-guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
e5615f23-c762-4d63-aeea-50a5ccc30444,1,"11. Berenson GS et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults.The Bogalusa Heart Study. New England Journal of Medicine, 1998, 338:1650-1656.",3,1,Processed,"The study examines family history of hypertension and arterial compliance in healthy young people using hemodynamic measurements. It does not involve pharmacogenetics, drug response, genotyping, genetic polymorphisms, or pharmacogenomic methods—only self-reported family history—so it is not relevant to pharmacogenetic approaches."
aff18653-4283-48e3-a857-730b35146628,1,"12. Thompson DW , Furlan AJ. Clinical epidemiology of stroke.Neurologic Clinics, 1996, 14:309-315.",3,1,Processed,"This is a clinical observational study of prognostic laboratory and clinical predictors (age, MCV, folate, WBC, ESR, glucose, etc.) in acute ischemic stroke. It contains no evaluation of genetic variants, genotype-guided drug therapy, pharmacogenetic testing, or drug–gene interactions. Pharmacogenetics is not addressed."
ce0a5714-788f-447e-9f58-675474f69573,1,"13. al Roomi KA, Heller RF , Wlodarczyk J. Hypertension control and the risk of myocardial infarction and stroke: a population-based study.Medical Journal of Australia, 1990, 153:595-599.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies, focusing on patient behaviour, health systems, measurement, and interventions across chronic diseases. It contains no assessment or discussion of pharmacogenetics, genomic testing, or personalized drug-response genetics; pharmacogenetic approaches are not addressed."
9baff031-7944-49ea-8481-cc3148408c9c,1,14. Borghi C et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term,3,1,Processed,"The article is a clinical and pharmacological review of zofenopril and the SMILE clinical trials in acute myocardial infarction. It discusses drug pharmacodynamics, pharmacokinetics, clinical outcomes, and subgroup analyses by clinical factors (age, hypertension, diabetes, metabolic syndrome, cholesterol) but contains no discussion of genetic polymorphisms, genotyping, gene–drug interactions, biomarkers, or personalized/pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
867751b7-2071-44d0-82d5-7981d91cd048,1,"15. Marmot MG, Poulter NR. Primary prevention of stroke.Lancet,1992, 339:344-347.",3,1,Processed,"The paper is an epidemiological review of stroke in Black Africans focusing on incidence, prevalence, risk factors (hypertension, sickle cell disease, infections, etc.), stroke types, prognosis and public-health prevention. It contains no discussion of pharmacogenetics, genetic determinants of drug response, or personalized/drug–gene approaches."
593f7f14-bc71-4a3e-b6b6-781a7bc7cb18,1,"17. Heller RF et al. Blood pressure measurement in the United Kingdom Heart Disease Prevention Project. Journal of Epidemiology & Community Health, 1978, 32:235-238.",3,1,Processed,"The report focuses on adherence to long-term therapies (behavioral, health-system, measurement, and economic aspects) across chronic diseases. It contains no discussion of pharmacogenetics, genetic predictors of drug response, or genotype-guided therapy. The closest related topics are drug resistance and treatment effectiveness, which are not pharmacogenetic approaches."
af0a6ef9-64cd-419b-ab10-75932ed4d8c9,1,"18. Sulbaran T et al. Epidemiologic aspects of arterial hypertension in Maracaibo, Venezuela. Journal of Human Hypertension, 2000, 14 (Suppl 1):S6-S9.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors, and disease‑specific adherence issues. It contains no discussion or assessment of pharmacogenetic approaches (genetic testing to tailor medications) or related genomic biomarkers, so it is not relevant to pharmacogenetics."
7e8d144d-1601-4261-a685-f16c029bcf97,1,"19. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? Journal of Cardiovascular Pharmacology,2000, 35 (Suppl 3):S23-S26.",3,1,Processed,"The article evaluates a free medication subsidy program for hypertension in rural China, focusing on medication adherence, medical costs, and blood pressure outcomes. It contains no discussion of genetics, genotyping, drug–gene interactions, personalized or genotype‑guided therapy, pharmacogenomic markers, or related methods. Therefore it is not relevant to pharmacogenetic approaches."
2a2e4539-bc95-4607-9c72-855993db23b1,1,"21. Burt VL et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey 1988-1991. Hypertension, 1995, 25:305-313.",3,1,Processed,"This 1997 review focuses on epidemiology, prevalence, risk factors, population genetics, and pathophysiology of hypertension in blacks. It discusses treatment rates and general genetic studies of hypertension loci but contains no assessment of pharmacogenetic approaches (drug–gene interactions, genetic predictors of antihypertensive response, or personalized therapy). Thus it is not relevant to pharmacogenetics."
5374ad4c-84cf-4d77-8d6d-8b4ae19eb9b3,1,"22. Hershey JC et al. Patient compliance with antihypertensive medication. American Journal of Public Health, 1980, 70:1081-1089.",3,1,Processed,"The paper is a behavioral/health services randomized trial examining family involvement and practitioner home visits to improve blood pressure control and medication compliance. It contains no discussion of genetics, genetic markers, genotype-guided therapy, or pharmacogenetic methods; it focuses on social support, home monitoring, and practitioner visits (published 1982, well before modern pharmacogenetics)."
7ae81391-bd25-4237-a3fd-f640791d2539,1,"23. Luscher TF et al. Compliance in hypertension: facts and concepts. Journal of Hypertension, 1985, 3:3-9.",3,1,Processed,"The article focuses on pharmacoadherence—definitions, measurement methods (direct, indirect, subjective), and behavioral/educational/technical interventions to improve medication-taking. It contains no discussion of genetics, genotyping, genetic markers, personalized drug response, or pharmacogenetic testing; therefore it is not relevant to pharmacogenetic approaches."
cb7a3f70-e543-4374-a069-e55137f1d2b9,1,"24. Hughes DA et al.The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.Health Economics,2001, 10:601-615.",3,1,Processed,"The paper focuses on adherence (persistence/compliance) to bisphosphonate therapy and its clinical/economic impact using a Markov microsimulation model. It contains no discussion of pharmacogenetic methods, genetic markers, genotype-guided therapy, or related analyses; thus it is not relevant to pharmacogenetic approaches."
587e42b3-ab8a-45f7-b128-cf3e5fc16b6a,1,"25. Morisky DE et al. Five-year blood pressure control and mortality following health education for hypertensive patients. American Journal of Public Health, 1983, 73:153-162.",3,1,Processed,"The article focuses on behavioral self-management, social cognitive theory, behavioral economics, and positive-affect interventions for chronic diseases (arthritis, cardiopulmonary conditions). It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized pharmacologic approaches."
dc052d3b-c084-4803-b801-f78a64f50fd6,1,"26. Psaty BM et al.The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. Journal of the American Medical Association, 1990, 263:1653-1657.",3,1,Processed,"The paper is a clinical review of antihypertensive treatment in patients with peripheral vascular disease, focusing on drug classes (beta blockers, ACE inhibitors, calcium antagonists), lifestyle measures, exercise, and effects on associated conditions and aneurysm growth. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or gene–drug interactions; therefore it is not relevant to pharmacogenetic approaches."
cbd88608-2084-47a6-9c49-bb5fffdfcbdf,1,27. Spector SL et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials.Journal of Allergy and Clinical Immunology.1986;77:6-70.,3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on patient behaviour, health systems, measurement, economics and interventions across chronic diseases. It contains no discussion of genetics, genomic testing, individualized drug response, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
251ea76e-8d49-416c-8098-127211e683c5,1,"28. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities.Medical Care,2001, 39:599-615.",3,1,Processed,"The paper evaluates the population-level impact of antihypertensive drug therapy using survey data, risk equations and health-economic calculations. It contains no discussion of genetic factors, genotype-guided prescribing, pharmacogenomics, biomarkers, or personalized drug response. The focus is epidemiologic and health-economics, not pharmacogenetic approaches."
c8d258d4-96bf-4963-84f1-539fd28576fc,1,"29. Piatrauskene I. [Hypertension: economic aspects.] [Russian] Sovetskoe Zdravookhranenie,1991, 4:22-25.",3,1,Processed,"The report focuses on adherence to long-term therapies, behavioural, health-system and economic factors across chronic conditions. It contains no discussion of pharmacogenetic approaches (genetic testing, genotype-guided prescribing, drug–gene interactions), so it is not relevant to pharmacogenetics."
8520bd78-a221-408c-8164-e7f8eb4e4acb,1,"30. McCombs JS et al.The costs of interrupting antihypertensive drug therapy in a Medicaid population. Medical Care,1994, 32:214-226.",3,1,Processed,"The paper examines continuity of care, provider counts, healthcare utilization, and pharmacy costs in HMOs; it contains no discussion of genetics, genotyping, drug–gene interactions, personalized drug selection, or pharmacogenetic approaches. Thus it is not relevant to pharmacogenetics."
bcf778ac-2c60-446b-9c37-dcba80c1ad70,1,"31. Tulenbaev MZ et al. [Economic efficacy of implementing a program to control arterial hypertension among industrial workers.] [Russian] Terapevticheskii Arkhiv,1987, 59:50-52.",3,1,Processed,"The report is focused on adherence to long-term therapies, behavioural, health-system and disease-management issues across chronic conditions; it contains no discussion of genetic testing, gene–drug interactions, personalized medicine or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
8e4e5e55-a26c-47dd-8ec1-d24f55cc8965,1,"32. Rizzo JA, Abbott TA, III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Economics, 1996, 5:249-265.",3,1,Processed,"The paper analyzes costs of medical care, absence, disability, and presenteeism for common physical and mental conditions and reports prescription drug expenditures, but it contains no discussion of genetics, pharmacogenetic testing, genotype-guided therapy, or personalized drug selection. Therefore it is not relevant to pharmacogenetic approaches."
8e4f23d8-8e4a-4584-8524-795e6ccb9fe5,1,"33. Cerveri I et al. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). European Respiratory Journal, 1999, 14:288-294.",3,1,Processed,"This is an observational clinical study of smoking prevalence and its impact on asthma control and treatment response (symptoms, spirometry, adherence) in Kuwaiti patients. It contains no pharmacogenetic methods, genotyping, gene–drug interaction analyses, or discussion of tailoring therapy based on genetic variation (only a brief citation about gene–environment linkage). Thus it is not relevant to pharmacogenetic approaches."
d19d2804-ed78-4839-895e-9e046d2d08df,1,"34. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Annals of Allergy, Asthma, & Immunology,1997, 79:177-185.",3,1,Processed,"The article discusses active vaccination against IL-5 for eosinophilic asthma—vaccine design (VLPs), immunology, preclinical/clinical efficacy, and therapeutic rationale. It contains no discussion of pharmacogenetics, genetic biomarkers, gene–drug interactions, or tailoring therapy based on genotype, so it is not relevant to pharmacogenetic approaches."
baca3b7a-bb9b-45f1-bfe2-7a89088ddd04,1,"35. Reid D et al. Management and treatment perceptions among young adults with asthma in Melbourne: the Australian experience from the European Community Respiratory Health Survey. Respirology, 2000, 5:281–287.",3,1,Processed,"The WHO report focuses on patient adherence, health systems, behavioural and socioeconomic determinants, and interventions for chronic diseases. It contains no discussion of genetic testing, genotype-guided prescribing, biomarkers, or personalized/pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
fb05b317-a30c-4a2e-80d0-2974a12b9299,1,"36. Pearson MH, Bucknall CE. Measuring clinical outcomes in asthma. London, Royal College of Physicians, 1999.",3,1,Processed,"This is a clinical guideline on asthma diagnosis and management (BTS/SIGN) covering diagnosis, monitoring, pharmacological and non‑pharmacological treatments, devices and service delivery. It contains no evaluation of genetic testing, genotype‑guided prescribing, or pharmacogenetic strategies and thus is not relevant to pharmacogenetics."
4e230188-dbfa-488d-babc-2f6c6c9c05a9,1,"37. Dekker FW et al. Compliance with pulmonary medication in general practice. European Respiratory Journal, 1993, 6:886-890.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, system-level, measurement and economic issues across chronic diseases. There is no discussion or assessment of pharmacogenetic approaches or genetic testing in the provided text."
556cfa94-6618-4a46-b0a6-061af09e218e,1,"38. Slack MK, Brooks AJ. Medication management issues for adolescents with asthma. American Journal of Health-System Pharmacy, 1995, 52:1417-1421.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies, focusing on behavioral, health-system, disease-specific and economic aspects. It discusses measurement, interventions, and policy for improving adherence across chronic conditions. There is no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, or related personalized medicine approaches; thus it is not relevant to pharmacogenetic assessment."
b3f05169-3e7f-4286-8e82-e49dc15effa7,1,"39. GINA Project (Global Initiative for Asthma). 2002, http://www.ginasthma.com.",3,1,Processed,"The document is a clinical guideline (GINA 2019) on asthma management and prevention. It covers diagnosis, phenotypes, assessments, treatment steps, medications, and implementation, but contains no substantive discussion of genetic markers, gene–drug interactions, pharmacogenetic testing, or personalized pharmacogenetic approaches. While it mentions clinical phenotypes, it does not assess pharmacogenetic strategies, so relevance to pharmacogenetics is nil."
7c814778-102a-4045-baa5-d98f6d268e05,1,"40. Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clinical Therapeutics,2000, 22:452-469.",3,1,Processed,"The paper evaluates a pharmacist-led educational intervention to improve medication adherence in COPD patients (MAQ scores, inhaler technique, smoking cessation, patient information leaflets, follow-up) and contains no discussion of genetics, genotyping, pharmacogenetic markers, genotype-guided therapy, or related methodologies. Therefore it is not relevant to pharmacogenetic approaches."
e6eef4b1-f3b7-4c52-902b-28f133b8700b,1,"1. Webb DG, Horne R, Pinching AJ.Treatment-related empowerment: preliminary evaluation of a new measure in patients with advanced HIV disease. International Journal of STD & AIDS, 2001, 12:103-107.",3,1,Processed,"The article is a systematic review of patient-reported measures of patient empowerment and psychometric properties. It focuses on PROM development, validation, and conceptual domains (empowerment, enablement, activation) and contains no discussion of pharmacogenetics, drug–gene interactions, genetic testing, or personalized pharmacotherapy."
f08042bb-131f-4f1c-9bad-153e293228e0,1,"2. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research, 1999, 47:555-567.",3,1,Processed,"The paper describes cultural adaptation and psychometric validation of the Beliefs about Medicines Questionnaire in Greek primary care patients; it focuses on patient beliefs, adherence and survey validation. It contains no discussion of genetics, genetic testing, gene–drug interactions, pharmacogenetic markers, or personalized pharmacogenomic approaches, so it is not relevant to pharmacogenetics."
11b9cbe2-9fb6-40fa-8510-76a2b6c89118,1,"3. Horne R. Patients’ beliefs about treatment: the hidden determinant of treatment outcome? Journal of Psychosomatic Research, 1999, 47:491-495.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, measurement, behavioural and health-system determinants, and disease-specific reviews (asthma, HIV, diabetes, TB, etc.). It discusses interventions, economics and patient/provider factors but contains no discussion of pharmacogenetics, genetic testing, or genetic tailoring of treatment. Therefore it is not relevant to pharmacogenetic approaches."
31e01126-8c0e-4a80-8f42-5b8510d7a945,1,"4. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, World Health Organization, 2002.",3,1,Processed,"The document is a WHO public-health policy/report on alcohol-related harms, epidemiology and prevention strategies. It contains no discussion of genetics, genetic testing, drug-response variability, personalized medicine, or pharmacogenetic approaches; treatment references are general and not pharmacogenetic."
a1be54df-dab4-434f-a6bf-76ceba4c539f,1,"6. Dunbar-Jacob J et al. Adherence in chronic disease. Annual Review of Nursing Research, 2000, 18:48-90.",3,1,Processed,"This CV focuses on nursing research in adherence, physical activity, chronic disease management, quality improvement, mobile health, and rheumatology; there is no mention of genetics, genomics, pharmacogenetics, genotype-guided therapy, or related methods or analyses. Therefore it is not relevant to pharmacogenetic approaches."
8588948e-f22b-444a-9b09-02cc412f534c,1,"7. Sarquis LM et al. [Compliance in antihypertensive therapy: analyses in scientific articles.] [Portuguese] Revista Da Escola de Enfermagem Da USP , 1998, 32:335-353.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, health-system, measurement, economic and disease‑specific issues. It contains no discussion of pharmacogenetics (genetic determinants of drug response) — only occasional references to drug resistance or biochemical adherence markers, which are not pharmacogenetic analyses. Therefore it is not relevant to pharmacogenetic approaches."
2384c023-a72a-49f4-a591-33ee028140a0,1,"8. Clark DO. Issues of adherence, penetration, and measurement in physical activity effectiveness studies. Medical Care,2001, 39:409-412.",3,1,Processed,"The paper focuses on medication adherence, self-management behaviors, prescription patterns and socioeconomic factors among type 2 diabetic patients. It contains no discussion of genetic testing, gene–drug interactions, genetic polymorphisms, personalized/precision dosing, or any pharmacogenetic methods or results, so it is not relevant to pharmacogenetic approaches."
5cc53e7b-07fa-408d-b6d6-b917e04c56b8,1,"9. Green CA.What can patient health education coordinators learn from ten years of compliance research? Patient Education & Counseling, 1987,10:167-174.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focused on behavioral, health-systems, and disease-specific factors and interventions. It discusses measurement of adherence, self‑management, economics, and policy for chronic conditions; there is no discussion of pharmacogenetic testing, genetic determinants of drug response, or personalized genomic approaches."
02b7b540-a85b-4bbd-af44-fc46e2b54129,1,"12. Macroeconomics and Health: Investing in Health for Economic Development – Report of the Commission on Macroeconomics and Health. Geneva, World Health Organization, 2001.",3,1,Processed,"The document is a WHO macroeconomics and health report focused on financing, health systems, population-level interventions, and R&D for drugs/vaccines and access to medicines. It contains no discussion or assessment of pharmacogenetic approaches, personalized medicine, genetic testing, or genotype-guided therapy."
f0d9feb2-0ad8-41ef-a439-36c1a0ff01a5,1,"13. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research.Annals of Behavioral Medicine, 1997, 19:239-263.",3,1,Processed,"The paper describes a randomized trial of NP/CHW-led behavioral and guideline-based pharmacologic management for CVD risk factors in community clinics. It contains no discussion of genetic testing, gene–drug interactions, genotype‑guided therapy, or any pharmacogenetic methods or outcomes. Pharmacotherapy is addressed only via standard treatment algorithms and adherence support, not pharmacogenetics."
a3280f65-51cf-410f-9f83-c4bcd2003a37,1,"14. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? Journal of Cardiovascular Pharmacology,2000, 35 (Suppl 3):S23-S26.",3,1,Processed,"The article evaluates a medication subsidy program for hypertension in rural China, focusing on adherence, medical costs, and blood pressure control using survey data and propensity-score matching. It contains no discussion of genetic testing, genotype-guided therapy, gene variants, pharmacogenomics, or any biomarkers—it is a health policy/economics and adherence study, not a pharmacogenetics assessment."
e7892858-d266-41bd-8eb0-3ce64303e059,1,"15. Luscher TF et al. Compliance in hypertension: facts and concepts. Journal of Hypertension (Suppl), 1985, 3:S3-S9.",3,1,Processed,"The article focuses on medication adherence and dosing frequency (QD vs BID) for cardiovascular drugs using pharmacy claims data and MPR metrics. It analyzes therapeutic classes, adherence rates, and associated limitations of claims-based measurement. There is no discussion of genetics, genotyping, pharmacogenetic testing, gene–drug interactions, or personalized/precision medicine approaches, so it is not relevant to pharmacogenetics."
5a2af8ed-561a-4a0c-9e41-5f1d06fab362,1,"16. Psaty BM et al.The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. Journal of the American Medical Association, 1990, 263:1653-1657.",3,1,Processed,"This review focuses on clinical use, trials, risks, dosing, timing, and guideline recommendations for perioperative beta‑blocker therapy in noncardiac surgery. It contains no discussion of pharmacogenetic or pharmacogenomic approaches (eg, genetic determinants of drug response, genotype‑guided dosing, CYP polymorphisms, or related testing), so it is not relevant to pharmacogenetics."
9bc148d4-8d17-4934-955c-5c4f695e5efd,1,"17. Rogers PG, Bullman W. Prescription medicine compliance: review of the baseline of knowledge – report of the National Council on Patient Information and Education. Journal of Pharmacoepidemiology, 1995, 3:3-36.",3,1,Processed,"The review focuses on behavioral, provider/system, and policy interventions to improve medication adherence (education, case management, reminders, copayment reduction, etc.) across chronic diseases. It contains no discussion of genetic testing, gene–drug interactions, genotype-guided prescribing, or pharmacogenetic interventions, so pharmacogenetics is not assessed."
a4f48362-e5c7-443c-8093-c2c3ff1b1963,1,"19. Khalil SA, Elzubier AG. Drug compliance among hypertensive patients in Tabuk, Saudi Arabia.Journal of Hypertension, 1997, 15:561-565.",3,1,Processed,"The article is an observational study of medication compliance in hypertensive patients, focusing on sociodemographic, behavioral, and health-system factors (attitude, physician visit interval, insurance, complications). It contains no discussion of genetics, genotyping, polymorphisms, drug metabolism, or personalized/pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
c8c79955-3902-4470-aa5b-0a9d118aae8b,1,"20. Elzubier AG et al. Drug compliance among hypertensive patients in Kassala, eastern Sudan. Eastern Mediterranean Health Journal, 2000, 6:100-105.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies, focusing on behavioural, health-system, measurement and disease-specific issues (asthma, diabetes, HIV, TB, etc.). It contains no discussion of genetic testing, gene–drug interactions, pharmacogenomic markers, or personalized drug selection—i.e. pharmacogenetics is not addressed."
94d2836b-2b1f-475c-af1e-57bf7f814d70,1,"21. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care,2001, 24:619-624.",3,1,Processed,"This paper is a meta-analysis of lifestyle (diet and exercise) education interventions to prevent type 2 diabetes, assessing outcomes such as 2‑hour plasma glucose and diabetes incidence. It focuses on behavioral interventions and population clinical outcomes and contains no discussion of genetics, pharmacologic treatments, gene–drug interactions, or genetic stratification, so it is not relevant to pharmacogenetic approaches."
cc279a33-c12e-42e5-b2e2-0d8f87444119,1,"22. Foreyt JP , Poston WS.The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. International Journal of Obesity, 1999, 23 (Suppl 7):S5-S11.",3,1,Processed,"The article is a review of lifestyle/behavioral treatments for obesity (diet, physical activity, behavioral therapy), with some discussion of pharmacotherapy and bariatric surgery. It contains no discussion of pharmacogenetic approaches, genetic predictors of drug response, or personalized pharmacogenetic strategies, so it is not relevant to pharmacogenetics."
1c4a9980-97e9-4e95-a5c2-0c52abd9c254,1,"23. Anderson BJ, Vangsness L, Connell A. Family conflict, adherence, and glycaemic control in youth with short duration Type 1 diabetes. Diabetic Medicine, 2002, 19:635-642.",3,1,Processed,"The paper is a psychosocial study of children’s appraisals of maternal involvement in managing type 1 diabetes and their associations with adherence, metabolic control, and quality of life. It does not discuss genetic factors, drug response variability, genotype–phenotype associations, pharmacogenetic testing, or any pharmacogenomic approaches. Thus it is not relevant to pharmacogenetics."
edc7f381-097b-4046-bef6-3ce6d2161900,1,"24. Thompson C et al. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. American Journal of Psychiatry, 2000, 157:338-343.",3,1,Processed,"The study examines medication adherence in older adults across countries—focusing on demographic, cognitive, behavioral, and health-service factors (e.g., dementia, alcohol misuse, medication review)—and contains no discussion, measurement, or analysis of genetic or pharmacogenetic factors. Therefore it is unrelated to pharmacogenetic approaches."
8d3533ef-c744-4a93-985f-79a079950a69,1,"25. Stein MD et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. American Journal of Drug & Alcohol Abuse, 2000, 26:195-205.",3,1,Processed,"The document is a public-health guidance on integrated prevention services for infectious diseases among persons who use drugs illicitly. It focuses on epidemiology, outreach, screening, vaccination, substance-use treatment (e.g., methadone, buprenorphine), and service integration. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized/genotype-guided therapy, so it is not relevant to pharmacogenetic approaches."
d8aca704-753d-4ecd-8279-2df7678c1206,1,"29. Bangsberg DR et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000, 14:357-366.",3,1,Processed,"The paper investigates the relationship between antiretroviral therapy adherence and residual HIV-1 viremia using pill counts and viral load assays. It contains no discussion or assessment of genetic factors, pharmacogenetic testing, host genotypes, drug metabolism polymorphisms, or tailored drug selection based on genetics. Therefore it is not relevant to pharmacogenetic approaches."
fdf6a8ee-52e1-4cb9-afd7-906815da0d5f,1,"30. Chesney MA. Factors affecting adherence to antiretroviral therapy.Clinical Infectious Disease, 2000, 30 (Suppl 2):S171-S176.",3,1,Processed,"The study evaluates an adherence counseling program for HIV-infected patients and measures clinical outcomes (viral load, CD4, weight) and qualitative patient feedback. It does not include pharmacogenetic analyses, genotype-guided therapy, genetic biomarkers, or assessments of host or drug metabolism genetics. (It even notes that viral genotyping for resistance was not performed.) Therefore it is not relevant to pharmacogenetic approaches."
d88d6735-3d69-49d7-ac91-123f7f9c0b02,1,"31. Murri R et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. Journal of Acquired Immune Deficiency Syndromes, 2000, 24:123-128.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, health‑system and economic aspects, measurement methods and disease‑specific management. It contains no discussion of pharmacogenetics, genotyping, genetic predictors of drug response, or tailoring therapy based on genetic markers, so it is not relevant to pharmacogenetic approaches."
0c8b0b46-ee0f-4e72-a015-151472d4fd20,1,"32. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy.Social Science and Medicine, 2000, 50:1599-1605.",3,1,Processed,"The paper focuses on adherence to antiretroviral therapy from a biosocial perspective (socioeconomic, cultural, health-system factors) and discusses drug resistance in relation to adherence, but it contains no discussion, assessment, or analysis of pharmacogenetic approaches or genetic determinants of drug response."
2dda2db2-74cf-4c61-9632-04a55e2b5e01,1,"33. Holman HR et al. Evidence that an education program for self-management of chronic disease can improve health status while reducing health care costs: a randomized trial.Abstract Book/Association for Health Services Research, 1997, 14:19-20.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies, focusing on behavioural, system, economic and clinical aspects of medication adherence across chronic diseases. It contains no discussion of pharmacogenetics, genotyping, genetic determinants of drug response, or personalized/precision medicine approaches, so it is not relevant to pharmacogenetic assessment."
59a63710-ef8b-4b65-860c-78b8d2091be5,1,"34. Gibson PG et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews, 2001.",3,1,Processed,"The review focuses on digital self-management interventions for asthma (web/telephone/computer tools, education, behavior-change techniques, implementation, and outcomes). It contains no discussion of genetics, genotyping, gene–drug interactions, personalized drug therapy based on genetic markers, or any pharmacogenetic methods or results. Therefore it is not relevant to pharmacogenetic approaches."
157d7f2a-3953-4716-81c7-74813c6387eb,1,"35. Sloss EM et al. Selecting target conditions for quality of care improvement in vulnerable older adults. Journal of the American Geriatrics Society, 2000, 48:363-369.",3,1,Processed,"The paper focuses on transitional care, communication of medication lists, advance directives, and pharmacist-led medication reconciliation between nursing homes and hospitals. It does not mention pharmacogenetics, pharmacogenomic testing, genotype-guided therapy, or related genetic approaches."
38b3ba92-60f6-4d7c-be2c-2e3bf1a517aa,1,"37. Massanari MJ. Asthma management: curtailing cost and improving patient outcomes. Journal of Asthma, 2000, 37:641-651.",3,1,Processed,"The document is an administrative annual evaluation of a Medicaid managed care program (enrollment, access, case management, quality indicators, lead management, grievance systems, marketing, and a 17P prenatal intervention). It contains no discussion of genetics, genetic testing, genotype-guided prescribing, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
04111ac6-02c7-42bd-bcf9-2e6574c9013d,1,"38. Kokubu F et al. [Hospitalization reduction by an asthma tele-medicine system.] [Japanese] Arerugi – Japanese Journal of Allergology, 2000, 49:19-31.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focusing on behavioural, health system, and economic factors across chronic diseases. It discusses measurement, interventions, and issues like drug resistance, but contains no assessment of pharmacogenetic approaches or genetic tailoring of therapy. Therefore it is not relevant to pharmacogenetics."
7c676013-a496-41d1-8d82-198207570274,1,"39. Serrier P et al. [Evaluation of an educational program on asthma for pharmacists.] [French] Presse Medicale, 2000, 29:1987-1991.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focused on behavioural, measurement, health‑system and disease‑specific interventions. It contains no assessment or discussion of pharmacogenetic approaches or genetic tailoring of therapy."
8362d3e4-66fe-4f92-8560-b8ada262c06f,1,"40. Strobach D et al. [Patient medication counselling – patient counselling about discharge medication]. [German] Medizinische Klinik, 2000, 95:548-551.",3,1,Processed,"The report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors, and disease‑specific adherence issues. It contains no discussion of pharmacogenetics, genetic testing, or personalized drug-response genetics (only brief mentions of drug resistance in infectious diseases), so it is not relevant to pharmacogenetic approaches."
4e4fe5eb-0c14-4258-b564-8c9faa0a25c9,1,"41. Piette JD et al. Do automated calls with nurse follow-up improve self-care and glycemic control among vulnerable patients with diabetes? American Journal of Medicine, 2000, 108:20-27.",3,1,Processed,"The paper reviews interactive voice response (IVR) systems for monitoring and managing chronic diseases (diabetes, heart failure, depression, etc.). It focuses on telephonic assessment feasibility, validity, clinical follow-up, and outcomes, with no discussion of genetic testing, genotype-guided therapy, drug–gene interactions, or any pharmacogenetic approaches."
70f3f0d8-4582-4586-9df3-bcff0d5f35eb,1,"42. Rice VH. Nursing interventions for smoking cessation. Cochrane Database of Systematic Reviews, 2001, Issue 1, 2001.",3,1,Processed,"This Cochrane review examines nursing-delivered smoking cessation interventions (advice, counselling, intensity, setting, follow-up) and mentions nicotine replacement therapy only as a non-genetic adjunct. It contains no evaluation of genetic factors, genotyping, gene–drug interactions, or personalized pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
99fcda5e-38aa-4b95-bf1c-740a4af0c6b3,1,"43. Banerjee A et al. Evaluation of a unified treatment regimen for all new cases of tuberculosis using guardian-based supervision. International Journal of Tuberculosis & Lung Disease, 2000, 4:333-339.",3,1,Processed,"The dissertation is a public-health program evaluation of community- vs health‑centre DOT for tuberculosis in Cambodia (treatment delivery, case finding, adherence, qualitative and quantitative assessments). It contains no discussion of genetics, genetic markers, drug metabolism, genotyping, polymorphisms or personalized/precision pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
933d22e4-5323-496d-9543-aae274ef27e1,1,"45. Nisbeth O, Klausen K, Andersen LB. Effectiveness of counselling over 1 year on changes in lifestyle and coronary heart disease risk factors. Patient Education & Counseling, 2000, 40:121-31.",3,1,Processed,"The paper is a consensus review on adherence interventions for primary cardiovascular prevention, focusing on behavioral, system-level, team-based, and medication-cost/polypill strategies. It contains no discussion of pharmacogenetics, genotype-guided prescribing, genetic testing, or related biomarkers — therefore it is not relevant to pharmacogenetic approaches."
84e8ee13-07fc-45b4-90d8-e2a2b9333782,1,"46. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. Journal of the American Pharmaceutical Association, 2000, 40:475-485.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors, and disease‑specific adherence interventions. The provided content contains no discussion of pharmacogenetics, genotyping, gene–drug interactions, or personalized/precision medicine approaches, so it is not relevant to pharmacogenetic assessment."
7273c3cc-4974-4be2-9bdf-548ebaf5bdac,1,"48. James M et al. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. British Medical Journal, 2000, 320:1627-1631 [erratum published in British Medical Journal, 2000, 321:424].",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, health-system and economic aspects across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, or personalized drug-gene interactions, so it is not relevant to pharmacogenetic approaches."
b387a449-d93a-410a-ba29-d29a5f4315ec,1,"49. McCulloch D. Managing diabetes for improved health and economic outcomes. American Journal of Managed Care, 2000, 6 (Suppl):S1089-S1095.",3,1,Processed,"The report focuses on adherence to long‑term therapies, behavioural, system and economic factors, and disease‑specific management; it contains no discussion of pharmacogenetic approaches, genetic testing, or personalized drug–gene interactions beyond general measurement/biochemical adherence markers."
41629348-e320-4bf6-9852-864605f59255,1,"50. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy.Annals of Pharmacotherapy,2000, 34:703-709.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies, focusing on patient behaviour, health‑system factors, measurement, and interventions across chronic diseases. It does not discuss pharmacogenetic testing, genetic determinants of drug response, or personalized/ genotype‑guided therapy—only occasional mentions of drug resistance in infectious diseases, which is unrelated to pharmacogenetic approaches."
ac29094c-0e18-4cbc-9162-7be99caf826e,1,"51. Tutty S, Simon G, Ludman E.Telephone counseling as an adjunct to antidepressant treatment in the primary care system. A pilot study.Effective Clinical Practice,2000, 3:170-178.",3,1,Processed,"The document is a WHO report focused on adherence to long-term therapies, behavioral, system-level, and disease-specific issues (asthma, HIV, diabetes, etc.). It discusses measurement, interventions, health economics and service delivery. It contains no discussion of pharmacogenetics, genomics, or personalized drug-response testing, so it is not relevant to pharmacogenetic approaches."
e4e5dde1-e39c-4057-a046-346e6f093450,1,"52. Solomon LJ et al. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking. Preventive Medicine,2000, 31:68-74.",3,1,Processed,"The article is a systematic review of peer-support programs for smoking cessation in disadvantaged groups, focusing on social/behavioral interventions, peer training, and outcomes. It does not discuss genetics, genetic testing, genotype-tailored treatments, or gene–drug interactions. While nicotine replacement therapy is mentioned, there is no consideration of pharmacogenetic approaches, so the paper is not relevant to pharmacogenetics."
48e69642-f226-406f-9ffd-c2b3130b3346,1,"53. Norris SL et al. Effectiveness of physician-based assessment and counseling for exercise in a staff model HMO. Preventive Medicine,2000, 30:513-523.",3,1,Processed,"The paper is a systematic review of primary-care counseling interventions to promote physical activity, summarizing trials, behavioral models, outcomes, harms, and feasibility. It contains no discussion of genetics, pharmacogenetics, drug responses, or genetic testing, so it is not relevant to pharmacogenetic approaches."
65e044cd-4010-4e8f-ae52-b619554aa4d5,1,"54. Salmon-Ceron D et al. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients.] [French] Annales de Medecine Interne, 2000, 151:297-302.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, covering behavioral, health-system, disease-specific, and measurement/intervention topics. It discusses patient behaviour, self-management, epidemiology, economics and some biochemical adherence markers, but contains no assessment of pharmacogenetic approaches, genetic testing, or drug–gene interactions. Therefore it is not relevant to pharmacogenetics."
9cb12e4f-7c62-465d-9bad-ad93938bbe9a,1,"55. Muller C, Hagele R, Heinl KW. [Differentiation and modification of compliance with reference to topical corticoid medication in patients with bronchial asthma.] [German] Pneumologie, 1996, 50:257-259.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies (behavioral, health-system, measurement, disease-specific reviews, economics and interventions). It does not discuss pharmacogenetics, genotype-guided therapy, genetic variability, or pharmacogenomic testing—so it is not relevant to pharmacogenetic approaches."
e6f91cec-17c0-4317-9581-ffdf535e7751,1,"56. Woller W et al. Cortisone image and emotional support by key figures in patients with bronchial asthma. An empirical study.Psychotherapy & Psychosomatics, 1993, 59:190-196.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focusing on behavioral, health-system and disease‑specific interventions and economics. It does not discuss pharmacogenetics, genetic testing, or personalized drug-response/genomic approaches—only general medication adherence and resistance issues—so it is not relevant to pharmacogenetic assessment."
90335c99-cc35-4ead-a32e-267d6ca3063a,1,"57. Wagner EH et al. Chronic care clinics for diabetes in primary care: A system-wide randomized trial. Diabetes Care,2001, 24:695-700.",3,1,Processed,"The article focuses on organizational primary care orientation and implementation of the Chronic Care Model for chronic disease management; it discusses health promotion, care coordination, information systems, and accountability measures. There is no discussion of genetics, genomics, drug-response variability, biomarkers, or pharmacogenetic testing or approaches."
03d24362-a1ed-4237-9b3f-d656ca17ddbf,1,"58. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. 1982.Journal of the American Medical Association, 1997, 277:582-594.",3,1,Processed,"The WHO 2003 report focuses on patient adherence to long-term therapies, behavioral, system and economic factors, and disease-specific adherence interventions. It contains no discussion of pharmacogenetics, genomics, genetic testing, gene–drug interactions, or personalized/precision medicine approaches. Therefore it is not relevant to pharmacogenetic assessment."
e1589a38-0ca4-448a-b787-0d55a1a1d95f,1,"60. DeBusk RF et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Annals of Internal Medicine, 1994, 120:721-729.",3,1,Processed,"The paper focuses on telephone quitlines and behavioral/organizational aspects of smoking cessation (reactive vs. proactive counseling, program usage, integration with physician advice and NRT). It contains no discussion of genetics, genotyping, individualized drug response, biomarkers, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
a6e44f8b-22db-4bd2-8437-a68bca4afb40,1,"61. Peters AL, Davidson MB, Ossorio RC. Management of patients with diabetes by nurses with support of subspecialists. HMO Practice, 1995, 9:8-13.",3,1,Processed,"The paper examines continuity of care and diabetes management outcomes (preventive services, visit frequency, HbA1c) in an HMO population. It does not discuss genetics, genetic testing, genotype-guided drug selection, or variability in drug response by genotype — i.e., no pharmacogenetic content."
15887d12-e291-4c2e-b017-c098b9aefcf6,1,"62. Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy,2000, 20:191S-199S.",3,1,Processed,"The paper focuses on adherence to epilepsy medical recommendations (questionnaires/scales, socio‑demographic and clinical factors, clinic visit frequency, polytherapy, alcohol/smoking) and validates an authors’ adherence scale using serum drug concentrations. It contains no discussion of genetic testing, polymorphisms, genotype‑guided dosing, pharmacogenomic markers or personalized pharmacogenetic approaches — therapeutic drug monitoring is used, but not pharmacogenetics."
4d58caaa-be49-44b1-9097-46c33779e4d6,1,"63. Ruggieron L et al. Impact of social support and stress on compliance in women with gestational diabetes. Diabetes Care,1990, 13:441-443.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies, focusing on patient behaviour, health systems, measurement, and interventions for chronic diseases. It does not discuss pharmacogenetics, genetic testing, drug–gene interactions, or personalized/precision medicine — therefore it is not relevant to pharmacogenetic approaches."
7d411aec-f1a8-4141-9cc8-83573aa11d46,1,"65. MacLean D, Lo R.The non-insulin-dependent diabetic: success and failure in compliance. Australian Journal of Advanced Nursing, 1998, 15:33-42.",3,1,Processed,"This WHO report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors, measurement methods and interventions across chronic diseases. It contains no discussion of genetic or pharmacogenetic testing, gene–drug interactions, individualized dosing based on genotype, or related molecular approaches. Therefore it is not relevant to pharmacogenetic assessment."
1e651b8d-e74a-4990-96d5-9309018c33b1,1,"66. Kyngas H. Predictors of good compliance in adolescents with epilepsy. Seizure, 2001, 10:549-553.",3,1,Processed,"The article reviews medication adherence (education, research, practice, policy) in Finland and contains no discussion of genetic factors, pharmacogenetic testing, genotype-guided therapy, or related methods. Its focus is on adherence, counselling, register-based epidemiology and health policy, not pharmacogenetics."
8fdbb4e0-d449-4b79-8c9d-84b84ac22ded,1,"67. Kyngas H, Rissanen M. Support as a crucial predictor of good compliance of adolescents with a chronic disease. Journal of Clinical Nursing, 2001, 10:767-774.",3,1,Processed,"The article investigates adherence to treatment in elderly patients with chronic heart failure using a questionnaire and examines psychosocial, educational and healthcare-related factors. It contains no discussion of genetics, gene–drug interactions, genotyping, biomarkers, or any pharmacogenetic methods or analyses, so it is not relevant to pharmacogenetic approaches."
27fc5a3f-a514-45e4-91a8-e14eab5f3bfe,1,"68. Pendley JS et al. Peer and family support in children and adolescents with type 1 diabetes. Journal of Pediatric Psychology,2002, 27:429-438.",3,1,Processed,"The article examines psychosocial factors (friendship support/conflict), mood, self-care behavior, and blood glucose control in adolescents with Type 1 diabetes using survey and ecological momentary assessment methods. It contains no discussion of genetics, pharmacogenetics, gene–drug interactions, genotyping, or medication-response variability, so it is not relevant to pharmacogenetic approaches."
bcbe1869-b146-4913-a080-31fa2e5ff62d,1,"69. Burroughs TE et al. Research on social support in adolescents with IDDM: a critical review.Diabetes Educator,1997, 23:438-448.",3,1,Processed,"The paper focuses on physiologic, psychosocial and clinical management of metabolic control in adolescents with type 1 diabetes, discussing insulin resistance, family/eating-disorder factors and general pharmacologic options (e.g., metformin, thiazolidinediones) but contains no discussion of pharmacogenetics, genotype-guided therapy, genetic markers, or related approaches."
a0b9989a-c996-48ba-bd5a-cdb56fc3096a,1,"70. Fitzgerald JT et al. Differences in the impact of dietary restrictions on African Americans and Caucasians with NIDDM. Diabetes Educator,1997, 23:41-47.",3,1,Processed,"The report focuses on adherence to long-term therapies, behavioural, system and disease-specific issues, measurement and interventions. It contains no discussion of pharmacogenetics/pharmacogenomics, genetic testing, or genotype-guided therapy—so it is not relevant to pharmacogenetic approaches."
37658db2-804a-4266-9adb-c89f4300ac42,1,"71. Wang CY , Fenske MM. Self-care of adults with non-insulin-dependent diabetes mellitus: influence of family and friends. Diabetes Educator,1996, 22:465-470.",3,1,Processed,"The WHO report focuses on patient adherence, behavioural, health-system and economic aspects of long-term therapies across various diseases; it does not discuss pharmacogenetic approaches or genetic tailoring of treatments, so it is not relevant to pharmacogenetics."
864ee2d4-cae6-4c25-86dd-244d289e39e5,1,"72. La Greca AM et al. I get by with a little help from my family and friends: adolescents’ support for diabetes care.Journal of Pediatric Psychology,1995, 20:449-476.",3,1,Processed,"This paper examines psychosocial aspects of peer relationships and their association with psychological well‑being, self‑care behavior, and blood glucose control in adolescents with Type 1 diabetes using survey and ecological momentary assessment methods. It contains no discussion of genetics, gene–drug interactions, genotype‑based treatment, or any pharmacogenetic approaches."
c5ed08a6-9140-401e-b2ee-33fb027b1337,1,"73. Garay-Sevilla ME et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. Journal of Diabetes & its Complications, 1995, 9:81-86.",3,1,Processed,"The paper focuses on social support, self-management, cultural/sex/peer factors, health literacy, and patient-centered care in type II diabetes. It does not discuss genetics, genetic testing, gene–drug interactions, or pharmacogenetic strategies; its mention of 'personalized' care refers to sociocultural tailoring rather than pharmacogenetics."
c49dd515-dd99-4498-9236-9137f6df007c,1,"74. Belgrave FZ, Lewis DM.The role of social support in compliance and other health behaviors for African Americans with chronic illnesses. Journal of Health & Social Policy, 1994, 5:55-68.",3,1,Processed,"The article focuses on adherence interventions for primary prevention of cardiovascular disease (patient communication, motivational interviewing, team-based care, polypills, reminders, mHealth, costs, health literacy, etc.). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or personalized drug selection by genetic markers, so it is not relevant to pharmacogenetic approaches."
e0f6db1e-2115-4076-b447-2e902cd12bf0,1,"75. Ruggiero L et al. Self-reported compliance with diabetes self-management during pregnancy.International Journal of Psychiatry in Medicine, 1993, 23:195-207.",3,1,Processed,"The document is a WHO 2003 report on adherence to long-term therapies focusing on patient behaviour, health systems, measurement, disease-specific adherence issues and interventions. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or related personalized-medicine approaches, so it is not relevant to pharmacogenetic assessment."
f20fc498-01c4-4a3d-9a41-6c0486210e48,1,"77. Nagasawa M et al. Meta-analysis of correlates of diabetes patients’ compliance with prescribed medications. Diabetes Educator,1990, 16:192-200.",3,1,Processed,"The review focuses on pharmacist-led interventions (education, adherence support, monitoring, medication review, self‑management) to improve HbA1c in type 2 diabetes. It contains no discussion of genetic testing, genotype-guided therapy, pharmacogenomics, gene–drug interactions, or individualized treatment based on genetic markers, so it is not relevant to pharmacogenetic approaches."
b3fd7a79-7c10-4fdb-91a9-d8ce85841f55,1,"78. Ruggiero L et al. Impact of social support and stress on compliance in women with gestational diabetes. Diabetes Care,1990, 13:441-443.",3,1,Processed,"The document is a WHO 2003 report on adherence to long‑term therapies, focusing on behavioural, health-system and socioeconomic determinants and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, or personalized drug-response genetics; therefore it is not relevant to pharmacogenetic approaches."
368454b9-5f85-46b6-aab7-1f136363a99d,1,"79. Fishman T.The 90-Second Intervention: a patient compliance mediated technique to improve and control hypertension. Public Health Reports, 1995, 110:173-178.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies, focusing on patient behaviour, health systems, epidemiology, measurements, and interventions across chronic conditions. It contains no discussion of pharmacogenetics, genetic testing, or personalized drug-response genetics, so it is not relevant to pharmacogenetic approaches."
e243939d-c025-40ed-8838-1a75b565333d,1,"80. Stanton AL. Determinants of adherence to medical regimens by hypertensive patients. Journal of Behavioral Medicine, 1987, 10:377-394.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, health-system, measurement, epidemiology and economic aspects across chronic diseases. It does not discuss pharmacogenetics, genotype-guided prescribing, genetic markers, or personalized drug-response genomics — only occasional mentions of drug resistance in HIV/TB, which is not pharmacogenetics. Therefore it is not relevant to pharmacogenetic approaches."
6685e394-b6f2-40cc-9fae-100fe8bb5257,1,"81. Kyngas HA. Compliance with health regimens of adolescents with epilepsy. Seizure, 2000, 9:598-604.",3,1,Processed,"The article reviews medication adherence, pharmacy education, research, practice and policy in Finland and contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or related molecular/genetic methods. Its focus is on adherence, counselling, register-based pharmacoepidemiology and service delivery rather than pharmacogenetic approaches."
88659d22-9db9-4c12-b757-e5a857df3607,1,"82. Kyngas HA, Kroll T , Duffy ME. Compliance in adolescents with chronic diseases: a review.Journal of Adolescent Health, 2000, 26:379-388.",3,1,Processed,"This paper describes development/validation of a Pediatric Endocrine Knowledge Assessment Questionnaire and an educational intervention for parents and children with endocrine disorders (congenital hypothyroidism, Hashimoto’s, GHD, Graves’, CAH). It focuses on patient knowledge, education, and adherence; there is no discussion of pharmacogenetics, genotyping, gene–drug interactions, or personalized drug response. Therefore it is not relevant to pharmacogenetic approaches."
5f75c541-9231-4290-a7a0-cf3e4e5d1fb1,1,"83. Cameron C. Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. Journal of Advanced Nursing, 1996, 24:244-250.",3,1,Processed,"The paper focuses on nursing, patient non‑compliance, social models of health and patient‑centred care. It discusses medication adherence and healthcare communication but contains no discussion of genetics, genomic testing, individualized drug response, or pharmacogenetic approaches."
5cfc4f13-299c-4a4f-b111-d5d82fc4e787,1,"84. Schlenk EA, Hart LK. Relationship between health locus of control, health value, and social support and compliance of persons with diabetes mellitus. Diabetes Care,1984, 7:566-574.",3,1,Processed,"This paper examines a behavioral/educational intervention (visualizing the tympanic membrane) to improve adherence in acute otitis media; it focuses on appointment-keeping, clinical outcomes, and the health belief model. There is no discussion of genetics, genotypes, drug metabolism, individualized drug response, or any pharmacogenetic methods or analyses."
4349632c-ae83-412d-bb9e-4fd292da6a41,1,"85. Levy RL. Social support and compliance: a selective review and critique of treatment integrity and outcome measurement. Social Science & Medicine, 1983, 17:1329-1338.",3,1,Processed,"The trial focuses on physiological and microbiome biomarkers (HRV, GI permeability, stool microbiome, fecal granins) to predict response to CBT versus a low‑FODMAP diet in pediatric DGBI. It does not include genetic testing, gene–drug interaction analyses, or any medication/pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
fbf4f2a8-a9f5-4fc5-95a5-7a18ce8a104e,1,"86. Doherty WJ et al. Effect of spouse support and health beliefs on medication adherence.Journal of Family Practice, 1983, 17:837-841.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, covering definitions, measurement, epidemiology, system- and patient-level interventions, disease-specific reviews and health economics. It discusses behavioural, social, and health‑system determinants and issues such as drug resistance in HIV/TB, but contains no assessment of pharmacogenetic approaches, genetic testing, genotype‑guided prescribing, or individualized pharmacogenomic strategies."
2ff163b2-bf3f-4a73-8476-50c33b6b5da4,1,"87. Kyngas HA. Compliance of adolescents with asthma. Nursing & Health Sciences, 1999, 1:195-202.",3,1,Processed,"The WHO report is focused on adherence to long-term therapies, behavioural, system-level and disease-specific factors and interventions (asthma, diabetes, HIV, TB, etc.). It discusses measurement, patient/provider/system determinants, and interventions to improve adherence; it contains no discussion of pharmacogenetic testing, genetic markers, genotype-guided prescribing, or personalized/precision pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
2fbe210e-866b-4c81-bae4-b305f538762d,1,"88. Weishut DJ. [Coping with AIDS in a support group – an encounter with the health system.] [Hebrew] Harefuah, 1996, 130:521-523.",3,1,Processed,"The WHO report is focused on adherence to long-term therapies (behavioral, health-system, economic and intervention aspects) across chronic diseases. It does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related personalized-drug-response literature. The only biological references concern biochemical markers for monitoring adherence, not pharmacogenetic approaches."
9eb69afc-0237-4855-b7c9-0e016b9aacdb,1,"89. Demas PA et al. Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study.Pediatrics, 2002, 110:e35.",3,1,Processed,"The report focuses on adherence to long-term therapies, covering behavioral, health-system, disease-specific, and economic aspects. It reviews interventions to improve adherence and does not discuss pharmacogenetic or pharmacogenomic approaches, personalized genetic testing, or genotype-guided therapy anywhere in the table of contents or the excerpted text."
5038ed39-848d-4888-8734-166d809b40a0,1,"90. Spire B et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Science & Medicine, 2002, 54:1481-1496.",3,1,Processed,"This systematic review examines patient-reported barriers and facilitators to adherence to HAART (qualitative and quantitative studies) across developed and developing countries. It focuses on psychosocial, regimen, access, and provider factors and does not address genetics, gene–drug interactions, pharmacogenetic testing, or personalized/genotype-guided therapy."
43717596-bb5c-4fd0-bb96-9556653dc1af,1,"91. Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens.AIDS Patient Care & STDs,2000, 14:155-168.",3,1,Processed,"The WHO 2003 report focuses on adherence to long‑term therapies, behavioural, health‑system and disease‑specific issues (diabetes, hypertension, HIV, asthma, TB, etc.), measurement and interventions. It contains no discussion of pharmacogenetics, genetic testing, or genotype‑guided therapy; therefore it is not relevant to pharmacogenetic approaches."
65b24a51-e5fe-4d4f-b0fe-df481da31adf,1,"92. Catz SL et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology,2000, 19:124-133.",3,1,Processed,"The paper is entirely focused on psychological constructs (perceived self-efficacy), health behavior theories, and measurement scales for behaviors like smoking, diet, exercise, and adherence. It contains no discussion of genetics, gene–drug interactions, biomarker-based treatment tailoring, or any pharmacogenetic methods or data, so it is not relevant to pharmacogenetic approaches."
0e0036f8-b96a-41a4-9a10-184962e51735,1,"93. Katapodi MC et al.The influence of social support on breast cancer screening in a multicultural community sample. Oncology Nursing Forum, 2002, 29:845-852.",3,1,Processed,"The article is a qualitative study of types of social support among African Americans with breast or prostate cancer. It focuses on emotional, instrumental, and informational support, religiosity, and caregiving—there is no discussion of genetics, drug response, biomarkers, or pharmacogenetic approaches. Thus it is not relevant to pharmacogenetics."
0d4a2dbd-0225-442b-8c1f-2cf8f0cbe6b7,1,"94. Abercrombie PD. Improving adherence to abnormal Pap smear follow-up. Journal of Obstetric, Gynecologic, & Neonatal Nursing,2001, 30:80-88.",3,1,Processed,"The WHO 2003 report focuses on adherence to long-term therapies, health systems, behavioural factors, measurement, disease-specific adherence (asthma, diabetes, HIV, TB, etc.) and interventions. It contains no discussion of genetic variability, pharmacogenetic testing, gene–drug interactions, or individualized drug selection based on genotype. Therefore it is not relevant to pharmacogenetic approaches."
07bd8615-aa7e-422a-af03-3ed518d21a5f,1,"95. Crane LA. Social support and adherence behavior among women with abnormal Pap smears. Journal of Cancer Education, 1996, 11:164-173.",3,1,Processed,"The WHO report centers on adherence to long-term therapies—behavioural, system, disease- and treatment-related factors and interventions—and does not discuss pharmacogenetics, genotyping, pharmacogenomic tailoring, or genetic biomarkers. It mentions drug resistance in contexts like HIV/TB related to adherence, but contains no assessment of pharmacogenetic approaches."
2a74b57e-42c7-4b4a-9ad7-859b91bdf0e9,1,"96. Owen N, Brown SL. Smokers unlikely to quit. Journal of Behavioral Medicine, 1991, 14:627-636.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, system and economic factors, and disease-specific adherence issues. It contains no discussion of genetics, individualized drug-response testing, or pharmacogenetic approaches; pharmacogenetics is not assessed or addressed."
f8f8723c-f03d-4a9b-835c-d9f6968ac7b2,1,"97. DiIorio C, Faherty B, Manteuffel B. Cognitive-perceptual factors associated with antiepileptic medication compliance. Research in Nursing & Health, 1991, 14:329-338.",3,1,Processed,"The document is a WHO 2003 report on adherence to long‑term therapies focusing on behavioural, system, disease‑management and economic aspects. It contains no discussion of pharmacogenetics, genetic testing, or genotype‑guided drug selection — its emphasis is on patient adherence, health systems and interventions rather than pharmacogenetic approaches."
a22ffc4c-3fb0-4136-9d5b-7d98c70ba8bd,1,"98. Orleans CT et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling.Journal of Consulting & Clinical Psychology,1991, 59:439-448.",3,1,Processed,"The paper is a 2001 review of smoking cessation treatments (treatment structure, psychosocial content, and pharmacotherapies such as NRT and bupropion). It contains no discussion of genetics, genotypes, genetic markers, or pharmacogenetic approaches to treatment or drug response; treatment-matching is discussed in psychosocial terms but not in genetic or pharmacogenetic terms. Thus it is not relevant to pharmacogenetics."
27082afb-9bad-4cc0-979b-16c316c9dd2e,1,"99. Guimon J.The use of group programs to improve medication compliance in patients with chronic diseases. Patient Education & Counseling, 1995, 26:189-193.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, health systems, behavioural determinants and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or related personalized-medicine approaches, so it is not relevant to pharmacogenetic assessment."
9cea5b5d-6aeb-41b0-a817-ed9fcb77596b,1,"100. Broadhead RS et al. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine, 2002, 55:235-246.",3,1,Processed,"The document is a WHO 2003 report on adherence to long‑term therapies focusing on patient behaviour, measurement, health systems, and interventions for chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, drug metabolism polymorphisms, or personalized genomic approaches; thus it is not relevant to pharmacogenetic assessment."
40613733-3250-4644-9660-be27d0634d31,1,"101. Magura S et al. Adherence to medication regimens and participation in dual-focus self-help groups. Psychiatric Services, 2002, 53:310-316.",3,1,Processed,"The article examines social/behavioral determinants (supportive interaction, facilitator input variety, time effects) of treatment adherence in mutual aid groups for young people with chronic conditions. It contains no discussion of genetics, pharmacogenetic testing, gene–drug interactions, or personalized drug-response tailoring, so it is not relevant to pharmacogenetic approaches."
3377f5c9-b41d-4af9-b3f1-a77e968eb930,1,"103. Richards W et al. A self-help program for childhood asthma in a residential treatment center.Clinical Pediatrics, 1981, 20:453-457.",3,1,Processed,"The document is a WHO report focused on adherence to long-term therapies, addressing behavioural, system-level, measurement and disease-management issues. It contains no discussion of genetic testing, gene–drug interactions, or personalized/pharmacogenetic approaches to therapy, so it is not relevant to pharmacogenetics."
d8a94b2f-667d-42f6-b090-aef03779f7ab,1,"104. Weishut DJ. [Coping with AIDS in a support group – an encounter with the health system.] [Hebrew] Harefuah, 1996, 130:521-523.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies (behavioural, health‑system, socioeconomic and disease‑specific factors and interventions). It discusses measurement, patient/provider/system determinants, and disease examples (diabetes, hypertension, asthma, HIV, TB) but contains no analysis of pharmacogenetics, genetic predictors of drug response, or genotype‑guided prescribing. Therefore it is not relevant to pharmacogenetic approaches."
f2e6c285-8eb8-4703-a64e-20a9242cd713,1,"105. Getahun H, Maher D. Contribution of ‘TB clubs’ to tuberculosis control in a rural district in Ethiopia. International Journal of Tuberculosis & Lung Disease, 2000, 4:174-178.",3,1,Processed,"This WHO report focuses on adherence to long‑term therapies—behavioral, system, measurement, disease‑specific and economic issues. It contains no discussion of pharmacogenetics, genotype‑guided therapy, genetic testing or related biomarkers; therefore it is not relevant to pharmacogenetic approaches."
5ee7b4be-505f-4696-a904-e96d0de5937d,1,"106. Garay-Sevilla ME et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. Journal of Diabetes & its Complications, 1995, 9:81-86.",3,1,Processed,"The thesis focuses on developing and testing a survey instrument about family dietary routines and diabetes self-management/education. It discusses nutrition, family routines, and behavioral aspects of diabetes care; there is no discussion of genetics, drug therapies, genotype-driven treatment, biomarkers, or pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
c96e6791-9258-4436-ba0a-cfd8b3b8dfeb,1,"107. Kulcar Z. Self-help, mutual aid and chronic patients’ clubs in Croatia, Yugoslavia: discussion paper.Journal of the Royal Society of Medicine, 1991, 84:288-291.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors across chronic diseases, measurement methods and interventions. It contains no discussion of pharmacogenetics, genotype‑guided prescribing, genetic testing, or personalized/precision medicine approaches, so it is not relevant to pharmacogenetic assessment."
e9f9d4fc-dca9-432f-9c69-7fb5cd011c01,1,"109. Lilja P . Recognizing the effect of social support on compliance to medical regimen in the elderly chronically ill. Home Healthcare Nurse,1984, 2:17-22.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focusing on patient behaviour, health systems, measurement, and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, genotype‑guided therapy, or personalized drug-response genetics, so it is not relevant to pharmacogenetic approaches."
55a968d3-53fd-427d-9c1e-4a16e0e31d51,1,"110. Koch T , Selim P , Kralik D. Enhancing lives through the development of a community-based participatory action research programme. Journal of Clinical Nursing, 2002, 11:109-117.",3,1,Processed,"This WHO report is focused on adherence to long-term therapies — behavioral, health system, measurement, economic and disease-specific interventions (asthma, diabetes, HIV, TB, etc.). The table of contents and text discuss patient behaviour, monitoring, self‑management and policy; there is no discussion of pharmacogenetics, genetic testing, or genotype‑guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
e017425a-0633-40c3-a547-08a98cb3f6b6,1,"111. Dias JC. [Community participation and control of endemic diseases in Brazil: problems and possibilities.] [Portuguese] Cadernos de Saude Publica, 1998, 14 (Suppl) 2:19-37.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, health systems, behavioural and socioeconomic determinants, and interventions for chronic diseases. There is no discussion of pharmacogenetics, genetic testing, individualized drug-genotype tailoring, or related molecular approaches in the provided content, so it is not relevant to pharmacogenetic assessment."
ff925576-ad89-4a2f-b997-c0cd1d309fe1,1,"112. Asthana S, Oostvogels R. Community participation in HIV prevention: problems and prospects for community-based strategies among female sex workers in Madras. Social Science & Medicine, 1996, 43:133-148.",3,1,Processed,"The document is a WHO 2003 report on adherence to long‑term therapies focusing on patient behaviour, health‑system factors, measurement of adherence, disease‑specific reviews and interventions. It discusses behavioural, organisational, economic and monitoring approaches (e.g. self‑report, pharmacy data, MEMS, biochemical markers) but contains no discussion of pharmacogenetics, genotype‑guided prescribing, genetic biomarkers or related personalized‑medicine strategies. Therefore it is not relevant to pharmacogenetic approaches."
e50a2435-6e0f-4cb8-a1e8-d0e4872a788f,1,"113. Loue S, Lloyd LS, Phoombour E. Organizing Asian Pacific Islanders in an urban community to reduce HIV risk: a case study.AIDS Education & Prevention, 1996, 8:381-393.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, health-system and economic factors, and disease-specific adherence issues. It contains no discussion of pharmacogenetics, genetic testing or genotype-guided therapy; therefore it is not relevant to pharmacogenetic approaches."
6f49128c-bf56-4234-a076-94f35d3636e3,1,"114. Freudenberg N. A new role for community organizations in the prevention and control of tuberculosis. Journal of Community Health, 1995, 20:15-28.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, health‑system and economic factors, and disease‑specific adherence issues. It does not discuss pharmacogenetics, genetic testing, genotype‑guided prescribing, or related personalized medicine approaches; therefore it is not relevant to pharmacogenetic assessment."
a0797266-a448-47b0-81d0-40557c369ea2,1,"115. Bermejo A, Bekui A. Community participation in disease control. Social Science & Medicine, 1993, 36:1145-1150.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, health-system, and economic determinants and interventions. It contains no discussion of pharmacogenetics, genetic testing, or genotype-guided therapy and does not assess pharmacogenetic approaches."
b407d741-592a-4786-b8ba-99b15ec312cd,1,"116. Kuehnert PL. Community health nursing and the AIDS pandemic: case report of one community’s response.Journal of Community Health Nursing, 1991, 8:137-146.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies (behavioral, system, measurement, disease-specific interventions and economics). It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, or personalized genomic approaches, so it is not relevant to pharmacogenetic assessment."
97fd621c-2448-425d-ade7-9c6d1a0a3ee1,1,"117. Delaney C. Reducing recidivism: medication versus psychosocial rehabilitation.Journal of Psychosocial Nursing & Mental Health Services,1998, 36:28-34.",3,1,Processed,"This WHO report focuses on patient adherence to long-term therapies, behavioural, health-system and socioeconomic determinants, measurement methods, and disease-specific management. It contains no discussion of pharmacogenetics, pharmacogenomic testing, genetic determinants of drug response, or personalized genomic approaches—so it is not relevant to pharmacogenetic assessment."
d2ae3bec-f1b5-4cae-8baf-8fa7297fe78e,1,"118. Davies M et al. Evaluation of a hospital diabetes specialist nursing service: a randomized controlled trial. Diabetic Medicine, 2001, 18:301-307.",3,1,Processed,"The paper is an epidemiological analysis of predictors of rehospitalization and 90-day mortality in diabetes-related hospital admissions using administrative/clinical data (ICD‑10 codes, comorbidities, hospital factors, logistic regression). It does not mention genetics, genotyping, drug–gene interactions, personalized drug response, or any pharmacogenetic methods or findings, so it is not relevant to pharmacogenetics."
9cdd730c-950b-4b46-9e40-7b573d8477dc,1,"119. Akbar DH, Al Gamdi AA. Common causes of admission in diabetics. Saudi Medical Journal, 2000, 21:539-542.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focusing on behavioural, health‑system, epidemiologic and economic aspects across chronic diseases. It contains no discussion of genetics, genotyping, genotype‑guided prescribing, pharmacogenetic markers or personalized drug metabolism — i.e. no assessment of pharmacogenetic approaches."
b8b28fd9-74fb-4c8d-8aea-352bc0144f37,1,"121. Steffens B. Cost-effective management of type 2 diabetes: providing quality care in a cost-constrained environment. American Journal of Managed Care, 2000, 6:S697-S703.",3,1,Processed,"The document focuses on business cases, cost-effectiveness, ROI, and implementation of diabetes self-management programs and community supports. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized drug therapy, so it is not relevant to pharmacogenetic approaches."
ee9d118d-09ae-4383-b99b-e24d564d9dbb,1,"122. Feuerstein M et al. Compliance – a joint effort of the patient and his doctor. Epilepsy Research, 1988, (Suppl) 1:51-56.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies (behavioural, system, measurement, disease-specific reviews and interventions) and contains no discussion of pharmacogenetics or genetic/individualized drug-response testing. It does not assess pharmacogenetic approaches, so relevance is minimal."
418b8e2e-2cda-47b9-9097-51dbe6e3135b,1,"123. Carter IR, Nash C, Ridgway A. On any Saturday – a practical model for diabetes education. Journal of the National Medical Association, 2002, 94:67-72.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, system and programmatic factors, measurement methods (questionnaires, MEMS, pharmacy data, biochemical markers), and disease‑specific reviews. It contains no discussion of pharmacogenetics, genetic markers, pharmacogenomic tailoring of therapy, or related genomic approaches. Therefore it is not relevant to pharmacogenetic assessment."
43b6ae6c-0687-4885-a223-0da67bf5eb7f,1,"124. O’Grady A et al. Effectiveness of changes in the delivery of diabetes care in a rural community.Australian Journal of Rural Health, 2001, 9:74-78.",3,1,Processed,"The WHO 2003 report focuses on adherence to long-term therapies, behavioural, health-system and economic factors, and disease-specific adherence issues. It does not discuss pharmacogenetics, genetic testing, or genotype-guided therapy; therefore it is not relevant to pharmacogenetic approaches."
fdb2ab88-72d2-4c44-bd9c-ccdd4204dd8c,1,"125. Ockene J. Strategies to increase adherence to treatment. In: Burke LE, Ockene IS, eds.Compliance in health care and research. Armonk, New York , Futura, 2001:43-55.",3,1,Processed,"The report focuses on adherence to long‑term therapies, behavioural, system and disease‑management issues; it does not discuss pharmacogenetics or genetic-based prescribing. No pharmacogenetic approaches are assessed."
56b2d5d7-2af0-4d1d-9683-34aac6526939,1,"126. Ockene IS et al. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population:Worcester Area Trial for Counseling in Hyperlipide",3,1,Processed,"The paper is an observational nutrition/epidemiology study on dietary carbohydrates, glycemic index/load, and body mass index. It contains no discussion of genes, genotypes, drug treatments, gene–drug interactions, or pharmacogenetic methods, so it is not relevant to pharmacogenetic approaches."
84c24e11-762f-4325-91a1-d10a1489cf47,1,"127. Ockene IS et al. Effect of training and a structured office practice on physician-delivered nutrition counseling: the Worcester-Area Trial for Counseling in Hyperlipidemia (WATCH).American Journal of Preventive Medicine, 1996, 12:252-258.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, health-system and behavioural factors, and disease-specific adherence interventions. It contains no discussion of pharmacogenetics, genetic testing, or genotype-guided therapy; thus it is not relevant to pharmacogenetic approaches."
5e02ce05-d7c2-4bce-857f-12a1ebcf1f08,1,"128. Ockene JK et al. Provider training for patient-centered alcohol counseling in a primary care setting. Archives of Internal Medicine, 1997, 157:2334-2341.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies (behavioral, system, economic, disease‑specific interventions and measurement). It contains no discussion of pharmacogenetics, genetic testing, genotype‑guided prescribing, or related molecular approaches, so it is not relevant to pharmacogenetic assessment."
584b2d68-c8b3-4130-a3f9-103e8656e7b8,1,"129. Canga N et al. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care,2000, 23:1455-1460.",3,1,Processed,"The WHO 2003 report excerpt focuses on adherence to long‑term therapies, behavioural, system, economic and disease‑management issues. It contains no discussion of genetic determinants of drug response, pharmacogenetic testing, or personalized/genotype‑guided therapy, so it is not relevant to pharmacogenetic approaches."
39365d53-d367-495f-866c-b8d5308feedb,1,"130. Ockene JK et al.The Physician-Delivered Smoking Intervention Project: factors that determine how much the physician intervenes with smokers. Journal of General Internal Medicine, 1994, 9:379-384.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioral, health-systems and economic factors, and disease-specific management (asthma, diabetes, HIV, etc.). It discusses measurement, interventions and policy but contains no assessment of pharmacogenetic or genetic-based therapeutic approaches; pharmacogenetics is not a topic covered in the provided text."
b7494e0f-3c0d-480f-86c8-deb3e9fda55b,1,"131. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Progress In Behavior Modification, 1992, 28:183-218.",3,1,Processed,"The thesis is a behavioral/psychological study developing a Processes of Change measure for vaping cessation using the Transtheoretical Model. It focuses on survey development, confirmatory factor analysis, stages of change, decisional balance, temptation, and nicotine dependence; there is no discussion of genetics, gene–drug interactions, genetic markers, or pharmacogenetic approaches."
b13312f7-58b4-4102-9ada-f5678460c4a4,1,"132. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. American Psychologist, 1992, 47:1102-1114.",3,1,Processed,"The paper focuses on psychological, social and behavioural factors affecting dietary change (food choice complexity, ambivalence, optimistic bias, stages-of-change). It contains no discussion of genetics, pharmacogenetics, drug–gene interactions, genotypes, or personalized drug therapy, so it is not relevant to pharmacogenetic approaches."
c58a8b60-ead5-4446-9097-dc90e666829e,1,"133. Prochaska JO, Redding C, Evers K.The Transtheoretical Model. In: Glanz K LF , Rimer BK, eds.Health behavior and health education: theory, research, and practice.San Francisco, Jossey-Bass, 1997.",3,1,Processed,"The article focuses on behavioral science theories (HBM, SCT, TTM, ecological models) and program implementation (WISEWOMAN, NBCCEDP, SHIP). It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, or personalized drug response, so it is not relevant to pharmacogenetic approaches."
86a718c1-20b3-42c0-a019-03cf1508178a,1,"134. Roter DL et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Medical Care,1998, 36:1138-1161.",3,1,Processed,"The paper focuses on patient-, physician-, and system-level interventions to improve hypertension control (education, home BP monitoring, behavioral counseling, decision-support, team-based care). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, gene–drug interactions, or related research, so pharmacogenetic approaches are not assessed."
09a72afb-f33a-48e2-a71d-74e7d513af8a,1,"135. McCann K. AIDS in the nineties: from science to policy. Care in the community and by the community. AIDS Care , 1990, 2:421-424.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies—behavioural, health‑system, measurement, and disease‑specific issues (diabetes, hypertension, asthma, HIV, TB, etc.). There is no discussion of genetics, genetic testing, genotype‑guided prescribing, pharmacogenetics, or personalized/precision medicine approaches, so it is not relevant to pharmacogenetic assessment."
e1097617-c1de-4c13-865d-464d73abcefe,1,"136. Lo R. Correlates of expected success at adherence to health regimen of people with IDDM. Journal of Advanced Nursing, 1999, 30:418-424.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies (behavioral, system and policy issues across chronic diseases). It focuses on patient adherence, measurement, interventions, economics and health systems; disease reviews and behavioral annexes are listed. There is no discussion of genetics, pharmacogenetics, genotyping, or individualized drug response based on genetic markers. Therefore it is not relevant to pharmacogenetic approaches."
5a79cdca-a30c-4885-b069-5ecfa3aca1d0,1,"1. Renders C, Valk G, Griffin S. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database of Systematic Reviews, 2001.",3,1,Processed,"This systematic review focuses on patient education and complex care interventions to prevent diabetic foot ulceration (RCTs, behaviour change, podiatry, screening, amputation outcomes). It contains no discussion of genetics, genotyping, drug-response variability, or any pharmacogenetic approaches—therefore not relevant to pharmacogenetics."
7d30b05d-a63b-4fab-9b94-803655150bd7,1,"2. Norris SLL et al. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care,2002, 25:1159-1171.",3,1,Processed,"The paper focuses on Diabetes Self-Management Training (DSMT), Medicare coverage, utilization scenarios, and microsimulation-based budget impact; it contains no discussion of genetics, pharmacogenetic testing, gene–drug interactions, genotype-guided therapy, or personalized medicine approaches. Therefore it is not relevant to pharmacogenetics."
d0814b3c-c8a1-4491-8be4-e899066cc09f,1,"3. Gozzoli V et al. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting.Swiss Medical Weekly,2001, 131:303-310.",3,1,Processed,"The WHO report is focused on adherence to long‑term therapies, behavioural, system and disease‑specific factors, measurement, and interventions. It contains no discussion of genetics, genotyping, genotype‑guided therapy, drug metabolizing enzymes, or other pharmacogenetic concepts — therefore it is not relevant to pharmacogenetic approaches."
20eeb5f8-1860-4906-ae4f-4780e97f6ee4,1,"4. Aubert RE et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. A randomized, controlled trial. Annals of Internal Medicine, 1998, 129:605-612.",3,1,Processed,"The paper describes a pharmacist-led diabetes disease management program, focusing on labor, time, and costs and on medication titration and education. It contains no discussion of genetics, genetic testing, gene-drug interactions, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
fcb0d464-3c2c-4412-87ea-1bb946f1c6ce,1,"5. Piette JD et al. Do automated calls with nurse follow-up improve self-care and glycemic control among vulnerable patients with diabetes? American Journal of Medicine, 2000, 108:20-27.",3,1,Processed,"The paper focuses on interactive voice response (IVR) systems for monitoring and managing chronic diseases (diabetes, hypertension, depression, etc.), assessing feasibility, reliability, validity, and clinical impact of IVR. It contains no discussion of genetics, genomic testing, drug–gene interactions, genotype-guided therapy, or any pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
d103154e-e0cd-49b9-938c-43a6b256ed2a,1,"6. Weinberger M et al. A nurse-coordinated intervention for primary care patients with non-insulin-dependent diabetes mellitus: impact on glycemic control and health-related quality of life. Journal of General Internal Medicine,1995, 10:59-66.",3,1,Processed,"The paper describes a randomized trial of nurse case manager and community health worker behavioral interventions for diabetes care in urban African Americans. It focuses on clinical outcomes (HbA1c, lipids, blood pressure), health behaviors, and care delivery; there is no discussion of genetics, genotyping, drug–gene interactions, or any pharmacogenetic approaches."
835c707f-2693-42c0-80b7-d804c559f257,1,"7. McCulloch DK et al. Improvement in diabetes care using an integrated population-based approach in a primary care setting. Disease Management, 2000, 3:75-82.",3,1,Processed,"The paper describes a clinical disease-severity stratification index for patients with diabetes and analyzes healthcare and pharmaceutical costs and case management. It contains no discussion of genetics, genotyping, drug–gene interactions, individualized drug selection, or pharmacogenetic testing or methods, so it is not relevant to pharmacogenetic approaches."
663248a5-ea1a-4763-8558-ab20d01e72f2,1,"8. Sadur CN et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care,1999, 22:2011-2017.",3,1,Processed,"The article focuses on group/ shared medical visits and care delivery models for diabetes management (nurse- or physician-led group visits, case management, patient education, reimbursement, practical implementation). It does not discuss pharmacogenetics, genetic testing, genotype-guided medication selection, or related pharmacogenomic approaches."
5b54604f-be2e-43ed-be1d-901c3377d4dc,1,"9. McCulloch DK et al. A population-based approach to diabetes management in a primary care setting: Early results and lessons learned. Effective Clinical Practice,1998, 1:12-22.",3,1,Processed,"The article describes public-health capacity-building, diabetes education, maternal screening, prosthetics/orthotics and community health promotion in Sri Lanka. It contains no discussion of genetics, drug–gene interactions, personalized medication, genomic testing or pharmacogenetic approaches; thus it is not relevant to pharmacogenetics."
53b096b9-beb3-4a3a-b042-282e659756ad,1,"10. Bodenheimer T , Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. Journal of the American Medical Association, 2002, 288:1909-1914.",3,1,Processed,"The article examines primary health care orientation and implementation of the Chronic Care Model in physician organizations; it focuses on organizational processes, care management, and chronic disease care delivery. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized pharmacologic approaches."
b61eba0d-6b52-41fc-b035-66e34c69798a,1,"12. Wagner EH et al. Effect of improved glycemic control on health care costs and utilization. Journal of the American Medical Association, 2001, 285:182-189.",3,1,Processed,"The article focuses on system-level quality improvement in diabetes care within managed care organizations—topics include clinical information systems, delivery redesign, guideline implementation, medication adherence, and coordination of care. It contains no discussion of genetics, pharmacogenetics, genotype-guided prescribing, biomarkers, or personalized drug-response approaches, so it is not relevant to pharmacogenetic assessment."
76a555d3-2b38-4f5b-b69b-f8760f5db5df,1,"13. Newell SA, Bowman JA, Cockburn JD. Can compliance with nonpharmacologic treatments for cardiovascular disease be improved?.American Journal of Preventive Medicine,2000, 18:253-261.",3,1,Processed,"The report is a meta‑review of interventions to improve patient adherence (behavioral, educational, technical, structural, and measurement issues). It contains no discussion of pharmacogenetics, genotyping, genetic predictors of drug response, or personalized pharmacogenomic approaches. Therefore it is not relevant to pharmacogenetic assessment."
d697fc5b-4dac-44ef-b509-01dba83450f2,1,"14. Monane M et al.The effects of initial drug choice and comorbidity on antihypertensive therapy compliance. Results from a population-based study in the elderly.American Journal of Hypertension, 1997, 10:697-704.",3,1,Processed,"The study evaluates telephone reminders, education, and choice of antihypertensive regimens to improve adherence and blood pressure control. It contains no discussion, data, or methods related to genetic variation, genotype-guided therapy, pharmacogenetic testing, or gene–drug interactions; therefore it is not relevant to pharmacogenetic approaches."
9da41cff-2438-4b28-bf18-0bf1c8e25306,1,"15. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy.Clinical Therapeutics,1998, 20:671-681.",3,1,Processed,"The paper examines Medicaid preferred drug lists and their impact on patient persistence, switching, and access to antihypertensive medications. It focuses on policy, adherence, and utilization patterns using pharmacy claims data and does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related biomarkers."
b5eebd55-7b68-42c4-82fe-16f368994bee,1,"17. Morisky DE et al. Five-year blood pressure control and mortality following health education for hypertensive patients. American Journal of Public Health, 1983, 73:153-162",3,1,Processed,"The article focuses on behavioral self-management, social-cognitive theory, behavioral economics, and positive-affect interventions for chronic diseases (arthritis, cardiopulmonary disease). It describes behavioral trials, patient education, and psychosocial constructs, with no discussion of genetics, pharmacogenetics, drug–gene interactions, genomic biomarkers, or personalized drug therapy. Therefore it is not relevant to pharmacogenetic approaches."
12aba964-d1a0-407d-a8b2-9462ae03317d,1,"18. Kotchen JM et al. Impact of a rural high blood pressure control program on hypertension control and cardiovascular disease mortality. Journal of the American Medical Association, 1986, 255:2177-2182.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioral, health-system, economic and disease-specific issues (asthma, HIV, diabetes, TB, etc.). It discusses adherence measurement, interventions, cost and health outcomes, but contains no discussion of pharmacogenetics, genotype-guided prescribing, or genetic testing approaches. Therefore it is not relevant to pharmacogenetic assessment."
6e4ea2bc-0edb-467d-b12f-63f403d1e88f,1,"19. Edmonds D et al. Does self-measurement of blood pressure improve patient compliance in hypertension? Journal of Hypertension,1985, (Suppl) 3:S31-S34.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, health-system and behavioural determinants, measurement and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, or personalized pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
6b9c9131-3045-4d71-8e4d-83c5685d48f0,1,"20. Stason WB et al. Effectiveness and costs of veterans affairs hypertension clinics. Medical Care,1994, 32:1197-1215.",3,1,Processed,"The article focuses on organizing care for chronic illnesses—practice redesign, patient self-management, protocols, information systems, and team-based care. It contains no discussion of genetics, genotype-guided therapy, pharmacogenetic testing, or personalized drug-response approaches, so it is not relevant to pharmacogenetics."
64efcd00-c373-4d95-bc37-a1227dfa2e99,1,"21. Steptoe A et al. Behavioural counselling in general practice for the promotion of healthy behaviour among adults at increased risk of coronary heart disease: randomised trial.British Medical Journal, 1999, 319:943-947.",3,1,Processed,"The review focuses entirely on primary care behavioral interventions to promote physical activity (counseling, prescriptions, referrals, trial designs, RE-AIM), with no discussion of genetics, pharmacology, biomarkers, or pharmacogenetic methods. Therefore it is not relevant to pharmacogenetic approaches."
b5c74b61-b538-4fac-86b5-3dcff01da2a1,1,"22. Richardson R et al. Learning curve. Hypertension: catch them when they're older.Nursing Times,2000, 96:42-43.",3,1,Processed,"This WHO report focuses on adherence to long-term therapies, behavioural, health-system, and economic determinants and interventions across chronic diseases. It does not discuss pharmacogenetics, genetic testing, genotype-guided prescribing, or related personalized-medicine approaches—so pharmacogenetic assessment is not addressed."
86aae430-0d54-4924-b29a-d5df48ea0f0f,1,"23. Bogden PE et al. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. Journal of General Internal Medicine, 1998, 13:740-745.",3,1,Processed,"The paper reviews team-based care (pharmacists, nurses), telemedicine/HIT, home BP monitoring, and cost-effectiveness for hypertension management. It contains no discussion of genetics, genetic testing, genotype-guided prescribing, biomarkers, or pharmacogenetic strategies—so it is not relevant to pharmacogenetics."
0d9f2224-0142-42b3-9348-89746393b0f8,1,"24. Gibson PG et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database of Systematic Reviews, 2002.",3,1,Processed,"The document is an evidence table of asthma self-management education studies (nurse-led programs, action plans, ED interventions, reviews). It focuses on behavioral/educational interventions, clinical outcomes, and health services use — with no mention of genetic markers, genotypes, gene–drug interactions, or personalized pharmacogenetic testing. Therefore it is not relevant to pharmacogenetics."
92b977ea-3e20-40d5-8bdb-cd8aa3a3ad7e,1,"26. Sommaruga M et al.The effects of a cognitive behavioural intervention in asthmatic patients. Monaldi Archives for Chest Disease, 1995, 50:398-402.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, system, measurement and economic factors across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, or personalized pharmacogenomic approaches (only brief mention of biochemical markers for adherence), so it is not relevant to pharmacogenetic assessment."
4e1165da-b485-4f38-b25b-614d74760626,1,"27. Liljas B, Lahdensuo A. Is asthma self-management cost-effective? Patient Education & Counseling, 1997, 32:S97-S104.",3,1,Processed,"This RCT evaluates an education programme delivered by general practice assistants for asthma and COPD patients (inhalation technique, symptoms, HRQoL, compliance, smoking cessation, coping). It contains no genetic or genomic data, no genotype–drug response analyses, and does not discuss personalized or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
99a0adc8-abb2-4d6a-a608-bb75db197a70,1,"28. Clark NM et al.The impact of health education on frequency and cost of health care use by low income children with asthma. Journal of Allergy & Clinical Immunology,1986, 78:108-115.",3,1,Processed,"The report focuses on asthma management through education, home environmental interventions, case management, and economic/business cases for payer coverage. It discusses pharmacotherapy broadly (e.g., medication adherence and copay strategies) but contains no assessment of pharmacogenetic or pharmacogenomic approaches, gene–drug interactions, genotype-guided therapy, genetic testing, or related science."
accf2d8b-696f-464e-ba52-c9cabe2f83e1,1,"29. Neri M et al. Economic analysis of two structured treatment and teaching programs on asthma. Allergy,1996, 51:313-319.",3,1,Processed,"This WHO report addresses adherence to long‑term therapies from behavioural, health‑system and economic perspectives across multiple chronic diseases. It focuses on patient/provider/system factors, measurement and interventions; it does not discuss pharmacogenetics, genotype‑guided prescribing, genetic biomarkers, or other pharmacogenetic approaches."
de1f5b1b-2dcf-4e33-8324-22211153b595,1,"31. Trautner C, Richter B, Berger M. Cost-effectiveness of a structured treatment and teaching programme on asthma. European Respiratory Journal, 1993, 6:1485-1491.",3,1,Processed,"The WHO report focuses on medication adherence, behavioural, health‑system and socioeconomic determinants and interventions for chronic disease management. It contains no discussion or assessment of pharmacogenetics, pharmacogenomic testing, genetic tailoring of therapy, or related molecular/biomarker approaches."
5558e6fb-3d7c-4b9e-a2e4-5c3ec301c919,1,"32. Kotses H et al. A self-management program for adult asthma. Part I: Development and evaluation. Journal of Allergy & Clinical Immunology, 1995, 95:529-540.",3,1,Processed,"The paper is a qualitative social/behavioral study of asthma self-management (focus groups, self-efficacy, stigma, GP relationships, action plans). It contains no discussion of genetics, pharmacogenetics, genetic testing, or personalized drug-response approaches, so it is not relevant to pharmacogenetic assessment."
f9450b8c-2984-4640-b3c1-b0f2bcb56c33,1,"33. Taitel MS et al. A self-management program for adult asthma. Part II: Cost-benefit analysis. Journal of Allergy & Clinical Immunology, 1995, 95:672-676.",3,1,Processed,"The document is focused on adherence to long-term therapies, behavioural, system and disease-specific issues. It contains no discussion of pharmacogenetic or genetic determinants of drug response (only brief mentions of drug resistance in infectious disease), so it is not relevant to pharmacogenetic approaches."
96b49c23-dc3b-48ad-bef7-1600df7c79f2,1,"34. Greineder DK, Loane KC, Parks P . Reduction in resource utilization by an asthma outreach program. Archives of Pediatrics & Adolescent Medicine, 1995, 149:415-420.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioural, health-system and economic factors, and disease-specific management (asthma, diabetes, HIV, TB, etc.). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or personalized/precision medicine approaches. Therefore it is not relevant to pharmacogenetic assessment."
0042634b-f84e-4b1d-8e59-408fabac76e6,1,"37. de Wit R et al. Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain. European Journal of Pain, 2001, 5:241-256.",3,1,Processed,"The document is focused on patient adherence, behavioural, health-system and disease-specific interventions; it contains no discussion of pharmacogenetic or pharmacogenomic approaches (no mention of genetics, genetic testing, polymorphisms, or personalised drug-response genetics). The only related items are general biochemical adherence markers and discussions of drug resistance, not pharmacogenetics. Therefore it is not relevant to pharmacogenetic assessment."
847d717c-bdd0-46d8-988a-105bfdb04395,1,"38. Rimer B et al. Enhancing cancer pain control regimens through patient education. Patient Education & Counseling, 1987, 10:267-277.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, health‑system and economic factors, and disease‑specific management and interventions. There is no discussion of pharmacogenetics, genetic testing, or genetically guided prescribing — pharmacogenetic approaches are not assessed."
cb26fb46-9572-4955-b418-d07699523a9b,1,"39. Jones WL et al. Cancer patients’ knowledge, beliefs, and behavior regarding pain control regimens: implications for education programs.Patient Education & Counseling, 1984, 5:159-164.",3,1,Processed,"The WHO report focuses on patient adherence, behavioral, health-system and economic aspects of long-term therapies across multiple conditions. It does not discuss pharmacogenetics, pharmacogenomic testing, genetic determinants of drug response, or personalized/precision-medicine approaches. Therefore it is not relevant to assessing pharmacogenetic approaches."
6cffe7e9-0f7a-4727-ba17-b2869e5daf1b,1,"41. MacDonald N et al. A Canadian survey of issues in cancer pain management. Journal of Pain & Symptom Management, 1997, 14:332-342.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, behavioral, health-system and disease-specific issues (asthma, diabetes, HIV, TB, etc.), measurement and interventions. It contains no discussion of pharmacogenetics, genetic testing, or personalized drug-response genetics, so it is not relevant to pharmacogenetic approaches."
a87b9eee-26c2-4f62-b965-80b798103996,1,"42. Ferrell BR, Dean GE. Ethical issues in pain management at home. Journal of Palliative Care,1994, 10:67-72.",3,1,Processed,"The document is a WHO 2003 report on adherence to long-term therapies focused on patient behaviour, health systems, measurement, and interventions for chronic diseases. It contains no discussion of pharmacogenetics, pharmacogenomics, genotyping, genetic testing, or personalized drug-response approaches, so it is not relevant to pharmacogenetic assessment."
b0fa6361-78d1-442b-b8b1-ff1b0f77e280,1,"43. Mullen PD. Compliance becomes concordance. British Medical Journal, 1997, 314:691-692.",3,1,Processed,"The paper is a qualitative study of medication expectations and patient–provider communication in heart failure patients with poor adherence. It focuses on adherence, meaning–response, symptom relief, and provider communication; it contains no discussion of genetics, genotyping, pharmacogenomics, personalized drug therapy based on genetic variants, or related methods. Therefore it is not relevant to pharmacogenetic approaches."
e3cc6acf-72df-4035-90e5-72ec7e064a0a,1,"44. Chelf JH et al. Cancer-related patient education: an overview of the last decade of evaluation and research. Oncology Nursing Forum, 2001, 28:1139-1147.",3,1,Processed,"The manuscript describes a quality improvement project to standardize oncology patient education using a picture-based booklet in Rwanda. It focuses on education, patient knowledge, satisfaction, and implementation logistics; it does not discuss genetic testing, drug–gene interactions, biomarkers, polymorphisms, personalized dosing, or any pharmacogenetic methods or results."
7545418a-8b59-401e-9575-6bc73cc978e0,1,"45. de Wit R et al. Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain. European Journal of Pain, 2001, 5:241-256.",3,1,Processed,"This WHO report is about adherence to long‑term therapies (behavioural, health system and programme factors) across chronic diseases. It contains no discussion of genetic markers, genotype‑guided prescribing, pharmacogenetic testing or personalized drug-response genetics. Thus it is not relevant to pharmacogenetic approaches."
aaed0759-f1c1-45c0-8bc2-1a0867743ffb,1,"46. Rimer B et al. Enhancing cancer pain control regimens through patient education. Patient Education & Counseling, 1987, 10:267-277.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, health system and economic factors across chronic diseases. It contains no discussion of genetic testing, genotype‑guided prescribing, biomarkers, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
88147551-a8fd-42e5-b2a5-830694611c88,1,"47. Katapodi MC et al.The influence of social support on breast cancer screening in a multicultural community sample. Oncology Nursing Forum, 2002, 29:845-852.",3,1,Processed,"The paper focuses on psychosocial factors (coping, social support, demographics, anxiety) in women awaiting possible breast cancer diagnosis. It contains no discussion of genetics, pharmacogenetics, drug therapies, or gene–drug interactions, so it is not relevant to pharmacogenetic approaches."
29fdec21-8d94-4862-9b4d-ce4e21f7c82e,1,"48. Abercrombie PD. Improving adherence to abnormal Pap smear follow-up. Journal of Obstetric, Gynecologic, & Neonatal Nursing,2001, 30:80-88.",3,1,Processed,"The document is a WHO 2003 report on adherence to long-term therapies, focusing on patient behaviour, health systems, measurement, and interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, pharmacogenomic-guided prescribing, or related personalized-medicine approaches, so it is not relevant to pharmacogenetic assessment."
0e315746-4eb2-49e7-b41e-fc0b911e387b,1,"49. Crane LA. Social support and adherence behavior among women with abnormal Pap smears. Journal of Cancer Education, 1996, 11:164-173.",3,1,Processed,"The WHO report is focused on adherence to long‑term therapies, behavioral, health system, epidemiologic and economic aspects across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized genetic approaches to therapy; therefore it is not relevant to pharmacogenetic assessment."
abd8031b-27ef-42ff-8a7e-714ebb07e838,1,"50. Owen N, Brown SL. Smokers unlikely to quit. Journal of Behavioral Medicine, 1991, 14:627-636.",3,1,Processed,"The document is a WHO report on adherence to long‑term therapies focusing on patient behaviour, health systems, measurement, economics and interventions for chronic diseases. It contains no discussion of genetic determinants of drug response, genotyping, pharmacogenomic testing, or personalized drug selection — therefore it is not relevant to pharmacogenetic approaches."
8b8eb5c1-b119-467b-9aed-e1eb413dfe4c,1,"51. DiIorio C, Faherty B, Manteuffel B. Cognitive-perceptual factors associated with antiepileptic medication compliance. Research in Nursing & Health, 1991, 14:329-338.",3,1,Processed,"The WHO 2003 report focuses on adherence to long‑term therapies, behavioural, system and disease‑specific factors and interventions. It contains no discussion of pharmacogenetics, genetic testing, or personalized genomic approaches to drug response; thus it is not relevant to pharmacogenetic assessment."
72830e2d-3442-404a-9196-a4a58000266e,1,"52. Orleans CT et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling.Journal of Consulting & Clinical Psychology,1991, 59:439-448.",3,1,Processed,"The paper reviews smoking-cessation treatments (structure, psychosocial content, and pharmacotherapies like NRTs and bupropion) and discusses treatment matching and process research, but contains no discussion or assessment of pharmacogenetic approaches, genetic markers, or genotype-based treatment personalization."
5f94fa7b-d9df-48d3-8e52-3f1be280f3cb,1,"53. Guimon J.The use of group programs to improve medication compliance in patients with chronic diseases. Patient Education & Counseling, 1995, 26:189-193.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioral, system and economic factors, and disease‑specific adherence issues. It does not discuss pharmacogenetic testing, genotype‑guided dosing, genetic predictors of drug response, or personalized/precision medicine approaches. (Mentions of drug resistance in HIV/TB relate to adherence, not pharmacogenetics.)"
9db8f82c-9a8b-436d-bf6e-936ce9320997,1,"54. Broadhead RS et al. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine, 2002, 55:235-246.",3,1,Processed,"This WHO report focuses on adherence to long‑term therapies, behavioural, health system and policy interventions across chronic diseases. It contains no discussion of pharmacogenetics, genetic testing, genotypes, or personalized drug-response based on genetic variation. Thus it is not relevant to pharmacogenetic approaches."
ccc6b1d6-913a-47a9-a38c-5503cf12653b,1,"57. Richards W et al. A self-help program for childhood asthma in a residential treatment center.Clinical Pediatrics, 1981, 20:453-457.",3,1,Processed,"The WHO report focuses on adherence to long‑term therapies, behavioural, system and economic determinants and interventions across chronic diseases. It contains no discussion or assessment of pharmacogenetics, pharmacogenomic testing, genetic predictors of drug response, or related individualized genetic approaches, so it is not relevant to pharmacogenetics."
27f74c89-c043-46e1-b814-0f38482bf0be,1,"58. Weishut DJ. [Coping with AIDS in a support group – an encounter with the health system.] [Hebrew] Harefuah, 1996, 130:521-523.",3,1,Processed,"The WHO report focuses on adherence to long-term therapies, health-system factors, behavioural determinants, disease-specific adherence issues and interventions. It contains no discussion of pharmacogenetics, genotyping, genetic determinants of drug response, or personalized/precision drug therapy; therefore it is not relevant to pharmacogenetic approaches."
73e28ab4-f299-45da-9b70-76234cf565f4,1,"59. Getahun H, Maher D. Contribution of ‘TB clubs’ to tuberculosis control in a rural district in Ethiopia. International Journal of Tuberculosis & Lung Disease, 2000, 4:174-178.",3,1,Processed,"The study investigates social, demographic, and access-related determinants of TB treatment adherence (e.g., distance, age, transport) and contains no discussion of genetics, pharmacogenetics, host or pathogen genotypes, drug metabolism, or genetically guided therapy."
9cbc74de-d982-4f41-be49-f057752064f1,1,"60. Garay-Sevilla ME et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. Journal of Diabetes & its Complications, 1995, 9:81-86.",3,1,Processed,"The article focuses on social support, self-management, cultural/sex/ literacy influences, peer and family roles in type II diabetes care. It does not discuss genetics, gene–drug interactions, genotyping, biomarkers, or pharmacogenetic testing. Mentions of 'new drugs' and 'personalized therapy' refer to clinical/behavioral personalization, not pharmacogenetics. Therefore it is not relevant to pharmacogenetic approaches."
19f198ec-5a7d-4917-abd1-ddc59e3032d3,1,"Danecek, P., Bonﬁeld, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., et al. (2021). Twelve years of SAMtools and BCFtools.Gigascience 10 (2), giab008. doi:10.1093/gigascience/giab008",3,1,Processed,"This is a bioinformatics protocol for population epigenomics (DNA methylation, WGBS, targeted bisulfite capture, TE insertion detection, variant calling) applied to plants (poplar and oak). It focuses on epigenetic variation, methylome analysis, and genomics workflows — there is no content on pharmacogenetics, drug response, or clinical/genetic variation related to pharmacology."
e2cfa91d-c098-4cb5-8e16-abdae72bc144,1,"De Coster, W., and Rademakers, R. (2023). NanoPack2: population-scale evaluation of long-read sequencing data. Bioinformatics 39 (5), btad311. doi:10.1093/bioinformatics/btad311",3,1,Processed,"The article describes discovery and genomic characterization of a novel rhabdovirus in a stranded dolphin and links it to encephalitis. It focuses on virology, pathology, necropsy, sequencing, and phylogenetics, with no discussion of pharmacogenetics, drug response, host genetic variation affecting therapy, or related topics."
f43a5011-c615-4938-9621-d7ac792565b8,1,"Ewels, P., Magnusson, M., Lundin, S., and Käller, M. (2016). MultiQC: summarize analysis results for multiple tools and samples in a single report.Bioinformatics 32 (19), 3047–3048. doi:10.1093/bioinformatics/btw354",3,1,Processed,"The manuscript focuses on sequencing workflows, primer design, and targeted whole-genome/amplicon sequencing for respiratory RNA viruses (SARS-CoV-2, RSV, Influenza). It describes laboratory methods (one‑step RT‑PCR, library prep, coverage analyses) and surveillance applications, with no discussion of drug–gene interactions, genotype-guided therapy, pharmacokinetics/pharmacodynamics, or clinical pharmacogenetic testing."
4f038064-c533-4316-a422-b1c23b788c16,1,"Li, H. (2021). New strategies to improve minimap2 alignment accuracy. Bioinformatics 37 (23), 4572–4574. doi:10.1093/bioinformatics/btab705",3,1,Processed,"This is a chromosome-level genome assembly and annotation of the medicinal plant Begonia fimbristipula focused on genome structure, repeats, gene prediction, and conservation/utilization. It does not address pharmacogenetics, drug response, genotype–drug interactions, or clinical/pharmacological variation. Therefore it is not relevant to pharmacogenetic approaches."
645d28b5-fdd2-4e2c-ab20-2a5169f2ddac,1,"Milani, L., Alver, M., Laur, S., Reisberg, S., Haller, T., Aasmets, O., et al. (2025). The Estonian Biobank’s journey from biobanking to personalized medicine.Nat. Commun. 16 (1), 3270. doi:10.1038/s41467-025-58465-3",3,1,Processed,"The paper focuses on NMR metabolomics, mortality prediction, and biological age estimation using metabolite biomarkers and common risk factors. It does not discuss drug response, drug–gene interactions, genetic variants affecting pharmacokinetics/pharmacodynamics, or any pharmacogenetic methods. The only medication-related mention is statin use as a covariate, which does not make the study pharmacogenetic."
582822d4-036e-4489-ba03-37583d894dbb,1,"Patterson, M., Marschall, T., Pisanti, N., van Iersel, L., Stougie, L., Klau, G. W., et al. (2015). WhatsHap: weighted haplotype assembly for future-generation sequencing reads. J. Comput. Biol.22 (6), 498–509. doi:10.1089/cmb.2014.0157",3,1,Processed,"This paper is focused on entomology and viral genomics — haplotype analysis of Varroa destructor mites and Deformed Wing Virus using long-read sequencing. It discusses mite population genetics, DWV transmission, and mentions acaricide use/resistance in passing, but contains no content on pharmacogenetic approaches (drug–gene interactions, genotype-guided therapy, or pharmacogenomic methods). Therefore it is not relevant to pharmacogenetics."
5b8085f0-041f-46be-ad53-97e99aecb548,1,"Pedersen, B. S., and Quinlan, A. R. (2018). Mosdepth: quick coverage calculation for genomes and exomes. Bioinformatics 34 (5), 867–868. doi:10.1093/bioinformatics/btx699",3,1,Processed,"This announcement reports the complete genome assembly of the tick-borne bacterium Borrelia miyamotoi and details sequencing, assembly, and plasmid content. It contains no discussion of human or microbial pharmacogenetics, drug response, genotype–drug associations, or pharmacogenomic methods, so it is not relevant to pharmacogenetic approaches."
29c0a458-c605-45c4-8dda-db031a140036,1,"Zheng, Z., Li, S., Su, J., Leung, A. W.-S., Lam, T.-W., and Luo, R. (2022). Symphonizing pileup and full-alignment for deep learning-based long-read variant calling. Nat. Comput. Sci.2 (12), 797–803. doi:10.1038/s43588-022-00387-x",3,1,Processed,"The paper focuses entirely on data compression methods for nanopore sequencing (ex-zd lossless and lossy compression), evaluation of impacts on basecalling and modification detection, and file-format/tooling. It does not discuss drug response, genotype–drug associations, therapeutic decision-making, or any pharmacogenetic analyses."
893dfecf-a47b-4dda-bc4d-6dd7241ab91f,1,"1. Haga SB, Orlando LA. Expanding Family Health history to Include Family Medication History. J Pers Med. 2023;13(3):410.  h t t  p s : /  / d o  i .  o r g / 1 0 . 3 3 9 0 / j p m 1 3 0 3 0 4 1 0     .",3,1,Processed,"The document is a guide on ocean acidification research, seawater carbonate chemistry, experimental methods and data reporting. It deals with marine chemistry, ecology, mesocosms, and data management — no discussion of genetics, pharmacology, drug response, biomarkers, or personalized medicine. Therefore it is not relevant to pharmacogenetic approaches."
f848b80d-6ffc-4805-8dc3-513b917a6fe1,1,"4. Ginsburg GS, Wu RR, Orlando LA. Family health history: underused for action-able risk assessment. Lancet. 2019;394(10198):596–603.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 1 6 / S 0 1 4 0 - 6 7 3 6 ( 1 9 ) 3 1 2 7 5 - 9     .",3,1,Processed,"The paper examines family health history data in surveys vs EHRs within the All of Us program and evaluates capture of medically actionable genetic disorders, but it contains no analysis of drug–gene interactions, genotype‑guided therapy, pharmacogenetic testing, or pharmacogenetic methods. Thus it is not relevant to pharmacogenetic approaches."
81f3e30f-e675-4b75-88b9-4ac90890da4c,1,11. Zambouri A. Preoperative evaluation and preparation for anesthesia and surgery. Hippokratia. 2007;11(1):13–21.,3,1,Processed,"The article is a general review of preoperative evaluation and perioperative management (cardiovascular/pulmonary risk, diabetes, anticoagulation, anesthetic considerations, drug management) and contains no discussion of genetics, gene-based drug response, pharmacogenetic testing, or personalized genomic approaches. Therefore it is not relevant to pharmacogenetics."
e0c670e8-5101-43ca-92f3-bf1e7edf2483,1,"17. Chavez-Yenter D, Goodman MS, Chen Y, et al. Association of Disparities in Family History and Family Cancer History in the Electronic Health Record with Sex, Race, hispanic or latino ethnicity, and Language Preference in 2 large US Health Care systems.",3,1,Processed,"This study examines disparities in genetic evaluation (referrals, testing, counseling) for Lynch syndrome in endometrial cancer patients. It focuses on referral patterns, MMR IHC tumor testing, and completion of germline testing/counseling — not on pharmacogenetic questions, drug–gene interactions, or use of genetic data to guide pharmacotherapy. Although it mentions molecular profiling for prognosis/therapy tailoring in general, it does not assess pharmacogenetic approaches."
ce05ec9c-53f5-4cf4-afff-7d2bfe1125a2,1,"30. Pasin L, Landoni G, Cabrini L, et al. Propofol and survival: a meta-analysis of randomized clinical trials. Acta Anaesthesiol Scand. 2015;59(1):17–24.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 1 1 1 / a a s . 1 2 4 1 5     .",3,1,Processed,"The paper is a clinical Bayesian network meta-analysis of anesthetic regimens and remote ischemic preconditioning in cardiac surgery focusing on mortality outcomes. It does not discuss genetic factors, genotyping, polymorphisms, drug–gene interactions, or any pharmacogenetic or pharmacogenomic approaches."
b98cc30f-3ab3-4b3a-93d0-bac5a5bedc91,1,47. Faculty of Pain Medicine of the Royal College of Anesthetists. Surgery and Opioids: Best Practice Guideline 2020. 2020.  h t t  p s : /  / f p  m .  a c .  u k / s  i t e  s /  f p m  / fi   l  e s /  d o  c u m  e n t s  / 2 0  2 0  - 0 9 / S u r g e,3,1,Processed,"This is a multidisciplinary standards document for pain management services (commissioning, service tiers, teams, pathways, governance, safeguarding, etc.). Although it includes chapters on medicines and pharmacists, the provided text contains no discussion of pharmacogenetics, genetic testing, pharmacogenomic-guided prescribing, or personalized-genetic approaches. Therefore it is not relevant to assessing pharmacogenetic approaches."
20e9aab5-7145-413b-850b-758de784159a,1,"60. Fortnum H, Lee AJ, Rupnik B, Avery A, Yellow Card Study Collaboration. Sur-vey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161–5.  h t t  p s : /  / d o  i .  o r g / 1 0 . ",3,1,Processed,"The article is a survey of consumer awareness and use of adverse drug reaction reporting systems in Australia; it addresses reporting practices, awareness, and system implications. It does not discuss genetic variation, pharmacogenetic testing, genotype–drug response relationships, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
82b1c3fb-21e8-4f26-8f59-ed8031938bcd,1,"62. Horne R, Faasse K, Cooper V, et al. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br J Health Psychol. 2013;18(1):18–30. https:/ /doi.or g/10.11 11/j .2044-8287.2012.02071.x.",3,1,Processed,"The study evaluates patient-reported outcomes and tolerance of 90 days of pre-operative endocrine therapy, focusing on symptoms, HRQoL, adherence, and perceived sensitivity to medicines (a self-reported scale). It does not include any genetic or pharmacogenetic testing, analyses of genetic variants, or discussion of genotype-guided therapy, so it is not relevant to pharmacogenetic approaches."
5d0844e5-6fc5-405c-bdfb-34504336f668,1,68. Mogil JS. Qualitative sex differences in pain processing: emerging evidence of a biased literature. Nat Rev Neurosci. 2020;21(7):353–65.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 3 8 / s 4 1 5 8 3 - 0 2 0 - 0 3 1 0 - 6     .,3,1,Processed,"The mini-review focuses on satellite glial cell biology, transcriptomics, imaging tools, cell models, and potential therapeutic targets in pain. It discusses gene expression, transgenic mouse lines, and ncRNAs, but does not address pharmacogenetics (genetic variation influencing drug response), genotype-guided therapies, or related clinical genetic testing. Therefore it is not relevant to pharmacogenetic approaches."
80b63d8f-e17c-4eac-8d05-13125022d1d9,1,"69. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111(1):52–8.  h t t  p s : /  / d o  i .  o r g / 1 0 . 1 0 9 3 / b j a / a e t 1 2 7     .",3,1,Processed,"The study is an epidemiological register-based analysis of pain in the foot/lower leg in individuals with cerebral palsy. It examines prevalence, associations with age, sex, GMFCS, range of motion, spasticity, and treatments (e.g., BTX-A, baclofen, surgery) but contains no discussion, data, or analysis of genetic variation, drug response genetics, pharmacogenetic markers, or personalized pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
232bd55c-20b2-4bf6-abe2-88a7f67ebe2c,1,"Valdez, R.; Yoon, P .W.; Qureshi, N.; Green, R.F.; Khoury, M.J. Family History in Public Health Practice: A Genomic Tool for Disease Prevention and Health Promotion. Annu. Rev. Public Health2010, 31, 69–87. [CrossRef]",3,1,Processed,"The paper investigates college students' interest in family health history education, preferred topics, and learning methods. It focuses on FHH collection, interpretation, and disease prevention education and does not discuss pharmacogenetics, drug–gene interactions, pharmacogenetic testing, or medication response. Any genetics mentions relate to general genetics courses, not pharmacogenetic approaches."
5042e6f4-423f-415c-a474-c95b14d681b9,1,"Orlando, L.A.; Wu, R.R.; Myers, R.A.; Neuner, J.; McCarty, C.; Haller, I.V .; Harry, M.; Fulda, K.G.; Dimmock, D.; Rakhra-Burris, T.; et al. At the intersection of precision medicine and population health: An implementation-effectiveness study of family h",3,1,Processed,"This CV lists work in epidemiology, health services research, EHR data extraction, opioid risk stratification, vitamin D, ketamine therapy, family history implementation, and related topics, but contains no papers, grants, or presentations that assess pharmacogenetic or pharmacogenomic approaches. At most one item references ‘precision medicine’ broadly (family health history risk assessment), which does not equate to pharmacogenetics."
52e1036d-209b-48fb-949f-24370dc5d2e9,1,"Cohn, W.F.; Ropka, M.E.; Pelletier, S.L.; Barrett, J.R.; Kinzie, M.B.; Harrison, M.B.; Liu, Z.; Miesfeldt, S.; Tucker, A.L.; Worrall, B.B.; et al. Health Heritage©, a Web-Based Tool for the Collection and Assessment of Family Health History: Initial User ",3,1,Processed,"The paper discusses genealogy, family health history, ancestry testing, and awareness/referral for hereditary cancer genetic testing (BRCA) and related disparities, but contains no discussion of pharmacogenetics, drug response, pharmacogenomic testing, or medication-related genetic approaches. Therefore it is not relevant to pharmacogenetic assessment."
0532909b-4ae5-4891-ac91-af7340f3800c,1,"Barrett, D.; Heale, R. What are Delphi studies? Evid. Based Nurs.2020, 23, 68–69. [CrossRef]",3,1,Processed,"The article focuses on education priorities for heart failure care in nursing homes using a modified Delphi method. It addresses topics like general HF education, person-centered care, medication management, telemedicine, and palliative care, but contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or related personalized medicine approaches."
3daa7a8a-882e-4806-8161-c089856e9e42,1,"Van der Kleij, R.; Kasteleyn, M.J.; Meijer, E.; Bonten, T.N.; Houwink, E.J.; Teichert, M.; van Luenen, S.; Vedanthan, R.; Evers, A.; Car, J.; et al. SERIES: eHealth in primary care. Part 1: Concepts, conditions and challenges. Eur. J. Gen. Pract.2019, 25,",3,1,Processed,"This scoping review focuses on digital health interventions (eHealth/mHealth/telemedicine, EHRs, AI) to improve primary health care and universal health coverage. It does not discuss pharmacogenetics, pharmacogenomics, drug–gene interactions, genetic testing, or personalized drug therapy—only occasional references to drug stock management and prescribing patterns. Therefore it is not relevant to pharmacogenetic approaches."
61cfbac1-908d-4ca6-8912-7f5a193ea1ad,1,The European Union. European Health Data Space. Available online: https://ec.europa.eu/health/ehealth-digital-health-and-care/european-health-data-space_en (accessed on 1 June 2022).,3,1,Processed,"This is a broad EU impact assessment on the European Health Data Space—focused on governance, interoperability, infrastructures, and secondary use of health data. It does not evaluate or assess pharmacogenetic approaches; at most it briefly mentions genomics/biobanks as data types, but there is no substantive analysis of pharmacogenetics."
c6e59bc1-a172-429d-a873-9642cb1fa559,1,"Houwink, E.J.F.; Kasteleyn, M.J.; Alpay, L.; Pearce, C.; Butler-Henderson, K.; Meijer, E.; Van Kampen, S.; Versluis, A.; Bonten, T.N.; Van Dalfsen, J.H.; et al. SERIES: eHealth in primary care. Part 3: eHealth education in primary care. Eur. J. Gen. Pract",3,1,Processed,"The article focuses on eHealth interventions for people with low socioeconomic position and uses a Delphi study to identify barriers and facilitators across development, reach, adherence, implementation, and evaluation. It does not discuss pharmacogenetics, pharmacogenomic testing, drug–gene interactions, or related topics; pharmacogenetic approaches are not assessed or mentioned."
3546e154-2eeb-43ff-849d-917ce77e6d37,1,"Williams, D. M., Davies, N. M. & Anderson, E. L. The proportion of Alzheimer’s disease attributable to apolipoprotein E. bioRxiv 2023.11.16.23298475 (2023) doi:10.1101/2023.11.16.23298475.",3,1,Processed,"The study is genetic epidemiology of APOE alleles and dementia risk in British South Asians (allele frequencies, Cox models, PAF, phenome‑wide associations for biomarkers). It does not analyze drug response, medication outcomes, gene–drug interactions, or pharmacogenomic biomarkers. While it briefly mentions implications for prediction/prevention and drug discovery, it contains no pharmacogenetic assessment."
1d621b7d-2011-42d4-98a6-011d45881b92,1,"Raulin, A.-C. et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener. 17, 72 (2022).",3,1,Processed,"The paper investigates neuronal metabolic reprogramming, ECM degradation, SRF/MRTF‑A signaling, and urea-driven neurodegeneration under hypoglycemia, using cellular and mouse models. Although it tests pharmacological inhibitors (e.g., CCG‑203971, NSC405020, pepstatin A), it contains no analysis of genetic variation, gene–drug interactions, patient genotypes, or other pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
a15394b6-a358-4ea4-9b5a-d7ee8fb36de7,1,"Ghisays, V. et al. Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program. Alzheimers. Dement. 21, e70245 (2025).",3,1,Processed,"This is a genetic epidemiology study of APOE alleles and dementia risk in British South Asians. It examines allele frequencies, hazard ratios, population attributable fractions and phenome-wide trait associations (lipids, CRP), but does not evaluate drug response, genotype-guided prescribing, gene–drug interactions, or any pharmacogenetic interventions. References to therapeutic implications are general; no pharmacogenetic analyses are performed."
2e1a36aa-f062-4ae8-8803-b6fbecb26f30,1,"Miyashita, A., Kikuchi, M., Hara, N. & Ikeuchi, T. Genetics of Alzheimer’s disease: an East Asian perspective. J. Hum. Genet. 68, 115–124 (2023).",3,1,Processed,"The manuscript focuses on polygenic/polygenic risk scores for Alzheimer’s disease, their transferability across ancestries, APOE effects, and associations with biomarkers and age at onset. It does not address drug response, treatment outcomes, medication dosing, adverse drug reactions, pharmacokinetics, or any gene–drug interactions — core topics of pharmacogenetics — so it is not relevant to pharmacogenetic approaches."
3eebb069-c002-458b-bdae-cc9ba91749a9,1,"Wang, Y. Z. et al. Effect of apolipoprotein E ε 4 and its modification by sociodemographic characteristics on cognitive measures in South Asians from LASI-DAD. Alzheimers. Dement. 20, 4854–4867 (2024).",3,1,Processed,"The manuscript is an observational genetic epidemiology study of APOE alleles and dementia risk in British South Asians. It focuses on allele frequencies, associations with dementia and lipid/biomarker traits, and population attributable fractions. It does not assess drug response, treatment stratification, genotype-guided therapy, or any pharmacogenetic outcomes, so it is not relevant to pharmacogenetics."
bd60e29a-cc88-454f-a576-7dffdff6f817,1,"Chaudhry, M. et al. Association of APOE polymorphisms and stressful life events with dementia in a Pakistani population. Neurosci. Lett. 570, 42–46 (2014).",3,1,Processed,"This is a genetic epidemiology study of APOE alleles and dementia risk in British South Asians. It assesses allele frequencies, disease associations, population attributable fractions, and phenome-wide trait associations, but does not examine drug response, medication effects, or genotype-guided therapy. Thus it is not relevant to pharmacogenetic approaches."
25c1a2b0-187f-48fb-a3fa-f0dc08db9246,1,"Agarwal, R. & Tripathi, C. B. Association of apolipoprotein E genetic variation in Alzheimer’s disease in Indian Population. Am. J. Alzheimers. Dis. Other Demen. 29, 575–582 (2014).",3,1,Processed,"This is a genetic association study of SOD1 polymorphisms and Alzheimer’s disease susceptibility in a Chinese Han population. It examines genotype, allele and haplotype frequencies and disease risk, not drug response, treatment efficacy, adverse reactions, or gene–drug interactions. The paper contains no pharmacogenetic analyses or discussion of pharmacotherapy."
894e0a71-e486-4c9f-8354-57552b807483,1,"Misra, A., Chakrabarti, S. S., Gambhir, I. S., Kaur, U. & Prasad, S. APOE4 allele in north Indian elderly patients with dementia or late onset depression-a multiple-disease case control study. Mol Biol Res Commun 8, 135–140 (2019).",3,1,Processed,"The study examines APOE allele frequencies and their association with dementia and metabolic traits in British South Asians; it does not evaluate drug response, treatment stratification, or genetic effects on pharmacokinetics/pharmacodynamics. Thus it is not pharmacogenetics-focused."
e7e5b0a9-09a8-4573-a149-ac41962e1e72,1,"Mukadam, N. et al. Incidence, age at diagnosis and survival with dementia across ethnic groups in England: A longitudinal study using electronic health records. Alzheimers. Dement. 19, 1300–1307 (2023).",3,1,Processed,"This is a genetic epidemiology study of APOE alleles and dementia risk in British South Asians. It assesses allele frequencies, risk associations, population attributable fractions, and phenome-wide trait associations. It does not evaluate drug response, drug–gene interactions, dosing, or any pharmacogenetic interventions — only a brief general mention of implications for prediction/prevention/drug discovery, not an assessment of pharmacogenetic approaches."
c81e7da5-bc2a-4d36-a924-9f379d312bb4,1,"Finer, S. et al. Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. Int. J. Epidemiol. 49, 20–21i (2020).",3,1,Processed,"The manuscript is a genetic epidemiology study of APOE alleles and dementia risk in British South Asians, reporting allele frequencies, hazard ratios, population attributable fractions and phenome-wide associations. It does not examine drug response, treatment stratification, genotype-guided prescribing, or any pharmacogenetic interventions or outcomes, so it is not relevant to pharmacogenetics."
130b994a-bd49-4b26-97f2-71be0ee09588,1,"Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).",3,1,Processed,"The paper is an epidemiological burden study of Alzheimer’s disease and other dementias in the MENA region (prevalence, deaths, DALYs, trends, SDI and population risk factors). It only briefly mentions genetic predisposition (APOE ε4) in passing but contains no assessment of pharmacogenetic approaches, drug–gene interactions, genotype-guided therapy, or pharmacogenetic data or recommendations."
14f1e32e-b008-4b4c-b435-c2457210f679,1,"Breedon, J. R. et al. Polygenic risk score prediction of multiple sclerosis in individuals of South Asian ancestry. Brain Communications 5, fcad041 (2023).",3,1,Processed,"This study focuses on genetic susceptibility to multiple sclerosis across ancestries (GWAS, HLA alleles, polygenic risk scores) rather than genetics of drug response. It does not analyze treatment response, drug–gene interactions, or pharmacogenomic markers; at most it briefly notes that improved causal variant mapping could aid drug-target discovery, but it does not assess pharmacogenetic approaches."
134bbf16-407e-4f4f-a50f-314875194523,1,"Jacobs, B. M. et al. Genetic architecture of routinely acquired blood tests in a British South Asian cohort. Nat. Commun. 15, 8929 (2024).",3,1,Processed,"The manuscript is a genetic epidemiology study of APOE alleles and dementia risk in British South Asians and includes phenome-wide trait associations (lipids, CRP). It does not evaluate drug response, treatment stratification, drug–gene interactions, or any pharmacogenetic markers or approaches; pharmacogenetics is not addressed."
5b2e2391-1ab1-4236-8296-a8847cc02db4,1,"Hodgson, S. et al. Genetic basis of early onset and progression of type 2 diabetes in South Asians. Nat. Med. 31, 323–331 (2025).",3,1,Processed,"The paper investigates APOE allele frequencies and their association with dementia risk and related biomarkers in British South Asians. It focuses on genetic epidemiology, population attributable fractions, and phenome-wide associations (lipids, CRP), but contains no analysis of drug response, genotype-guided therapy, pharmacokinetics, pharmacodynamics, or clinical pharmacogenetic recommendations. Therefore it is not relevant to pharmacogenetic approaches."
3b63b0b7-e959-4b83-94f5-e9fbf6faaf39,1,"Zhong, L. et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol. Neurodegener. 11, 2 (2016).",3,1,Processed,"The manuscript is a GWAS meta-analysis using an association-clustering algorithm (OASIS/OLI) to identify SLE susceptibility genes and pathways. It discusses gene discovery and possible targets for biology/drug discovery but contains no analyses or discussion of pharmacogenetics (drug–gene interactions, genotype-guided therapy, pharmacokinetics/dynamics, or pharmacogenetic biomarkers). Thus it is not relevant to pharmacogenetic approaches."
eb25425e-c86b-42fd-8ee5-d7b29f613c6e,1,"Wilkinson, T. et al. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur. J. Epidemiol. 34, 557–565 (2019).",3,1,Processed,"This study validates dementia case ascertainment using routine healthcare datasets (primary care, hospital admissions, mortality) in UK Biobank. It focuses on diagnostic coding accuracy and algorithms for identifying dementia cases, not on drug–gene interactions, genetic predictors of drug response, or pharmacogenetic methods. There is no evaluation of pharmacogenetic approaches."
dedc60ac-df6a-4b35-9df1-9aacbf8be142,1,"Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine 59, 102954 (2020).",3,1,Processed,"This is a phenome-wide association study of APOE genotypes and disease risks. It examines genotype–phenotype associations and biomarkers, not gene–drug interactions, drug response, drug dosing, or therapeutic stratification. While it briefly remarks on therapeutic implications of mimicking APOE effects, it does not assess pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
4298392a-171d-42cb-8460-7d53419f06be,1,"Levin, M. L. The occurrence of lung cancer in man. Acta Unio Int. Contra Cancrum 9, 531–541 (1953).",3,1,Processed,"This paper reviews methods for estimating population attributable and preventable fractions for cancer risk factors (tobacco, alcohol, BMI, infections, occupational and environmental exposures, etc.) and public-health policy implications. It does not discuss pharmacogenetic approaches or pharmacogenomic interventions; the lone brief mentions of genetic variation (e.g., ALDH2) are about effect modification of risk, not pharmacogenetics."
30e48904-dec8-4aea-944d-0833ba4e5090,1,"Hanley, J. A. A heuristic approach to the formulas for population attributable fraction. J. Epidemiol. Community Health 55, 508–514 (2001).",3,1,Processed,"This study examines APOE allele frequencies and their association with dementia risk and biomarker traits in a British South Asian cohort. It focuses on genetic epidemiology, risk estimates (hazard ratios, population attributable fractions), and phenome-wide associations, but does not evaluate drug response, gene–drug interactions, dosing, adverse reactions, or any pharmacogenetic interventions. Therapeutic implications are discussed generally, but no pharmacogenetic analyses are performed."
f2f07dab-59e3-44f2-8e73-31c19418d9d9,1,"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).",3,1,Processed,"This is a clinical case report of osteogenesis imperfecta due to a TMEM38B splice-site variant focused on genetic diagnosis, phenotype, and allele frequency. It does not discuss genotype-guided drug selection, pharmacokinetics, drug response biomarkers, dosing, or other pharmacogenetic analyses. Bisphosphonate therapy is mentioned historically but not in a pharmacogenetic context."
dd025e78-a95d-41d9-85b4-dd8000deea0d,1,"Mukadam, N., Giannakopoulou, O., Bass, N., Kuchenbaecker, K. & McQuillin, A. Genetic risk scores and dementia risk across different ethnic groups in UK Biobank. PLoS One 17, e0277378 (2022).",3,1,Processed,"The paper evaluates genetic risk scores (APOE and polygenic risk) for dementia across ethnic groups and associations with outcomes. It does not address drug response, drug metabolism, medication selection, or any pharmacogenetic methods or applications, so it is not relevant to pharmacogenetics."
3d726e1a-8deb-4364-8c0d-0ee0f5326a2f,1,"Le Guen, Y. et al. Association of African ancestry-specific APOE missense variant R145C with risk of Alzheimer disease. JAMA 329, 551–560 (2023).",3,1,Processed,"This is a genetic association study of APOE variants and Alzheimer disease risk across age, sex, and ancestry. It focuses on disease risk, genotype-phenotype associations, and implications for trial design, not on drug response, medication safety, dose optimization, or genotype-guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
e1398a9d-7ec5-4a19-a973-bc76d9fff71a,1,"1. van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043–1048 (2016).",3,1,Processed,"The supplementary material focuses on genomic quality control, population stratification, and analyses of telomere length in ALS cases and controls (including C9orf72 expansion). There is no discussion of drugs, drug response, treatment stratification, dosing, or pharmacogenetic markers, so it does not assess pharmacogenetic approaches."
2a79d99b-cb17-4786-805c-7d2dff131bbd,1,"2. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).",3,1,Processed,"The material focuses on genomic quality control, population filtering, and telomere-length association analyses in ALS (including C9orf72 status). There is no discussion of drug response, medication, dosing, gene–drug interactions, or pharmacogenetic study design or assays, so it is not relevant to pharmacogenetics."
c0ec42eb-690e-44aa-8c4a-449791ce2b0f,1,"3. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics (2011) doi:10.1093/bioinformatics/btr330.",3,1,Processed,"This paper describes the Variant Call Format (VCF) and VCFtools for storing and processing genomic variant data and discusses file format, compression, indexing and software utilities. It does not address pharmacogenetic approaches, drug response, or clinical pharmacogenomics—only generic sequence-variation data storage and tools—so it is not relevant to pharmacogenetics."
1f6fe111-9d93-45f4-9b71-2d819af048f9,1,Depression in adults: treatment and management NICE guideline Published: 29 June 2022 www.nice.org.uk/guidance/ng222,3,1,Processed,"This NICE guideline addresses diagnosis, psychological and pharmacological treatment, monitoring and service delivery for depression, but it contains no evaluation or discussion of pharmacogenetic testing or genotype-guided prescribing. Medication recommendations focus on choice, dosing, monitoring and withdrawal, not on genetic predictors of response or safety, so it is not relevant to pharmacogenetic approaches."
f1ee10b8-ae34-47c8-a20d-bc0524269b3c,1,Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).,3,1,Processed,"The briefing is about the CORTRAK 2 electromagnetic enteral access system for guiding nasoenteral feeding tube placement, its clinical evidence, costs, and implementation. It contains no discussion of genetics, genetic testing, drug–gene interactions, or personalized/ pharmacogenetic approaches."
88a0ec06-c2fa-43d3-8112-35b11e21b9e7,1,International Classification of Diseases-11 (ICD-11),3,1,Processed,"The text is the ICD-11 Reference Guide (structure, coding, chapters, mortality/morbidity rules, extension codes, etc.). It focuses on disease classification and coding systems and contains no discussion of pharmacogenetics, pharmacogenomic testing, drug–gene interactions, or genotype-guided therapy, so it is not relevant to pharmacogenetic approaches."
274a0014-0b77-47ba-b351-0e01a073fb8c,1,Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5),3,1,Processed,"The document presents DSM-5 diagnostic criteria for opioid use disorder (symptom checklist, severity thresholds). It contains no discussion of genes, genetic testing, genotype-guided prescribing, pharmacogenetic markers, drug metabolism variants, or personalized medication strategies, so it is not relevant to pharmacogenetic approaches."
0ccd10be-d41d-476e-b35b-d140d7428e3b,1,NICE guideline on depression in adults with a chronic physical health problem,3,1,Processed,"The guideline focuses on recognition, assessment and management of depression in people with chronic physical health problems, including psychosocial interventions, stepped care, and drug–drug interaction considerations. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or related biomarkers—only general pharmacology and interaction guidance—so it is not relevant to pharmacogenetic approaches."
d73b2338-1522-43b7-9c0e-190765f58d74,1,NICE's information on making decisions about your care.,3,1,Processed,"The document is an NHS/NICE guideline on shared decision making covering leadership, training, decision aids, risk communication and implementation. It contains no discussion or assessment of pharmacogenetic approaches (no mention of genetics, pharmacogenomics, genotype-guided prescribing or related evidence), so it is not relevant to pharmacogenetics."
99c96e22-5fc2-426d-8d38-2301d72f7c94,1,Making decisions using NICE guidelines,3,1,Processed,"This guideline is about shared decision making across healthcare (training, organisational embedding, decision aids, risk communication and patient involvement). It contains no discussion of genetics, pharmacogenetics/pharmacogenomics, genotype-guided prescribing, drug–gene interactions, or genetic testing to inform treatment. The only medicine-related mention is about patient decision aids and medicines optimisation in general, not pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
a9247257-8871-4abb-bf3b-320098c61294,1,decision-making and mental capacity,3,1,Processed,"The guideline focuses on decision-making, mental capacity, advance care planning, capacity assessments and best-interests processes under the Mental Capacity Act. It contains no discussion of pharmacogenetics, genetic testing, drug-gene interactions, personalised prescribing or related methodologies, so it is not relevant to pharmacogenetic approaches."
6cc11e2b-f09a-4e6d-a458-5c76fcf333e6,1,medicines adherence,3,1,Processed,"The guideline focuses on patient involvement, communication, adherence support, and medicines review processes. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or personalized pharmacogenomic approaches, so it is not relevant to pharmacogenetic assessment."
dbfdab4b-48e0-4c15-8113-d058deb82a78,1,medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults,3,1,Processed,"The guideline focuses on clinical prescribing, monitoring and withdrawal management for dependence-forming medicines (opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants). It makes no mention of pharmacogenetics, genetic testing, genotype-guided dosing or related biomarkers, so it does not assess pharmacogenetic approaches."
d2e4c544-3946-4551-808d-fa7d8b3e57a8,1,medicines optimisation,3,1,Processed,"This guidance focuses on medicines optimisation, patient-centred use, adherence, safety, review and multidisciplinary practice. It contains no discussion of genetics, genotyping, biomarker-driven prescribing, or pharmacogenetic testing or approaches, so it is not relevant to pharmacogenetics."
62cba8ee-a8dd-4564-a555-7828d7e8da9b,1,multimorbidity,3,1,Processed,"The paper focuses on prevalence and patterns of multimorbidity among tuberculosis patients in India using a cross-sectional, questionnaire-based approach. It contains no discussion of genetic testing, gene–drug interactions, pharmacogenomic markers, personalized drug response, or any pharmacogenetic methodology. The only drug-related mention concerns side effects of anti-TB treatment in general, not pharmacogenetic assessment."
2adf6282-1bc7-4c10-b3b9-317f76a939a3,1,service user experience in adult mental health,3,1,Processed,"The guideline focuses on service user experience, access, assessment, care pathways, crisis and hospital care, and legal/organizational issues. It only briefly references pharmacological treatments in general and contains no discussion of pharmacogenetic testing, genomic markers, or personalized medication selection, so it is not relevant to pharmacogenetic approaches."
62194235-01d3-4d93-a09c-eb6e03d03db5,1,shared decision making,3,1,Processed,"This document is CDC guidance on HPV vaccination and shared clinical decision-making for adults 27–45 years, focusing on vaccine indications, timing, and risk factors. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided drug selection, or individualized drug response."
5f0365fc-ca79-48f6-bcc7-fe4e901aed1e,1,supporting adult carers,3,1,Processed,"The guideline focuses on support for adult unpaid carers (identification, assessments, training, psychosocial support, workplace and end-of-life issues). It contains no discussion of genetics, pharmacogenetics, genomic testing, or personalized drug therapy—only brief general mentions of medication review and medicines optimisation, which are not pharmacogenetic in nature."
13b2bf8f-f49e-474d-82c1-296c4636150c,1,NICE guideline on bipolar disorder,3,1,Processed,"This NICE guideline focuses on clinical assessment and management of bipolar disorder (pharmacological choices, monitoring, safety, and psychosocial interventions) and makes no mention of pharmacogenetic testing, genotype-guided prescribing, or related biomarkers. Therefore it is not relevant to pharmacogenetic approaches."
11d71f0a-8a66-4200-8ddc-fb39601c5f0b,1,NICE guideline on post-traumatic stress disorder,3,1,Processed,"This NICE guideline addresses recognition, psychosocial care and general pharmacological treatment options for PTSD (e.g. SSRIs, venlafaxine, antipsychotics) but contains no discussion or evaluation of pharmacogenetic testing, genotype‑guided prescribing, biomarkers, or personalized genomic approaches. It is a clinical practice guideline rather than an assessment of pharmacogenetic strategies."
737d65c3-1834-4cc7-9ac2-4a6db9c6f3fb,1,NICE guidelines on mental health problems in people with learning disabilities and autism spectrum disorder,3,1,Processed,"The guideline addresses pharmacological management broadly (prescribing responsibility, monitoring, interactions, dose titration, and review) but contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, or personalised drug-response biomarkers. Therefore it is not relevant to pharmacogenetic approaches."
3ce3d5af-0e79-4e1e-8d1b-cd6a4061484d,1,"NICE guideline on dementia: assessment, management and support for people living with dementia and their carers",3,1,Processed,"The guideline focuses on clinical assessment, diagnosis, care coordination, non‑pharmacological and pharmacological management of dementia and support for carers. It includes standard drug recommendations and brief notes that some young‑onset dementias may have a genetic cause, but it contains no evaluation or recommendations about pharmacogenetic testing, gene-guided prescribing, pharmacogenomic markers, or personalized drug selection based on genotype. Therefore it is not relevant to pharmacogenetic approaches."
ef142c34-11a9-4360-a71c-71a3472e8ddb,1,NICE guideline on self-harm,3,1,Processed,"The guideline is focused on assessment, psychosocial interventions, safety planning, service models, training and safer prescribing in the context of self-harm. Although it discusses medication toxicity and medicines review, it contains no discussion of pharmacogenetics, genotyping, pharmacogenomic-guided prescribing, CYP polymorphisms or related personalised medicine approaches. Therefore it is not relevant to pharmacogenetic assessment."
5b0f411a-7acd-45fa-9788-9d57ee1d54dd,1,NICE guideline on antenatal and postnatal mental health,3,1,Processed,"The guideline focuses on recognition, assessment and clinical management of perinatal mental health and on medication safety, teratogenic risks and monitoring in pregnancy and breastfeeding. It contains no discussion of pharmacogenetic testing, genotype-guided prescribing, genetic biomarkers, or tailored drug selection based on genetic information. Therefore it is not relevant to pharmacogenetic approaches."
a7371b2f-23ef-4e9d-a99b-e542c61014c7,1,NICE guideline on menopause,3,1,Processed,"The guideline focuses on clinical identification and management of menopause (HRT, CBT, genitourinary care, risks, screening and research priorities) and does not discuss pharmacogenetics, genetic testing, genotype-guided prescribing, or individualized drug response based on genetic variants. There is no evaluation of pharmacogenetic approaches in the recommendations or research sections."
3c35d9b6-6758-41d8-aeb8-569edcaf21fe,1,evidence review I: patient choice,3,1,Processed,"The document is an evidence review about patient choice in depression treatments, summarising qualitative studies on clinician–patient relationships, access, information needs, stigma, and service constraints. It discusses antidepressant use and psychological therapies but contains no discussion of pharmacogenetics, genetic testing, genotype-guided prescribing, biomarkers, or related interventions. Therefore it is not relevant to pharmacogenetic approaches."
fb5a6225-577a-4a7d-bc5c-6367a421edb8,1,evidence review A: patient information,3,1,Processed,"This evidence review focuses on patients' information and support needs in gout (qualitative studies, education, diet, long‑term management, roles of GPs/nurses/pharmacists). It does not assess pharmacogenetic approaches; genetics is only briefly mentioned as a risk factor, with no discussion of pharmacogenetics, genotyping, or personalized drug responses."
8c987931-8ce5-4fe9-9b30-e792f9c3cdd7,1,evidence review B: prescribing strategies,3,1,Processed,"The review focuses on prescribing strategies and interventions to limit dependence and withdrawal (dose/regimen comparisons, tapering, prescriber/patient education, psychological support) across opioids, gabapentinoids, Z‑drugs and antidepressants. There is no discussion or analysis of genetic testing, pharmacogenetic markers, genotype-guided dosing, or related methods anywhere in the text or appendices. Therefore it is not relevant to pharmacogenetic approaches."
a0558581-a181-4022-bcf0-cdf110d0dae2,1,evidence review C: safe withdrawal,3,1,Processed,"The guideline focuses on safe prescribing, monitoring and withdrawal management for dependence-forming medicines (opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants) and makes no reference to pharmacogenetics, genetic testing, genotype-guided prescribing, or related biomarkers."
f3c6ad3f-9f8b-4d92-9295-dadf36c03832,1,evidence review D: withdrawal symptoms,3,1,Processed,"The review focuses on clinical efficacy, dosing, safety, resource impact and implementation of buprenorphine prolonged‑release injection (Buvidal). It contains no discussion of pharmacogenetics, genotyping, genetic markers, CYP metabolism or genetically guided dosing/personalization."
afc84a4b-e1f3-4549-a233-d5e9d903e52f,1,evidence review F: monitoring,3,1,Processed,"The document is an evidence review and guideline on the optimal frequency of blood sampling and monitoring for neonates on parenteral nutrition (glucose, calcium, phosphate, potassium, triglycerides, liver function, iron status). It contains no discussion of genetics, genomic testing, drug–gene interactions, or pharmacogenetic approaches; recommendations are clinical and laboratory-monitoring focused. Therefore it is not relevant to pharmacogenetics."
9fc8d9c3-8174-4623-87d3-bd3b5dfbaab8,1,evidence review C: preventing relapse,3,1,Processed,"The review focuses on prediction models for relapse in psychosis using prodromal symptoms and administrative/clinical variables; it contains no assessment of genetic or genomic markers, pharmacogenetic predictors, gene–drug interactions, or related methods. Therefore it is not relevant to pharmacogenetic approaches."
4a8e3e1b-2173-4910-ba57-8e547fc446cf,1,evidence review D: further-line treatment,3,1,Processed,"The guideline is about recognition, assessment, and clinical management of depression (psychological therapies, pharmacological options, monitoring, stopping/tapering, augmentation, ECT, service delivery). It contains no discussion or evaluation of pharmacogenetic testing, gene-guided prescribing, CYP genotyping or pharmacogenomic approaches to personalize antidepressant therapy."
36f0848e-1204-4cd9-8e4a-292cd652975d,1,evidence review E: chronic depression,3,1,Processed,"The review focuses on screening accuracy and treatment (SSRIs and psychotherapy) for pediatric depression, and on harms like suicidality. It contains no analysis of pharmacogenetic approaches; genetics is only mentioned as an excluded modifier. Therefore pharmacogenetics is not assessed."
1c3c0d29-6adc-468c-be26-55f0a509afac,1,evidence review F: depression with coexisting personality disorder,3,1,Processed,"The document is an evidence review of treatments for depression with coexisting personality disorder (psychological, psychosocial, pharmacological and physical interventions) and summarizes RCTs comparing therapies and antidepressant drugs. It contains no discussion of genetic testing, gene–drug interactions, pharmacogenetic markers, or personalized/genotype-guided prescribing. Therefore it is not relevant to pharmacogenetic approaches."
ee97a013-1ffa-4b97-8098-60763adc6fb0,1,evidence review G: psychotic depression,3,1,Processed,"This evidence review focuses on clinical and pharmacological treatments (antidepressants, antipsychotics, ECT, psychological interventions) for psychotic depression and reports RCT comparisons, relapse prevention and adverse effects. It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, CYP genotypes, or personalized/genomic prescribing approaches, so it is not relevant to pharmacogenetic assessment."
903e60a4-a4bf-41b7-b108-1b1adef71fcb,1,evidence review H: access to services,3,1,Processed,"The document is an evidence review and guideline on improving access to depression services for vulnerable groups, focusing on service delivery models (collaborative care, teletherapy, culturally adapted interventions), uptake and satisfaction. It does not mention pharmacogenetics, genetic testing, genotype-guided prescribing, or related biomarkers, so it is not relevant to pharmacogenetic approaches."
ddc18ade-5bd8-44b0-8989-05f20a87d518,1,evidence review A: service delivery,3,1,Processed,"This systematic review focuses on speech-language service delivery for children (treatment formats, providers, settings, and behavioral therapy dosage). It addresses intervention models and clinical outcomes in communication disorders and contains no discussion of drugs, genetics, genomic markers, or personalized medicine; therefore it is not relevant to pharmacogenetic approaches."
d0c40079-9009-4f9f-a5bf-0ebc7b06a7ed,1,"vortioxetine for treating major depressive episodes (TA367, 2015)",3,1,Processed,"The document is a NICE technology appraisal of vortioxetine focusing on clinical trial efficacy, safety, and cost-effectiveness for major depressive episodes. It contains no discussion of genetic testing, biomarker-guided treatment, pharmacogenetic markers, genotype-based dosing, or related methods — therefore it is not relevant to pharmacogenetic approaches."
2c001eb9-836f-403e-a347-bc7ad8cbf107,1,"guidance on vortioxetine for treating major depressive episodes (TA367, 2015)",3,1,Processed,"The document is a NICE technology appraisal of vortioxetine covering clinical trial evidence, safety, and cost‑effectiveness modeling for treating major depressive episodes. It contains no discussion of genetic testing, genotype‑guided treatment, biomarkers, or pharmacogenetic approaches; therefore it is not relevant to pharmacogenetics."
7bb9cfc0-bef7-443b-bb7f-4ab55409780a,1,"guidance on esketamine nasal spray (TA854, 2022)",3,1,Processed,"The document is a NICE decision review of esketamine nasal spray for treatment‑resistant depression focusing on clinical trial evidence, comparators, economic modelling, and implementation. It contains no discussion of pharmacogenetics, genetic testing, biomarkers, or genotype‑guided treatment, so it is not relevant to pharmacogenetic approaches."
fc38567b-cd31-476d-8b37-dea01fde62b5,1,NICE clinical knowledge summary on switching antidepressants,3,1,Processed,"The document is a clinical formulary/guideline for treating depression in children and adolescents focusing on drug choices, dosing, monitoring, adverse effects, switching strategies and service pathways. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, CYP polymorphisms, or related topics, so it is not relevant to pharmacogenetic approaches."
3f70684b-023e-4ef2-b9bb-6e7dd9c41ab4,1,NICE's information on prescribing medicines,3,1,Processed,"The document is a NICE guideline summary on type 2 diabetes medication choice and management focusing on clinical factors (comorbidities, renal/cardiovascular risk, drug classes, monitoring, tolerability, cost). It contains no discussion of pharmacogenetics, genetic testing, or genotype-guided prescribing, so it is not relevant to pharmacogenetic approaches."
1b8b0664-2249-4fb8-85e5-42f9519090b6,1,NHS lithium treatment pack,3,1,Processed,"The document is a clinical safety bundle for lithium inpatient care covering monitoring, dosing, drug interactions, toxicity recognition, and care planning. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, or genetic markers affecting lithium response or safety."
1f422610-0a34-4d0c-8359-5aa41f1b2466,1,Electroconvulsive Therapy Accreditation Service (ECTAS),3,1,Processed,"This is a dataset/report on electroconvulsive therapy (ECT) practice, patient demographics, clinical outcomes, cognitive assessments and service delivery during 2020. It contains no discussion of genetics, genotyping, drug–gene interactions, biomarker-guided prescribing, or any pharmacogenetic methods or findings, so it is not relevant to pharmacogenetic approaches."
d6eeef2a-e2a2-4594-84c8-9bb7ec179fcd,1,ECT Accreditation Service Standards for Administering ECT,3,1,Processed,"The document is an accreditation standards manual for electroconvulsive therapy (ECT) clinics covering clinic facilities, staff, training, consent, anaesthesia, monitoring and protocols. It contains no discussion of pharmacogenetics, genetic testing, drug-gene interactions, or personalized pharmacotherapy—only routine references to medications and anaesthetic agents. Therefore it is not relevant to pharmacogenetic approaches."
6b025b1d-ede8-433d-a619-79d722cfbe78,1,ECTAS minimum dataset,3,1,Processed,"The report is an activity dataset for electroconvulsive therapy (ECT) covering clinic participation, patient demographics, reasons for referral, treatment counts and outcomes. It contains no discussion of pharmacogenetics, genetic testing, drug response genetics, genotypes, or related methodologies — therefore it is not relevant to pharmacogenetic approaches."
57ab9d58-ea61-4822-b470-23db590fcb1e,1,Royal College of Psychiatrists,3,1,Processed,"The guideline focuses on assessment, diagnosis, service design and pharmacological/psychosocial management of adult ADHD. It contains no substantive evaluation of pharmacogenetic testing or genotype-guided treatment—only a brief note that some individuals are poor metabolisers of atomoxetine—so it is not relevant to pharmacogenetic approaches."
2993f325-c60c-494b-a5d1-8b184ecec3b9,1,NICE interventional procedures guidance on repetitive transcranial magnetic stimulation for depression,3,1,Processed,"The document is a NICE interventional-procedures guidance on repetitive transcranial magnetic stimulation (rTMS) for depression. It focuses on the procedure, indications, efficacy, safety, and clinical governance. It does not discuss pharmacogenetic testing, gene–drug interactions, biomarkers, genotyping-guided therapy, or any genetics-based patient selection—so it is not relevant to pharmacogenetic approaches."
78488679-e8e1-4621-9cf9-757277e218b6,1,NICE interventional procedures guidance on implanted vagus nerve stimulation for treatment-resistant depression,3,1,Processed,"The document is an interventional procedures guidance on implanted vagus nerve stimulation for treatment‑resistant depression, focusing on surgical technique, safety, efficacy, governance and research needs. It contains no discussion of pharmacogenetics, genetic testing, or genetically guided medication strategies, so it is not relevant to pharmacogenetic approaches."
1c25b0b7-fab5-4588-8e57-7710d83b9963,1,Medicines and Healthcare products Regulatory Agency,3,1,Processed,"The document is MHRA guidance on GxP data integrity, covering data governance, audit trails, validation, retention, and IT/cloud supplier considerations. It focuses on regulatory data management and quality controls and contains no discussion of pharmacogenetics, genomics, genetic markers, genotyping, or individualized drug response. (Note: the acronym GPvP here refers to pharmacovigilance, not pharmacogenetics.)"
e3f0eba8-91e7-4e13-a47d-ccf1b745e229,1,Yellow Card Scheme,3,1,Processed,"The document is a summary of Yellow Card adverse‑event reports and regulatory actions (pharmacovigilance, medication errors, interactions, device issues). It contains no discussion of genetic variants, genotype‑guided therapy, biomarkers, pharmacogenetic testing, or personalized/precision dosing — therefore it is not relevant to pharmacogenetic approaches."
fc8b2b55-2313-4bfb-8139-6c5d12595ff3,1,BNF,3,1,Processed,"The document is the Algol 60 language grammar in BNF (program/statement/declaration/expressions/lexical tokens). It describes programming-language syntax and tokens, with no discussion of genes, drugs, variants, pharmacokinetics, pharmacodynamics, clinical applications, or any pharmacogenetic concepts."
9a43b4b9-9924-4407-ad29-8b3de2967810,1,Mental Health Act 2007,3,1,Processed,"This is a policy/legal briefing on the Mental Health Act 2007 (England), covering topics such as supervised community treatment, changes to professional roles (AMHP/RC), deprivation of liberty safeguards, advocacy and children’s safeguards. It contains no discussion of pharmacology, genetics, personalized medicine, drug-response testing or pharmacogenetic approaches."
8a8841ee-e02e-4ba8-8850-9b06882db37c,1,Mental Capacity Act 2005,3,1,Processed,"This is the Mental Capacity Act 2005 (UK) — legislative text about capacity, powers of attorney, Court of Protection, research safeguards and advocacy. It does not discuss pharmacogenetics, genetic testing, drug–gene interactions, or personalized medicine; at most it contains general research provisions but no assessment of pharmacogenetic approaches."
a8a858f0-5a2b-4123-b5bc-a2c57b55766d,1,Equality Act 2010,3,1,Processed,"The text is the UK Equality Act 2010 (legislation on discrimination, protected characteristics, public duties, services, premises, employment, education, etc.). It is a legal/statutory document with no discussion of drugs, genetics, biomarkers, individualized therapy, or pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
cb51334b-6248-4c1c-aada-349000aa93da,1,NHS constitution,3,1,Processed,"The text is the National Honor Society constitution and handbook material about school chapter governance, membership, selection, discipline, and activities. It contains no discussion of pharmacogenetics, medical genetics, drug response, or related scientific methods, so it is not relevant to pharmacogenetic approaches."
54eee828-6a65-400d-af17-791ed5999e56,1,"Think Local, Act Personal Care and Support Jargon Buster",3,1,Processed,"The document is a social care jargon factsheet from Mencap covering terms and services related to social care, mental health and disability support. It contains no discussion of pharmacogenetics, genetic testing, drug metabolism, biomarkers, or personalized pharmacotherapy, so it is not relevant to pharmacogenetic approaches."
4c7dca1e-a88a-4274-95fe-c21cd1122a28,1,NICE glossary,3,1,Processed,"The document is a glossary/extract of the NICE clinical guideline on food allergy in children and young people, defining clinical terms (eg, anaphylaxis, IgE-mediated reactions) and listing implementation resources. It contains no discussion of genetics, pharmacogenetic testing, drug–gene interactions, or personalized drug response—so it is not relevant to pharmacogenetic approaches."
cba9665c-fc42-40ce-bc6f-70f8c86bc0a3,1,NICE topic page on depression,3,1,Processed,"The paper focuses on multimodal deep learning (text and image) and topic modeling for automatic depression detection. It discusses BERT, VGG, LSTM, and neural topic models, with no discussion of genetics, drugs, drug–gene interactions, biomarkers, or individualized pharmacological responses. Therefore it is not relevant to pharmacogenetic approaches."
b8907bf3-b0f9-4269-8597-b7bb1ef17d2e,1,resources to help you put NICE guidance into practice,3,1,Processed,"The document is a clinical guideline on intravenous fluid therapy (assessment, monitoring, resuscitation, maintenance, replacement, training) and contains no discussion of genetics, genetic testing, or pharmacogenetic approaches. It focuses on fluid/electrolyte management and hospital protocols, so it is not relevant to pharmacogenetics."
038fa1f7-4e29-4f77-813b-34f963c083cd,1,NICE guideline CG90 (published October 2009),3,1,Processed,"The guideline is a clinical treatment and management document for depression (psychological therapies, pharmacotherapy, ECT, service delivery). It does not discuss pharmacogenetic testing, genotyping, pharmacogenomic predictors of drug response, or personalized genetic-based prescribing. While it mentions drug interactions, pharmacokinetics (half-life) and monitoring, there is no assessment of pharmacogenetic approaches."
a67b15eb-16cf-43a3-b169-4d1848839afd,1,CG123,3,1,Processed,"El texto es un acuerdo del Instituto Nacional Electoral sobre la incorporación del identificador para personas no binarias en la credencial para votar y analiza normas, sentencias y procedimientos administrativos y de registro civil. No contiene referencias a genética, farmacología, respuesta a fármacos, polimorfismos genéticos ni metodologías farmacogenéticas, por lo que no es relevante para enfoques farmacogenéticos."
898c183a-830f-4e17-bcc5-4a86ccde1c0c,1,QS8,3,1,Processed,"This document is an Alesis QS7/QS8 synthesizer reference manual (hardware, MIDI, audio, editing, and setup). It is technical documentation for a musical instrument and contains no discussion of pharmacology, genetics, or pharmacogenetic approaches."
93fb4eab-9e41-4b86-ab1b-5b64c6c00636,1,NICE guideline on borderline personality disorder,3,1,Processed,"The guideline focuses on recognition, psychological treatments, service organisation and limited pharmacological recommendations for borderline personality disorder and crises; it contains no discussion of genetics, genetic testing, or tailoring drug choice/dosing based on genetic profiles. Therefore it is not relevant to pharmacogenetic approaches."
5149a655-fb3f-4d49-9611-c3c2726364b2,1,NICE guideline on psychosis and schizophrenia in adults,3,1,Processed,"This NICE guideline focuses on clinical recognition, pharmacological and psychological management, monitoring and service delivery for psychosis and schizophrenia. It contains no discussion of genetic testing, pharmacogenetic markers, genotyping, CYP enzyme testing, or personalized/precision medicine approaches—so it does not assess pharmacogenetic approaches."
f21e0c1b-eb12-4f1c-a99a-101d59f413ad,1,previous NICE guideline and supporting documents,3,1,Processed,"The document is the USCIS Form I-765 instructions about employment authorization categories, filing requirements, and supporting documentation. It deals with immigration status, EAD categories, and procedural guidance; it contains no discussion of pharmacogenetics, genetics, drug–gene interactions, or related scientific content."
82a06ad7-e876-48ed-89f0-c4dbcd9a2fc6,1,NHS advice on mental wellbeing,3,1,Processed,"The document is an executive summary of the NHS Staff and Learners’ Mental Wellbeing Commission addressing workplace mental health, training, organisational roles and wellbeing support. It contains no discussion of pharmacogenetics, genetic testing, drug metabolism, or personalized medication approaches, so it is not relevant to pharmacogenetic assessment."
c320445b-7b4f-41df-8f39-50839fa4f052,1,ISBN: 978-1-4731-4622-8,3,1,Processed,"This document is a glossary and list of abbreviations for the NICE guideline on depression in adults. It defines terms and lists medication- and trial-related abbreviations but contains no discussion, assessment, or recommendations about pharmacogenetic testing, genetic markers, genotype-guided prescribing, or related methods. Therefore it is not relevant to pharmacogenetic approaches."
fab54b1e-98b7-41ec-b4b9-6e95a91b86a9,1,British National Formulary (BNF). (2025) Amitriptyline hydrochloride. [Online] Available at: https://bnf.nice.org.uk/drugs/amitriptyline-hydrochloride/ [Accessed 22 April 2025],3,1,Processed,"This patient information leaflet for amitriptyline covers indications, dosing, side effects, precautions and storage but contains no discussion of pharmacogenetics: there is no mention of genetic testing, genes/enzymes (e.g. CYP2D6/CYP2C19), genotype-guided dosing, metaboliser phenotypes, or personalised prescribing based on genetic information."
90919da6-87e9-4a9c-a5e5-0fb82258746b,1,British National Formulary (BNF). (2025) Tricyclic and related antidepressant drugs in antidepressant drugs. [Online] Available at: https://bnf.nice.org.uk/treatment-summaries/antidepressant-drugs/ [Accessed 22 April 2025],3,1,Processed,"This is a patient information leaflet on amitriptyline for neuropathic pain (uses, dosing, side effects, precautions, storage, contacts). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, CYP enzymes, or personalized/precision-medicine approaches."
2992f1f2-2f93-4fbc-81d4-91cb6a539a33,1,"Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD008242. DOI: 10.1002/14651858.CD008242.pub3 [Accessed 22 April 2025]",3,1,Processed,"The slides cover non‑opioid pharmacologic pain management (NSAIDs, acetaminophen, topical agents, antidepressants, AEDs, NMDA antagonists, guidelines, and efficacy/safety data) but contain no discussion of pharmacogenetics, genetic testing, genotype‑guided prescribing, CYP variants, or personalized genomic approaches."
f47b6743-2531-4114-b218-805a3a736b02,1,National Institute for Health and Care Excellence (NICE). (2013) Neuropathic pain in adults: pharmacological management in non-specialist settings Clinical guideline [CG173]. [Online] Available at: https://www.nice.org.uk/guidance/cg173 [Accessed 22 April,3,1,Processed,"The document describes a surgical/interventional procedure (transcranial MRI‑guided focused ultrasound thalamotomy) for neuropathic pain, including technique, efficacy and safety. It contains no discussion of pharmacogenetics, genetic testing, genotype‑guided drug selection, or related concepts; at most it mentions pharmacological treatments for neuropathic pain as background, but not any pharmacogenetic approaches."
b8328740-6b7b-4d54-a7c2-9697d9e55f27,1,"Sabaté E, World H Organization, editors. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.",3,1,Processed,"The document is a WHO report on adherence to long-term therapies (behavioural, system-level, and disease-management issues). It contains no discussion or evaluation of pharmacogenetic approaches, genomic testing, or personalized drug-response genetics—so pharmacogenetics is not assessed."
4f89109b-a752-4bdc-854a-f740558645b6,1,"Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health out- comes in ageing populations: a systematic review and meta‐analysis. Br J Clin Pharmacol. 2019;85:2464–78.",3,1,Processed,"The paper focuses on drug pricing, Medicare cost-savings from the Inflation Reduction Act, and projections for diabetes medications in Louisiana; it contains no discussion of genetics, genetic testing, genotype-guided therapy, biomarker-driven prescribing, or other pharmacogenetic concepts."
e97d67dd-a00c-4ed3-b11d-090b9c5122d2,1,"Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes Mellitus. Arch Intern Med. 2006;166:1836–41.",3,1,Processed,"The study is an institutional cross-sectional survey of medication adherence and associated factors (drug access, glucometer ownership, diabetes knowledge, medication type) among type 2 diabetes patients. It contains no discussion of genetics, genotyping, gene–drug interactions, polymorphisms, biomarkers, or any pharmacogenetic methods or outcomes, so it is not relevant to pharmacogenetic approaches."
d6cbdc0c-8949-4f66-b0ad-8aeb60783f8a,1,"Lin C-S, Khan H, Chang R-Y, Liao W-C, Chen Y-H, Siao S-Y, et al. A study on the impact of poor medication adherence on health status and medical expense for diabetes mellitus patients in Taiwan: a longitudinal panel data analysis. Medicine. 2020;99:e20800",3,1,Processed,"The paper investigates medication adherence among hypertensive diabetic patients using questionnaires (MMAS-8) and clinical measures (blood pressure, HbA1c) and analyzes demographic and behavioral factors. It contains no discussion or data on genetics, genomic testing, pharmacogenetic markers, genotype-guided therapy, drug-metabolizing enzymes, or personalized pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
9090842c-bad3-48a5-8339-167f4cb5a204,1,"Valgimigli M, Garcia-Garcia HM, Vrijens B, Vranckx P , McFadden EP , Costa F, et al. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from t",3,1,Processed,"The study examines self-reported non-adherence to P2Y12 inhibitors and clinical outcomes using the NARC classification; it contains no assessment of pharmacogenetics (no genotyping, no discussion of CYP2C19 or other genetic polymorphisms, no genotype-guided therapy)."
1404df61-1bce-452e-9038-c30c480befe5,1,"Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a system- atic review. BMJ Open. 2018;8:e016982.",3,1,Processed,"The paper focuses on using pharmacy dispensing data and big-data methods to measure medication adherence (PDC) and evaluate a pharmacist-led intervention. It contains no discussion of genetics, genotyping, gene–drug interactions, or personalized pharmacogenetic testing—so it is not relevant to pharmacogenetic approaches."
aa1c1322-b573-4082-ae39-ac35dd7ba153,1,"Shrestha P , Ghimire L. A review about the effect of life style modification on diabetes and quality of life. Global J Health Sci. 2012;4:185–90.",3,1,Processed,"The paper focuses on lifestyle factors and health outcomes across chronic diseases using survey-based network analysis during COVID-19. It contains no discussion of genetics, pharmacogenomics, gene–drug interactions, medication response variability, genetic markers, or personalized drug therapy—so it does not assess pharmacogenetic approaches."
2cb7c042-029e-416f-9d26-286bd1b2faf1,1,"Chauke GD, Nakwafila O, Chibi B, Sartorius B, Mashamba-Thompson T. Factors influencing poor medication adherence amongst patients with chronic disease in low-and-middle-income countries: a systematic scoping review. Heliyon. 2022;8:e09716.",3,1,Processed,"The article is a cross-sectional survey of medication adherence in cardiovascular disease using the MMAS‑8 questionnaire; it contains no discussion, measurements, or analysis of genetics, genotyping, gene–drug interactions, biomarker-driven dosing, or any pharmacogenetic approaches."
662cb1d7-016a-4f62-aebd-58bf27ec4189,1,"Leung DY, Bai X, Leung AY, Liu BC, Chi I. Prevalence of medication adherence and its associated factors among community-dwelling chinese older adults in Hong Kong. Geriatr Gerontol Int. 2015;15:789–96.",3,1,Processed,"The article is a cross-sectional study of medication non-adherence in community-dwelling adults, focusing on prevalence, reasons (e.g., fear of dependence, forgetting, label comprehension), and associated sociodemographic and clinical factors (depression, multimorbidity). It contains no discussion of genes, genotypes, pharmacogenetic testing, drug–gene interactions, polymorphisms, or individualized drug response based on genetics, so it is not relevant to pharmacogenetic approaches."
d5c3cb3e-c222-410a-afce-8dc4362ec10c,1,"Nakajima R, Watanabe F, Kamei M. Factors associated with medication non-adherence among patients with lifestyle-related non-communicable diseases. Pharm (Basel). 2021;9:90.",3,1,Processed,"The article investigates factors associated with medication non-adherence (health beliefs, lifestyles, trouble taking medication) in patients with lifestyle-related NCDs. It contains no discussion of genetics, pharmacogenetics, genotype-guided therapy, genetic markers, drug metabolism variants, or related methods, so it is not relevant to pharmacogenetic approaches."
0fe73dd9-2288-42e0-a8ae-362eb869e4b9,1,"Atinga RA, Yarney L, Gavu NM. Factors influencing long-term medication non-adherence among diabetes and hypertensive patients in Ghana: a qualitative investigation. PLoS ONE. 2018;13:e0193995.",3,1,Processed,"The study is a qualitative investigation of factors influencing long-term medication non-adherence among diabetes and hypertensive patients in Ghana (perceptions of efficacy, herbal/spiritual recourse, polypharmacy, work schedules, social norms, provider communication, etc.). It contains no discussion, methods, data, or references related to pharmacogenetics, genetic testing, genotype-guided therapy, or pharmacogenomic approaches."
7743a9d9-00fd-441e-bef6-07d789e47dd0,1,"Lin L-K, Sun Y, Heng BH, Chew DEK, Chong P-N. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diabetes Research and Care. 2017;5:e000429.",3,1,Processed,"The paper examines medication burden, regimen complexity (MRCI), adherence (PDC), and associations with glycemic control in T2DM patients. It contains no discussion, data, methods, or results related to pharmacogenetics, genotyping, genetic variants, or genotype-guided therapy—therefore it is not relevant to pharmacogenetic approaches."
b26aa810-84b8-4973-9da6-b34dc32bc0d3,1,"Alefishat E, Jarab AS, Al-Qerem W, Abu-Zaytoun L. Factors associated with medication non-adherence in patients with dyslipidemia. Healthc (Basel). 2021;9:813.",3,1,Processed,"The article focuses on medication adherence, patient beliefs, regimen complexity, and clinical/demographic predictors in dyslipidemia patients. It contains no discussion of genetics, genotyping, gene–drug interactions, or pharmacogenetic testing or strategies, so it does not assess pharmacogenetic approaches."
8bc48bda-6ba0-45aa-a4c5-f16edaa08808,1,"van der Laan DM, Elders PJM, Boons CCLM, Nijpels G, Hugtenburg JG. Factors associated with nonadherence to cardiovascular medications: a cross-sec- tional study. J Cardiovasc Nurs. 2019;34:344.",3,1,Processed,"The study focuses on medication non-adherence (prevalence, reasons, and sociodemographic/clinical correlates) in community-dwelling adults in Singapore. It contains no discussion of genetics, genetic testing, drug–gene interactions, personalized drug selection, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
ab09dd70-6b21-4c0d-8662-90156f613f7f,1,"Mechta Nielsen T, Frøjk Juhl M, Feldt-Rasmussen B, Thomsen T. Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research. Clin Kidney J. 2018;11:513–27.",3,1,Processed,"The manuscript focuses on financial toxicity and its association with medication adherence in haemodialysis patients, using patient-reported measures (COST, ASK-12) and sociodemographic/clinical covariates. It contains no discussion, data, methods, or results related to genetics, genotyping, pharmacogenomics, gene–drug interactions, or personalized drug response—therefore it is not relevant to pharmacogenetic approaches."
e18c4c89-a00e-4b57-aabb-df94aacd9249,1,World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.,3,1,Processed,"The document is a WHO report on adherence to long-term therapies focusing on behavioural, system, and disease-management interventions. It discusses compliance, measurement, health-system factors, and disease-specific adherence issues but contains no discussion of pharmacogenetics, genetic testing, or genetically guided prescribing. Therefore it is not relevant to pharmacogenetic approaches."
3a21c795-e0ea-4868-9877-406e96bf3815,1,"Kumar A, Mohammadnezhad M, May W. Perception of factors influencing noncompliance with medication among cardiac patients in Fiji: a qualitative study. Patient Prefer Adherence. 2021;15:1843–52.",3,1,Processed,"The study is a cross-sectional survey of medication non-adherence and its sociodemographic, clinical and behavioural correlates in community-dwelling adults. It does not discuss genes, genotyping, gene–drug interactions, biomarkers, or any pharmacogenetic/pharmacogenomic methods or personalized drug-response testing. Therefore it is not relevant to pharmacogenetic approaches."
7140ff5a-d077-4b23-9f9b-7de0d3a764fe,1,"Park HY, Seo SA, Yoo H, Lee K. Medication adherence and beliefs about medi- cation in elderly patients living alone with chronic diseases. Patient Prefer Adherence. 2018;12:175–81.",3,1,Processed,"The article is a scoping review of barriers and facilitators to medication adherence in chronic diseases, focusing on socioeconomic, patient, health-system, pharmacotherapy and disease-related factors. It does not discuss pharmacogenetics, pharmacogenomic testing, genotype-guided therapy, or related precision-medicine approaches; even adverse drug reactions are discussed in general terms without genetic investigation. Search terms and objectives center on adherence and education rather than pharmacogenetics."
a1ddc4c2-c30c-4580-a711-34005d87bc71,1,"Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteris- tics associated with medication adherence. Clin Med Res. 2013;11:54–65.",3,1,Processed,"The study examines demographic and clinical differences and 2-year recurrence rates in bipolar disorder onset types; it does not evaluate pharmacogenetics, drug-response genomics, genetic markers, or pharmacogenomic testing. Family psychiatric history is mentioned but no genetic or pharmacogenetic analyses are reported."
09d4c7b4-50ae-4584-83a4-eb10bb84fdce,1,"Mathes T, Jaschinski T, Pieper D. Adherence influencing factors – a systematic review of systematic reviews. Archives of Public Health. 2014;72:37.",3,1,Processed,"The paper is a cross-sectional study of medication non-adherence and its behavioral, socioeconomic, therapy- and health-system-related determinants in community-dwelling adults. It contains no discussion, data, or analysis related to genetics, genotyping, genetic variants, drug–gene interactions, or genotype-guided/pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
cb14ae9b-39eb-43c9-a41a-3af300e61a27,1,"Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: a systematic review. Aging Med (Milton (NSW)). 2018;1:254–66.",3,1,Processed,"The paper is a cross-sectional study of medication non-adherence and its sociodemographic, clinical, and psychosocial determinants in Singapore. It focuses on adherence behaviors, reasons for non-adherence, and associated factors (e.g., depressive symptoms, employment, number of medications) and contains no discussion, data, or assessment of pharmacogenetics, genetic testing, or genotype-guided therapy."
dcdb9108-eee5-4c5a-aada-19ce0ff13a80,1,"Sherman BW, Lynch WD. The association of smoking with medical treatment adherence in the workforce of a large employer. Patient Prefer Adherence. 2014;8:477–86.",3,1,Processed,"The paper is a cross-sectional survey of medication non-adherence and its psychosocial, socioeconomic, and clinical determinants in community-dwelling adults. It focuses on adherence behaviors, reasons (e.g., fear of dependence, forgetting, regimen complexity), and associated factors (depression, employment, number of medications), with no discussion of genetics, pharmacogenomics, genotype-guided prescribing, biomarker testing, or any pharmacogenetic approaches."
fb2a59b7-5d8a-4f5c-bd86-2c647f1da4ae,1,"Grodensky CA, Golin CE, Ochtera RD, Turner BJ. Systematic review: Effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases. J Stud Alcohol Drug. 2012;73:899–910.",3,1,Processed,"The article examines changes in risky alcohol use after the COVID-19 outbreak using web surveys and focuses on epidemiology, lifestyle, chronic and mental health conditions. It contains no discussion of genetics, pharmacogenetics, drug-gene interactions, or personalized pharmacotherapy, so it is not relevant to pharmacogenetic approaches."
b00e7726-8bde-4bbe-8801-f83152fe413e,1,"Simon E, Levin JB, Mbwambo J, Blixen C, Lema I, Aebi M, et al. Alcohol use in Tanzanians with chronic psychotic disorders and poor medication adher- ence. South Afr J Psychiatry. 2021;27:1–10.",3,1,Processed,"The paper focuses on self-reported medication non-adherence, reasons for non-adherence, and associated sociodemographic and clinical factors in community-dwelling adults. It contains no mention of genetic data, genotyping, gene–drug interactions, pharmacogenomic testing, or personalized drug-response strategies, so it is not relevant to pharmacogenetics."
d674dc8e-d9d4-4307-9233-dea67fce9565,1,"Hung A, Blalock DV, Miller J, McDermott J, Wessler H, Oakes MM, et al. Impact of financial medication assistance on medication adherence: a systematic review. J Managed Care Specialty Pharm. 2021;27:924–35.",3,1,Processed,"The study focuses on medication non-adherence, its prevalence, reasons and sociodemographic/psychosocial predictors in community-dwelling adults in Singapore. It contains no discussion, data, methods, or results related to genetics, genotyping, gene–drug interactions, personalized medicine, or pharmacogenetic testing, so it is not relevant to pharmacogenetic approaches."
5e5737f1-bc66-40d8-a127-62fff88389ad,1,"Aziz H, Hatah E, Bakry MM, Islahudin F. How payment scheme affects patients’ adherence to medications? A systematic review. Patient Prefer Adherence. 2016;10:837–50.",3,1,Processed,"The paper focuses on predictors of medication adherence in patients with cirrhosis (demographics, disease severity, knowledge, social support, self-care agency, pill burden) and construction of a nomogram. It contains no discussion, data, methods or results related to genetics, genotyping, drug-gene interactions, or pharmacogenetic testing, so it is not relevant to pharmacogenetic approaches."
8eff2d67-18ed-4597-81bf-f7420b77e63f,1,Kish L. A procedure for objective respondent selection within the household. J Am Stat Assoc. 1949;44:380–7.,3,1,Processed,"The document is a survey methodology report focused on within-household respondent selection methods for telephone and mail surveys (e.g., Kish, birthday, Westat, Pew methods). It addresses sampling, nonresponse, and total survey error—no content relates to pharmacogenetics, genetics, pharmacology, or personalized medicine."
d5c30cc8-80ed-48c1-b00b-1e353c68d282,1,"Momirović A, Ganza M, Čulig B, Leppée M, Prga Borojevic I. Psychometric properties of the Culig’s questionnaire. Psychiatria Danubina. 2016;28:234–41.",3,1,Processed,"The study focuses on medication non-adherence (prevalence, reasons, and sociodemographic/clinical correlates) in community-dwelling adults; it contains no discussion, measurement, or evaluation of pharmacogenetics, genotyping, genetic predictors of drug response, or personalized genetic-guided therapy."
2bf2ff60-b3d1-4a29-a8e3-f1846695cb4d,1,"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.",3,1,Processed,"The document focuses on screening, assessment, and management of depression and anxiety (PHQ‑2/9, GAD‑2/7), suicide risk, and detection of misuse/overuse in primary care/Medicaid populations. It contains no discussion of pharmacogenetics, genetic testing, gene‑drug interactions, biomarkers, or genomics-based treatment selection."
abca255b-2b91-4cdc-bb58-7f0089c98485,1,"Unni EJ, Gupta S, Sternbach N. Trends of self-reported non-adherence among type 2 diabetes medication users in the United States across three years using the self-reported medication adherence reasons Scale. Nutr Metabo- lism Cardiovasc Dis. 2022;32:151–9",3,1,Processed,"The document focuses on nurse education to improve medication adherence among patients with anxiety disorders and reviews behavioral, educational, and system-level interventions. It contains no discussion of pharmacogenetics, pharmacogenomic testing, genetic predictors of drug response, or genotype-guided prescribing. Therefore it is not relevant to pharmacogenetic approaches."
261156ae-5c43-4fb9-a5ec-31b99d4ed008,1,"Foley L, Larkin J, Lombard-Vance R, Murphy AW, Hynes L, Galvin E, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. BMJ Open. 2021;11:e044987.",3,1,Processed,"The editorial focuses on medication adherence, interventions, measurement tools, and healthcare system factors; it does not discuss pharmacogenetic testing, genotype-guided therapy, or genetic determinants of drug response. Therefore it is not relevant to pharmacogenetic approaches."
edd0c5ff-b832-4c45-afe6-4e03d5a0ef4d,1,"Sweileh WM, Zyoud SH, Abu Nab’a RJ, Deleq MI, Enaia MI, Nassar SM, et al. Influence of patients’ disease knowledge and beliefs about medicines on medication adherence: findings from a cross-sectional survey among patients with type 2 diabetes mellitus in ",3,1,Processed,"The study focuses on medication adherence, health beliefs, provider–patient relationship, and sociodemographic/clinical factors in type 2 diabetes patients; it uses MMAS-4 and survey-based measures. There is no mention of genetics, genotyping, gene–drug interactions, biomarkers, or pharmacogenetic testing or analysis, so it is not relevant to pharmacogenetic approaches."
42d3e7d1-0d77-4761-a09d-2e3ae899e9fe,1,Schultz DL. Timing is everything: The importance of taking medication on time. AllazoHealth. 2022. https://allazohealth.com/resources/timing-is-everything-the-importance-of-taking-medication-on-time/ . Accessed 20 Dec 2022.,3,1,Processed,"The study focuses on medication non-adherence, its prevalence, reasons and associated sociodemographic/clinical factors in community-dwelling adults. It does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related biomarker approaches anywhere in the text."
b7ab354e-e294-45ed-8e97-22a66dad8f78,1,"Mentz RJ, Greiner MA, Muntner P , Shimbo D, Sims M, Spruill TM, et al. Inten- tional and unintentional medication non-adherence in African Americans: insights from the Jackson Heart Study. Am Heart J. 2018;200:51–9.",3,1,Processed,"The paper is a cross-sectional study of medication non-adherence and its sociodemographic, clinical, and behavioural determinants in community-dwelling adults. It contains no discussion of genetics, genetic testing, pharmacogenomics, genotype-guided prescribing, or related methods, so it is not relevant to pharmacogenetic approaches."
61fd0b92-ebd1-4f3e-a035-a95285f15c66,1,"Gast A, Mathes T. Medication adherence influencing factors—an (updated) overview of systematic reviews. Syst Reviews. 2019;8:1–17.",3,1,Processed,"The paper is a systematic overview of factors influencing medication adherence (socioeconomic, therapy-, disease-, patient- and health system-related factors). It contains no discussion of genetics, genotyping, pharmacogenetic testing, gene–drug interactions, biomarkers, or personalized pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
b2362743-aee5-4c0a-b19e-dc70610e575f,1,"Mahmood S, Jalal Z, Hadi MA, Khan TM, Haque MS, Shah KU. Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis. Int J Clin Pharm. 2021;43:486–501.",3,1,Processed,"The study is a cross-sectional clinical investigation of antihypertensive medication adherence and its association with hypertensive crisis, using questionnaires (MGL scale, HADS) and clinical/demographic data. It contains no genetic testing, discussion of genetic variants, pharmacogenomic markers, or personalized drug-response approaches, so it is not relevant to pharmacogenetics."
c3b5c4fb-ccc8-499b-aacd-2e8ee6960b0a,1,"Lopes J, Santos P . Determinants of non-adherence to the medications for dyslipidemia: a systematic review. Patient Prefer Adherence. 2021;15:1853–71.",3,1,Processed,"This study examines medication non-adherence prevalence, reasons and sociodemographic/clinical correlates in community-dwelling adults using survey data. It does not discuss genetics, genotyping, gene–drug interactions, genotype-guided therapy, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
8550fc08-819b-4211-b1ca-86488008f31f,1,"Yoon S, Kwan YH, Yap WL, Lim ZY, Phang JK, Loo YX et al. Factors influencing medication adherence in multi-ethnic asian patients with chronic diseases in Singapore: a qualitative study. Front Pharmacol. 2023;14.",3,1,Processed,"The paper is a scoping review of community hospital models and research in high-income countries, focusing on service types (acute vs post-acute), patient populations, COVID-19 responses, rehabilitation, and research gaps. It contains no discussion of pharmacogenetics, pharmacogenomics, genetic testing, drug–gene interactions, or related personalized medicine approaches, so it is not relevant to pharmacogenetic assessment."
b8ff1eda-78ae-401b-b9e0-68a8eb1f7f4a,1,"Suppiah S, Tan YW, Cheng GH-L, Tang WE, Malhotra R. Mediators of the association of limited English health literacy with medication non-adherence among Singaporean elderly. Proc Singap Healthc. 2020;29:25–32.",3,1,Processed,"The paper is a cross-sectional study of medication non-adherence and its behavioral, sociodemographic and clinical determinants in community-dwelling adults. It focuses on adherence reasons (forgotten doses, fear of dependence, depressive symptoms, polypharmacy, etc.) and does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related biomarkers."
1a065d21-714a-48ec-8c7d-91d78f6584e8,1,"1.  Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B,  et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation.  Glob Heart. 2017; 12(4): 273–84. DOI: https://doi.org/10.1016/j.gheart.2017.01.015",3,1,Processed,"This is an ESC clinical guideline on atrial fibrillation diagnosis and management (anticoagulation, ablation, rate/rhythm control, screening, comorbidities). It does not assess or focus on pharmacogenetic approaches (no substantive discussion of genotype-guided dosing/testing such as CYP2C9/VKORC1-guided warfarin management); pharmacogenetics is not a primary topic."
00069b2a-3b76-4ae5-851f-d6fbc80c82ae,1,"2. Zaidel EJ, Leng X, Adeoye AM, Hakim F, Karmacharya B, Katbeh A,  et al. Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reduc",3,1,Processed,"The paper is a qualitative health-systems study on barriers and facilitators to use of NOACs (direct oral anticoagulants) in Nepal, focusing on awareness, infrastructure, monitoring, cost, policy and training. It contains no discussion of pharmacogenetics, genotyping, genetic variability in drug response, or personalized genetic-guided anticoagulant therapy."
d0247010-2a89-44a0-874f-bd9553ac5d48,1,"3. Chugh SS, Roth GA, Gillum RF, Mensah GA.  Global Burden of Atrial Fibrillation in Devel - oped and Developing Nations. Glob Heart . 2014; 9(1): 113–9. DOI: https://doi.org/10.1016/j. gheart.2014.01.004",3,1,Processed,"The article is an epidemiologic overview of the global burden of cardiovascular diseases (IHD, stroke, atrial fibrillation, PAD, myocarditis, endocarditis, aneurysm) and trends from 1990–2010. It focuses on incidence, mortality, DALYs, regional variation, and surveillance needs; it contains no discussion of pharmacogenetics, drug–gene interactions, genetic testing, or personalized drug-response strategies."
753e6495-3b41-4baf-8dd4-3ec15708a6c1,1,"8. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited. Stroke. 2013; 44(11): 3103–8. DOI: https://doi.org/10.1161/STROKEAHA.113.002329",3,1,Processed,"The paper develops and validates a clinical nomogram to predict occult atrial fibrillation after ischemic stroke using clinical, laboratory, and imaging variables (age, heart rate, CRP, NT‑proBNP, hemorrhagic transformation). It contains no genetic data, pharmacogenetic markers, drug–gene interaction analyses, or discussion of genotype‑guided therapy, so it is not relevant to pharmacogenetic approaches."
ae5c2077-6a2c-489a-a1ce-a5eea03c74f8,1,"11.  Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime Risk for Devel - opment of Atrial Fibrillation. Circulation. 2004; 110(9): 1042–6. DOI: https://doi.org/10.1161/01. CIR.0000140263.20897.42",3,1,Processed,"The study examines socioeconomic differences in prescribing rates of NOACs using EHR data and zip-code–based income measures. It contains no genetic or genomic data, genotyping, gene–drug interaction analysis, or discussion of pharmacogenetic-guided therapy, so it does not assess pharmacogenetic approaches."
b3bb8337-ac95-4217-8fbd-bc016eb1baaa,1,"15. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the num- ber of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34(35): 2746–51. DOI: https://doi.org/10.1093/eurhe",3,1,Processed,"The study examines bleeding risk from pharmacodynamic and pharmacokinetic drug–drug interactions (notably CYP3A4 inhibition by certain SSRIs) but contains no assessment of genetic variation, genotyping, CYP polymorphisms, or any pharmacogenetic methods or analyses. It does not address genotype-guided therapy or personalized dosing."
022a50a8-9019-4482-b9e7-9a2c244480d9,1,"17.  Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E, et al. The Impact of Risk Factors and Comor- bidities on The Incidence of Atrial Fibrillation. Mater Sociomed. 2017; 29(4): 231–6. DOI: https://doi. org/10.5455/msm.2017.29.231-236",3,1,Processed,"The study examines clinical outcomes of atrial fibrillation in hospitalized multiple myeloma patients and anticoagulation use, but contains no discussion, data, or analysis of genetic variation, gene–drug interactions, pharmacogenomic testing, or pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
fe7ca9e9-120d-4ba9-baaa-8f1093d02b76,1,"19. Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A,  et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: A multi- country patient-level meta-analysis of 141,220 sc",3,1,Processed,"This trial evaluates point-of-care single-lead ECG screening for atrial fibrillation in primary care and subsequent anticoagulant use; it contains no assessment of genetic markers, gene–drug interactions, or pharmacogenetic testing or approaches."
738fd937-a5a7-4d85-9c8b-429a32462f2c,1,"20. Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA,  et al. European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans. Circulation. 2010; 122(20): 2009–15. DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.958306",3,1,Processed,"The manuscript is an epidemiologic study of genome-wide European ancestry and incident atrial fibrillation among self-identified Black participants. It examines ancestry proportions, AF incidence, covariates, and meta-analysis with other cohorts. It does not assess drug response, genotype-guided therapy, pharmacokinetics/pharmacodynamics, drug–gene interactions, or any pharmacogenetic approaches (medication use is only included as a covariate), so it is not relevant to pharmacogenetics."
1b7dc0ee-0a32-4c86-bd92-4db85572b084,1,"22. Jensen PN, Thacker EL, Dublin S, Psaty BM, Heckbert SR. Racial Differences in the Incidence of and Risk Factors for Atrial Fibrillation in Older Adults: The Cardiovascular Health Study. J Am Geriatr Soc. 2013; 61(2): 276–80. DOI: https://doi.org/10.11",3,1,Processed,"This CV lists epidemiology and clinical research (cardiovascular disease, stroke, cognitive decline, Parkinson’s, gerontology) and some pharmacoepidemiology activities, but contains no substantive work on pharmacogenetic methods or drug–gene interactions. Thus it is not relevant to pharmacogenetic approaches."
3ea3511e-9a53-473d-8f8d-9d5fea0d97d6,1,"24. Soni A, Earon A, Handorf A, Fahey N, Talati K, Bostrom J, et al. High Burden of Unrecognized Atrial Fibrillation in Rural India: An Innovative Community-Based Cross-Sectional Screening Program. JMIR public health and surveillance. 2016; 2(2): e159. DO",3,1,Processed,"The paper describes an IoT-based ECG and vital-signs monitoring system (hardware, sensors, microcontroller, signal processing, mobile app, and cloud integration). It contains no discussion of genetics, drug response, genotyping, or any pharmacogenetic methods or analyses—thus it is not relevant to pharmacogenetics."
86917a53-abbd-4580-817a-eec919d39fa1,1,"25. Soni A, Karna S, Fahey N, Sanghai S, Patel H, Raithatha S, et al. Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. Int J Cardiol. 2019; 280: 84–8. DOI: https:/",3,1,Processed,"The paper is an epidemiologic/meta-analysis of single‑timepoint atrial fibrillation screening, yield, stroke-risk (CHA2DS2‑VASc), and numbers needed to screen; it discusses anticoagulation guidelines and screening logistics but contains no discussion of genetic testing, pharmacogenetic markers, drug–gene interactions, or tailored drug therapy based on genotype. Therefore it is not relevant to pharmacogenetics."
3977527e-80a6-4ba3-891d-83252a034b6b,1,"26. Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kothari S, Narula D,  et al. Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies. Indian J Med Res. 2012; 135(3): 322–30.",3,1,Processed,"The paper is a clinical observational study of ECG findings in hypertensive disorders of pregnancy and does not discuss genetics, pharmacogenetics, genotype-guided therapy, or differential drug response by genetic variation. Mentions of antihypertensive drugs are clinical only, with no pharmacogenetic assessment."
22ed81fc-4400-4667-886d-f32ec2c34ff1,1,"27. Saggu DK, Sundar G, Nair SG, Bhargava VC, Lalukota K, Chennapragada S,  et al. Prevalence of atrial fibrillation in an urban population in India: The Nagpur pilot study. Heart Asia. 2016; 8(1): 56–9.",3,1,Processed,"The roadmap focuses on global AF epidemiology, screening, digital technologies, and anticoagulation access/adherence (NOACs, VKA management, health systems) with no discussion of pharmacogenetic testing, genotyping-guided dosing, or pharmacogenomic approaches. Thus it is not relevant to pharmacogenetics."
c9417888-0d72-4328-ae37-cf1b55c30b05,1,"28. Chan N-y, Choy C-c. Screening for atrial fibrillation in 13,122 Hong Kong citizens with smartphone electrocardiogram. Heart. 2017; 103(1): 24–31. DOI: https://doi.org/10.1136/heartjnl-2016-309993",3,1,Processed,"The study focuses on remote screening for atrial fibrillation using a smartphone-case single-lead ECG and centralized ECG analysis, with endpoints around AF detection, time to diagnosis, and initiation of anticoagulation. It contains no discussion of genetic testing, genotype-guided drug selection, gene–drug interactions, or any pharmacogenetic methods. Therefore it is not relevant to pharmacogenetic approaches."
381ca3ea-bdb5-4d62-8a18-bb52ac756b2e,1,"29. Noubiap JJ, Nyaga UF.  A review of the epidemiology of atrial fibrillation in sub-Saharan Africa. J Cardiovasc Electrophysiol. 2019; 30(12): 3006–16. DOI: https://doi.org/10.1111/jce.14222",3,1,Processed,"The Roadmap focuses on public-health strategies for atrial fibrillation (screening, digital technologies, prevention, anticoagulation uptake, NOAC access, rate/rhythm control and health-system barriers), with no evaluation or discussion of pharmacogenetic testing or genotype-guided drug therapy. Genetic mentions relate to AF epidemiology only, not pharmacogenetic approaches."
d759d11d-69fc-43f2-8c09-4e47782930a4,1,"30. Mandi DG, Bamouni J, Naïbé DT, Yaméogo RA, Kaboré E, Kambiré Y, et al. Epidemiology and long- term prognosis of atrial fibrillation in rural African patients. The Egyptian Heart Journal. 2019; 71(1): 6. DOI: https://doi.org/10.1186/s43044-019-0005-3",3,1,Processed,"The paper is an observational study of atrial fibrillation prevalence, risk factors, and anticoagulation practice in an Ethiopian cardiac clinic. It contains no discussion, data, methods, or results related to genetics, genotyping, gene–drug interactions, or pharmacogenetic testing (e.g., CYP2C9, VKORC1), so it is not relevant to pharmacogenetic approaches."
5b93f120-be86-4f56-bbcb-bdde8aa84f1a,1,"31.  Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H,  et al. Burden of non- communicable diseases in sub-Saharan Africa, 1990–2013; 2017: Results from the Global Burden of Disease Study 2017. The Lancet Global Health. 2019; 7(10): e1",3,1,Processed,"The manuscript is an observational study of predictors of coronary artery disease in HFrEF patients (demographics, ECG, echocardiography, risk factors, angiography) and development of a clinical nomogram. It does not discuss genetics, gene–drug interactions, genomic markers, or tailored pharmacotherapy—only routine medications at discharge—so it is not relevant to pharmacogenetic approaches."
abdbedf6-f513-438e-a299-dede3ec3b9e6,1,"33. Muthalaly RG, Koplan BA, Albano A, North C, Campbell JI, Kakuhikire B,  et al. Low population prevalence of atrial fibrillation in rural Uganda: A community-based cross-sectional study. Int J Cardiol. 2018; 271: 87–91. DOI: https://doi.org/10.1016/j.i",3,1,Processed,"The review focuses on epidemiology, diagnosis, and health-service management of cardiac arrhythmias in sub‑Saharan Africa (prevalence, CPR, device availability, anticoagulation use, and procedural capacity). It does not evaluate pharmacogenetic approaches or drug–gene interactions; genetic mentions concern rare inherited arrhythmia syndromes but not pharmacogenetics or personalized drug response."
d55cf650-8ccc-4eb2-9a2e-87625fafdf5a,1,"34. Paixão GMM, Silva LGS, Gomes PR, Lima EM, Ferreira MPF, Oliveira DM,  et al. Evaluation of Mortality in Atrial Fibrillation: Clinical Outcomes in Digital Electrocardiography (CODE) Study. Glob Heart. 2020; 15(1): 48. DOI: https://doi.org/10.5334/gh.77",3,1,Processed,"The paper focuses on electrocardiographic predictors of mortality using a large tele-ECG database, AI for ECG interpretation, and epidemiology. It contains no discussion of genetics, genotyping, drug–gene interactions, personalized drug therapy, pharmacokinetics, or pharmacodynamics — i.e., no pharmacogenetic content."
a7774abb-f12a-4fc9-bb9e-d571d858fed5,1,"35. Marcolino MS, Palhares DM, Benjamin EJ, Ribeiro AL. Atrial fibrillation: prevalence in a large data- base of primary care patients in Brazil. Europace. 2015; 17(12): 1787–90. DOI: https://doi.org/10.1093/ europace/euv185",3,1,Processed,"The study is an observational registry of atrial fibrillation patients focusing on sex differences in anticoagulant use and clinical outcomes. It contains no discussion of genetic testing, genotype-guided dosing, polymorphisms (eg, CYP2C9, VKORC1), or any pharmacogenetic methods or analyses. Therefore it is not relevant to pharmacogenetic approaches."
f0b12d8a-bc33-4be5-8476-4e4e82b088e4,1,"37. Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J.  Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med . 2014; 7: 441–8. DOI: https://doi.org/10.2147/IJGM.S62819",3,1,Processed,"The study is a prospective observational safety/effectiveness registry of edoxaban in NVAF patients and does not include any pharmacogenetic aims, methods, or genotyping endpoints. Apart from a single passing sentence noting Brazil’s ethnic diversity (and a citation on pharmacogenetics), there is no assessment, collection, or analysis of genetic data or pharmacogenetic approaches in the protocol or outcomes."
4ba96f6d-7bf7-4106-8923-d767b81960c0,1,"38. Joseph PG, Healey JS, Raina P, Connolly SJ, Ibrahim Q, Gupta R,  et al. Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle- aged individuals. Cardiovasc Res; 2020. DOI: https:",3,1,Processed,"The review focuses on atrial fibrillation, vascular cognitive impairment/dementia, epidemiology, pathophysiology, and clinical prevention/management (anticoagulation, rhythm/rate control, devices, public health, COVID-19). It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, or gene–drug interactions (e.g., warfarin pharmacogenetics), so it is not relevant to pharmacogenetic approaches."
fc8ee01b-d5ea-48c8-af12-dbbc420f8d11,1,"39. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Per - spectives from the international, observational, pr",3,1,Processed,"The document is a catalogue of TRI clinical research publications (GARFIELD-AF, GARFIELD-VTE, RIVER, ETHIC, etc.) focusing on anticoagulant treatment patterns, outcomes, registries, observational methods and related analyses. There are no mentions of genetic testing, gene variants, pharmacogenomic markers (e.g., CYP2C9, VKORC1), genotyping, or tailored drug therapy based on genetics. Therefore it does not assess pharmacogenetic approaches."
b00d3497-db05-49ca-93fa-4e27d54b7b30,1,"40. Goto S, Oh S, Cools F, Koretsune Y, Angchaisuksiri P, Rushton-Smith S, et al. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights. Eur Heart J . 2013; ",3,1,Processed,"The document is a list of clinical research publications and abstracts (GARFIELD-AF, GARFIELD-VTE, ETHIC, RIVER, etc.) focusing on anticoagulation treatment patterns, outcomes, risk scores, and real-world registry data. It contains no mention of genetic testing, genotype-guided therapy, pharmacogenetic markers (e.g., CYP variants), or analyses of genetic influences on drug response. Therefore it is not relevant to pharmacogenetic approaches."
3713d643-9941-422f-9ef6-d514e200b0b7,1,"42. Narasimhan C, Verma JS, Ravi Kishore AG, Singh B, Dani S, Chawala K, et al. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart J. 2016; 68(5): 663–70. DOI: https://doi.org/10",3,1,Processed,"The scoping review focuses on epidemiology, clinical characteristics, management (anticoagulant prescribing patterns) and outcomes of atrial fibrillation in Middle Eastern Arabs and South Asians. It explicitly excluded genetics in eligibility criteria and contains no analysis or discussion of pharmacogenetic approaches (e.g., genetic predictors of drug response, genotype-guided therapy). Any mention of medications (VKAs, NOACs) relates to usage patterns, not pharmacogenetics."
d3a2d31e-4656-4d51-8393-8fc5ad80d8aa,1,"43. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: The RE-LY Atrial Fibrillation Regist",3,1,Processed,"The review focuses on epidemiology, clinical management, diagnostics, devices and health-system gaps for cardiac arrhythmias in sub‑Saharan Africa. It does not evaluate pharmacogenetic testing, genotype‑guided drug therapy, or drug–gene interactions. (It only briefly notes inherited arrhythmia syndromes and a CACNA1C variant but contains no assessment of pharmacogenetic approaches.)"
e52b1daa-5ab9-4157-beb6-2e25ffa90a5b,1,"44. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibril - lation on the Risk of Death. Circulation. 1998; 98(10): 946–52. DOI: https://doi.org/10.1161/01. CIR.98.10.946",3,1,Processed,"The editorial focuses on clinical treatment strategies for atrial fibrillation—catheter ablation vs antiarrhythmic drugs—and cites trials, outcomes, safety, and implementation barriers. It contains no discussion of genetic testing, genotype-guided drug selection, pharmacogenomic biomarkers, drug–gene interactions, or any pharmacogenetic methods."
312e02c9-a335-4c23-ac1b-95496334818e,1,"46. Andersson T, Magnuson A, Bryngelsson I-L, Frøbert O, Henriksson KM, Edvardsson N,  et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: A Swedish nationwide long-term case-control study. Eur Heart J.",3,1,Processed,"The article focuses on clinical outcomes of mechanical thrombectomy in acute ischemic stroke patients with and without atrial fibrillation. There is no discussion of pharmacogenetics, genetic markers, genotype-guided therapy, or drug–gene interactions; the content is procedural/interventional and outcome-focused rather than pharmacogenetic."
9cada18c-f77b-4324-85d9-ef66ea8f626b,1,"47. Sepehri Shamloo A, Dagres N, Müssigbrodt A, Stauber A, Kircher S, Richter S, et al. Atrial Fibril - lation and Cognitive Impairment: New Insights and Future Directions. Heart Lung Circ. 2020; 29(1): 69–85. DOI: https://doi.org/10.1016/j.hlc.2019.05.18",3,1,Processed,"This 2020 ESC atrial fibrillation guideline is a broad clinical practice document focused on diagnosis, stroke prevention, anticoagulation strategies (VKA/NOAC), rhythm/rate control, ablation, and integrated care. It does not assess or prioritize pharmacogenetic approaches (e.g., genotype-guided warfarin or NOAC use); there are no recommendations or substantive discussion of pharmacogenomic testing or genotype-directed dosing. Hence pharmacogenetics is not a relevant focus."
bde1c8e7-dc86-4477-9118-291d94f5c8b0,1,"52. Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe J, DiNicolantonio JJ,  et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. J Progress in cardiovascular diseases. 2015; 58(2): 117–25. DOI: https://doi.org/10.10",3,1,Processed,"This is a comprehensive clinical guideline on diagnosis and management of atrial fibrillation (anticoagulation, rate/rhythm control, ablation, lifestyle, etc.). It focuses on clinical recommendations (INR/TTR for VKAs, NOAC dosing, bleeding/stroke risk scores) and does not evaluate or recommend pharmacogenetic testing or genotype-guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
d050f975-3483-474a-9175-37b3afb27f72,1,"53. Du X, Dong J, Ma C.  Is atrial fibrillation a preventable disease? J Am Coll Cardiol . 2017; 69(15): 1968–82. DOI: https://doi.org/10.1016/j.jacc.2017.02.020",3,1,Processed,"The article is a global roadmap on atrial fibrillation focusing on detection, prevention, digital technologies, and anticoagulation policy/implementation (including NOAC access). It does not discuss pharmacogenetic testing, genotype-guided dosing, or pharmacogenomic strategies for anticoagulant or antiarrhythmic therapy. The only genetics-related content refers to population differences in AF risk, not pharmacogenetics."
516f8576-5a9e-4dac-bf97-8832e697e38a,1,"54. Ahmadi SS, Svensson A-M, Pivodic A, Rosengren A, Lind M.  Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: A Swedish cohort study. J Cardiovascular diabetology. 2020; ",3,1,Processed,"The Roadmap focuses on epidemiology, screening, digital technologies, prevention, and management of atrial fibrillation (including anticoagulation with VKAs and NOACs), but contains no substantive discussion or assessment of pharmacogenetic approaches (eg. genetic-guided dosing or pharmacogenomic testing). Only brief mentions of genetic differences in AF risk are present, not pharmacogenetics for therapy."
d38d920e-fe30-4a19-a16a-adcef5063a05,1,"57. Wändell P, Carlsson AC, Gasevic D, Holzmann MJ, Ärnlöv J, Sundquist J, et al. Socioeconomic fac- tors and mortality in patients with atrial fibrillation—a cohort study in Swedish primary care. European J of public health. 2018; 28(6): 1103–9. DOI: htt",3,1,Processed,"No pharmacogenetics content. The paper examines social determinants of health and their association with incident stroke in the REGARDS cohort, focusing on demographics, socioeconomic, neighborhood factors, clinical risk factors, and health behaviors. It contains no genetic data, gene–drug interaction analyses, genotype-guided therapy, or discussion of pharmacogenetic approaches."
42438ebb-011c-4b7b-bf1b-3a22fb3416ae,1,"59. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME,  et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA. ",3,1,Processed,"The trial evaluates a lifestyle weight-loss and cardiometabolic risk-factor management intervention for atrial fibrillation; it contains no genetic testing, genotype-guided drug selection, gene–drug interaction analyses, or any pharmacogenetic endpoints. Medication use is described but not informed by or analyzed with respect to genetics."
e8b52cf5-e197-4381-a5c4-02f31e8c3f0b,1,"61.  Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M.  Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ. 1998; 316(7147): 1784–5. DOI: https://doi. org/10.1136/bmj.316.7147.1784",3,1,Processed,"The article focuses on clinical cardiovascular issues and management in masters athletes (atrial fibrillation, myocardial fibrosis, coronary artery disease, aortic dilation) and discusses general pharmacologic therapies (e.g., anticoagulants, antiarrhythmics, statins) but contains no discussion of pharmacogenetics, genetic-guided drug selection, or related testing. Therefore it is not relevant to pharmacogenetic approaches."
3f06f236-f72e-4f7e-b4d4-19faf09c2943,1,"62. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J. 2008; 29(1): 71–8. DOI: https://doi.org/10.1093/eurheartj/ehm555",3,1,Processed,"The review focuses on endurance sport and atrial fibrillation, discussing epidemiology, mechanisms (remodeling, autonomic balance, microRNA, mechano-gated channels), clinical management (CARE + detraining, anticoagulation, ablation) and eligibility for sports. It only briefly mentions genetics as a possible modulator of risk but contains no discussion or assessment of pharmacogenetic approaches, drug–gene interactions, genotype-guided therapy, or personalized pharmacotherapy."
1ce900c5-e7d0-4565-a20d-4cd6e67b3048,1,"63. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J,  et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace. 2008; 10(5): 618–23. DOI: https://doi.org/10.1093/euro",3,1,Processed,"The review discusses endurance sport and atrial fibrillation and only briefly mentions genetics as a possible modulator of risk; it does not assess pharmacogenetic approaches, genetic testing, or drug–gene interactions, nor does it discuss tailoring pharmacotherapy based on genetic information. Therefore it is not relevant to pharmacogenetics."
b556ebf3-9630-4970-8ba3-5367ca3fa0cd,1,"64. Nielsen JR, Wachtell K, Abdulla J.  The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr Fibrillation. 2013; 5(5): 789.",3,1,Processed,"The Roadmap focuses on global detection, prevention, digital technologies, anticoagulation implementation (NOACs vs VKAs), screening, and health-system barriers for atrial fibrillation. It does not discuss genotype-guided prescribing, genetic determinants of drug response, or pharmacogenetic testing for anticoagulant or antiarrhythmic therapy. The only genetics-related content refers to population/familial AF risk and ancestry differences in AF prevalence, which is not pharmacogenetics."
028c0c7e-e819-4054-9366-714a3e0d503b,1,"65. Epstein LJ, Kristo D, Strollo PJ, Jr., Friedman N, Malhotra A, Patil SP,  et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009; 5(3): 263–76. DOI: https://doi.org/10.5",3,1,Processed,"The document is a clinical facilitator guide on obstructive sleep apnea covering history, diagnosis, testing, and therapies (CPAP, devices, surgery, weight loss). It contains no discussion of pharmacogenetics, genetic testing, genotype–drug response, or personalized pharmacologic approaches—only a brief list of medications that can cause sleepiness, which is not pharmacogenetics."
1935c34e-968e-4264-9b80-0503ab64baae,1,"66. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol. 2018; 3(6): 532–40. DOI: https://doi.org/10.10",3,1,Processed,"The review focuses on the epidemiology, pathophysiology, diagnosis, and treatment (notably CPAP and procedural outcomes) of obstructive sleep apnea and its association with atrial fibrillation. It contains no discussion of pharmacogenetics, genetic predictors of drug response, or genotype-guided therapy; the brief mentions of antiarrhythmic drug efficacy do not involve genetic or pharmacogenetic assessment."
335f0b39-45b1-472a-9425-3cef53fbde17,1,"67. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registr",3,1,Processed,"The paper examines secondary prevention, risk factor control, lifestyle and general pharmacotherapy in CHD patients across EUROASPIRE IV/V. It contains no discussion of genetics, gene–drug interactions, genetic testing, or tailoring of therapy based on genotype, so it does not assess pharmacogenetic approaches."
af8a5250-d7f2-451a-9f95-7af970b6e596,1,"68. Proia KK, Thota AB, Njie GJ, Finnie RK, Hopkins DP, Mukhtar Q, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014; 47(1): 86–99. DOI: https://doi.org/10.1016/j.amepre.2014.03.004",3,1,Processed,"The article is a systematic review and meta-analysis of team-based care interventions for hypertension (physician-, nurse-, pharmacist-, and community health worker-led teams) and focuses on blood pressure outcomes, intervention structure, and duration. It contains no discussion of genetics, genotyping, gene–drug interactions, or personalized pharmacogenetic strategies, so it is not relevant to pharmacogenetics."
368685e2-48f4-47a2-b424-496698f26cf9,1,"71.  Johansson C, Dahlqvist E, Andersson J, Jansson JH, Johansson L. Incidence, type of atrial fibrilla - tion and risk factors for stroke: A population-based cohort study. Clin Epidemiol. 2017; 9: 53–62. DOI: https://doi.org/10.2147/CLEP.S122916",3,1,Processed,"The paper focuses on atrial fibrillation detection from ECG RR‑interval features using signal preprocessing and machine learning (traditional and ensemble classifiers). It discusses signal denoising, QRS detection, feature extraction, and classifier performance on the PhysioNet 2017 dataset. There is no discussion of genetics, genotypes, drug responses, biomarkers, or any pharmacogenetic methods or implications, so it is not relevant to pharmacogenetics."
2afefcf3-99c4-4b44-a1f5-56825fb801d4,1,"72. Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ,  et al. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017; 136(14): 1276–83. DOI: https://doi.org/10.1161/CIRCULATIO NAHA.117.028845",3,1,Processed,"The study is an observational cohort evaluating plasma biomarkers (homocysteine and uric acid) for predicting subclinical atrial fibrillation in patients with cardiac implantable devices. It contains no genetic testing, genotyping, drug–gene interaction analyses, or any assessment of drug response by genotype — therefore it is not relevant to pharmacogenetic approaches."
0b1b5466-6d27-4ea4-9357-9ef7cfa90378,1,"73. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C,  et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).",3,1,Processed,"This is a comprehensive clinical guideline on atrial fibrillation diagnosis and management (anticoagulation, rate/rhythm control, ablation, screening, lifestyle, etc.). It does not review or assess pharmacogenetic approaches (no discussion of genotype-guided dosing, genetic testing, or pharmacogenomic recommendations), so pharmacogenetics is not a focus."
78230af3-9f2a-4f1d-b7f7-212dfbabbd62,1,"76. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrilla - tion: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investi - gation of Rhythm Management (AFFIRM) study. Am ",3,1,Processed,"The paper reports a clinical trial of early rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, clinical outcomes). It contains no assessment of genetic testing, pharmacogenomics, gene–drug interactions, genotypes, or related analyses. Thus it is not relevant to pharmacogenetic approaches."
deb24572-d9e5-4db0-91da-58b33818e127,1,"77. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH,  et al. Asympto - matic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot Gen - eral Registry. Am J Med . 2015; 128(5): 509–18.e2. DOI: ht",3,1,Processed,"The paper reports clinical registry data on asymptomatic vs symptomatic atrial fibrillation, focusing on demographics, comorbidities, treatments, and outcomes (anticoagulant use, cardioversion, mortality). It contains no discussion, data, or analysis of genetics, genotyping, gene–drug interactions, or genotype-guided (pharmacogenetic) approaches."
4039d9dc-414e-4fd0-b713-9c81fd973256,1,"78. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY,  et al. Pattern of atrial fibril - lation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol . 2013; 167(6): 2682–7. DOI: https://doi.org/10.1016/j.ijca",3,1,Processed,"The roadmap focuses on epidemiology, screening, digital technologies, anticoagulation access (VKA vs NOAC), health-system barriers, and implementation strategies for AF. It discusses INR monitoring, TTR and drug interactions but contains no substantive discussion or assessment of pharmacogenetic or pharmacogenomic approaches (e.g., genotyping to guide anticoagulant dosing). Therefore it is not relevant to pharmacogenetics."
4f2b1035-53f5-4d15-8c92-3b5f61841368,1,"80. Edwards SJ, Wakefield V, Jhita T, Kew K, Cain P, Marceniuk G.  Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. Health Technol Assess. 2020; 24(5): 1–184. DOI: https://do",3,1,Processed,"The article focuses on cryptogenic stroke, atrial fibrillation detection, and insertable cardiac monitors. It does not evaluate pharmacogenetic approaches (no discussion of drug–gene interactions, genotype‑guided anticoagulation, or pharmacogenomic testing). Although genomics is briefly mentioned in a general risk‑stratification context, the paper does not assess pharmacogenetics."
12bc1aaf-194e-48cb-9517-797ea1be2296,1,"83. Brasier N, Raichle CJ, Dörr M, Becke A, Nohturfft V, Weber S, et al. Detection of atrial fibrilla - tion with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019; 21(1): 41–7. DO",3,1,Processed,"The paper focuses on wearable heart rhythm recordings, AF detection, device data integration, AI, screening, and telemedicine. It contains no discussion of genetics, drug–gene interactions, genetic testing, or personalized drug response; pharmacogenetic approaches are not addressed."
1593cf6f-b0a5-46cd-a60b-052b17464f33,1,"84. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol . 2019; 74(19): 2365–75. DOI: https://doi.org/10.1016/j. jacc.2019.08.019",3,1,Processed,"This study evaluates PPG-based mobile/wearable screening for atrial fibrillation and subsequent app-based management (anticoagulation uptake, clinical pathways). It contains no discussion of genetics, genotyping, gene–drug interactions, or genotype-guided therapy—i.e., no pharmacogenetic methods or analyses—so it is not relevant to pharmacogenetics."
88f5b2d7-45d4-4bed-853d-35e9c0957d6e,1,"85. Castaneda D, Esparza A, Ghamari M, Soltanpur C, Nazeran H.  A review on wearable photop - lethysmography sensors and their potential future applications in health care. Int J Biosens Bioelectron. 2018; 4(4): 195–202. DOI: https://doi.org/10.15406/ijbs",3,1,Processed,"The manuscript is a review of wearable photoplethysmography (PPG) sensors, signal features (including second derivative/APG), motion-artifact mitigation, and applications for heart rate, vascular aging and respiration. It contains no discussion of genetics, genotyping, drug response, pharmacokinetics/pharmacodynamics, or personalized drug therapy — i.e., no pharmacogenetic content — so it is not relevant to pharmacogenetic approaches."
b600c77c-bbe5-4cba-9522-18d3c0c91f15,1,"89. Statista. Wearable user penetration rate in the United States, in 2017, by age; 2020.",3,1,Processed,"The paper is a systematic review and meta-analysis of smartwatch (PPG/ECG) diagnostic accuracy for detecting cardiac arrhythmias. It focuses on wearable sensors, algorithms, and screening/clinical implications, with no discussion of genetics, genotyping, drug response, or genotype-guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
6a2df441-91b8-45d1-a9f7-53fca2038364,1,90. National Institute for Health and Care Excellence (NICE). WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension; 2013: https://www.nice. org.uk/guidance/mtg13.,3,1,Processed,"The document focuses on atrial fibrillation screening and detection using Microlife blood pressure monitors, device accuracy, clinical trials, and NICE recommendations. It contains no discussion of genetics, drug–gene interactions, genotype-guided therapy, or any pharmacogenetic approaches."
5f8b62df-48df-4e0e-ae28-b8f9c3bbd0b9,1,"91.  Yan BP, Lai WHS, Chan CKY, Au ACK, Freedman B, Poh YC,  et al. High-Throughput, Contact-Free Detection of Atrial Fibrillation From Video With Deep Learning. JAMA Cardiol. 2020; 5(1): 105–7. DOI: https://doi.org/10.1001/jamacardio.2019.4004",3,1,Processed,"The article focuses on AI-enabled mobile health technologies for arrhythmia detection, monitoring, and management (wearables, PPG/ECG, AI algorithms, screening trials). It contains no discussion of pharmacogenetics, drug–gene interactions, genotype-guided therapy, or any molecular genetic testing for drug response. Therefore it is not relevant to pharmacogenetic approaches."
1e023ec6-552e-41ec-af3a-b564942a7243,1,"93. Behzadi A, Sepehri Shamloo A, Mouratis K, Hindricks G, Arya A, Bollmann A. Feasibility and Reliability of SmartWatch to Obtain 3-Lead Electrocardiogram Recordings. Sensors (Basel) . 2020; 20(18). DOI: https://doi.org/10.3390/s20185074",3,1,Processed,"The Roadmap focuses on epidemiology, screening, digital technologies, anticoagulation access (NOACs vs VKAs), and health-system implementation for AF. It does not evaluate or discuss pharmacogenetic approaches (e.g., genotype-guided dosing, CYP2C9/VKORC1, or genomic predictors of drug response); the only genetics mention concerns population differences in AF prevalence, not pharmacogenetics."
5ee287d0-c5a2-44d9-b82b-d2270d80c5dd,1,"94. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. J Am Coll Cardiol. 2018; 71(21): 2381–8. DOI: https://doi.org/10.1016/j.jacc.2018.03.003",3,1,Processed,"The paper evaluates a wearable ECG device (AMAZFIT) for arrhythmia detection in elderly patients, focusing on diagnostic accuracy (sensitivity, specificity) and device feasibility. It contains no discussion of genetics, gene–drug interactions, genotype-based dosing, biomarkers, or personalized pharmacotherapy—core topics of pharmacogenetics—so it is not relevant to pharmacogenetic approaches."
32754d3b-07c5-4792-a0a4-d076d7ab413e,1,"95. Gwynn J, Gwynne K, Rodrigues R, Thompson S, Bolton G, Dimitropoulos Y, et al. Atrial Fibrilla - tion in Indigenous Australians: A Multisite Screening Study Using a Single-Lead ECG Device in Aborigi - nal Primary Health Settings. Heart Lung Circ; 2020.",3,1,Processed,"The paper is a practical guide on digital devices for arrhythmia detection and management (ECG/PPG devices, screening, telemonitoring, data protection, athlete use, QT monitoring). It does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related approaches. Although antiarrhythmic drug initiation and QT monitoring are mentioned, no pharmacogenetic assessment or recommendations are presented."
db99a227-c250-4b82-81ae-d4c64c95605e,1,"96. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M.  Mass Screening for Untreated Atrial Fibrillation: The Strokestop Study. Circulation. 2015; 131(25): 2176–84. DOI: https:// doi.org/10.1161/CIRCULATIONAHA.114.014343",3,1,Processed,"The paper reports a randomized population screening trial for atrial fibrillation and clinical outcomes of screening and anticoagulant use. It does not discuss genetic testing, genotype-guided drug selection, gene–drug interactions, or any pharmacogenetic methods or findings. Therefore it is not relevant to pharmacogenetic approaches."
67a26445-b5d3-42f2-a51e-a28b7f122cde,1,"97. Diamantino AC, Nascimento BR, Beaton AZ, Nunes MCP, Oliveira KKB, Rabelo LC,  et al. Atrial fibrillation detection with a portable device during cardiovascular screening in primary care. Heart. 2020; 106(16): 1261–6. DOI: https://doi.org/10.1136/heart",3,1,Processed,"The article focuses on screening for subclinical atrial fibrillation in hemodialysis patients using a portable ECG device and reports prevalence and device diagnostic performance. It does not discuss genetic testing, gene–drug interactions, genotype-guided therapy, or any pharmacogenetic methods or findings; medication use is mentioned only descriptively."
56d8e4f3-100e-4d0e-ae58-38ecfbcfc6c6,1,"98. Silver LSA, Johnson C, Taylor K, Jiang J, Anderson M, Rainie L.  Mobile Connectivity in Emerging Economies Pew Research Center; 2019.",3,1,Processed,"The Roadmap focuses on epidemiology, screening, digital technologies, anticoagulation access (NOACs vs VKAs), clinical management, and health-system implementation for atrial fibrillation. It does not discuss genotype-guided therapy, genetic testing for drug response, pharmacogenetic dosing (e.g., CYP2C9/VKORC1 for warfarin), or any pharmacogenomic approaches. The only genetic mentions relate to familial risk/ancestry and AF epidemiology, not pharmacogenetics."
6cc41ef6-f697-4552-b891-1851dba232fd,1,99. Communications TGSfM. The Mobile Economy 2020; 2020.,3,1,Processed,"The paper is a global roadmap on atrial fibrillation focused on epidemiology, screening, digital technologies, anticoagulation access (including NOACs), health-system barriers, prevention, and implementation—particularly in LMICs. It does not discuss pharmacogenetic testing, gene-drug interactions (e.g., CYP2C9/VKORC1 and warfarin), or any pharmacogenetic-guided treatment strategies. Apart from brief mentions of genetic differences in AF risk, there is no assessment of pharmacogenetic approaches."
cd83a9da-be8c-4b01-8e42-48f55864ed50,1,"102. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ,  et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outc",3,1,Processed,"The paper focuses on artificial intelligence applications in cardiac electrophysiology (ECG/PPG analysis, imaging, wearable monitoring, mapping, virtual-heart modelling, ablation, and devices). It does not discuss pharmacogenetic approaches, drug–gene interactions, or pharmacogenomic-guided therapy; any drug-related mentions (e.g., dofetilide concentration) are about noninvasive monitoring, not genetics."
64b864ed-6fd6-447e-acac-8d2665e8b548,1,"103. Kashou AH, Rabinstein AA, Attia IZ, Asirvatham SJ, Gersh BJ, Friedman PA, et al. Recurrent cryp - togenic stroke: A potential role for an artificial intelligence-enabled electrocardiogram? HeartRhythm Case Rep. 2020; 6(4): 202–5. DOI: https://doi.org",3,1,Processed,"The paper (and its search hits) focus on deep learning and imaging modalities for coronary atherosclerosis (CT, CTA, IVUS, OCT, MRI) — diagnostic, segmentation, plaque characterization and prognostic imaging. There is no substantive discussion of pharmacogenetics, genotype–drug interactions, or genotype-guided therapy; only an isolated unrelated reference to pharmacogenomics in the broader search results. Therefore it is not relevant to pharmacogenetic approaches."
72b3d2c5-bbca-471c-80a4-cf5bc3fd70ae,1,"104. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med . 2018; 378(23): 2191–201. DOI: https://doi.org/10.1056/NEJMoa1802686",3,1,Processed,"The article evaluates clinical and economic outcomes of empiric anticoagulation (DOACs vs aspirin) in ESUS patients confirmed free of AF and models stroke/bleeding costs. It contains no discussion or analysis of pharmacogenetics, genotype-guided therapy, genetic markers, or related testing; therefore it is not relevant to pharmacogenetic approaches."
79d43fa2-39ed-4a6f-96cd-526ba74d57fc,1,"105. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for Pre - vention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019; 380(20): 1906–17. DOI: https://doi.org/10.1056/NEJMoa1813959",3,1,Processed,"The manuscript is a clinical/epidemiologic study of atrial cardiopathy biomarkers (PTFV1, NT‑proBNP, left atrial size) and prognosis in embolic stroke of undetermined source (ESUS). It focuses on imaging, ECG/biomarker findings and clinical outcomes, and discusses anticoagulation trials, but contains no investigation of genetic variation, genotype‑guided therapy, drug response differences, or any pharmacogenetic methods. Therefore it is not relevant to pharmacogenetic approaches."
10c7f24c-69e0-4128-aae4-95b8611d8788,1,"107. Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A,  et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017; 14(7): e55–e96. DOI: https://doi.org/10.1016/j.hr",3,1,Processed,"The document is a clinical guideline focused on ambulatory cardiac event monitoring (Holter, patch monitors, external and implantable loop recorders, mobile telemetry), indications, billing codes and evidence for arrhythmia detection and stroke workup. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or genotype-guided therapy, so it is not relevant to pharmacogenetic approaches."
68b270f6-c986-4a1b-9660-ae0755df6622,1,"108. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a Home- Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018; 320(2): 1",3,1,Processed,"The article focuses on digital health technologies for diabetes and metabolic disease (wearables, apps, continuous glucose monitoring, telemedicine, remote trials, education, etc.) and contains no discussion of genetic testing, pharmacogenomics, genotype-guided therapy, drug–gene interactions, or related concepts. Therefore it is not relevant to pharmacogenetic approaches."
b49fbf3e-f5a9-42db-9afc-261d9524ccde,1,"112. Chen Y, Huang QF, Sheng CS, Zhang W, Shao S, Wang D, et al. Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): A prospective multicenter study. PLoS Med . 2020; 17(7)",3,1,Processed,"This narrative review addresses contemporary oral anticoagulant use, prescribing patterns, adherence, policy and health-system barriers for atrial fibrillation in China. It contains no discussion of pharmacogenetic testing, genotype-guided dosing, genetic variants (e.g., VKORC1/CYP2C9) or other pharmacogenomic approaches, so it is not relevant to pharmacogenetics."
69cef605-bb18-4940-9a96-8bac23b05396,1,"113. Orchard J, Neubeck L, Freedman B, Li J, Webster R, Zwar N, et al. eHealth Tools to Provide Struc - tured Assistance for Atrial Fibrillation Screening, Management, and Guideline-Recommended Therapy in Metropolitan General Practice: The AF – SMART Stud",3,1,Processed,"The document is a compilation of clinical and technological studies about mobile ECG devices (AliveCor/Kardia) including AF detection, remote monitoring, screening, device accuracy, and algorithm/AI development. It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, or genotype-guided therapy. References to drug effects (e.g., QT-prolonging medications) focus on ECG monitoring rather than genetic predictors of drug response."
58115de2-3246-4f5f-93cf-c77cf30c2ae6,1,"115. Alkmim MB, Figueira RM, Marcolino MS, Cardoso CS, Pena de Abreu M, Cunha LR, et al. Improv - ing patient access to specialized health care: the Telehealth Network of Minas Gerais, Brazil. Bull World Health Organ. 2012; 90(5): 373–8. DOI: https://doi.",3,1,Processed,"The paper develops and validates a clinical risk score for 2-year mortality in Chagas cardiomyopathy using demographic, clinical, ECG, and NT-proBNP data. It does not include genetic testing, gene–drug interactions, or any pharmacogenetic analyses; mentions of treatment (e.g., benznidazole) are observational and not linked to genetic factors. Therefore it is not relevant to pharmacogenetics."
74def32f-2062-4ee4-89f3-9198c8d811e3,1,"116. Bunch TJ, Steinberg BA.  Revisiting Rate versus Rhythm Control in Atrial Fibrillation — Timing Matters. N Engl J Med; 2020. DOI: https://doi.org/10.1056/NEJMe2027180",3,1,Processed,"This is a narrative review of rhythm vs rate control in atrial fibrillation, focusing on catheter ablation, antiarrhythmic drugs, clinical trials (AFFIRM, CABANA, EAST‑AFNET4), and early intervention. It discusses therapies, outcomes, and procedural/clinical factors but contains no assessment of pharmacogenetic approaches, genotype‑guided therapy, or genetic testing."
3883d5c8-417c-4886-a192-af234ecd0eb6,1,"117. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med; 2020. DOI: https://doi.org/10.1056/NEJMoa2019422",3,1,Processed,"The article reports randomized trial subanalyses of early rhythm control vs usual care in atrial fibrillation, focusing on clinical outcomes, comorbidity burden (CHA2DS2‑VASc), and safety of therapies (drug toxicity, bradycardia, ablation complications). It contains no discussion, data, or assessment of pharmacogenetics, genetic testing, drug–gene interactions, or genotype‑guided therapy."
982af818-14e3-4166-8e00-b8dc344d802c,1,"119. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting Thromboem - bolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018; 118(12): 2171–87. DOI: https://d",3,1,Processed,"The paper is a clinician survey about interpretation and use of the CHA2DS2‑VASc stroke risk score in atrial fibrillation, focusing on components (C, H, V), guideline adherence, and referencing tools. It contains no discussion of genetics, genotyping, gene–drug interactions, or genotype‑guided therapy, and does not evaluate pharmacogenetic approaches."
b20143c7-59af-4d8f-b38e-ee11b0a5ddb8,1,"120. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014; 160(11): 760–73. DOI: https://doi.org/10.7326/M13",3,1,Processed,"The paper is a clinical review of the relationship between atrial fibrillation/atrial myopathy and stroke, discussing epidemiology, pathophysiology, biomarkers, and anticoagulation strategies. It contains no discussion of pharmacogenetics (e.g., genetic determinants of drug response, genotype-guided therapy, CYP/VKOR variants) or related methods, so it is not relevant to pharmacogenetic approaches."
5bea6d64-f14a-4a45-8a95-883ed264194b,1,"121. Tamariz LJ, Bass EB.  Pharmacological rate control of atrial fibrillation. Cardiol Clin . 2004; 22(1): 35–45. DOI: https://doi.org/10.1016/S0733-8651(03)00111-5",3,1,Processed,"The article is a global roadmap on atrial fibrillation focusing on epidemiology, screening, digital technologies, prevention, rate/rhythm control, anticoagulation (including NOACs), and health‑system implementation, especially for LMICs. It does not discuss pharmacogenetic approaches (e.g., genotype‑guided dosing, CYP/VKORC1 testing, or other pharmacogenomic strategies) beyond a brief mention of genetic differences in AF prevalence. Therefore it is not relevant to pharmacogenetics."
a3141410-1daf-449c-a267-d37222731cb6,1,"122. Nikolaidou T, Channer KS.  Chronic atrial fibrillation: A systematic review of medical heart rate control management. Postgrad Med J . 2009; 85(1004): 303–12. DOI: https://doi.org/10.1136/ pgmj.2008.068908",3,1,Processed,"The article is a global roadmap on atrial fibrillation focused on epidemiology, screening, digital technologies, anticoagulation access (NOACs vs VKAs), management strategies, and health‑system implementation—particularly for LMICs. It does not discuss pharmacogenetics, genotype‑guided dosing, or related testing/biomarkers. Thus it is not relevant to pharmacogenetic approaches."
d9e260ce-a943-4d1a-bd5f-867ec9156e83,1,"124. Mkoko P, Bahiru E, Ajijola OA, Bonny A, Chin A.  Cardiac arrhythmias in low- and middle-income countries. Cardiovasc Diagn Ther. 2020; 10(2): 350–60. DOI: https://doi.org/10.21037/cdt.2019.09.21",3,1,Processed,"The paper focuses entirely on cardiac monitoring strategies (timing, device modalities, cost-effectiveness, and a stepwise TIAS algorithm) to detect atrial fibrillation after stroke. It contains no discussion of genetics, genotype-guided therapy, pharmacogenetic testing, gene–drug interactions, or pharmacogenetic-based treatment decisions, so it is not relevant to pharmacogenetic approaches."
d5b238cd-b7fa-471f-b772-5664e2046fff,1,"125. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14(10): e275–e444.",3,1,Processed,"This is a surgical case report focused on thoracoscopic ablation for atrial fibrillation in a patient with a persistent left superior vena cava, including imaging, virtual reality planning, and operative technique. It contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized drug therapy; aside from a brief note that the AF was drug‑refractory, pharmacologic or genetic approaches are not assessed."
c9ece275-46e2-4051-bec0-bddbe7df1eea,1,"126. Middeldorp ME, Ariyaratnam J, Lau D, Sanders P.  Lifestyle modifications for treatment of atrial fibrillation. Heart. 2020; 106(5): 325–32. DOI: https://doi.org/10.1136/heartjnl-2019-315327",3,1,Processed,"The paper is a global roadmap on atrial fibrillation focusing on epidemiology, screening, digital technologies, prevention, and anticoagulation access (NOACs vs VKAs), with no discussion of pharmacogenetic or genotype-guided treatment approaches. Genetics is mentioned only as a risk factor for AF incidence, not in the context of pharmacogenetics or personalized drug dosing."
af623748-7a47-4af4-ba38-a21c696a7e82,1,"127. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,  et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)",3,1,Processed,"This is the 2020 ESC clinical guidelines for diagnosis and management of atrial fibrillation focusing on screening, anticoagulation strategies, rhythm/rate control, ablation, and allied clinical interventions. The provided text contains no evaluation or discussion of pharmacogenetic testing or genotype-guided therapy, so pharmacogenetics is not addressed."
895f6111-0cba-45a7-a207-6e268852c50b,1,"128. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B,  et al. A rand - omized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011; 5",3,1,Processed,"This 2012 ESC focused update on atrial fibrillation addresses clinical management (anticoagulation, NOACs, LAA closure, cardioversion, ablation, antiarrhythmic drugs, bleeding/stroke risk scores, etc.) but contains no discussion of pharmacogenetic testing, genotype-guided dosing, genetic predictors of drug response, or related terminology. Thus it is not relevant to pharmacogenetic approaches."
6e229dac-9243-4d06-a6ea-7927c6bb0ca2,1,"130. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T,  et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J. 2004; 25(15): 1318–24. DOI: https://doi.org/10.1016/j.ehj.2004",3,1,Processed,"The article reviews emergency management of atrial fibrillation (rate vs rhythm control, cardioversion, anticoagulation) and discusses specific drugs and clinical trials, but contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, or gene–drug interactions. Thus it is not relevant to pharmacogenetic approaches."
0493c5c5-06d0-4692-a9cd-7f80a9f3f318,1,"131. Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract. 2005; 59(12): 1395–400. DOI: https://doi.org/10.1111/j.1368-5031.2005.007",3,1,Processed,"This is a comprehensive clinical guideline on atrial fibrillation diagnosis and management (anticoagulation, rate/rhythm control, ablation, lifestyle, etc.). The excerpt contains no evaluation or discussion of pharmacogenetic approaches (e.g., genotype-guided dosing, genetic biomarkers, VKORC1/CYP2C9 testing for warfarin, or other pharmacogenomic strategies). Therefore it is not relevant to pharmacogenetics."
6fed3d17-eb22-4124-913c-72582314c2b0,1,"132. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S,  et al. Vernakalant hydrochlo - ride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circula - tion. 2008; 117(12): 1518–25. DOI: https://",3,1,Processed,"This ESC focused update on atrial fibrillation deals with clinical management (risk scores, anticoagulation with VKAs/NOACs, device therapies, cardioversion, ablation, antiarrhythmic drugs) and contains no discussion of pharmacogenetic testing, genotype-guided dosing, genetic biomarkers (e.g., CYP2C9/VKORC1) or related topics. Therefore it is not relevant to pharmacogenetic approaches."
54d9ef0e-f7b9-4103-9f83-63317d5d4410,1,"133. Conde D, Costabel JP, Caro M, Ferro A, Lambardi F, Corrales Barboza A,  et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013; 168(3): 2423–5. DOI: https://doi.org/10.1016/j.ijcard.2013.02.006",3,1,Processed,"This is a clinical guideline on diagnosis and management of atrial fibrillation focused on stroke prevention, anticoagulation strategies (VKAs and NOACs), rate/rhythm control, ablation, and integrated care. The provided excerpts discuss drug choices, dosing, bleeding risk scores, and VKA time-in-range but contain no evaluation of pharmacogenetic testing, genotype-guided dosing, or genetic biomarkers. Thus pharmacogenetic approaches are not assessed in this document."
d84c28ef-d720-40e4-8ad5-ddf1e8df6b42,1,"134. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C.  Comparison of intravenous flecainide, propafenone, and amiodarone for conver - sion of acute atrial fibrillation to sinus rhythm. Am J Cardiol . 2000",3,1,Processed,"This is the 2020 ESC clinical guideline for diagnosis and management of atrial fibrillation focused on clinical care (diagnosis, anticoagulation, ablation, cardioversion, risk scores, lifestyle, etc.). It does not evaluate or discuss pharmacogenetic testing or genotype-guided therapy (e.g., CYP2C9/VKORC1 for warfarin or other pharmacogenomic markers), so it is not relevant to pharmacogenetic approaches."
e4bb1337-f160-4869-9b91-014e03c081f2,1,"135. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P,  et al. ESC-EURObservational Research Programme: The Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace. 2012; 14(8): 1094–103. DOI",3,1,Processed,"This is the 2020 ESC clinical guideline on diagnosis and management of atrial fibrillation. It covers clinical assessment, anticoagulation, rhythm/rate control, ablation, and related topics but does not evaluate or focus on pharmacogenetic testing or genotype-guided drug therapy in the provided content."
848f9e3c-05e5-4785-8e7f-3cbeb0272756,1,"136. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P,  et al. The atrial fibrillation ablation pilot study: A European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm",3,1,Processed,"This is a broad clinical guideline on diagnosis and management of atrial fibrillation focusing on epidemiology, screening, anticoagulation, rate/rhythm control, ablation, and comorbidity management. It discusses drug choices and monitoring (e.g. VKAs vs NOACs) but contains no substantive assessment of pharmacogenetic approaches (genotype-guided dosing or genetic testing) as a diagnostic or therapeutic strategy. Therefore it is not relevant to pharmacogenetics."
d438d2a3-b594-4159-912a-a140561a6ca9,1,"137. Arbelo E, Brugada J, Blomstrom-Lundqvist C, Laroche C, Kautzner J, Pokushalov E,  et al. Con - temporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year fol - low-up findings from the ESC-EHRA atrial fibrillatio",3,1,Processed,"The Roadmap focuses on epidemiology, screening, digital technologies, prevention, anticoagulation access (NOACs), rate/rhythm control, and health-system strategies—primarily policy, clinical management, and technology. It does not assess pharmacogenetic or pharmacogenomic approaches (no discussion of genotype-guided dosing, CYP/VKORC1 testing, or similar), aside from a brief note on genetic differences in AF risk which is not pharmacogenetics."
99928522-554f-4725-a8b6-3e6d333a8556,1,"138. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L,  et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018; 20(1): 157–208. DOI: htt",3,1,Processed,"The 2020 ESC AF Guidelines focus on diagnosis and clinical management of atrial fibrillation (anticoagulation, rate/rhythm control, ablation, lifestyle, etc.). The document does not evaluate or discuss pharmacogenetic testing or genotype‑guided drug therapy (e.g., CYP2C9/VKORC1 for warfarin, CYP2C19 for antiplatelets), so it is not relevant to pharmacogenetic approaches."
d6a88761-7f32-46f7-90ed-fa05761998dc,1,"139. Hindricks G, Sepehri Shamloo A, Lenarczyk R, Kalarus Z, Arya A, Kircher S, et al. Catheter abla - tion of atrial fibrillation: Current status, techniques, outcomes and challenges. Kardiol Pol . 2018; 76(12): 1680–6. DOI: https://doi.org/10.5603/KP.a2",3,1,Processed,"This is the 2020 ESC clinical guideline on diagnosis and management of atrial fibrillation focusing on epidemiology, screening, anticoagulation, rate/rhythm control, ablation, and related clinical pathways. It contains no substantive discussion of pharmacogenetics, genotype-guided prescribing, or genetic testing for drug response, so it is not relevant to pharmacogenetic approaches."
0005833d-f1d0-4f73-b3c5-65766ce9cb6a,1,"140. Keegan R, Aguinaga L, Fenelon G, Uribe W, Rodriguez Diez G, Scanavacca M, et al. The first Latin American Catheter Ablation Registry. Europace. 2015; 17(5): 794–800. DOI: https://doi.org/10.1093/ europace/euu322",3,1,Processed,"The paper focuses on interventional electrophysiology and catheter ablation procedures, outcomes, and service delivery in South Africa. It contains no discussion of pharmacogenetics, genetic testing, drug-gene interactions, or personalized pharmacotherapy, so it is not relevant to pharmacogenetic approaches."
5c150eb4-fecb-4756-8aeb-3b2ff60992a4,1,"141. Keegan R, et al. Catheter ablation of atrial fibrillation in Latin America: Results of the first registry of the Latin American Society of Pacing and Electrophysiology Cardiac (SOLAECE). RevUrugCardiol. 2016; 31(1): 165–75.",3,1,Processed,"The Roadmap focuses on AF epidemiology, screening, digital technologies, management strategies (rate/rhythm control), and anticoagulation policy (NOACs vs VKAs) and health-system implementation—primarily public-health, clinical, and technological issues. It contains no discussion of pharmacogenetics, genotype‑guided dosing, genetic polymorphisms (e.g., CYP2C9/VKORC1), or genetic testing strategies, so pharmacogenetic approaches are not assessed."
28776b64-126d-4f20-a59a-9be3c62923e2,1,"142. Bonny A, Ngantcha M, Scholtz W, Chin A, Nel G, Anzouan-Kacou J-B,  et al. Cardiac Arrhythmias in Africa: Epidemiology, Management Challenges, and Perspectives. Journal of the American College of Cardiology. 2019; 73(1): 100–9. DOI: https://doi.org/10",3,1,Processed,"The article is a systematic review of the epidemiology, diagnosis and treatment infrastructure for cardiac arrhythmias in sub‑Saharan Africa. It discusses prevalence, devices, CPR, and availability/use of drugs (e.g., anticoagulants) and briefly cites some genetic findings (e.g., CACNA1C variant, long‑QT genetics) but contains no assessment of pharmacogenetic approaches, drug–gene interactions, or implementation of pharmacogenomics. Thus it is not relevant to pharmacogenetics."
dc3fa4c1-5ca5-433c-b8f0-554b465542ec,1,"145. Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P,  et al. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace: European pacing, arrhythmias, and cardiac electrophysiolo",3,1,Processed,"The article is a systematic review of the epidemiology, diagnosis and treatment infrastructure for cardiac arrhythmias in sub‑Saharan Africa. It focuses on prevalence, clinical management (CPR, devices, anticoagulation), service availability and barriers. It does not assess pharmacogenetic approaches; only incidental mentions of genetic variants and inherited arrhythmia syndromes appear, but there is no discussion of genetic influences on drug response or pharmacogenetic strategies."
b4d0a07c-dfe7-44db-a6b9-7d554f6760d2,1,146. Ettarh R.  Patterns of international collaboration in cardiovascular research in sub-Saharan Africa. Cardiovascular Journal of Africa . 2016; 27(3): 194. DOI: https://doi.org/10.5830/CVJA-2015- 082,3,1,Processed,"The Roadmap focuses on global detection, management, digital technologies, and anticoagulant access/implementation for atrial fibrillation. It discusses epidemiology, screening, NOACs vs VKAs, adherence, and health-system barriers, with only brief mentions of genetic differences in AF risk. There is no assessment of pharmacogenetic testing, genotype-guided therapy, or drug–gene interactions—so pharmacogenetics is not addressed."
2173020f-e67b-4efe-8f50-fba1a376c979,1,"147. Mkoko P, Bahiru E, Ajijola OA, Bonny A, Chin A.  Cardiac arrhythmias in low-and middle-income countries. Cardiovascular Diagnosis and Therapy . 2020; 10(2): 350. DOI: https://doi.org/10.21037/ cdt.2019.09.21",3,1,Processed,"The study is a retrospective clinical epidemiology analysis of demographic and clinical predictors (age, gender, smoking, BMI, hypertension, diabetes, CHD, thyroid disease, ejection fraction) of paroxysmal arrhythmias from ambulatory ECG records. It contains no genetic or pharmacogenetic data, no discussion of drug–gene interactions, genotyping, or personalized pharmacotherapy, so it is not relevant to pharmacogenetic approaches."
321b5a42-ecd3-4b8d-b179-6dddd2802d34,1,"148. Agyepong IA, Sewankambo N, Binagwaho A, Coll-Seck AM, Corrah T, Ezeh A,  et al. The path to longer and healthier lives for all Africans by 2030: The Lancet Commission on the future of health in sub-Saharan Africa. The Lancet. 2017; 390(10114): 2803–5",3,1,Processed,"The report is a broad Lancet Commission on health systems and public-health priorities in sub‑Saharan Africa (financing, UHC, commodity security, workforce, infectious and chronic disease control, innovation). It contains discussion of medicines, supply chains, diagnostics and vaccines but includes no discussion of pharmacogenetics, genetic testing, personalized drug response, or genotype‑guided therapy. Therefore it is not relevant to pharmacogenetic approaches."
dbac50f9-81ac-4550-96f5-992e5e70fd4b,1,149. The World Bank. Universal Health Coverage (UHC) in Africa: A Framework for Action: Main Report. The World Bank; 2016.,3,1,Processed,"The report focuses on antimicrobial resistance as a public‑health, agricultural and economic problem — surveillance, stewardship, policy, veterinary use, and financing. It does not discuss pharmacogenetics, personalized drug response testing, or use of human genetic markers to guide therapy. Any mention of microbial genetics is about resistance emergence/spread, not pharmacogenetic approaches to patient care."
8e7f8881-9719-43c3-bdb7-c81d1dfadd52,1,"151. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R,  et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol . 2013; 29(11): 1443–7. DOI: https://doi.org/10.1016/j. cjca.2013.06.015",3,1,Processed,"The article is a review of percutaneous and surgical left atrial appendage occlusion, covering devices, imaging, procedural techniques, and antithrombotic management. It does not discuss pharmacogenetics, genetic testing, genotype-guided therapy, or related personalized pharmacogenomic approaches. Mentions of anticoagulant classes (DOACs, VKA) and antithrombotic regimens are clinical/pharmacologic but not pharmacogenetic."
a994b054-2c64-4ca9-8d62-857a37031606,1,"152. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD.  Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: A meta-analysis. Eur J Cardiothorac Surg. 2015; 47(5): 847–54. DOI: https://doi.or",3,1,Processed,"The article focuses on imaging-based structural and functional assessment of the left atrial appendage in patients with mitral valve disease and atrial fibrillation (CT morphology, volumes, stasis/thrombus, surgical considerations). It contains no discussion of genetic variation, drug–gene interactions, genotype-guided therapy, or any pharmacogenetic analyses. Anticoagulant use is mentioned clinically but not in a pharmacogenetic context."
6c4f7cd3-d8b1-4be2-b727-4e9a7d5d34d7,1,"154. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B,  et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EW",3,1,Processed,"The review focuses on left atrial appendage anatomy, imaging, device-based occlusion strategies, procedural guidance and post‑procedural antithrombotic management. It contains no discussion of pharmacogenetics, genotype‑guided therapy, drug–gene interactions, or genetic testing. Therefore it is not relevant to pharmacogenetic approaches."
ad0a46a9-3d8e-46a7-84ee-3d98d8af1360,1,"156. Laing R, Waning B, Gray A, Ford N, Hoen E.  25 years of the WHO essential medicines lists: pro - gress and challenges. The Lancet . 2003; 361(9370): 1723–9. DOI: https://doi.org/10.1016/S0140- 6736(03)13375-2",3,1,Processed,"The paper evaluates geospatial access to basic surgical services and infrastructure across seven countries; it contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or personalized medicine. References to medications are about essential drug availability, not pharmacogenetic approaches."
8ec75a21-d859-4d2f-a128-fa09a5dd8d24,1,"157. Di Cesare M, Jarvis JD, Scarlatescu O, Leng X, Zaidel EJ, Burrone E, et al. NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions. Glob Heart. 2020; 15(1): 67. DOI: https://doi.org/10.5334/gh.774",3,1,Processed,"The paper is a qualitative health-systems assessment of barriers and facilitators to NOAC use in Nepal. It focuses on awareness, infrastructure, policy, cost, monitoring (INR), and training. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing, or related concepts, so it is not relevant to pharmacogenetic approaches."
042f281c-fba3-4bfe-b29b-4a95706a0720,1,"158. Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP.  A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018; 39(32): 2975–83. DOI: https://doi.org/10.",3,1,Processed,"This EHRA Practical Guide focuses on clinical use of NOACs in AF—eligibility, dosing, renal/hepatic function, drug–drug interactions, monitoring, bleeding and perioperative management. It discusses pharmacokinetics and P‑gp/CYP interactions but contains no assessment of pharmacogenetic or genotype‑guided approaches (no discussion of genotyping, CYP2C9/VKORC1, or other pharmacogenomic markers). Therefore it is not relevant to pharmacogenetics."
78b7c9bc-d6e9-4486-a827-a5dcd6434e7a,1,"159. Chao TF, Chiang CE, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Evolving Changes of the Use of Oral Anti- coagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. Circulation. 2018; 138(14): 1485–7. DOI: https://doi.org/10.1",3,1,Processed,"This is the 2020 ESC Guidelines for diagnosis and management of atrial fibrillation — a broad clinical guideline focusing on diagnosis, anticoagulation, rhythm/rate control, ablation, and management pathways. It contains no substantive assessment or recommendations on pharmacogenetic testing or genotype-guided therapy (e.g., warfarin/DOAC pharmacogenetics), beyond incidental references in literature. Thus pharmacogenetics is not a focus of the paper."
4922951a-99e0-4718-b221-ffaca80c060f,1,"160. Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GYH.  Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide populat",3,1,Processed,"The paper is an observational, population-based study of antithrombotic prescribing trends (VKAs, NOACs, aspirin) in Korean AF patients. It contains no discussion, data, or analyses related to genetics, genotype-guided therapy, pharmacogenetic markers (e.g., CYP2C9, VKORC1), or personalized dosing—therefore it is not relevant to pharmacogenetic approaches."
203e9301-fb76-4d09-a1d8-00a3cd698a1b,1,"161. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analy",3,1,Processed,"This RE-LY trial analysis examines clinical anticoagulation control (centre mean TTR) and compares dabigatran versus warfarin outcomes by quality of INR control. It does not assess genetic determinants of drug response, include genotyping, or evaluate pharmacogenetic dosing strategies (eg CYP2C9/VKORC1 effects on warfarin). Therefore it is not relevant to pharmacogenetic approaches."
1243d683-ca91-448f-a2fa-b56d88bfae49,1,"162. Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG.  Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International Reali - seAF Survey. Arch Cardiovasc Dis . 2014; 107(2): 77–87.",3,1,Processed,"The Roadmap focuses on global AF epidemiology, screening, digital technologies, anticoagulation policy/implementation (NOACs vs VKAs), rate/rhythm control and health-system barriers. It does not discuss pharmacogenetics, genotyping, CYP/VKORC1-guided dosing, or personalized drug-response testing — therefore it is not relevant to pharmacogenetic approaches."
f7b837d1-d190-400c-aef0-2756a34102fa,1,"164. Chang SS, Dong JZ, Ma CS, Du X, Wu JH, Tang RB,  et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke. 2016; 47(7): 1803–",3,1,Processed,"The paper describes a surgical thoracoscopic left atrial appendage excision for stroke prevention in nonvalvular AF patients. It focuses on operative technique, clinical outcomes, and anticoagulation management but contains no discussion of genetics, genetic testing, genotype-guided drug therapy, pharmacogenetic markers, or personalized pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
64c91b05-0eb0-4d1d-9b83-1ab0057a559d,1,"169. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G,  et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: Data from the ROCKET AF clinical trial. J Am Heart Assoc . 2013; 2(1): e0",3,1,Processed,"The paper analyzes clinical outcomes of rivaroxaban versus warfarin by center-level time in therapeutic range (cTTR). It focuses on anticoagulation quality, INR control, regional/practice factors, and clinical endpoints (stroke, bleeding). It does not discuss genetic variants, genotyping, CYP2C9/VKORC1, or any pharmacogenetic testing or analyses, so it is not relevant to pharmacogenetics."
969db17e-8090-4624-adf4-f36dda39fee6,1,"170. Lowres N, Freedman B.  Time to develop guidelines for screening and management of atrial fibril - lation in Indigenous Australians. Med J Aust . 2020; 212(5): 212–3. DOI: https://doi.org/10.5694/ mja2.50513",3,1,Processed,"The article is a global roadmap on atrial fibrillation focusing on epidemiology, screening, digital technologies, anticoagulation access (NOACs vs VKAs), health‑system barriers, and management strategies. It does not discuss pharmacogenetic testing, genotype‑guided dosing, or other pharmacogenetic approaches (only a brief mention of genetic differences in AF risk), so pharmacogenetics is not assessed."
49d06089-b6bd-4935-b820-020722fab39c,1,"171. Nedkoff L, Kelty EA, Hung J, Thompson SC, Katzenellenbogen JM.  Differences in stroke risk and cardiovascular mortality for Aboriginal and other Australian patients with atrial fibrillation. Med J Aust. 2020; 212(5): 215–21. DOI: https://doi.org/10.5",3,1,Processed,"The study is an epidemiologic analysis of stroke incidence and predictors in adults with congenital heart disease using administrative hospital data. It does not include genetic testing, drug–gene interaction analyses, personalized medicine, or any pharmacogenetic methods. Medications (eg, antithrombotics) are mentioned qualitatively, but no pharmacogenetic approaches are assessed."
35fedbb7-e3d0-428c-b215-950fa51be186,1,"173. Marcolino MS, Polanczyk CA, Bovendorp AC, Marques NS, Silva LA, Turquia CP, et al. Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: A cost- minimization analysis. Sao Paulo Med J . 2016; 134(4): 322–9. D",3,1,Processed,"The article evaluates economic and social costs and quality-of-life for warfarin versus DOACs in atrial fibrillation; it contains no discussion of pharmacogenetics, genetic testing, genotype-guided dosing (eg CYP2C9/VKORC1), or related methods. Therefore it is not relevant to pharmacogenetic approaches."
d7a86b0a-377a-4170-9b81-6786f444223b,1,"174. Deshpande CG, Kogut S, Laforge R, Willey C.  Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral antico - agulants. Curr Med Res Opin. 2018; 34(7): 1285–9",3,1,Processed,"The study examines persistence with oral anticoagulants (DOACs and VKAs), predictors (demographics, clinical and socioeconomic factors) and clinical outcomes; it contains no assessment of genetic factors, genotyping, pharmacogenetic-guided therapy, or mention of genetic polymorphisms relevant to anticoagulant dosing. Thus it is not relevant to pharmacogenetics."
a0f9ae4e-570d-4eba-9c41-a53ecae34db8,1,"175. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D,  et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016;",3,1,Processed,"The paper focuses on real-world medication adherence trajectories to direct oral anticoagulants in atrial fibrillation patients using EHR/pharmacy data and group-based trajectory modelling. There is no discussion of genetic testing, genotypes, pharmacogenetic markers, gene–drug interactions, or any pharmacogenetic approaches or analyses. Therefore it is not relevant to pharmacogenetics."
bc4cc426-714a-424b-a1a4-00976309f9d6,1,"176. Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN,  et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration. BMC Cardiovasc Disord . ",3,1,Processed,"The study is an observational pharmacoepidemiologic analysis of persistence with oral anticoagulation and associated clinical outcomes (DOACs vs VKAs) using administrative data. It contains no assessment of genetic testing, genotype–phenotype relationships, genotype-guided dosing, or any pharmacogenetic analyses or measures, so it is not relevant to pharmacogenetic approaches."
efcff3ab-6e60-40a6-b92a-19faff4a4333,1,"178. Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A. Comparison of Treatment Persistence with Da bi - gatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French Natio",3,1,Processed,"The Roadmap focuses on global AF burden, screening, digital technologies, anticoagulation access (NOACs vs VKAs), care models and health-system barriers. It does not discuss pharmacogenetic testing, genotype-guided dosing (e.g., warfarin CYP2C9/VKORC1), or other pharmacogenomic approaches, so relevance to pharmacogenetics is negligible."
77d5176b-067d-42ee-86d2-99d0454593c8,1,"179. Mueller T, Alvarez-Madrazo S, Robertson C, Bennie M. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiol Drug Saf. 2017; 26(11): 1378–86. DOI",3,1,Processed,"The paper reviews prescribing initiatives, managed entry of new medicines, antimicrobial stewardship, generics/biosimilars and polypharmacy in Scotland. It contains no discussion or assessment of pharmacogenetic testing, genotype-guided therapy, pharmacogenomic markers, or related precision-medicine approaches, so it is not relevant to pharmacogenetics."
e50b70b7-9377-4506-b8e4-3ff213bf53c9,1,"181. Emren SV, Senoz O, Bilgin M, Beton O, Aslan A, Taskin U,  et al. Drug Adherence in Patients with Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC- TR. Clin Appl Thromb Hemost. 2018; 24(3): 525–31. DO",3,1,Processed,"The study examines real-world adherence and persistence to oral anticoagulants in patients with atrial fibrillation using claims data. It contains no genetic or genomic data, no discussion of gene–drug interactions, pharmacogenomic biomarkers (e.g., CYP2C9, VKORC1), genotype-guided dosing, or any pharmacogenetic methods or outcomes. Thus it is not relevant to pharmacogenetic approaches."
8a648a8a-fe21-4eaa-aed3-0fcf209644d1,1,"183. Harper P, Pollock D, Stephens M. Dabigatran persistence and adherence in New Zealand: a nation - wide retrospective observational study. BMJ Open. 2018; 8(4): e020212. DOI: https://doi.org/10.1136/ bmjopen-2017-020212",3,1,Processed,"Die Dissertation beschäftigt sich mit Prädiktion und Prävention medikationsassoziierter Ereignisse anhand von Sekundärdaten (Abrechnungsdaten), Adhärenz, STOPP/START-Kriterien und statistischen Vorhersagemodellen. Es finden sich keinerlei Hinweise auf Genetik, Genotypisierung, pharmakogenetische Marker oder -Analysen. Daher ist sie in Bezug auf pharmakogenetische Ansätze nicht relevant."
12f1ee4a-719f-4dbe-9257-7e508af2f002,1,"184. Reading SR, Black MH, Singer DE, Go AS, Fang MC, Udaltsova N, et al. Risk factors for medica - tion non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord . 2019; 19(1): 38. DOI: https://doi.org/10.1186/s12872-019-1019-1",3,1,Processed,"The study is a multicenter cross-sectional survey of medication adherence, multimorbidity, polypharmacy, and potentially inappropriate medication use in older adults; it contains no assessment, discussion, or measurement of pharmacogenetic or pharmacogenomic approaches (no genetic testing, genotype-guided therapy, CYP/metabolism analyses, or related concepts)."
5cb206d5-e0d0-4078-a82a-639f0507221b,1,"186. Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C,  et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: Results from the REPOSI study. Eur J Intern Med. 2011; 22(6): 597–602. DOI: https",3,1,Processed,"The article investigates prevalence and risk factors of polypharmacy in medical outpatients (age, education, disease load, number of prescribers, specific chronic diseases). It contains no discussion of genetics, pharmacogenetics, gene–drug interactions, genetic testing, or personalized medicine approaches, so it is not relevant to pharmacogenetic assessment."
4be58886-e027-4875-9c79-913da3114d1e,1,"187. Noseworthy PA, Brito JP, Kunneman M, Hargraves IG, Zeballos-Palacios C, Montori VM,  et al. Shared decision-making in atrial fibrillation: Navigating complex issues in partnership with the patient. J Interv Card Electrophysiol; 2018. DOI: https://doi",3,1,Processed,"This is a broad clinical guideline on atrial fibrillation covering comorbidity management, anticoagulation, rate/rhythm control, ablation, screening and implementation. It contains no substantive evaluation or recommendations on pharmacogenetic testing or genotype-guided prescribing (e.g., no discussion of VKORC1/CYP2C9-guided warfarin dosing or other pharmacogenetic approaches). Any mentions of genomics/GWAS are background research, not pharmacogenetic assessment."
0026762d-edf7-4dac-a81b-934db64515b2,1,"188. Pritchett RV, Bem D, Turner GM, Thomas GN, Clarke JL, Fellows R, et al. Improving the Prescrip - tion of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2019; 119(2): 294–307. DOI: https://doi.org/10.1055/s-0038-16768",3,1,Processed,"The review focuses on interventions (education, guidelines, decision support, audits, multidisciplinary programs) to improve clinicians’ prescribing of oral anticoagulants in atrial fibrillation. It contains no assessment or discussion of pharmacogenetic approaches (genotyping, CYP2C9/VKORC1-guided dosing, pharmacogenomic testing), so pharmacogenetics is not relevant to this paper."
d2b480bc-3a2c-499e-b51a-8e86f5c69389,1,"190. Lowres N, Giskes K, Freedman B.  Next frontier for stroke prevention in atrial fibrillation: Ensuring anticoagulant persistence. Heart; 2020. DOI: https://doi.org/10.1136/heartjnl-2020-318392",3,1,Processed,"The article is a broad roadmap on atrial fibrillation focusing on epidemiology, prevention, screening, digital technologies, anticoagulation uptake, and health-system barriers. It does not discuss pharmacogenetic testing, genotype-guided prescribing (eg CYP2C9/VKORC1 for warfarin), or other personalized pharmacogenetic approaches beyond a brief mention of genetic differences in AF prevalence. Therefore it is not relevant to pharmacogenetic approaches."
6d255ce8-a2a0-4764-ba89-1671055cdffa,1,191. Nutbeam D. The evolving concept of health literacy. Soc Sci Med. 2008; 67(12): 2072–8. DOI: https:// doi.org/10.1016/j.socscimed.2008.09.050,3,1,Processed,"The paper focuses on public health data dashboards, overdose surveillance, community partnerships, and data literacy (PreventOverdoseRI, VILLAGE, PROVIDENT). It discusses mapping, predictive analytics at the neighborhood level, and communication/engagement strategies, but contains no discussion of pharmacogenetics, genetic testing, drug–gene interactions, or individualized genomic approaches to drug response."
1f71f366-5063-4e67-b30d-06f16eb4cd92,1,"192. Lane DA, Meyerhoff J, Rohner U, Lip GYH. Atrial fibrillation patient preferences for oral anticoagu - lation and stroke knowledge: Results of a conjoint analysis. Clin Cardiol. 2018; 41(6): 855–61. DOI: https://doi.org/10.1002/clc.22971",3,1,Processed,"This ESC 2020 guideline on atrial fibrillation is a broad clinical management document (diagnosis, anticoagulation, rhythm/rate control, ablation, surgery, screening, lifestyle, etc.) and does not assess or focus on pharmacogenetic approaches. While it discusses anticoagulants (VKAs and NOACs), bleeding/stroke risk scores, and therapeutic monitoring (e.g. TTR for warfarin), it contains no substantive evaluation of genetic testing for drug selection or dosing, nor recommendations about genotype-guided therapy. Therefore pharmacogenetics is not relevant to this paper."
7b3c3c35-ed0a-491b-8091-cd31c264664c,1,"194. Amara W, Larsen TB, Sciaraffia E, Hernández Madrid A, Chen J, Estner H, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Hea",3,1,Processed,"The Roadmap focuses on epidemiology, screening, digital technologies, clinical management (rate/rhythm control), anticoagulation access (NOACs vs VKAs), health systems and implementation in LMICs. It contains only a brief note that genetic differences affect AF occurrence but contains no evaluation of pharmacogenetic approaches (e.g., genotype-guided dosing, CYP/VKORC1 testing, or pharmacogenomic implementation). Therefore it does not assess pharmacogenetics."
77ab0302-e97c-490b-8aa6-63929a1f0400,1,"195. Seligman WH, Das-Gupta Z, Jobi-Odeneye AO, Arbelo E, Banerjee A, Bollmann A,  et al. Devel - opment of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcom",3,1,Processed,"The Roadmap focuses on global AF burden, screening, digital technologies, anticoagulation access (NOACs vs VKAs), service delivery and education. It does not discuss pharmacogenetics (e.g., genotype-guided dosing, CYP/VKORC1 variants, or pharmacogenomic implementation), so it is not relevant to pharmacogenetic approaches."
39111084-e380-4dae-b320-a383b559a1a8,1,"196. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace; 2020.",3,1,Processed,"The thesis focuses on cardiovascular clinical registries, data standards, and quality indicators (EuroHeart initiative) and discusses registry methodology, quality measurement and implementation. It contains no discussion of pharmacogenetics, genetic testing, gene–drug interactions, or related concepts, so it is not relevant to pharmacogenetic approaches."
a64f827d-f19e-4ff0-a6d4-bb32a9c3019b,1,"197. Smet L, Heggermont WA, Goossens E, Eeckloo K, Vander Stichele R, De Potter T,  et al. Adher - ence, knowledge, and perception about oral anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after radiofrequency a",3,1,Processed,"The paper is a broad roadmap on atrial fibrillation covering epidemiology, screening, digital technologies, anticoagulation (NOACs vs VKAs), and health-system implementation, but it contains no discussion or assessment of pharmacogenetic approaches (e.g., genotyping, CYP2C9/VKORC1-guided dosing, or personalized pharmacogenomic strategies). Therefore it is not relevant to pharmacogenetics."
6d429252-30ad-4da0-930e-19835ce945eb,1,"200. Marquez-Contreras E, Martell-Claros N, Marquez-Rivero S, Hermida-Campa E, Gracia-Diez C, Sanchez-Lopez E,  et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: Education and dru",3,1,Processed,"The document is a comprehensive white paper on therapeutic adherence (behavioral, organizational, educational and economic aspects) with no discussion of pharmacogenetics. Chapters and recommendations focus on adherence measurement, patient education, SPD, multidisciplinary care and digital tools; while direct drug/biomarker measurements are briefly mentioned, there is no reference to genotyping, pharmacogenetic-guided prescribing, or related personalized genetic approaches."
5e26e297-7a37-45f7-b65c-b230add03d67,1,"201. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, et al. A multifaceted interven - tion to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): An international, cluster-randomised trial. The Lancet . 2017; ",3,1,Processed,"This ESC 2020 atrial fibrillation guideline focuses on clinical diagnosis and management (anticoagulation, rate/rhythm control, ablation, screening, lifestyle, etc.) and does not evaluate or discuss pharmacogenetic approaches or genotype-guided therapy."
aff2090a-59d2-4e75-8491-133220d1c723,1,"202. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol . 2020; 75(13): 1523–34. DOI: https://doi. org/10.1016/j.jacc.2020.01.052",3,1,Processed,"The article focuses on community screening for atrial fibrillation (devices, screening strategies, guidelines, AI, biomarkers and polygenic risk scores for risk prediction). It does not assess pharmacogenetic approaches (no discussion of genotype-guided drug therapy, drug metabolism genes, or pharmacogenomic implementation)."
7f669893-0188-4ffc-85f2-5bda25255282,1,"204. Stephan LS, Almeida ED, Guimaraes RB, Ley AG, Mathias RG, Assis MV, et al. Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making. Arq Bras Cardiol. 2018; 110(1): 7–15.",3,1,Processed,"The issue contents and the quoted articles focus on clinical cardiology topics (device readmissions, arrhythmia, stents vs CABG, effects of aromatase inhibitors, exercise, kidney disease in diabetes, etc.) and procedural/epidemiologic/biomarker assessments. There is no mention of genetics, genotyping, gene–drug interactions, or genotype-guided therapy; therefore it does not assess pharmacogenetic approaches."
ad745d5c-5c40-414e-81af-471ce3a5ba1a,1,"205. Rolls CA, Obamiro KO, Chalmers L, Bereznicki LRE.  The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation. Cardiovasc Ther. 2017; 35(6). DOI: h",3,1,Processed,"The article is a global public-health roadmap on atrial fibrillation focusing on screening, digital technologies, anticoagulation access (NOACs), care pathways and health-system barriers. It mentions genetics only in the context of AF epidemiology/risk, but contains no evaluation or discussion of pharmacogenetic approaches (e.g., genotype-guided drug dosing or pharmacogenomic testing), so pharmacogenetics is not assessed."
251c251d-3051-41a5-b5f9-ba099330079e,1,"206. Heidbuchel H, Dagres N, Antz M, Kuck K-H, Lazure P, Murray S,  et al. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: A European Society of Cardiology internat",3,1,Processed,"This is a comprehensive clinical guideline on atrial fibrillation management (diagnosis, anticoagulation, rate/rhythm control, ablation, comorbidity/risk-factor management and screening). It contains no substantive assessment of pharmacogenetic approaches, gene-guided prescribing, or routine genetic testing to guide therapy; genomics is only mentioned peripherally in epidemiology/references. Therefore it is not relevant to pharmacogenetics."
c45a17d9-3e8b-4747-ac11-6dfcf84e1553,1,"208. Orchard JJ, Neubeck L, Orchard JW, Puranik R, Raju H, Freedman B,  et al. ECG-based car - diac screening programs: Legal, ethical, and logistical considerations. Heart Rhythm . 2019; 16(10): 1584–91. DOI: https://doi.org/10.1016/j.hrthm.2019.03.025",3,1,Processed,"The paper evaluates a smartphone-based 12-lead ECG device for detecting cardiac rhythm abnormalities. It focuses on device accuracy, sensitivity, specificity, and clinical screening, with no mention of genetics, pharmacogenomics, drug–gene interactions, or individualized drug response. Therefore it is not relevant to pharmacogenetic approaches."
8576b0b7-d406-4660-9159-512d9b1c8bcf,1,"209. Zhang L, Gallagher R, Neubeck L.  Health-related quality of life in atrial fibrillation patients over 65 years: a review. Eur J Prev Cardiol . 2015; 22(8): 987–1002. DOI: https://doi.org/10.1177/2047487314538855",3,1,Processed,"This is a clinical guideline on diagnosis and management of atrial fibrillation (anticoagulation, rate/rhythm control, ablation, screening, etc.). It contains no evaluation of pharmacogenetic testing or pharmacogenetic-guided therapy (e.g., warfarin genotyping, CYP/VKORC1 discussion), so pharmacogenetics is not assessed."
8d1b5aec-2a0e-4339-9efa-9c9bc0f8ba1a,1,"210. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,  et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1–e88.",3,1,Processed,"This is the 2020 ESC clinical practice guidelines for diagnosis and management of atrial fibrillation focusing on clinical assessment, anticoagulation strategies, rhythm/rate control, ablation, and comorbidity management. The document does not evaluate or emphasize pharmacogenetic approaches (no discussion of genetic testing for drug dosing or gene–drug interactions), so pharmacogenetics is not relevant to the paper."
12aa8ba4-c0d6-4c37-ac67-db5d5e3d671c,1,211. Kirchhof P. The future of atrial fibrillation management: Integrated care and stratified therapy. The Lancet. 2017; 390(10105): 1873–87. DOI: https://doi.org/10.1016/S0140-6736(17)31072-3,3,1,Processed,"The article is a global roadmap on atrial fibrillation focusing on epidemiology, screening, digital technologies, and anticoagulation access/implementation (NOACs vs VKAs, INR monitoring, adherence). It does not discuss pharmacogenetic testing, genotype-guided dosing (eg CYP2C9/VKORC1), or other pharmacogenetic approaches."
09f9de88-b568-4c43-8a4b-3d7efedc41e6,1,"212. Pastori D, Menichelli D, Violi F, Pignatelli P, G YHL. The Atrial fibrillation Better Care (ABC) path - way and cardiac complications in atrial fibrillation: A potential sex-based difference. The ATHERO-AF study. Eur J Intern Med; 2020. DOI: https://",3,1,Processed,"The paper is an observational clinical outcomes registry of AF patients with/without CAD focusing on antithrombotic treatment patterns and 1‑year clinical events. It contains no discussion of genetics, genetic testing, polymorphisms, drug–gene interactions, or pharmacogenetic-guided therapy, so it is not relevant to pharmacogenetics."
2a8df4a3-c900-4281-b1e4-205c29589a2d,1,"213. Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016; 388(10050): 1161–9. DOI: https://doi.org/10.10",3,1,Processed,"The study is an international registry of atrial fibrillation outcomes and regional variations in clinical care (stroke, death, heart‑failure admissions, anticoagulant use, blood‑pressure control). It contains no genetic testing, genotype–phenotype analyses, drug–gene interactions, or discussion of pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
a40d4abd-77e5-4e7d-8c47-0560cc431b40,1,"214. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD,  et al. 50 year trends in atrial fibril - lation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. The Lancet. 2015; 386(9989): 154–62. DOI:",3,1,Processed,"The review focuses on the clinical association and mechanistic (electrical, structural, autonomic) links between diabetes mellitus and atrial fibrillation, animal models, and general therapeutic observations (insulin, thiazolidinediones). It contains no discussion of genetics, genetic markers, drug–gene interactions, or pharmacogenetic study designs. Thus it is not relevant to pharmacogenetic approaches."
7e860121-5d70-4116-9ee5-a5ac2451abaa,1,"215. Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, et al. Atrial flutter: Clinical risk fac - tors and adverse outcomes in the Framingham Heart Study. Heart Rhythm. 2016; 13(1): 233–40. DOI: https://doi.org/10.1016/j.hrthm.2015.07.031",3,1,Processed,"This is an observational cohort study comparing clinical outcomes (ischemic stroke, heart failure, mortality) between atrial fibrillation and atrial flutter using administrative claims data. It does not include any genetic data, genotyping, drug–gene interactions, or analyses of differential drug responses by genotype. Medications are considered as covariates, but no pharmacogenetic approaches are assessed."
fc58d241-46fc-45da-a90b-eb63235ce857,1,"216. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA,  et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020; 141(16): e750–e",3,1,Processed,"This AHA scientific statement focuses on clinical management of acute atrial fibrillation in hospitalized patients (substrates/triggers, rate/rhythm control, anticoagulation, monitoring, perioperative care). Although it discusses pharmacologic agents and anticoagulant choices, it contains no discussion of pharmacogenetic testing, genotype-guided therapy, genetic markers, or personalized pharmacogenomic dosing—so it is not relevant to pharmacogenetic approaches."
7101e5b8-3c9e-4a07-8e39-fc0fd9156c8e,1,"217. Wong JA, Conen D, Van Gelder IC, McIntyre WF, Crijns HJ, Wang J,  et al. Progression of Device- Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. J Am Coll Cardiol. 2018; 71(23): 2603–11. DOI: https://doi.org/10.1016/j.jacc.2018",3,1,Processed,"This AHA scientific statement focuses on clinical management of acute atrial fibrillation (triggers, rate/rhythm control, anticoagulation, monitoring, perioperative care) and does not discuss pharmacogenetics, genotyping, genetic predictors of drug response, or genotype-guided therapy."
7f25bab4-f068-4cc6-91e1-0f4757047909,1,"218. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL,  et al. Rhythm control versus rate con - trol for atrial fibrillation and heart failure. N Engl J Med . 2008; 358(25): 2667–77. DOI: https://doi. org/10.1056/NEJMoa0708789",3,1,Processed,"The article is a narrative review of invasive rhythm-control strategies for atrial fibrillation (catheter ablation modalities, energy sources, procedural techniques). It does not discuss pharmacogenetics, genetic testing, genotype-guided drug therapy, or drug–gene interactions. Although antiarrhythmic drugs are mentioned, no pharmacogenetic approaches are assessed."
e54c3f53-41dc-4fc9-91ac-3ed28a0d06c4,1,"219. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L,  et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med . 2018; 378(5): 417–27. DOI: https:// doi.org/10.1056/NEJMoa1707855",3,1,Processed,"The article is a multicenter prospective registry of catheter ablation outcomes for atrial fibrillation, focusing on procedural techniques, clinical predictors of arrhythmia recurrence, and safety. It does not discuss genetic testing, genotype-guided therapy, pharmacogenomic markers, or any pharmacogenetic approaches. Mentions of drug therapy (amiodarone, beta‑blockers, DOACs/warfarin) are routine clinical treatments, not linked to pharmacogenetics."
fd91f323-b278-4e21-87f1-05252d8cc967,1,"220. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipol",3,1,Processed,"This is a general clinical guideline on diagnosis and management of atrial fibrillation covering screening, anticoagulation, rate/rhythm control, ablation, and comorbidity management. It does not evaluate or focus on pharmacogenetic approaches; at most there are isolated literature citations that mention genetic factors, but no assessment or recommendations on pharmacogenetics."
56aa4d46-fc3a-4131-96ef-1c3b711a3732,1,"221. Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G,  et al. Relationships of Overt and Silent Brain Lesions with Cognitive Function in Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019; 73(9): 989–99. DOI: https://doi.org/10.1016",3,1,Processed,"This is a comprehensive 2020 ESC guideline on atrial fibrillation covering diagnosis, integrated management, anticoagulation, rhythm/rate control, ablation, and peri‑procedural care. The provided excerpt contains no discussion of pharmacogenetic testing, genotyping, gene–drug interactions, or personalized drug selection based on genetic markers (e.g., CYP2C9/VKORC1). Therefore it is not relevant to pharmacogenetic approaches."
1f5f3b5a-e2e1-4d22-81e3-a39f204627e8,1,"223. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clini - cal Atrial Fibrillation (ARTESiA) trial. Am Heart J. 20",3,1,Processed,"The paper reports a prospective clinical study of arrhythmias after TAVI using implantable cardiac monitors. It focuses on electrophysiologic outcomes (AF, AV block, VT, pacemaker implantation), device monitoring, and clinical predictors (e.g., left atrial volume), with no mention of genetics, genotyping, drug–gene interactions, or pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
6dcb5563-a096-4628-9f95-d2eb5743c7b9,1,"224. Rivard L, Khairy P, Talajic M, Tardif JC, Nattel S, Bherer L,  et al. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Can J Cardiol. 2019; 35(",3,1,Processed,"This is a broad clinical guideline on atrial fibrillation management (diagnosis, anticoagulation, rhythm/rate control, comorbidity management, screening, procedures). It does not evaluate or focus on pharmacogenetic approaches (no discussion of genotype-guided prescribing, pharmacogenetic testing, or gene–drug interactions). Any mention of genomics or biomarkers is incidental and not an assessment of pharmacogenetics."
af20c2d3-1440-48b0-964a-e3085fb88c52,1,"225. Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B,  et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol. 2012; 67(3): 273–8. DOI: https://doi.o",3,1,Processed,"This EHRA practical guide focuses on digital devices for detection, monitoring, and management of arrhythmias (ECG/PPG devices, screening, telemanagement, athlete use, GDPR). It discusses drug monitoring (QTc) and inherited arrhythmia syndromes but contains no assessment of pharmacogenetic approaches or the use of genetic information to guide drug therapy."
071e8dee-0d5e-460c-9d62-2283426453c0,1,"226. Zhou Z, Hu D. An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China. J Epidemiol. 2008; 18(5): 209–16. DOI: https://doi.org/10.2188/jea. JE2008021",3,1,Processed,"The Roadmap focuses on global atrial fibrillation prevention, detection, digital technologies, and anticoagulation access (NOACs vs VKAs), but contains no evaluation of pharmacogenetic methods (e.g., genotype-guided dosing, CYP/VKORC1 variants, or pharmacogenomic testing). It only briefly notes genetic differences in AF prevalence, not pharmacogenetic approaches to therapy."
b90c542a-1ea7-44e9-8ac5-053238ac2e6e,1,"227. Wang Z, Chen Z, Wang X, Zhang L, Li S, Tian Y, et al. The Disease Burden of Atrial Fibrillation in China from a National Cross-sectional Survey. Am J Cardiol . 2018; 122(5): 793–8. DOI: https://doi. org/10.1016/j.amjcard.2018.05.015",3,1,Processed,"The article studies environmental determinants (air pollution, temperature, wind, AQI) and their association with atrial fibrillation incidence using epidemiologic and logistic regression methods. It contains no discussion of genetics, drug response, gene–drug interactions, or any pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
25c3c1dd-1c8c-4d7d-9970-5aa14b06d0d1,1,"228. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R,  et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial. BMJ (Clinical research ed) . 2007; 335(7",3,1,Processed,"The paper focuses on feasibility of population screening for paroxysmal atrial fibrillation using hand-held ECG devices, comparing remote vs practice-based delivery, uptake, ECG quality, AF detection rates and anticoagulation initiation. It contains no discussion of genetics, genetic testing, genotype-guided therapy, or pharmacogenetic approaches."
5ee23d71-a5c0-469d-969d-8a68cbcff35c,1,"229. Davis RC, Hobbs FDR, Kenkre JE, Roalfe AK, Iles R, Lip GYH, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. EP Europace. 2012; 14(11): 1553–9. DOI: https://doi.org/10.1093/europace/eus087",3,1,Processed,"The report focuses on screening strategies, diagnostic test accuracy and cost-effectiveness for atrial fibrillation (ECG, pulse palpation, photoplethysmography, BP monitors, screening formats and anticoagulant use). It contains no evaluation of pharmacogenetic testing, genotype-guided therapy, or genetic biomarkers—so it is not relevant to pharmacogenetics."
8676c242-6013-4a1f-986a-f8672e2cd206,1,"230. Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: Its prevalence and risk factor profile in the German general population. Deutsches Ärzteblatt International . 2012; 109(16): 293. DOI: https://doi.org/10.3238/arztebl.2012.0",3,1,Processed,"The report focuses on screening strategies, detection methods, epidemiology, and management (anticoagulation) of atrial fibrillation. It contains no discussion of genetic testing, genotype-guided drug selection, or pharmacogenetic approaches to therapy, so it is not relevant to pharmacogenetics."
f94ead7b-5f70-4456-8d41-1ac3045e177c,1,"231. Bilato C, Corti M-C, Baggio G, Rampazzo D, Cutolo A, Iliceto S, et al. Prevalence, Functional Impact, and Mortality of Atrial Fibrillation in an Older Italian Population (from the Pro.V.A. Study). Am J Cardiol . 2009; 104(8): 1092–7. DOI: https://doi",3,1,Processed,"This EU Risk Management Plan for rivaroxaban focuses on indications, dosing, safety, pharmacovigilance and post‑authorisation studies. It contains no evaluation of genetic markers, genotype‑guided dosing, pharmacogenomic analyses, or other pharmacogenetic approaches (only mentions pharmacokinetic interactions like CYP3A4/P‑gp inhibitors), so it is not relevant to pharmacogenetics."
3f722543-6c42-4bae-bd4c-0529a1e8810f,1,"232. Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, et al. Prevalence of atrial fibril - lation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: The FAI Project. Europace. 2019; 2",3,1,Processed,"The paper focuses on non-invasive ECG-based modeling of AV-nodal refractory period and conduction delay and on correlating electrophysiological variability with response to rate-control drugs. It does not include genetic data, genetic predictors, genotyping, or analyses of genotype–drug response relationships, so it is not a pharmacogenetics study."
29751d76-61e7-40f7-8335-e362a95dc979,1,234. Monteiro P. The SAFIRA study: A reflection on the prevalence and treatment patterns of atrial fibrilla - tion and cardiovascular risk factors in 7500 elderly subjects. Revista Portuguesa de Cardiologia (English edition). 2018; 37(4): 307–13. DOI: htt,3,1,Processed,"The roadmap focuses on epidemiology, screening, digital technology, prevention, and anticoagulation management for atrial fibrillation; it does not assess pharmacogenetic approaches (no discussion of genotype-guided drug therapy, warfarin/CYP2C9–VKORC1 testing, or pharmacogenomic implementation). The only related mention is brief note of genetic differences in AF prevalence, not pharmacogenetics."
a6c840fa-be47-450f-ad11-2b6f42720cd7,1,"235. Gómez-Doblas JJ, Muñiz J, Martin JJA, Rodríguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of Atrial Fibrillation in Spain. OFRECE Study Results. Revista Española de Cardiología (English Edition). 2014; 67(4): 259–69. DOI: https://doi.org/10.1016",3,1,Processed,"The RMP is focused on safety, pharmacovigilance, epidemiology, and risk minimisation for dabigatran (bleeding risk, renal function, paediatric data, PV studies, educational materials). It contains no discussion of genetic factors, pharmacogenetic testing, gene–drug interactions, or assessment of genetic influences on efficacy/toxicity, so it is not relevant to pharmacogenetic approaches."
add62c4a-2071-4cf6-a985-09c60d4b08c7,1,"237. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M.  Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population. Circulation. 2013; 127(8): 930–7. DOI: https://doi.org/10.1161/CIRCULATIO NAHA.112.126656",3,1,Processed,"The study is a randomized trial of remote ECG screening for atrial fibrillation, focusing on detection rates, device use, patient experience, clinical events, and costs. It contains no discussion of genetics, genotyping, drug-gene interactions, or any pharmacogenetic testing or approaches (only mentions anticoagulant use broadly), so it is not relevant to pharmacogenetics."
4255d9c3-0143-4fab-815d-2351b102c089,1,"239. Koopman JJE, van Bodegom D, Westendorp RGJ, Jukema JW. Scarcity of atrial fibrillation in a tra - ditional African population: A community-based study. BMC Cardiovasc Disord. 2014; 14(1): 87. DOI: https://doi.org/10.1186/1471-2261-14-87",3,1,Processed,"The thesis focuses on vascular and pulmonary complications of type 2 diabetes in sub‑Saharan Africans, migration effects, inflammation, uric acid and epidemiology. It contains no discussion of pharmacogenetics, drug–gene interactions, genetic predictors of drug response, CYPs, or personalized pharmacotherapy. Therefore it is not relevant to pharmacogenetic approaches."
197c7de8-628b-4db8-b9cd-20e55368c5e3,1,"241. Tegene E, Tadesse I, Markos Y, Gobena T. Prevalence and risk factors for atrial fibrillation and its anti- coagulant requirement in adults aged ≥40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study. Int J Cardiol Heart Vasc .",3,1,Processed,"The paper evaluates a smartphone-based ECG device (Spandan) for arrhythmia detection and compares its diagnostic accuracy to standard ECG and cardiologist interpretation. It focuses on electrophysiology, device validation, and clinical diagnostics; there is no discussion of genetics, drug response, genotyping, biomarkers, or pharmacogenetic approaches. Therefore it is not relevant to pharmacogenetics."
6ba55e0d-d150-4cc8-a189-6f7b7e30a0f8,1,"242. Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synop - sis of 23 factors in 32 population-based cohor",3,1,Processed,"The manuscript reports clinical epidemiology, comorbidities, medication use, and one-year outcomes in AF patients with and without CAD. It contains no discussion of pharmacogenetics, genetic testing, genotype-guided therapy, gene–drug interactions, or related methods — therefore it is not relevant to pharmacogenetic approaches."
1077cbc9-28de-48c1-a70b-630cd039bc41,1,"243. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10): e56–e528.",3,1,Processed,"The paper is a data‑mining/systematic review of Traditional Chinese Medicine herbs used for chronic heart failure, focusing on herb frequency, symptom–herb associations, pharmacological actions of herbs, and potential for health products. It contains no discussion of genetic variation, genotype‑guided dosing, pharmacogenomic biomarkers, or any pharmacogenetic methods or results, so it is not relevant to pharmacogenetic approaches."
a6d8e948-def2-4909-afe5-b0040763c5de,1,"244. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S,  et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options—A report from the 3rd Atrial Fibrillation Competence NETwork/European He",3,1,Processed,"This is the 2020 ESC clinical practice guideline for diagnosis and management of atrial fibrillation focusing on screening, anticoagulation, rhythm/rate control, ablation, lifestyle and comorbidity management. It does not evaluate or discuss pharmacogenetic testing, genotype-guided therapy, or personalized pharmacogenetic approaches; therefore it is not relevant to pharmacogenetics."
5c6810da-3557-48ca-a32d-07762087d07a,1,"245. Chang SH, Kuo CF, Chou IJ, See LC, Yu KH, Luo SF,  et al. Association of a Family History of Atrial Fibrillation with Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study. JAMA Cardiol. 2017; 2(8): 863–70. DOI: https:",3,1,Processed,"This is a comprehensive clinical guideline on atrial fibrillation diagnosis and management (anticoagulation, ablation, rate/rhythm control, screening, etc.). It does not focus on pharmacogenetic approaches (no discussion of genotype-guided therapy, genetic testing, or pharmacogenomic recommendations), so pharmacogenetics is not a relevant topic for this document."
2db1a417-1aed-410c-ad4a-bc122aa151ca,1,"247. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M,  et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010; 304(20): 2263–9. DOI: https://doi.org/10.1011/jama.2010.1690",3,1,Processed,"This is the 2020 ESC clinical guideline on diagnosis and management of atrial fibrillation. It covers epidemiology, diagnosis, anticoagulation, rhythm/rate control, ablation, and related clinical management topics but does not focus on or assess pharmacogenetic approaches (no discussion of genotype-guided therapy, CYP/VKORC1 testing, or similar pharmacogenomic strategies in the provided text). Therefore it is not relevant to pharmacogenetics."
f82f60b3-8483-4fc5-89b9-1888a9ec5afe,1,"248. Zoller B, Ohlsson H, Sundquist J, Sundquist K.  High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc . 2012; 2(1): e003384. DOI: https://doi.org/10.1161/JAHA.112.003384",3,1,Processed,"This is the 2020 ESC clinical guidelines for atrial fibrillation focusing on diagnosis, stroke prevention, anticoagulation strategies (NOACs vs VKAs), rate/rhythm control, ablation, and integrated care. It does not evaluate or discuss pharmacogenetic testing or pharmacogenomic-guided therapy (e.g. CYP2C9/VKORC1-guided warfarin dosing); any drug-dosing or TTR comments are clinical, not genetic. Therefore pharmacogenetics is not assessed."
7aa1ba4c-fb67-456c-8380-d1fa17f7a3f7,1,"249. Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE.  A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J Cardiol. 2013; 29(4): 483–91. DOI: https://doi.org/10.1016/j.cjca.2012.07.0",3,1,Processed,"This is the 2020 ESC Guidelines for atrial fibrillation focusing on diagnosis, clinical management, anticoagulation strategies, ablation, and lifestyle/comorbidity management. The document discusses drug choices (VKAs vs NOACs), dosing, and bleeding/stroke risk scores but contains no substantive assessment of pharmacogenetic testing, genotype-guided dosing, or genetic biomarkers. Therefore it is not relevant to pharmacogenetic approaches."
dd371a4a-8740-403a-bc98-e8869286d011,1,"250. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, et al. Risk of arrhyth - mias in 52 755 long-distance cross-country skiers: A cohort study. Eur Heart J. 2013; 34(47): 3624–31. DOI: https://doi.org/10.1093/eurheartj/eht188",3,1,Processed,"This is a clinical guideline on diagnosis and management of atrial fibrillation focused on screening, anticoagulation, rate/rhythm control, ablation, and comorbidity management. It does not evaluate or develop pharmacogenetic approaches; genetic mentions are incidental in references and do not constitute an assessment of pharmacogenetics."
6884d293-dde6-42d2-a355-c0f00ebe625a,1,"251. Shamloo AS, Dagres N, Arya A, Hindricks G.  Atrial fibrillation: A review of modifiable risk factors and preventive strategies. Rom J Intern Med. 2019; 57(2): 99–109. DOI: https://doi.org/10.2478/rjim- 2018-0045",3,1,Processed,"The paper uses Mendelian randomization to test causal effects of genetically predicted obstructive sleep apnea on atrial fibrillation. It focuses on genetic epidemiology and causal inference, not on drug response, gene–drug interactions, biomarkers for therapy selection, or pharmacogenetic methods. There is no assessment of pharmacogenetic approaches or medication-genotype relationships."
33b9c726-bcc7-466c-be4a-95d73919c28e,1,"252. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol . 1994; 74(3): 236–41. DOI: https://doi.org/10.1016/0002-9149(94)90363-8",3,1,Processed,"The document is the 2020 ESC Guidelines for diagnosis and management of atrial fibrillation and covers clinical topics (diagnosis, anticoagulation, ablation, stroke prevention, lifestyle, device monitoring, etc.). It contains no substantive discussion of pharmacogenetic testing or genotype-guided therapy (e.g., VKORC1/CYP2C9, CYP2C19) and does not assess pharmacogenetic approaches, so it is not relevant to pharmacogenetics."
fe5068b5-d4f6-49e0-97b5-ba543706fde3,1,"253. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA,  et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016; 133(5):",3,1,Processed,"This meta-analysis assesses clinical effects of SGLT2 inhibitors on arrhythmia in heart failure patients using RCT data; it contains no evaluation of genetic variation, genotype-guided therapy, pharmacogenomic biomarkers, or analyses stratified by genetic variants. Mechanistic discussion (mitochondria, SGLT1/2 expression) is molecular but not pharmacogenetic. Therefore it is not relevant to pharmacogenetic approaches."
4b2883db-1947-4c56-abbe-9a6892277558,1,"254. Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB,  et al. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Associatio",3,1,Processed,"This is the 2020 ESC clinical guidelines for diagnosis and management of atrial fibrillation—a broad, clinical practice document covering diagnosis, anticoagulation, rate/rhythm control, ablation, and comorbidity management. It does not focus on or assess pharmacogenetic approaches (no substantive discussion of genotype‑guided therapy, genetic testing, or pharmacogenetic dosing strategies in the visible content). Therefore it is not relevant to pharmacogenetics."
a783be24-e429-48b9-a301-3e70e925b371,1,"255. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271(11): 840–4. DOI: https://doi.org/10.1001/jama.1994.0351035",3,1,Processed,"The study is an observational cohort of inpatient atrial fibrillation management in Syria focusing on clinical treatments, outcomes, and risk factors (smoking, COPD, thyroid disease, valvular disease). It does not mention genetic testing, genotype-guided therapy, drug–gene interactions, or any pharmacogenetic methods or analyses. Therefore it is not relevant to pharmacogenetic approaches."
c64e92dd-3755-4c8a-9ffd-ee73949bb5fd,1,"256. Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S.  Arrhythmias in Adults with Congenital Heart Disease: What Are Risk Factors for Specific Arrhythmias? Pacing Clin Electrophysiol. 2017; 40(4): 353–61. DOI: https://doi.org/10.1111/pace.12",3,1,Processed,"This document is the 2020 ESC Guidelines on diagnosis and management of atrial fibrillation focused on clinical diagnosis, stroke prevention, anticoagulation, rate/rhythm control, ablation, and integrated care. It does not assess pharmacogenetic approaches in any substantive way (only a few isolated references to genetic studies), so pharmacogenetics is not a topic of the guideline."
575c75f7-72fb-4ccc-b124-986bb1021d12,1,"257. Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, et al. Association of sick sinus syn - drome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities study and Cardiovascular Health Study. PLoS One. 201",3,1,Processed,"This CV/publication list is focused on cardiovascular and chronic disease epidemiology, biomarkers, cohort studies, and some genetic association/GWAS work, but contains no substantive work on pharmacogenetics or drug–gene interaction studies. Aside from a few papers mentioning medication (e.g., statin therapy) or genetic loci, there is no emphasis on pharmacogenetic approaches, so relevance to pharmacogenetics is minimal."
63f3b521-bfc5-4953-9762-def1b6814e2c,1,"258. Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complica - tions. 2018; 32(5): 501–11. DOI: https:/",3,1,Processed,"The paper is an epidemiological cohort study of fasting glucose and risk of atrial fibrillation and heart failure. It analyzes metabolic biomarkers, BMI, and clinical outcomes, and briefly discusses lifestyle interventions and drug classes (e.g., SGLT2 inhibitors) only in a general context. It contains no genetic data, no analysis of genotype–drug response interactions, and does not assess pharmacogenetic approaches."
b6b52755-e6be-4102-bc4b-82040c204dce,1,"259. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY,  et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123(25): 2946–53. DOI: h",3,1,Processed,"The paper is an epidemiologic cohort analysis of heart failure subtypes and atrial fibrillation incidence/prevalence in the ARIC study. It focuses on clinical phenotypes, echocardiography, and standard covariates (e.g., blood pressure, diabetes, medications) with no mention of genetics, genotype–drug interactions, biomarker-guided therapy, or any pharmacogenetic analyses. Therefore it is not relevant to pharmacogenetic approaches."
355ebf3d-4cb9-409d-99ad-1cbb4c0a7e72,1,"260. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R,  et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi- Ethnic Study of Atherosclerosis, and the Cardiova",3,1,Processed,"The article is a global roadmap on atrial fibrillation focusing on epidemiology, prevention, screening, digital technologies, anticoagulation delivery (NOACs vs VKAs), and health-system implementation. It does not discuss pharmacogenetic testing, genotype-guided dosing, gene–drug interactions, or other pharmacogenomic approaches. Therefore it is not relevant to pharmacogenetics."
208bee5a-9e8c-46f0-9693-ac88e8df08a0,1,"261. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. J Cardiovasc Electrophysiol. 2018; 29(5): 725–32. DOI: https://doi.org/10.1111/jce.13458",3,1,Processed,"This is a clinical guideline on atrial fibrillation diagnosis and management covering screening, anticoagulation, rhythm and rate control, ablation, surgery, and comorbidity management. It does not evaluate or make recommendations about pharmacogenetic testing or genotype-guided therapy; any genetic mentions are incidental in cited studies rather than an assessment of pharmacogenetic approaches."